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Abstract
This thesis details the synthesis of cobalt picolinamide complexes with potential
chemotherapeutic applications. The anti-cancer, anti-bacterial and anti-fungal
activity of these complexes was probed, with lead complexes undergoing further
mechanistic investigations.
Three series of cobalt picolinamide complex were investigated: cobalt(III) tris-
picolinamide, cobalt(II) bis-picolinamide and cobalt(III) mixed ligand complexes.
Cobalt tris-picolinamide complexes consist of a cobalt(III) ion surrounded by three
picolinamide ligands, bound through the pyridyl and amide nitrogen atoms. A
minor isomer with different ligand coordination was formed under certain reaction
conditions, provided that an electron donating group is present as a substituent on
the picolinamide ligand. The formation of cobalt bis-picolinamide complexes was
also only successful when electron donating groups were present on the
picolinamide ligand. These complexes contain a cobalt(II) ion with two picolinamide
ligands and two axial thiocyanate ligands. The cis/trans orientation of the
thiocyanate ligands varies dependent upon the position of the picolinamide ligand
substituent. Mixed ligand complexes consist of a cobalt(III) ion with two
picolinamide ligands and one β-diketonate or ferrocenyl β-diketonate ligand. 
Complexes were screened for their anti-cancer potential against a number of cell
lines. Cobalt bis-picolinamide and mixed ligand complexes were non-toxic. Some
cobalt tris-picolinamide complexes displayed cytotoxicity, with the minor isomer
displaying greater activity than the analogous major isomer. The two lead
complexes were active against cancer cells and cancer stem cells. The mechanism
of action is proposed to be inhibition of cell proliferation through interruption of
the cell cycle at M phase. The lead complexes did not undergo hydrolysis, in
contrast to the mixed ligand complexes containing the ferrocenyl β-diketonate 
ligand. The lead complexes could also adsorb onto an artificial biomembrane
surface, unlike the inactive complexes, implying a correlation between cytotoxicity
and cellular uptake. Additionally, cobalt bis-picolinamide complexes displayed anti-
fungal activity against C. albicans, with the thiocyanate ligands essential for activity.
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Glossary
Anaemia: decrease in the total amount of red blood cells or haemoglobin in the
blood
Angiogenesis: the formation of new blood vessels
Apoptosis: the process of programmed cell death
Autophagy: destructive mechanism of the cell that disassembles unnecessary or
dysfunctional components
Biofilm: any group of microorganisms in which cells adhere to each other and to a
solid surface
Carcinogenesis: the initiation of cancer formation
Carcinoma: a cancer arising in the epithelial tissue of the skin or of the lining of the
internal organs
Chromosome: a thread-like structure of nucleic acids and protein found in the
nucleus, carrying genetic information in the form of genes
Cytosol: the aqueous component of the cytoplasm of a cell
Emesis: the action or process of vomiting
Eukaryote: an organism with a complex cell or cells, in which the genetic material is
organised into a clearly defined membrane-bound nucleus
Genome: the genetic material of an organism
Homeostasis: the tendency towards a relatively stable equilibrium between
interdependent elements, especially as maintained by physiological processes
Hypoxia: deficiency in the amount of oxygen reaching the tissues
Iatrogenic: relating to illness caused by medical examination or treatment
Infarction: obstruction of the blood supply to an organ or region of tissue, typically
by a thrombus or embolus, causing local death of the tissue
Intercalation: insertion of a molecule into DNA between the bases
Kinase: an enzyme that catalyses the transfer of phosphate groups from high-
energy, phosphate-donating molecules to specific substrates
Leukopenia: a decrease in the number of white blood cells (leukocytes) in the
blood
xv
Lymphoma: a cancer of the lymphatic system
Metastasis: the spread of a cancer or other disease from one organ or part of the
body to another
Mitochondria: an organelle in which the biochemical processes of respiration and
energy production occur
Mitosis: a part of the cell cycle when replicated chromosomes are separated into
two new nuclei
Morbidity: the condition of being diseased
Mutation: a change that occurs in the DNA sequence
Nephrotoxicity: toxicity to the kidneys
Neurotoxicity: toxicity to the nervous system
Normoxia: normal levels of oxygen reaching the tissues
Oncogene: a gene that has the potential to cause cancer
Ototoxicity: toxicity to the ear leading to hearing loss
Paresthesia: an abnormal sensation such as tingling, tickling, pricking, numbness or
burning of the skin with no apparent physical cause
Polyp: a small growth, usually benign and with a stalk, protruding from a mucous
membrane
Protease: any enzyme that performs proteolysis by hydrolysis of peptide bonds
Proteasome: protein complexes which degrade unneeded or damaged proteins by
proteolysis
Replication: the biological process of producing two identical replicas of DNA from
one original DNA molecule
Telomerase: a protein which adds a repeat sequence to the end of telomeres
Telomere: a region of repetitive nucleotide sequences at each end of a
chromosome
Transcription: the first step of gene expression, in which a particular segment of
DNA is copied into RNA
Ubiquitination: the addition of ubiquitin to a substrate protein to signal
degradation by the proteasome
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1. Introduction
1.1 Cancer
A frequently quoted statistic is that one in two people in the UK will develop cancer
in their lifetime.1 Cancer is the leading cause of death in the UK, with 163,444 deaths
in 2014 (greater than 25 % of the total number of deaths)2 and an annual NHS spend
of over £ 5 billion (6 % of total NHS budget).3 There were 356,860 new cases in 2014
and despite there being over 100 different types of cancer, over half of new cases
are accounted for by lung, breast, prostate and colorectal cancers.4 Worldwide,
cancer is estimated to be the cause of a total of 13 % of all deaths with the majority
of these occurring in low- or middle-income countries.5-7 As the global population
grows and ages, the burden of cancer is likely to become ever more significant.
Cancer is an umbrella term for a heterogeneous group of disorders which are
characterised by uncontrollable cell division and tissue invasion. The “multiple-hit
model” states that the transformation of a normal cell to a cancerous cell
(carcinogenesis) results from the accumulation of harmful genetic mutations.8
Mutations can be inherited or, in the vast majority of cases, acquired. Acquired
mutations may result from physical factors such as UV and ionising radiation,
chemical factors such as tobacco and asbestos or biological factors such as infection
with HPV.9 A number of DNA repair processes exist to remove mutations. However,
these are not 100 % efficient and indeed efficiency of DNA repair decreases with age
and consequently there is greater potential for the accumulation of mutations.
In carcinogenesis, there are six essential cellular processes which are subverted
through mutation; collectively these acquired capabilities dictate malignant growth
(Table 1.1). The mechanism by which these capabilities are acquired, and their
chronology, will differ between malignancies. The subversion of these physiological
processes is possible due to two enabling characteristics: genomic instability and
tumour-promoting inflammation. Emergent processes, which may be recognised as
essential in the future, are deregulation of cellular energetics and evasion of immune
destruction.10, 11
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Table 1.1: Six cellular processes of carcinogenesis10, 11
Acquired capability Example of mechanism
Limitless replicative potential Activation of telomerase
Self-sufficiency in growth signals Activation of ras oncogene
Insensitivity to growth inhibition signals Deactivation of pRb tumour suppressor
Evasion of apoptosis Production of IGF survival factors
Sustained angiogenesis Production of VEGF inducer
Tissue invasion and metastasis Inactivation of E-cadherin
Cancer produces its physiological effects in a number of different ways. However,
especially in early stage disease, these may be barely discernible. Local effects are
due to the physical presence of a tumour, for example polyps in colorectal cancer
causing rectal bleeding and anaemia.12 Systemic effects, for example fatigue and
weight loss, are distant effects unrelated to tumour load but are thought to be
mediated by tumour necrosis factor-α (TNFα).13 Metastasis, the spread of cancer to
secondary tissues, can produce effects due to tumour load in these secondary
tissues, for example a persistent cough due to lung metastases.14
Prognosis is variable and much will depend on the disease stage. There are a number
of techniques for cancer treatment, including surgery, chemotherapy, radiotherapy,
biological or hormonal treatments and transplantation. Factors such as tumour type,
tumour location and disease stage influence treatment options. In the majority of
cases a combination of therapies are employed.15
The origins of chemotherapy can be traced back to the World Wars. The use of
chemical warfare in World War I is well documented; autopsies of victims of mustard
gas attacks were noted to have leukopenia (a decrease in white blood cells). In World
War II, following the air raid on Bari Harbour in 1943 which led to the accidental
release of 100 tons of mustard gas,16 patients were noted to have leukopenia and
bone marrow aplasia (cessation of the production of blood cells by the bone
marrow). These observations led to the investigation of the therapeutic potential of
nitrogen mustard. Marked regression of lymphomas was noted in both animal and
human subjects. Following publication of these results after declassification in 1946,
mustine (Figure 1.1) became the first ever chemotherapy agent.17
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Figure 1.1: Structure of mustine (mechlorethamine)
1.2 Metal based drugs
Several metal ions have key roles in normal biology, for example in signal conduction
(sodium and potassium), energy transfer (magnesium), oxygen transport (iron) and
electron transfer (copper). Drugs containing metals offer many advantages over
traditional organic compounds. Firstly, more diverse coordination numbers and
geometries are available compared to carbon based chemistry. Variable oxidation
states at the metal centre may allow participation in redox chemistry with the
potential to be involved in mechanism of action or drug activation. Compounds may
be charged allowing interaction with oppositely charged biomolecules such as
negatively charged DNA. Interactions with cellular components may also be
facilitated by ligand exchange or aquation processes. Finally, advantage can be taken
of properties displayed by metals which are not found in biology.18 Despite these
advantages, the prevalence of metal ions in nature and the historical use of metals
in medicine, for example gold-based medicines in Ancient China and Arabia around
1500 BC,19 research into the medicinal impact of metals was neglected until the
latter half of the twentieth century. Interest was renewed with the discovery of the
bacteriostatic and bactericidal activity of cobalt and ruthenium complexes by Dwyer
in the 1950s.20 Nowadays, a number of metal based drugs are routinely available for
a multitude of diseases including arthritis (gold), syphilis (arsenic), leishmaniasis
(antimony) and peptic ulcers (bismuth) among others.21
Identification of metal based drugs tends to rely on synthesis of libraries of small
molecules followed by screening against cultured cells or in animals. General rules
exist to aid in the design of these small molecules, the most well-known being the
Lipinski rules.22 Lipinski’s rules state it is more likely that a drug will show poor
absorption or permeation if the following criteria are not followed:-
1. Molecular weight is less than 500 Da
2. There are no more than 5 hydrogen bond donors
3. There are no more than 10 hydrogen bond acceptors
4. The log P value (octanol-water partition coefficient) is less than 5
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However, these rules are more relevant for organic molecules and thus the two-pole
complementary principle was developed for use with inorganic molecules.23 The
criteria for assessment of the anti-cancer activity of metal drugs are as follows:-
1. Contain hydrophilic and hydrophobic groups
2. Dipole moment is not equal to zero for active intermediate complex
3. Appropriate hydrolysis rate under physiological conditions to give an active
intermediate with at least two water molecules in the cis configuration
4. Appropriate Pearson “hard-soft” degree
5. Left handed enantiomer (Λ) if chirality is present 
However, it is important that these are used as guides as opposed to strict rules, so
as not to restrict the types of complexes researched. For example, a number of trans
platinum(II) complexes have displayed good anti-cancer activity despite the fact that
according to the two-pole complementary principle the cis isomer is generally
considered preferable.24, 25 The development of new drugs may take advantage of
research that has been carried out for inorganic complexes not in the biological field,
for example work on ruthenium Grubb’s-type catalysts has helped inform research
into the similarly structured ruthenium arene anti-cancer complexes.26
The field of medicinal inorganic chemistry changed in 1969 with the publication by
Rosenberg of the anti-cancer properties of a previously discovered platinum
diammine complex.27 This paved the way for further research into firstly platinum
anti-cancer drugs and then into the anti-cancer potential of a number of metals
including antimony, bismuth, cobalt, copper, gallium, gold, iridium, iron, osmium,
palladium, rhodium, ruthenium, silver, tin, titanium, vanadium and zirconium. 28-36
Currently, the only approved metal-based anti-cancer drugs are cisplatin,
carboplatin, oxaliplatin and arsenic trioxide.
1.3 Cisplatin
Cisplatin is one of the most widely used chemotherapy drugs in the world but was
happened upon accidentally in the late 1960s during experiments on the effect of
electric currents on cell division in Escherichia coli (E. coli). 37, 38 E. coli cells were
grown in ammonium chloride buffer and current was applied using platinum
electrodes. As the experiments progressed, the E. coli cells were noted to change
shape from the classical rod-shape to “long and filamentous” cell structures.38 This
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was found to be due to inhibition of binary fission (the prokaryotic mechanism of cell
division) without inhibition of cell growth. This inhibitory factor was a platinum
hydrolysis product which formed on the surface of the platinum electrodes. This
compound was determined as cis-[PtCl2(NH3)2] (cisplatin) (Figure 1.2); the equivalent
trans complex was found to be inactive.38
Figure 1.2: Structure of cisplatin
The potential inhibitory effect of cisplatin on eukaryotic cells, specifically cells which
had undergone malignant transformation, was probed further by Rosenberg.
Cisplatin and its 6-coordinate analogue cis-[PtCl4(NH3)2] were tested on a murine
model using transplantable sarcoma 180 tumours. Cisplatin was found to induce
complete tumour regression and re-implantation of sarcoma tumours was strongly
rejected.39 Clinical trials were initiated in 1971 and the drug was FDA approved in
1978.40 Today, almost four decades since approval, cisplatin remains the
cornerstone of chemotherapy for bladder, cervical, ovarian, testicular, non-small cell
lung cancer and malignant mesothelioma.41
The mechanism of action of cisplatin is by induction of apoptosis due to interaction
with DNA (Figure 1.3). When cisplatin enters the bloodstream, the high chloride
environment (approximate chloride concentration 100 mM) prevents exchange of
labile chloride ligands with water. Intact cisplatin may be transported into cells
passively by diffusion or be actively transported across membranes. Transporters
currently associated with this cisplatin active transport are copper transporter 1
(Ctr1), copper transporter 2 (Ctr2), P-type copper transporting ATPases (ATP7A and
ATP7B), organic cation transporter 2 (OCT2) and multi-drug extrusion transporter 1
(MATE1).42 The low intracellular chloride environment (approximate chloride
concentration 10 mM) allows exchange of one or both chloride ligands with water
to form a charged complex.
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Figure 1.3: Mechanism of cisplatin action43
These charged platinum species can enter the nucleus and interact with electron
dense regions of DNA. The primary site of interaction is the N7 atom of guanine;
however, interaction with lone pair nitrogen atoms on adenine and cytosine also
occurs, resulting in the formation of a DNA adduct (Figure 1.4a). Interaction of
cisplatin with an additional residue results in ring closure and the formation of the
bifunctional adduct. Adducts formed may be either interstrand or intrastrand and
may consist of either 1,2 or 1,3-crosslinks; the most common adducts formed are
intrastrand Pt-GG (47 - 50 %) or Pt-AG (23 - 28 %).44-48 Crosslink formation leads to
destacking of purine and pyrimidine rings and thus introduces a 32 - 35° bend
towards the major groove into the helix49 (Figure 1.4b), leading to either DNA repair
via nucleotide excision repair or initiation of apoptosis.50, 51
Cisplatin induced DNA damage activates numerous factors including p53, c-Abl,
caspases 6 and 7, PKC, ERK and various microRNAs causing cell cycle arrest.
Downstream signalling and activation processes lead to amplification of
pro-apoptotic factors and imbalance against anti-apoptotic factors within the cell
leading to apoptosis.52
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a) b)
Figure 1.4: Cisplatin binding to DNA a) DNA binding sites for cisplatin53 b) cisplatin-
DNA adduct (intrastrand Pt-GG) showing helical distortion54
Cisplatin is a successful drug with impressive potency e.g. 90 % cure rate for
testicular cancer.55 However, there are a number of issues and side-effects
associated with cisplatin therapy which limits its clinical use. One problem with
cisplatin is that following intravenous administration, cisplatin can interact with a
number of plasma proteins, particularly those containing thiol groups.56 Thiol
containing proteins are abundant both extracellularly and intracellularly, for
example albumin and glutathione respectively. This limits the bioavailability of
cisplatin thus reducing the elimination half-life and limiting efficacy; it may also cause
drug deactivation57 and adverse drug reactions (ADRs).58 Another of the main
problems with cisplatin are the severe ADRs which can affect patient compliance and
carry an associated inherent risk of morbidity and mortality. The most common and
clinically important ADRs include nephrotoxicity, neurotoxicity, ototoxicity and
emesis. Nephrotoxicity, occurring in approximately a third of patients, results from
direct injury to the renal tubules leading to a reduction in glomerular filtration rate
and electrolyte disturbances; severe damage can result in acute kidney injury.59, 60
Neurotoxicity is characterised by a sensory neuropathy leading to neuropathic pain
and paresthesias; the mechanism involved is unclear but may involve mitochondrial
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changes and activation of protein kinases.61 Ototoxicity is a significant problem;
especially in paediatric patients where 60 % will suffer permanent bilateral hearing
loss, which in turn may affect speech and language development with subsequent
social and educational consequences.62 A further problem is the development of
resistance, which may force increased dosage with the subsequent increase in risk
or severity of ADRs and of course eventual discontinuation of cisplatin therapy.
Intrinsic and acquired resistance is seen in a number of cancers e.g. colon cancer
(intrinsic), ovarian and non-small cell lung cancer (acquired). The mechanisms
involved in cisplatin resistance include reduction in cellular uptake mediated by
transporters, production of intracellular thiol-containing proteins and increased
capacity for DNA repair and tolerance of DNA damage.63-65
1.4 Alternative platinum anti-cancer drugs
Cisplatin paved the way for research into metal-based anti-cancer drugs; but despite
its huge success, problems such as toxicity, resistance, the intravenous
administration route and inactivity against common cancers such as lung cancer
have encouraged research into new platinum anti-cancer drugs. To date, only two
other platinum anti-cancer drugs have gained FDA approval: carboplatin in 1989 and
oxaliplatin in 2002 (Figure 1.5).53 Both carboplatin and oxaliplatin are structurally
similar to cisplatin with a square planar structure around a central platinum(II) atom
with two amine groups in the cis configuration, and thus these drugs exert their
anti-cancer effects via a similar pathway.
Figure 1.5: Structures of a) carboplatin b) oxaliplatin
In carboplatin, the leaving group is a cyclobutanedicarboxylate which is more stable
than the chloride leaving groups in cisplatin. The aquation of carboplatin is thus
slower than cisplatin, which has led to the suggestion that the mechanism of action
differs from cisplatin which requires aquation for activity.66 This decreased hydrolysis
rate also means that carboplatin shows vastly reduced binding to thiol-containing
proteins compared to cisplatin and hence greater bioavailability and a longer
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half-life.37, 67 The main advantage of carboplatin over cisplatin is the reduced toxicity,
with vastly reduced nephrotoxicity and less severe emesis;68 however a greater
degree of myelosuppression is seen.69 Carboplatin is FDA approved for ovarian and
non-small cell lung cancer70 where it has replaced cisplatin in the majority of cases.
Oxaliplatin (Figure 1.5b) is FDA approved for colorectal and stage III colon cancer and
is being investigated for other cancers.71 It is currently the only platinum-based drug
to show activity against colorectal cancer, especially when used in combination with
5-fluorouracil and leucovorin.72 Interestingly, oxaliplatin displays some activity
against cisplatin resistant cell lines, implying a different mechanism of action.73
Oxaliplatin contains an oxalate leaving group and a diaminocyclohexane ligand, the
R,R isomer of this non-leaving group ligand is more effective than the S,S isomer due
to the ability to form hydrogen bonds between the ligand amine and the guanine
oxygen in a Pt-GG lesion.74, 75
In addition to carboplatin and oxaliplatin, there are three platinum anti-cancer drugs,
heptaplatin, lobaplatin and nedaplatin (Figure 1.6), which are licensed in individual
countries: Korea, China and Japan respectively.76 A number of platinum drugs are
also under investigation in either pre-clinical or clinical trials. Areas of research
include adaptations of cisplatin to improve tissue and cellular targeting such as the
addition of glucose or amino acid residues, investigation into novel platinum(II) drugs
such as polynuclear platinum drugs or drugs based on transplatin, investigation into
platinum(IV) pro-drugs for the release of cisplatin e.g. satraplatin, iproplatin and
improved delivery of cisplatin through the use of nanoparticles, carbon nanotubes
and polymeric micelles e.g. ProLindac, lipoplatin.77
Figure 1.6: Structures of a) heptaplatin b) lobaplatin c) nedaplatin
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1.5 Ruthenium anti-cancer drugs
After platinum, ruthenium is the metal undergoing the most extensive investigation
in anti-cancer research, with three ruthenium-based drugs having undergone clinical
trials: NAMI-A, KP1019 and NKP1339. Ruthenium has a number of useful properties
for drug design: it can exchange with O and N donors in a similar way to platinum
and with comparable kinetics allowing complexes to reach their target without
becoming fully dissociated. Under physiological conditions three oxidation states (II,
III, IV) are accessible and thus ruthenium(III) or ruthenium(IV) prodrugs can be
reduced to the more active ruthenium(II) in the hypoxic tumour environment,
allowing improved tumour selectivity. Ruthenium can also mimic iron to be
transported into tumour cells via transferrin receptors, again allowing greater
selectivity.78
One of the first ruthenium complexes to be investigated was the cytological dye
“ruthenium red” which inhibits mitochondrial calcium transport through interaction
with membrane transporters.79 Other early compounds included six coordinate
ruthenium analogues of cisplatin.80 The major limiting factor against the utility of
these complexes was poor aqueous solubility, hence the highly soluble
ruthenium(II)-DMSO complexes were investigated.
1.5.1 NAMI-A
Imidazolium [trans-imidazole-DMSO-tetrachlororuthenate(III)] (NAMI-A) (Figure
1.7a) was the first ruthenium anti-cancer drug to enter clinical trials. This drug was
initially synthesised as the sodium salt (NAMI) (Figure 1.7b), however this led to
co-precipitation of DMSO with the sodium ion and therefore the sodium counterion
was replaced with an imidazolium ion to give NAMI-A.81 NAMI-A is stable in the solid
state but in solution undergoes pH dependent aquation of two chloride ligands
followed by the DMSO ligand leading to the formation of a polyoxo species.82-84
Figure 1.7: Structure of a) NAMI-A b) NAMI
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NAMI-A displayed potent anti-metastatic activity against lung metastases of several
solid tumours, especially non-small cell lung cancer (NSCLC), as opposed to activity
against the primary tumour. This is important as metastasis is the major cause of
cancer mortality and the lungs are the primary site of metastasis.14, 83 In addition,
this anti-metastatic activity was coupled with low systemic toxicity. Initial clinical trial
results were promising with considerable reduction in metastasis and improved
survival times.85-87 However, NAMI-A did not progress beyond phase II clinical trials
due to insufficient efficacy in NSCLC patients when co-administered with
gemcitabine (a licensed NSCLC drug) compared to gemcitabine alone.88 Interestingly,
NAMI-A has also been shown to have anti-plasmodial activity against Plasmodium
falciparum, the major parasite of four species responsible for malaria.89
Despite extensive research, the mechanism of action of NAMI-A is uncertain.
NAMI-A can transiently block the cell cycle at G2M phase90 and bind to both DNA
and RNA,91, 92 however these interactions are observed at higher concentrations and
are not thought to be physiologically relevant. It is more likely that the mechanism
of action involves inhibition of angiogenesis through inhibition of vascular
endothelial growth factor (VEGF),93 cytoskeletal remodelling through the disruption
of matrix metalloproteinase (MMP) release94 and interaction with actins and
collagens,87, 95, 96 and facilitation of the interaction between cancer cells and tumour
infiltrating lymphocytes among others.97
1.5.2 KP1019 and NKP1339
Indazolium [trans-tetrachloro-bis(indazole)-ruthenate(III)] (KP1019) (Figure 1.8a)
was developed from the analogous imidazole complex (KP418) (Figure 1.8b) which
displayed high activity against rat colorectal carcinoma models.98 KP1019 shows
improved activity in the rat colorectal cancer model than KP418 with reduced
mortality and weight loss; it was also found to be more active than 5-fluorouracil (a
licensed colorectal cancer drug).99 NKP1339 (Figure 1.8c) is the sodium salt of
KP1019 and displays improved solubility and formulation characteristics and is the
current lead compound for this class of drugs.100, 101
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Figure 1.8: Structures of a) KP1019 b) KP418 c) NKP1339
KP1019 displayed promising activity with low systemic toxicity in phase I trials for
patients with a variety of advanced solid tumours. The clinical effects did not appear
to correlate with the dosage. Pharmacokinetic analysis found that the drug was
bound mainly to plasma proteins with a long half-life and low clearance.102 Due to
solubility issues, further clinical trials were performed with NKP1339. Anti-cancer
activity was promising with NKP1339, but less potent compared to KP1019, with low
systemic toxicity. It is therefore thought that these two drugs share similar
mechanisms of action.103, 104
KP1019 and NKP1339 are thought to undergo reduction from ruthenium(III) to
ruthenium(II) following rapid intracellular uptake,103 as opposed to when bound to
plasma proteins such as albumin and transferrin.105, 106 The aquation of the drugs is
accelerated upon reduction to ruthenium(II) resulting in a species which shows
greater reactivity with biomolecules.107-109 KP1019 and NKP1339 have been found to
induce the formation of reactive oxygen species (ROS)110, 111 which can then lead to
damage to the mitochondria. In addition, NKP1339 is a direct nitric oxide scavenger
which suggests that this drug may induce effects in cell migration and angiogenesis.93
1.5.3 Ruthenium arene complexes
The most numerous group of ruthenium anti-cancer compounds currently under
investigation are the ruthenium arene complexes. Ruthenium arene complexes tend
to consist of ruthenium(II) stabilised by a facially bound η6-arene, often one or two
labile ligands are present. The two main groups of ruthenium arene compounds
which have been studied are RAPTA complexes and RAED-type complexes (Figure
1.9).
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Figure 1.9: General structures of a) RAPTA b) RAED type complexes
RAPTA complexes are “piano stool” complexes developed by Dyson and contain a
η6-arene, an amphiphilic monodentate 1,3,5-triaza-7-phosphatricyclodecane (pta)
ligand and two free coordination sites which tend to be occupied by labile chloride
ligands. The pta ligand provides aqueous solubility dependent upon the nature of
the arene ligand, more electron withdrawing groups leading to poorer stability,
which allows improved hydrolytic stability and facilitates drug administration.112, 113
The first RAPTA complex, RAPTA-C (Figure 1.10a), displayed in vitro DNA damaging
ability in a pH dependent manner and therefore it was hypothesised that these
complexes could provide selective DNA damage in hypoxic tissue such as cancer
cells.114 A large number of different RAPTA complexes with variations to the arene
ring and substituents of the pta ligand have been investigated for their anti-cancer
potential. In general, these complexes displayed moderate activity towards TS/A
adenocarcinoma cell lines with no toxicity towards the non-cancerous HBL-100 cell
line. RAPTA-T (Figure 1.10b) in particular displayed good selectivity for the cancerous
cells.115 RAPTA-T also displayed potent anti-metastatic activity and appeared
selective for invasive cancer cells and metastases. This activity is thought to be due
to the action of RAPTA-T on cell surface molecules and the cytoskeleton leading to
the loss of cellular flexibility which is required for cellular detachment and tissue
invasion.116 Replacement of the chloride ligands with more stable leaving groups has
little effect on activity and thus hydrophobicity can be tuned by the exchange of
chloride ligands for neutral two electron donor ligands such as imidazole.113 Both
RAPTA-C and RAPTA-T are able to interact with DNA and a number of different
proteins e.g. chromatin,117 glutathione,118 cytochrome c,119 superoxide dismutase120
and metallothioneins,121 and inhibit different enzymes e.g. thioredoxin reductase,
cathepsin B122 and PARPs;123 these interactions are thought to be important for the
mechanism of drug action which has yet to be elucidated.
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Figure 1.10: Structures of a) RAPTA-C b) RAPTA-T
RAED-type complexes were initially investigated by Sheldrick who demonstrated the
anti-tumour potential of a ruthenium(II) ethylenediamine chloride
hexafluorophosphate salt (Figure 1.11).124 Extensive development of this original
structure has been carried out by Sadler, with variation of both the arene and
bidentate ligand.125 In these ruthenium arene complexes, fine tuning of the chelating
ligand can improve aqueous stability and control ligand exchange kinetics; the arene
can influence cellular transport and the leaving group can assist in controlling the
activation.126 Structure-activity relationship investigations have revealed that the
optimum structures contain a stable bidentate N,N donor ligand, a hydrophobic
arene and a labile halide ligand.124, 125, 127
Figure 1.11: Structure of [(η6-benzene)Ru(en)Cl]PF6
The anti-cancer potential of a wide variety of these ruthenium arene complexes has
been studied; cytotoxicity was noted against ovarian cancer and NSCLC cell lines,
with an increase in activity correlating with increase in arene ring size (Figure 1.12),
a trend which is also noted for hydrolysis and hydrophobicity with ring size.126-128
Ru
H2N NH2
Cl
R
R
=
Figure 1.12: Ruthenium arene complexes with increasing arene ring sizes
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Variation of the ligand in ruthenium p-cymeme complexes also has significant
implications for activity (Figure 1.13). Complexes containing two monodentate
N-donor ligands as opposed to the bidentate ethylenediamine (en) ligand show very
low activities.125 Bidentate N,N and N,O ligands based on amino acids were less
cytotoxic than the en ligand. Replacement of the σ-donor en ligand with π-acceptor 
2,2’-bipyridine ligand led to almost complete inactivation.129 Amongst polar
substituents to the bidentate ligand, 2-phenoxy derivatives display the most potent
activity but generally non-polar substituents conferred greater activity than polar
substituents.129 In order to improve DNA capacity, the neutral en has been replaced
with an anionic β-diketonate ligand. These complexes can hydrolyse readily and 
display selective binding to adenosine.130
Figure 1.13: Ruthenium p-cymene complexes with varying bidentate ligands
In general, it appears that ruthenium arene complexes with labile halide ligands
undergo aquation intracellularly. Similar to cisplatin, the rate of aquation can vary
substantially depending upon the nature of the bidentate ligand;131 for example
acetylacetonate (acac) containing complexes aquate more rapidly than en
containing complexes. This is ascribed to the more electron donating nature of the
acac ligand.130, 132 Interaction with DNA is thought to be crucial to the mechanism of
action as ruthenium(II) can bind to guanine and thymidine residues.132, 133 The
preference for guanine binding may allow these drugs to target guanine rich regions
of DNA such as the telomeres (repeat sequences which act as caps at the ends of
chromosomes). A ruthenium arene complex with an en ligand has the ability to
unwind supercoiled DNA and induce interstrand and intrastrand Ru-GG crosslinks
similar to cisplatin. Overall, fewer interactions with proteins are observed which may
account for the low systemic toxicity and aid the transport of drugs to the target
cells.134
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1.6 Rhodium and iridium anti-cancer drugs
In contrast to ruthenium, there have been relatively few investigations into the
biological activity of the neighbouring metal rhodium. The discovery that dimeric
rhodium(II) carboxylates (Figure 1.14) exhibit anti-cancer activity prompted
increased research into rhodium complexes.135-138 These type of complexes display
improved cytotoxicity correlating with greater lipophilicity which in turn is
dependent on the size of the alkyl group attached to the carboxylate.139 The
mechanism of action is unclear; it may be through DNA binding akin to cisplatin or
inhibition of enzymes involved in DNA synthesis due to complex binding to protein
sulphydryl sites.140, 141
Figure 1.14: General structure of rhodium carboxylates complexes
Recently, rhodium carboxylate complexes containing bipyridine or phenathroline
ligands have displayed cytotoxicity.142, 143 A range of carboxylate complexes have also
been shown to increase the radiation sensitisation of cancer cells in vitro, an effect
ascribed to their ability to deplete intracellular thiols.144 Similar complexes with
various anti-malarial drugs as additional ligands also show activity, with the most
active complex containing the drug mepacrine.145
The most widespread investigation into rhodium drugs has been through the
synthesis of rhodium analogues of previously known ruthenium(III) complexes, these
tend to show lower activity as they are unlikely to be activated by reduction unlike
their ruthenium counterparts.146, 147 However, some complexes defy this trend, for
example a rhodium chloride complex with diaminopyridine displayed significant
anti-tumour effects while in addition displaying no greater nephrotoxicity than
cisplatin.148
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There have been several studies on rhodium complexes with polyaromatic ligands
such as modified bipyridyl, phenylpyridyl or phenathroline ligands, inspired by
previously known rhodium complexes with luminescent properties. The large planar
aromatic nature of these ligands is attractive as there is the potential for DNA
intercalation. Complexes were found to be cytotoxic against a number of cell lines
with the polyaromatic ligands providing increased hydrophobicity and altering the
metal redox properties. However, despite the intercalating ability of the aromatic
ligands DNA did not appear to be the primary target.149 The nature of the
polyaromatic ligand had a significant effect on cytotoxicity; for example in facial
rhodium(III) polypyridyl complexes (Figure 1.15) potency was increased in the order
dppn > dppz > dpq, phen >> bpy.150-153 Other similar complexes display anti-cancer
effects through a number of different mechanisms including inhibition of various
enzymes,154, 155 inhibitors of protein-protein interactions,156 oxidative DNA
damage157 and through DNA intercalation.158 One intercalator in particular shows
specific binding to destabilised regions in DNA close to base pair mismatches.159
Figure 1.15: Structures of Rh(III) fac-[RhCl3(DMSO)] with 2-2’ bipyridine (bpy), 1,10-
phenathroline (phen), dipyrido[3,2-d:2’,3’-f]quinoxaline (dpq), dipyrido[3,2-
a:2’,3’-c]phenazine (dppz) and benzo[i]dipyrido[3,2-a:2’,3’-c]phenazine dppn
ligands
A variety of rhodium(I) complexes have also displayed anti-cancer activity including
square planar cis-1,5-cyclooactadiene (COD) complexes with a number of additional
ligands such as acacs.160, 161 Some of these complexes displayed anti-metastatic
effects which are thought to be due to modifications occurring at the primary
tumour site.162 Cationic rhodium COD complexes containing anti-parasitic drugs also
show cytotoxicity,163 as do rhodium carbonyl complexes with sulphonamide
derivatives which are cytotoxic to tumour cells without associated nephrotoxicity.164
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As with rhodium, there has been relatively little investigation into the anti-cancer
potential of its fellow group IX metal iridium. Iridium complexes have frequently
been studied as analogous complexes for known ruthenium(III) complexes. Such
iridium complexes, similar to the analogous rhodium complexes, tend to show lower
cytotoxicity due to the reduced likelihood of activation by reduction or by ligand
exchange/aquation due to less rapid exchange kinetics.165 However, this relative
inertness to substitution can be exploited to form kinetically inert complexes which
can act as enzyme inhibitors. Iridium complexes with pyridocarbazole act as a
structural mimics of staurosporine, a protein kinase inhibitor (Figure 1.16).166 This
type of complex selectively inhibits Flt4 kinase, a protein kinase involved in the
maintenance of the lymphatic system, and shows good cytotoxicity results.
Variations in the axial ligands can result in selectivity for different protein kinases.167
Figure 1.16: Iridium(III) pyridocarbazole complex
Several iridium arene “piano stool” complexes have been investigated by Sadler as
counterparts to the ruthenium arene complexes (Figure 1.17). The iridium(III) centre
is stabilised by pentamethylcyclopentadiene (Cp*), which also enhances the lability
of a monodentate ligand which helps overcome issues associated with slow ligand
exchange reactions as for the analogous ruthenium complexes ligand exchange
appears to be an important step in the mechanism of action.168
Figure 1.17: General structure of iridium arene complexes
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Cytotoxicity of these complexes was found to be dependent upon the nature of the
arene, complexes with phenyl or biphenyl substituted Cp* as the arene were more
active than complexes containing Cp* as the arene moiety. Enhanced cytotoxicity
was correlated with increased hydrophobicity, cellular accumulation and DNA
binding and intercalating ability.31 The nature of the bidentate ligand also has a large
effect on cytotoxicity with complexes containing phenylpyridine ligands (C,N
coordination) showing enhanced cytotoxicities compared to the analogous
complexes containing bipyridine ligands (N,N coordination).169 Complexes
containing ketoiminate ligands (N,O coordination) were also found to have improved
activity compared to complexes containing picolinamide (N,N coordination) or
napthoquinone ligands (O,O coordination).170, 171
Iridium complexes with polyaromatic ligands, similar to the previously discussed
rhodium complexes, have also been investigated. Similar trends to the rhodium
complexes are noted with improved cytotoxicity with an increase in the length of the
polyaromatic ligand, despite the fact that DNA interaction or intercalation is not
observed at a significant level.150, 151, 157 Facial isomers were found to be more toxic
than the meridional isomers, in contrast to the rhodium complexes.172 Further
studies with the 5,6-dimethylsubstituted phenathroline ligand showed that these
complexes displayed remarkably improved activity compared to the unsubstituted
phenathroline analogues158 and that the mechanism of action was through the
production of ROS leading to apoptosis through the intrinsic mitochondrial
pathway.152
1.7 Cobalt anti-cancer drugs
Research into cobalt containing drugs is in its infancy in comparison with metals such
as platinum and ruthenium. However, cobalt has a number of useful properties
which may be exploited in drug design: under physiological conditions two oxidation
states (II, III) are accessible and thus cobalt(III) prodrugs can be reduced to more
active cobalt(II) drugs in a hypoxic tumour environment; this allows improved
tumour selectivity.173 Cobalt(III) is generally kinetically inert; however it may
undergo ligand exchange reactions, such as aquation, with comparable kinetics to
platinum(II) and ruthenium(III) which allows the potential for the activation by
aquation mechanism.165 Cobalt is an essential trace element and as such is relatively
non-toxic; this allows the creation of potential drugs with less systemic toxicity than
is noted with for example platinum based drugs. In addition, as cobalt is present
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physiologically there are transport mechanisms for the movement of cobalt
containing molecules such as cobalamin into cells which may be exploited for
improved drug delivery.
The first investigations into the biological potential of a variety of cobalt(III)
complexes were described by Dwyer in 1952 (Figure 1.18). These complexes were
found to induce death in mice through paralysis and respiratory failure. In addition,
the 1:10-bis(salicylideneamino)-4,7-dithiadecane cobalt iodide complex (Figure
1.18e) exhibited anti-bacterial properties against both Escherichia coli and
Staphylococcus haemolyticus.20 Further investigations into charged and neutral
cobalt complexes found these complexes to be potent competitive inhibitors of
cholinesterase, hypothesised to be the mechanism of action.174 This work led to the
investigation of substituted phenathroline cobalt complexes which showed potent
anti-bacterial activity.175 The anti-cancer potential of these complexes were not
investigated and despite the promising anti-bacterial properties, the potential of
cobalt complexes as drugs was overlooked for many years.
Figure 1.18: Cobalt complexes investigated by Dwyer a) cobalt tris-acetylacetone b)
cobalt tris-glycine c) cobalt tris-ethylenediamine nitrate d) cobalt 1:8-
bis(salicylideneamino)-3,6-dithiaoctane chloride e) cobalt 1:10-
bis(salicylideneamino)-4,7-dithiadecane iodide
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1.7.1 Cobalt complexes with non-bioactive ligands
There are currently no FDA approved cobalt-containing drugs, however Doxovir
(CTC-96) is currently in Phase II clinical trials as an anti-viral agent. Doxovir is a
cobalt(III) Schiff base complex with two axially bound imidazole derivatives (Figure
1.19) which exhibits potent activity against drug resistant strains of herpes simplex
virus 1 (HSV-1) and has shown to be effective in the treatment of herpetic keratitis
and adenovirus keratoconjunctivitis.176-179 The mechanism of action is thought to
involve exchange of an axial ligand for a histidine residue at the active site of a
HSV-1 serine protease.180, 181 Variation in the axial ligand permits binding to histidine
residues of zinc finger motifs, common to many transcription factors, preventing
interaction of the transcription factor with its specific response element in DNA. This
has been shown to interrupt transcription and cell signalling pathways in cancer cell
lines.180, 182-186 Other histidine containing enzymes e.g. thermolysin, α-thrombin and 
MMP-2 may also be targeted by Doxovir.181, 187
Figure 1.19: Structure of Doxovir (CTC-96)
Following the discovery of Doxovir and its ability to disrupt signalling pathways
involved in cancer, a few isolated investigations into the anti-cancer potential of
various cobalt(II) and cobalt(III) Schiff base complexes have been performed. Cobalt
complexes based on the structure of Doxovir, with the same Schiff base backbone
and variable axial ligands including nicotinamide and isonicotinamide, were found to
undergo aquation readily under physiological conditions and exhibited potent anti-
tumour and anti-metastatic activity in a mouse model. The mechanism of action is
thought to be through the interactions with MMPs and the induction of ROS leading
to DNA damage and apoptosis.188 The biological potential of cobalt(II) and cobalt(III)
Schiff base complexes containing hydroxyaminoethylamine, phenylmethylamine,
ethylenediamine, hydroxybenzylideneamine and aminophenyl morpholine
derivatives has been investigated. The lack of understanding of structure-activity
relationships in cobalt Schiff base complexes is apparent when examining these
studies as the complexes with ethylenediamine and hydroxybenzylideneamine
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moieties showed moderate activity, whereas complexes with morpholine derivatives
were non-toxic; ethylamine and phenylmethylamine derivatives were found to
inhibit urease, but their anti-cancer potential was not evaluated.189-192 Schiff base
complexes with heterocyclic substituents showed moderate activity against cancer
cell lines with reduced toxicity to non-cancerous cell lines and a tridentate Schiff base
complex containing a phenylimiomethyl derivatives was non-toxic.193, 194 A cobalt(II)
Schiff base complexes with isonicotinic hydrazine moieties formed a water soluble
coordination polymer showed good DNA and protein binding, radical scavenging and
good anti-cancer activity with low systemic toxicity.195
Coordination complexes of cobalt with other non-Schiff base type ligands have also
been investigated. Cytotoxicities in the low micromolar range were observed in
cobalt complexes with macrocyclic ligands196 in comparison to a moderately active
cobalt thiocarbazate complex197 and inactive cobalt phenathroline maltol
complexes.198 In contrast, other cobalt phenathroline complexes had promising anti-
cancer activities with some selectivity for cancerous cells over non-cancerous cells
and evidence for DNA cleavage and inhibition of topoisomerase I.199-203 When
surfactant groups were included activity was often improved with enhanced DNA
damage and induction of apoptosis.204-206 Cobalt thiosemicarbazone complexes have
shown good to moderate anti-cancer activities with the ability to inhibit DNA
synthesis and induce DNA strand breaks.207-210 A heterobimetallic ruthenium-cobalt
complex with phenathroline ligands has been shown to undergo photoreactive
release of the cobalt centre following irradiation with visible light and reduction of
the cobalt(III) centre to cobalt(II).211 A cobalt complex with bipyridine and azide
ligands (Figure 1.20) showed good anti-cancer activity with strong minor groove DNA
binding, plasma protein binding and the ability to cleave plasmid DNA by the
oxidative pathway via the induction of hydroxyl radicals.212
Figure 1.20: Cobalt bipyridine-azide complex
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A cobalt polyquinoline complex with good anti-cancer activity has been found to
intercalate DNA and induce cleavage of plasmid DNA.213 A cobalt flumequine (a
fluoroquinolone antibiotic) complex was shown to intercalate DNA but was
non-toxic to cancer cells, unlike the analogous copper and zinc complexes which
were cytotoxic.214 Organometallic cobalt carborane and supramolecular
ruthenium-cobalt heterobimetallic rectangles have also shown promising
anti-cancer properties, with the rectangles able to modulate autophagy and induce
apoptosis.215, 216
1.7.2 Cobalt complexes with bioactive ligands
The dicobalt(0) hexacarbonyl cluster, [Co2(CO)6], attached via an alkyne linker is
known to modify the activity of small molecules.217 These species may more readily
form carbenium ions adjacent to the cobalt carbonyl cluster, which allows the
possibility of targeting areas of negative charge such as the sugar phosphate
backbone of DNA.218 A variety of cobalt carbonyl acetylene complexes were
investigated for their anti-cancer activity with the lead complex being identified as
Co-ASS, a cobalt carbonyl complex with an aspirin derivative (Figure 1.21).219-222
Studies on further cobalt aspirin derivatives found that the hydrophobic aspirin
moiety aided cell uptake, presumably through passive diffusion; however
hydrophobicity and cell uptake did not determine the cytotoxicity.220 Aspirin is a non-
steroidal anti-inflammatory drug (NSAID) with moderate anti-cancer activity through
the inhibition of cyclooxygenase (COX) enzymes leading to cell cycle arrest and
apoptosis.223 Co-ASS was found to be a potent inhibitor of both COX-1 and COX-2
which correlated with cytotoxicity.224 The differences in the properties of aspirin and
Co-ASS may be explained by differences in mechanism as aspirin causes acetylation
of serine residues at the active site of the COX enzymes whereas Co-ASS causes
acetylation of lysine residues in the substrate channel of the COX enzymes. In
addition, Co-ASS showed pro-apoptotic, anti-metastatic and anti-angiogenic
properties mediated by the inhibition of NF-κB and MMPs and induction of caspases, 
implying that the mechanism of action is in fact multifactorial.224 Co-ASS has also
been observed to reduce intracellular ROS suggesting the intracellular release of
carbon monoxide (CO), i.e. Co-ASS acts as a CO-releasing molecule (CORM).225
Introduction of a cyclopentadienyl (Cp) component to coordinate the cobalt carbonyl
cluster led to improved cytotoxicity and COX inhibition in comparison to aspirin but
not in comparison to Co-ASS.226
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Figure 1.21: Structure of Co-ASS
Coordination complexes of cobalt with other NSAIDs including mefenamic acid,227-
230 tolfenamic acid,231, 232 naproxen,233, 234 meloxicam,235, 236 diclofenac,237 diflunisal,
flufenamic acid and niflumic acid230 have also been prepared. These complexes show
several promising biological functions such as strong DNA and plasma protein
binding, high anti-oxidant capacity and inhibition of carbonic anhydrase. However,
anti-cancer activities have only been studied for a few of these complexes with
promising results against cancer cell lines and a cancer stem cell line.228, 233
Organometallic cobalt complexes of tamoxifen derivatives (a breast cancer drug),
with a cobalt arene moiety replacing a phenyl ring of the parent drug, showed strong
oestrogenic activity with the cobalt hydroxytamoxifen derivatives and good
cytotoxicities for the cobalt bis-aminoethoxytamoxifen derivatives.238
A few examples of dicobalt hexacarbonyl complexes with small molecules other than
NSAIDs have also been investigated. Complexes with deoxyuridine and
fructopyranose derivatives showed only moderate anti-cancer activity.239, 240
Complexes with imidazoline ligands as oestrogen carriers showed good oestrogenic
activity but poor cytotoxicity.241 Complexes with targeting peptides such as
encephalin and neurotensin have also shown good to moderate anti-cancer
activity.242, 243
Some dicobalt hexacarbonyl complexes have been shown to act as CORMs, similar
to one of the Co-ASS derivatives investigated. Initial studies on the [Co2(CO)6] cluster
with simple alkyl and aryl ligands attached via an alkyne found that the ligand had a
large effect on the number of CO molecules released, the rate of CO release,
cytotoxicity and cell viability.244 Further investigations with more diverse ligands has
found that the mechanism of action may be through cell cycle inhibition and
induction of ROS generation leading to apoptosis by the loss of mitochondrial
membrane potential and initiation of the late apoptotic pathway.245, 246
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1.7.3 Bioreductive cobalt prodrugs
A prodrug is an inactive compound which can be activated or metabolised to a form
a drug.247 Cobalt has two readily available oxidation states (II and III) with significant
differences in lability and reactivity; conversion between the two states may be
synonymous with the conversion from prodrug to drug. The local microenvironment
of a tumour is often deprived of oxygen (hypoxic), with a low pH and a reducing
environment in comparison to non-cancerous cells.248-250 Hypoxic cancer cells are
frequently resistant to conventional cancer therapeutics and thus the development
of cobalt(III) prodrugs which can undergo bioreductive activation selectively in
hypoxic regions are attractive.248, 251, 252 Cobalt(III) complexes are generally
kinetically inert due to high stabilisation of the d6 low spin state, whereas cobalt(II)
complexes are high spin d7 and thus more labile and able to undergo ligand
exchange. The cobalt(III) complex acts as the inactive prodrug which is reduced to
the cobalt(II) species which may itself be reversibly reoxidised to enhance selectivity
(Figure 1.22).253, 254 Generally a drug molecule is attached to a cobalt(III) scaffold and
released upon reduction, however there are cases where the cobalt(II) complex itself
acts as the drug. Ubiquitous reductive enzymes such as cytochrome P450 and
xanthine oxidase are thought to be responsible for the bioreduction.255 However it
has been speculated that the rate of reoxidation is more important than the rate of
reduction.256 The cytosolic reduction potential is approximately -200 to -400 mV. An
ideal hypoxia activated prodrug should have a biocompatible reduction potential but
also a high activation threshold as normal cells may also be hypoxic under certain
conditions.248, 257, 258 The reduction potential, charge, solubility, hydrophobicity and
other important biological factors of a cobalt(III) prodrug may be tuned by variations
of the ancillary ligands.
Figure 1.22: Proposed mechanism of action of cobalt(III) prodrugs
The most investigated cobalt complexes for hypoxic activation have included
nitrogen mustard ligands; however some studies have been performed with DNA
intercalators.259 Nitrogen mustards are approved anti-cancer drugs which alkylate
DNA, form interstrand crosslinks and thereby initiate apoptosis.260, 261 Cobalt(III)
complexes with nitro and amine ligands were found to be effective radiosensitisers
for hypoxic cells, with complexes containing acac and nitrogen mustard ligands
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particularly effective.262 The mustard bis(2-chloroethyl)amine (bca) was studied
(Figure 1.23a) because of its deactivation upon coordination to the cobalt(III) centre
as the nitrogen lone pair is involved in bonding and may not form the aziridinium ion
which is essential for DNA alkylation, upon bioreduction to cobalt(II) the cytotoxic
bca is released. The cobalt-bca complex was more active against normoxic cells
(normal oxygen levels) compared to hypoxic cells, however this complex was found
to circumvent mustard related resistance possibly due to improved cellular
uptake.263
Figure 1.23: Structures of cobalt acac mustard complexes with a) bis(2-
chloroethyl)amine (bca) b) N,N-bis(2-chloroethyl)ethylenediamine (dce)
c) N,N’-bis(2-chloroethyl)ethylenediamine (bce)
Further cobalt(III) mustard complexes with aziridine groups were investigated;
however these were readily reduced with facile release of the cytotoxic ligand.264, 265
In order to prepare more stable complexes, the bidentate mustards N,N-bis(2-
chloroethyl)ethylenediamine (dce) and N,N’-bis(2-chloroethyl)ethylenediamine
(bce) were utilised (Figure 1.23b and Figure 1.23c). These complexes were able to
selectively kill hypoxic cells with cytotoxicity attributed to the free cytotoxic mustard
ligand. The dce complexes were more cytotoxic and showed greater hypoxic
selectivity than the bce complexes due to the more positive reduction potentials of
these complexes and thus more rapid release of the mustard ligand.265-268 The most
effective cobalt-dce complex showed up to 20-fold hypoxic selectivity and was active
against tumour spheroids, which have hypoxic centres and thus toxicity is thought
to be due to release of dce in the hypoxic core followed by diffusion into the
normoxic regions.264, 267 Mechanistic investigations showed that the mustard ligand
was rapidly released independent of oxygen status with no reoxidation of the
cobalt(II) species. Therefore the hypoxic selectivity is hypothesised to be due to
competition between the cobalt(III) species and oxygen for intracellular
reductants.269 It was suggested that stability of the cobalt(III) complex is an
important factor in hypoxic selectivity, however cobalt complexes with more stable
tridentate mustard ligands did not display enhanced hypoxic selectivity.264
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Hypoxic selectivity can be improved by tuning the ancillary acac ligand, with methyl
and ethyl acac analogues showing improved selectivity compared to the
unsubstituted acac.267 The effect of replacement of the ancillary acac ligand in the
cobalt-dce and bce complexes on hypoxic selectivity was investigated. Bis-troplonate
and dithiocarbamate complexes were unsuitable due to high reduction potentials
leading to complexes which were easily reduced with the facile release of the
cytotoxic ligand and thus no hypoxic selectivity.270, 271 Anionic carbonate and oxalate
complexes were less cytotoxic than free dce with lower hypoxic selectivity than the
acac complex.272 Complexes with triazoles have been shown to have structural and
redox properties suitable for bioreduction in hypoxia, but these have yet to undergo
biological investigation.273
Activation of cobalt(III) complexes by reduction in hypoxia can result in a cobalt(II)
complex which is active, rather than leading to the release of an active drug.
Cobalt(III) complexes with two 2,4-diiodo-6-((pyridine-2-ylmethylamino)methyl)
phenol ligands could be reduced in the presence of ascorbic acid to cobalt(II)
complexes with the subsequent release of one of the ligands. These cobalt(II)
complexes are hypothesised to undergo ligand exchange with amino acid residues
at the active site of the 20S and 26S proteasomes leading to inhibition of the
proteasomes and induction of apoptosis.274, 275
1.7.4 Cobalt chaperones with bioactive ligands
The ability of cobalt(III) to undergo bioreduction has allowed the development of
cobalt(III) scaffolds to selectively deliver target drugs to hypoxic sites. Selective
delivery of MMP inhibitors to hypoxic cells has been investigated extensively (Figure
1.24). MMPs degrade the extracellular matrix and in cancer these enzymes are often
overexpressed, facilitating tumour cell invasion and metastasis.276 Current MMP
inhibitors, such as marimastat and batimastat, have been developed as
anti-metastatic agents but contain an exposed hydroxamic group which is inherently
reactive and prone to undergo side-reactions in vivo resulting in poor bioavailability
and drug efficacy.277 Marimastat may coordinate to cobalt through the hydroxamic
group which effectively shields the drug from side reactions in normoxic regions, the
reduction of cobalt(III) to cobalt(II) in hypoxic regions then allows the selective
release of the drug. Tripodal tetradentate ligands, mainly tris(2-methylpyridyl)amine
(tpa), have been employed as the scaffold to maximise stability.278, 279 The
cobalt(III)-tpa marimastat complex (Figure 1.24) suppressed tumour growth in a
mouse model to a greater extent than free marimastat, however the complex was
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also discovered to potentiate metastasis.278 In similar complexes with simple alkyl
and aryl hydroxamic acids (to act as a model of marimastat) it was found that both
the hydroxamate or hydroximate forms could be adopted. These forms are
associated with different reduction potentials and thus the ability of these to be
released from the complex in a hypoxic environment is also divergent. Different
scaffold ligands have been developed to tune hypoxic dependent drug release and
also pH dependent release.279-281
Figure 1.24: Structure of cobalt tpa marimastat complex
Other cobalt scaffolds which have been investigated include cobalt cyclens and
cobalt cyclams with a variety of drugs such as 8-hydroxyquinoline and
azachloromethylbenzindoline (azaCBI). These complexes are able to release the
cytotoxic ligand in hypoxic cells upon exposure to ionising radiation leading to
improved selectivity for hypoxic cells over normoxic cells.282-285 Modification of
azaCBI allowed tuning of drug release and thus improved hypoxic selectivity.286
Cobalt cyclam complexes with azaCBI displayed good cytotoxicity and hypoxic
selectivity, however cytotoxicity was not improved with increased concentrations of
cytochrome P450 oxidoreductase, a known initiator of other hypoxia-activated
drugs.287
Cobalt curcumin complexes have recently undergone investigation with a variety of
scaffold ligands. Curcumin is a natural product with anti-cancer effects but shows
poor bioavailability.288 Complexes with tpa, phenanthroline and phenolate ligands
have all shown improved cellular uptake compared to the free ligand. Photorelease
of curcumin following irradiation with visible light is noted leading to improved
cytotoxicity in light compared to dark conditions allowing improved cell targeting.
The mechanism of these complexes is thought to be through the generation of ROS
leading to apoptosis.289-292
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1.7.5 Cobalamin-drug conjugates
Cobalamin (vitamin B12) is an essential water soluble vitamin which consists of a
planar corrin ring coordinating a central cobalt(III) ion with an associated nucleotide
derivative (Figure 1.25). Cancerous cells, along with other rapidly dividing cells, have
a high requirement for cobalamin and thus the formation of cobalamin-drug
conjugates has been investigated as a method of selectively targeting cancer cells
and thus improve the pharmacokinetic properties of any associated drug conjugate.
Conjugation of a drug to cobalamin occurs at four main sites: the β-axial position of 
the cobalt metal centre, the peripheral propionamide sites on the corrin ring, the
5’-hydroxyl group of the ribose and the phosphate group of the ribose unit (Figure
1.25).293 Following cellular internalisation of the cobalamin-drug conjugate, the bond
between cobalamin and the drug is easily broken to allow release of the cytotoxic
drug.
Figure 1.25: Structure of cobalamin including potential conjugation sites
(red arrows)
Cobalamin conjugates with known drugs such as chlorambucil and colchicine have
shown good anti-cancer activity. The cobalamin-chlorambucil conjugate was as toxic
as the free drug; however the colchicine conjugate was found to be less toxic than
the free drug. This is possibly due to incomplete release of the drug from the
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conjugate due to the nature of the hydrazine linker, designed to enable pH
dependent release of the drug.294, 295 Cobalamin conjugates with cisplatin and
cisplatin isomers were active or moderately active against cancer cell lines, however
the activity was poorer than free cisplatin possibly due to low cellular
accumulation.296, 297 Conjugates of cobalamin with complexes of toxic metal ions
such as gadolinium(III) were cytotoxic and reduced tumour viability, whereas
complexes with technetium allowed visualisation through computed tomography
(CT) and single-photon emission computed tomography (SPECT).298, 299 Conjugates of
cobalamin with a rhenium carbonyl complex were cytotoxic and allowed
visualisation of the cell through fluorescence.300 The use of cobalamin as a scaffold
for controlled photoreactive drug release with red, far-red and near infrared (NIR)
light is also under investigation.301 Small molecules may also be transported as
conjugates with cobalamin, for example nitric oxide (NO) in the form
nitrosylcobalamin. Nitrosylcobalamin is internalised through endocytosis with the
consequential release of NO which may inhibit normal metabolism, inducing DNA
damage and apoptosis.302, 303 In vivo studies of nitrosylcobalamin in dogs showed
promising improvements in tumour size following treatment with low systemic
toxicity.304
1.8 Metal picolinamide complexes
Complexes incorporating picolinamide ligands have been reported with a wide
variety of metals including copper, nickel, iron, manganese, zinc, cadmium, cobalt,
ruthenium, osmium and the lanthanides amongst others.170, 305-311 The McGowan
group has extensively researched picolinamide complexes with ruthenium, rhodium,
iridium, titanium and copper for application in catalysis and drug discovery.170, 171, 312-
314
Ruthenium, rhodium and iridium arene complexes with picolinamide ligands have
been investigated for their anti-cancer potential within the McGowan group.
Picolinamide ligands within ruthenium p-cymene complexes were found to adopt
different coordination modes (N,N or N,O bound) depending upon the nature of the
ligand substituent modulated by temperature and pH (Figure 1.26a and Figure
1.26b). Neutral complexes with N,N bound picolinamide underwent rapid hydrolysis,
rapid binding to guanine and significant cytotoxicity (IC50 < 25 μM); in contrast 
monocationic complexes with N,O bound picolinamide underwent slow hydrolysis,
did not bind to DNA and were non-cytotoxic.310 The positioning, number and nature
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of the substituents on the picolinamide ligand was found to have a significant effect
on cytotoxicity.170 Analogous monocationic ruthenium p-cymene complexes with
N-methyl picolinamide ligands (N,O bound) are non-toxic.315 Rhodium and iridium
Cp* complexes with picolinamide ligands (Figure 1.26c) showed moderate
anti-cancer activity (IC50 = 30 - 80 μM), with improvements in activity when the 
picolinamide ligand is substituted for a ketoiminate ligand (IC50 = 3 - 5 μM).171
Rhodium and iridium picolinamide complexes with functionalised Cp* arene
containing hydroxyl tethered arms of various carbon chain lengths displayed
cytotoxicity (IC50 = 50 - 130 μM) against a number of different cell lines (Figure
1.26d). Cytotoxicity improved proportionally with carbon chain length, with the most
promising results for the 14-carbon tethered Cp* rhodium and iridium picolinamide
complexes. The mechanism of action of these complexes may involve disruption of
cell anti-oxidant function through inhibition of thioredoxin reductase.316
Figure 1.26: Metal arene picolinamide complexes a) neutral ruthenium p-cymene
complexes with N,N-bound picolinamide b) monocationic ruthenium
p-cymene complexes with N,O-bound picolinamide c) rhodium and iridium
Cp* picolinamide complexes d) rhodium and iridium hydroxyl tethered Cp*
picolinamide complexes
Ruthenium and rhodium coordination complexes with picolinamide ligands have
also been investigated for their anti-cancer potential within the McGowan group.
These complexes consist of two picolinamide ligands, one N,N bound and one
N,O bound, and two labile halide ligands attached to a ruthenium(III) or rhodium(III)
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central ion (Figure 1.27). Ruthenium and rhodium complexes with labile chloride
ligands formed a mixture of three geometric isomers: cis-trans-cis, cis-cis-cis and
trans-trans-trans. However, when iodide ligands are present only the
trans-trans-trans isomer is formed. This is thought to be due to the larger ionic radius
of the iodide, compared to the chloride ion, which means that the iodide ions
preferentially adopt the trans position to minimise electronic overlap. Ruthenium
and rhodium complexes with iodide ligands displayed improved cytotoxicity
(IC50 = 1 - 40 μM) compared to the complexes with chloride ligands (IC50 = 5 - 90 μM). 
In addition, substitutions in the meta and para positions of the picolinamide aryl ring
were associated with improved cytotoxicity. In the chloride complexes, improved
cytotoxicity was associated with increased hydrolysis rates. Whereas in the iodide
complexes, improved cytotoxicity was associated with decreased hydrolysis rates.312
Figure 1.27: Metal bis-picolinamide bis-halide complexes. Geometric (cis / trans)
descriptors are designated in the order: halide ligand, picolinamide pyridyl
ring, picolinamide amide group. M = Ru, Rh
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1.9 Objectives
The objective of this research was the exploration of the chemistry and biology of a
variety of cobalt picolinamide complexes with different structural features. Metal
picolinamide complexes previously investigated contain a number of elements which
are thought to be important for anti-cancer activity (Figure 1.28). The planar
aromatic pyridyl and aryl rings of the picolinamide ligand provide a potential site for
π-π stacking interactions with nucleobases within DNA. The acidic amide proton of 
the picolinamide ligand provides a potential hydrogen bonding site for interactions
with biomolecules. The substituents on the picolinamide aryl ring can affect the
hydrophobicity and cellular uptake of the complex and can affect the anti-cancer
activity. The presence of a labile halide or pseudohalide ligand allows the possibility
of activation by ligand exchange to form more reactive species which may then
interact with target biomolecules.
Figure 1.28: Potential cobalt picolinamide complexes including sites of potential
variation
There have only been a few reported cobalt picolinamide complexes with even fewer
having undergone biological investigation. There are a number of features of cobalt
picolinamide complexes which may be varied in order to fully explore the potential
of these complexes. The oxidation state of the central cobalt ion may be varied as
cobalt(II) and cobalt(III) complexes are stable in biological systems. The number of
picolinamide ligands and the nature of the ligand binding to the metal (N,N or
N,O coordination) can be varied and will affect the overall charge of the complex and
the number of possible isomers. The substituents present on the picolinamide aryl
ring can be varied to investigate how differing electronic and steric groups affect the
biological activity. Additional ligands may also be varied from labile halide ligands to
more stable alternative bidentate ligands. This research aimed to investigate the
importance of all of these different structural variations within cobalt picolinamide
complexes with respect to the biological activity of the complexes.
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Synthesis and characterisation of cobalt (III) tris-picolinamide
complexes
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2. Cobalt (III) tris-picolinamide complexes
In comparison to other transition metals, particularly ruthenium, the study of
picolinamide ligands with cobalt is in its infancy. At present there are only a limited
number of cobalt(III) tris-picolinamide complexes which have been published in the
literature. The first synthesis of these complexes was reported by Chan and
revealed octahedral cobalt(III) complexes with six nitrogen atoms in the inner
coordination sphere provided by three bidentate N-aryl picolinamide ligands.1
These complexes went on to show high activity and selectivity in the catalytic
oxidation of ethylbenzene to acetophenone.1 An alternative synthetic route to
these complexes was reported five years later by Gupta with further investigation
into the anti-bacterial properties of these complexes, with the complex containing
a 2-pyridyl group in particular displaying strong activity against various strains of
Pseudomonas, E. coli and Shigella.2 Complexes containing picolinamide ligands
coordinated through the two nitrogen atoms can be converted to an isomer where
one of the ligands is instead coordinated through one nitrogen and an oxygen
atom. Acidic conditions permit the protonation of one of the ligands which then
switches its coordination from N,N to N,O resulting in a monocationic complex
(Figure 2.1).3 In ruthenium picolinamide complexes, N,N coordination of the ligand
is associated with improved anti-cancer activity compared to N,O coordination.4
Figure 2.1: Conversion of picolinamide ligand coordination modes
Related cobalt(III) complexes with the same inner coordination sphere provided by
two tridentate picolinamide ligands have also been reported.5 The complex
containing a 2-pyridyl group was also found to show promise as an anti-bacterial
agent, in common with the analogous bidentate picolinamide complex.2 When a
nitrogen atom is incorporated into the picolinamide aryl ring, this confers the
ability to coordinate an additional metal centre resulting in heterobimetallic
complexes which can proceed to form networks (Figure 2.2). To date, complexes of
cobalt(III) with zinc(II), cadmium(II) and mercury(II) have been reported.6-9
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Bidentate picolinamide ligands may also act as tridentate ligands if the substituent
on the aryl ring is a coordinating group such as a thiol.10
Figure 2.2: Cobalt heterobimetallic complexes reported
2.1 Picolinamide ligands
Picolinamide ligands have the ability to coordinate to a metal centre in a number of
different ways: as neutral N,O donors or monoanionic N,N or N,O donors (Figure
2.3). Complexes containing more than one picolinamide ligand therefore have the
potential to contain ligands with different coordination modes. N,N coordination to
the metal centre stabilises higher oxidation states due to the strong σ-donor effect, 
whereas N,O coordination tends to stabilise lower oxidation states.11, 12 The nature
of the ligand coordination can thus affect not only the chemical but also the
biological properties of the complex as has been observed previously.4
Figure 2.3: Coordination modes for picolinamide ligand a) neutral N,O donor
b) monoanionic N,O donor c) monoanionic N,N donor
The N-aryl picolinamide ligands used in this work are shown in Figure 2.4. Ligands
with electron withdrawing or electron donating groups were synthesised in order
to examine the effect of electronics on the properties of the complex.
Fluoro-containing ligands were synthesised with the aim of increasing efficacy, as a
number of successful drugs contain fluoro groups.13, 14 All ligands apart from ligand
1.22 have been synthesised previously in the literature and are not discussed
further.15-20 Ligands were synthesised via the condensation reaction of picolinic
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acid with the respective aniline in the presence of pyridine and triphenylphosphite
(Scheme 2.1a).21 Synthesis of ligand 1.11 by this method resulted in poor yields
(< 10 %) and was therefore synthesised via an alternative condensation reaction
involving dichloromethane, triethylamine and phosphorus oxychloride (Scheme
2.1b).22
Figure 2.4: Picolinamide ligands synthesised within this thesis
Scheme 2.1: Synthetic routes for picolinamide ligands
The 1H NMR spectra of the picolinamide ligands are all very similar with the pyridyl
protons (7.48 - 8.81 ppm) typically having higher chemical shifts than the aryl
protons (6.81 - 8.64 ppm). A broad singlet corresponding to the amide proton
appears downfield, in the range 9.95 - 10.93 ppm depending upon the nature of
the substitution on the aryl ring; this signal is the most characteristic for ligand
formation.
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2.1.1 X-Ray crystallography of ligand 1.22
Ligand 1.22 crystallised in a monoclinic cell and structural solutions were
performed in the P 21 space group with a single molecule in the asymmetric unit
(Figure 2.5). Selected bond lengths and angles are stated in Table 2.1. There is
evidence within the crystal structure for an intramolecular hydrogen bond between
the amide proton and the pyridyl nitrogen (N(1)...N(2) = 2.662(6) Å).
Figure 2.5: Molecular structure of ligand 1.22. Displacement ellipsoids are at the
50 % probability level
Table 2.1: Selected bond lengths and angles for ligand 1.22
Bond Distance / Å Bond Angle / °
C(5)-C(6) 1.328(6) N(1)-C(5)-C(6) 116.9(4)
C(6)-O(1) 1.216(6) C(5)-C(6)-O(1) 120.6(5)
C(6)-N(2) 1.354(6) O(1)-C(6)-N(2) 126.2(5)
N(2)-C(7) 1.412(6) C(6)-N(2)-C(7) 129.3(4)
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2.2 Cobalt tris-picolinamide complexes (N,N coordination)
The cobalt picolinamide complexes synthesised within this section are shown in
Figure 2.6. Complexes were synthesised via the complexation reaction of
picolinamide ligand with cobalt chloride in the presence of triethylamine, similar to
the synthesis reported by Qi et al. (Scheme 2.2).1
Figure 2.6: Cobalt picolinamide complexes synthesised within this section
N
O
N
H
+ CoCl2.6H2O Co
N
N N
N
N
N
NEt3
EtOH / H2OR
Scheme 2.2: Synthetic route for cobalt tris-picolinamide complexes in this section
In this synthesis, cobalt is oxidised from Co(II) in the metal chloride precursor to
Co(III) in the metal complex, which then permits the complexation of three ligands
to the metal centre. All three ligands coordinate through the pyridyl nitrogen and
amide nitrogen, acting as monoanionic donors to help stabilise the 3+ oxidation
state of the central cobalt ion, as has been reported previously.1, 2 The presence of
triethylamine as a base in the reaction appears to be responsible for the oxidation
of the cobalt in an aerobic atmosphere. This oxidation can also occur with other
bases including additional amine containing bases, hydroxides, carbonates and to a
lesser extent hydrogen carbonates; this observation is consistent with the
literature.23 Cobalt may also be oxidised with hydrogen peroxide followed by
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complexation to the deprotonated ligand, however this reaction results in poorer
conversion of the metal precursor to the final complex. The synthesis was
successful with the majority of picolinamide ligands, however larger groups in the
ortho position on the aryl ring were not well tolerated. Complexes with a proton or
a fluorine atom at the ortho position were successfully synthesised but attempts
with larger atoms, such as chlorine, were unsuccessful; this was presumably due to
steric crowding around the metal centre.
2.2.1 Characterisation of cobalt tris-picolinamide complexes (N,N
coordination)
The cobalt(III) picolinamide complexes are low spin d6 and thus diamagnetic. The
1H NMR spectra of these complexes are all very similar with the pyridyl protons
(9.24 - 6.98 ppm) typically having higher chemical shifts than the aryl protons
(7.87 - 4.99 ppm). Pyridyl and aryl protons tend to be shifted upfield in the complex
in comparison to in the free ligand, however one set of pyridyl protons are shifted
downfield. Examples of the 1H NMR chemical shifts for complex 2.7 compared to
the ligands are shown in Figure 2.7 and Table 2.2. Three distinct or overlapping sets
of signals for the picolinamide protons are seen in the final complex as the three
ligands are inequivalent due to the slightly distorted octahedral geometry of the
complex.
N
N
H
O
Cla
b
c
d
h
j
k
l
NH
a
b
c+h
d
j
k
l
a a ab bbc c cd dd h+k h+j hj jk kl l l
Figure 2.7: 1H NMR spectra of complex 2.7 and ligand 1.7
Complex
Ligand
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Table 2.2: 1H NMR chemical shifts for complex 2.7 and ligand 1.7
Proton
environment
1H NMR chemical shift / ppm
Ligand Complex
Pyridyl 8.63
8.32
7.95
7.52
9.04, 8.57 and 7.23
8.38, 8.02 and 7.77
8.17, 7.89 and 7.82
7.71, 7.36 and 7.31
Aryl 7.95
7.64
7.32
7.14
6.84, 6.37 and 5.89
7.17, 6.58 and 6.18
7.17, 7.02 and 6.75
7.26, 6.95 and 6.58
The IR spectra of complexes 2.1a - 2.18a all display a weak aryl CH stretch at
3035 - 3090 cm-1 and a two medium intensity CO stretches at 1615 - 1635 cm-1 and
1585 - 1600 cm-1. There are also several bands of varying intensities in the region
500 - 1600 cm-1. The disappearance of the broad NH stretches (3250 - 3400 cm-1) is
characteristic of complex formation as the picolinamide ligands coordinate through
the amide nitrogen. The CO stretch is shifted to a lower wavenumber in the
complex compared to the free ligand as is expected due to the weakening of the
CO bond following coordination to the metal centre.1-3
The UV/vis spectrum of complex 2.1a is shown in Figure 2.8. The spectrum shows
an intense ligand based absorbance (π-π*) at approximately 200 nm with two less 
intense charge-transfer bounds at around 265 and 300 nm. No d-d transitions are
seen in the 400 - 800 nm region.1-3
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Figure 2.8: UV/vis spectrum of complex 2.1a
2.2.2 X-Ray crystallography of cobalt tris-picolinamide complexes (N,N
coordination)
Complexes crystallised in either a monoclinic (2.2, 2.3, 2.6, 2.7, 2.10, 2.13) or
triclinic (2.1a, 2.4, 2.5, 2.8, 2.9, 2.11, 2.12, 2.14a, 2.15a - 2.17a) cell and structural
solutions were performed in the P 21/n (2.3, 2.6), P 21/c (2.2, 2.7, 2.10, 2.13) or
P 1 (2.1, 2.4, 2.5, 2.8, 2.9, 2.11, 2.12, 2.14a - 2.17a) space group with one (2.2,
2.3, 2.6 - 2.11, 2.13 - 2.17a), two (2.4, 2.5, 2.12, 2.16a) or three (2.1a) molecules in
the asymmetric unit (Figure 2.9). Selected bond lengths and angles are stated in
Table 2.3 and Table 2.4 respectively.
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2.3 2.4
2.5 2.6
2.7 2.8
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2.9 2.10
2.11 2.12
2.13 2.14a
Cobalt tris-picolinamide complexes Chapter 2
66
2.15a 2.16a
2.17a
Figure 2.9: Molecular structures of complexes 2.1a - 2.17a. Displacement ellipsoids
are at the 50 % probability level. Hydrogen atoms and co-crystallising solvent
molecules are omitted for clarity. For clarity only complex 2.1a is labelled, the
remaining complexes follow the same atom numbering scheme
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Table 2.3: Selected bond lengths for complexes 2.1a - 2.17a
Distance / Å
Co(1)-N(1) Co(1)-N(2) Co(1)-N(3) Co(1)-N(4) Co(1)-N(5) Co(1)-N(6)
2.1a 1.968(4) 1.962(5) 1.928(5) 1.955(5) 1.961(4) 1.928(5)
2.2 1.9688(18) 1.9738(19) 1.9325(18) 1.9479(19) 1.9512(18) 1.9211(18)
2.3 1.955(9) 1.981(7) 1.950(8) 1.939(9) 1.961(7) 1.949(9)
2.4 1.954(2) 1.968(2) 1.942(2) 1.9411(18) 1.968(2) 1.921(2)
2.5 1.962(4) 1.977(4) 1.936(4) 1.949(4) 1.963(4) 1.913(4)
2.6 1.973(3) 1.968(3) 1.932(3) 1.942(3) 1.965(2) 1.926(3)
2.7 1.966(4) 1.966(4) 1.949(4) 1.933(3) 1.936(4) 1.924(4)
2.8 1.974(5) 1.957(5) 1.952(4) 1.936(5) 1.955(5) 1.918(4)
2.9 1.962(3) 1.974(3) 1.932(3) 1.939(3) 1.949(3) 1.937(3)
2.10 1.965(2) 1.966(2) 1.924(2) 1.942(2) 1.947(2) 1.933(2)
2.11 1.962(3) 1.961(3) 1.933(3) 1.939(3) 1.929(3) 1.919(3)
2.12 1.954(5) 1.969(5) 1.933(6) 1.944(5) 1.951(5) 1.929(6)
2.13 1.954(7) 1.977(7) 1.937(7) 1.950(7) 1.975(7) 1.942(7)
2.14a 1.9567(15) 1.9636(13) 1.9278(15) 1.9336(15) 1.9497(14) 1.9420(14)
2.15a 1.9289(18) 1.9298(19) 1.9323(18) 1.9526(18) 1.9694(19) 1.9720(18)
2.16a 1.958(7) 1.963(6) 1.946(7) 1.945(7) 1.944(7) 1.935(7)
2.17a 1.932(2) 1.944(2) 1.934(2) 1.938(2) 1.960(2) 1.985(2)
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Table 2.4: Selected bond angles for complexes 2.1a - 2.17a
Angle / °
N(1)-Co(1)-N(2) N(2)-Co(1)-N(3) N(2)-Co(1)-N(4)
2.1a 81.66(18) 89.68(19) 95.4(2)
2.2 81.56(7) 88.99(8) 96.29(8)
2.3 82.5(3) 88.0(3) 95.8(3)
2.4 82.04(9) 88.19(9) 95.93(8)
2.5 81.21(15) 87.74(16) 94.67(15)
2.6 82.03(11) 88.46(11) 96.70(11)
2.7 82.04(15) 87.96(16) 94.66(15)
2.8 82.2(2) 89.24(19) 93.7(2)
2.9 82.43(13) 89.97(13) 96.92(13)
2.10 82.42(9) 87.56(10) 97.27(9)
2.11 82.18(12) 86.77(12) 95.47(13)
2.12 82.1(2) 88.6(2) 94.9(2)
2.13 82.3(3) 87.7(3) 93.2(3)
2.14a 82.37(6) 89.23(6) 95.19(6)
2.15a 81.79(8) 89.16(7) 95.88(8)
2.16a 82.4(3) 88.7(3) 94.4(3)
2.17a 81.49(9) 88.32(8) 95.41(9)
All complexes show a distorted octahedral geometry around the central cobalt
atom with the relevant bond angles in the range 81.5 - 97.3°, deviating from the
expected 90° (Table 2.4). This distortion can be ascribed to the restrictions imposed
by the bidentate picolinamide ligand. The cobalt-pyridyl nitrogen bond lengths are
in the range 1.92 - 1.99 Å and the cobalt-amide nitrogen bond lengths are in the
range 1.93 - 1.98 Å. This is consistent with related low spin Co(III) compounds
which have reported Co-Npyridyl bond lengths of 1.91 - 1.96 Å and Co-Namide bond
lengths of 1.902 - 1.99 Å.1, 3, 5, 7 These are also shorter than in related Co(II)
compounds which have reported Co-Npyridyl bond lengths of 2.07 - 2.15 Å.24-26 There
is evidence from the crystal structure for intermolecular hydrogen bonds, these
tend to be either between the amide oxygen and a neighbouring pyridyl CH group
Cobalt tris-picolinamide complexes Chapter 2
69
or between a solvent molecule and the amide oxygen or pyridyl CH, with bond
distances in the range 2.82 - 3.19 Å. (Figure 2.10). Other interactions observed in a
few instances include π-π stacking interactions between aryl rings in neighbouring 
molecules, with π-π interactions in the range 3.64 - 3.99 Å (Figure 2.10).
a)
b)
Figure 2.10: Intermolecular interactions a) hydrogen bonding between complexes
b) hydrogen bonding between complex and solvent molecules and π-π 
stacking between complexes
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2.3 Cobalt tris-picolinamide complexes (mixed coordination)
The cobalt picolinamide complexes synthesised within this section are shown in
Figure 2.11. Complexes were synthesised via the complexation reaction of
picolinamide ligand with cobalt chloride in the presence of triethylamine, similar to
the synthesis of complexes with N,N coordination (Chapter 2.2) except with
ethanol as the sole solvent as opposed to an ethanol-water mixture (Scheme 2.3).
Figure 2.11: Cobalt picolinamide complexes synthesised within this section
Scheme 2.3: Synthetic route for cobalt tris-picolinamide complexes in this section
Similar to the previous synthesis, cobalt is oxidised from Co(II) to Co(III) by
triethylamine followed by the complexation of three ligands to the metal centre.
Large groups or atoms e.g. chloro, methyl in the ortho position on the aryl ring do
not result in complexation. The only difference between the synthetic pathway for
these complexes compared to the previous N,N coordination complexes is the
solvent: ethanol as opposed to a 2:1 ethanol-water mixture. This difference in
solvent results in a mixture of products: the previous N,N coordination complex
and its isomer, the mixed coordination complex shown above. These products have
different retention factors which permits their separation by column
chromatography to give two differently coloured complexes: red and brown
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respectively. There is no interconversion between the two coordination isomers in
solution over the period of one month, as evidenced by the lack of changes in the
UV/vis spectra of the complexes over time (Figure 2.12).
Figure 2.12: UV/vis spectra of complexes 2.1a and 2.1b over time
In these previously unreported mixed coordination complexes, two of the three
ligands coordinate through the pyridyl nitrogen and amide nitrogen, whereas the
third ligand coordinates through the pyridyl nitrogen and the amide oxygen.
Combined the three ligands act as monoanionic donors to stabilise the Co(III) ion.
This differs from the previously reported type of mixed coordination complexes
where the N,O donor ligand coordination is in the neutral mode as opposed to the
monoanionic mode resulting in a monocationic complex.4 These mixed
coordination complexes are only formed when electron donating groups are
present as substituents on the aryl ring. When an electron donating group is
present, electron density can be donated towards the amide oxygen through the
conjugated π-system thus making this oxygen more nucleophilic and allowing 
coordination to the metal centre. However, it does not appear that this resonance
effect is so great that the mixed coordination complex is the only product. In fact,
even in this synthetic pathway the mixed coordination product is the minor
product with approximately a 2:1 ratio in favour of the formation of the N,N
coordination complex over the mixed coordination complex. There does not appear
to be any correlation between the strength or number of electron donating
substituents and the overall yield of the mixed coordination complex. Further
experiments altering the solvent (toluene, acetonitrile, methanol, chloroform and
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tetrahydrofuran) did not result in an increase in formation of this mixed
coordination complex. Conversely, as soon as water is included in the solvent
mixture the mixed coordination complex is no longer formed and only the N,N
coordination complex is observed. The role of water in this reaction is unknown;
potentially its highly polar nature allows improved stabilisation of the N,N
coordinated ligand through hydrogen bonding and as such only the N,N
coordination complex is formed.
2.3.1 Characterisation of cobalt tris-picolinamide complexes (mixed
coordination)
The cobalt(III) picolinamide complexes are low spin d6 and thus diamagnetic. The
1H NMR spectra of these complexes are all very similar with the pyridyl protons
(8.99 - 6.96 ppm) typically having higher chemical shifts than the aryl protons
(7.50 - 5.98 ppm). Pyridyl and aryl protons tend to be shifted upfield in the complex
in comparison to in the free ligand, however one set of pyridyl protons are shifted
downfield. In comparison to the analogous N,N coordination complexes
(2.1a - 2.18a), a greater amount of signal overlap is observed leading to fewer
peaks in the spectrum but a greater number of multiplets. Examples of the 1H NMR
chemical shifts for complex 2.1b compared to the ligand are shown in Figure 2.13
and Error! Reference source not found.. Three distinct or overlapping sets of signals
for the picolinamide protons are seen in the final complex as the three ligands are
inequivalent due to the slightly distorted octahedral geometry of the complex.
Table 2.5: 1H NMR chemical shifts for complex 2.1b and ligand 1.1
Proton
environment
1H NMR chemical shift / ppm
Ligand Complex
Pyridyl 8.62
8.31
7.91
8.31
8.99, 8.03 and 7.70
8.43 and 7.76
8.03 and 7.95
7.70, 7.65 and 7.10
Aryl 7.80
7.40
7.16
6.98 and 6.92
7.35 and 6.98
6.98 and 6.92
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Figure 2.13: 1H NMR spectra of complex 2.1b and ligand 1.1
The IR spectra of complexes 2.1b - 2.18b are similar to the equivalent N,N
coordination isomers (2.1a - 2.18a). All complexes display a weak aryl CH stretch at
3025 - 3080 cm-1 and a two medium intensity CO stretches at 1620 - 1640 cm-1 and
1560 - 1590 cm-1. There are also several bands of varying intensities in the region
500 - 1600 cm-1. The disappearance of the broad NH stretches (3250 - 3400 cm-1) is
characteristic of complex formation. The CO stretch is shifted to a lower
wavenumber in the complex compared to the free ligand as is expected due to the
weakening of the CO bond following coordination to the metal centre.1-3
The UV/vis spectrum of complex 2.1b is shown in Figure 2.14. The spectrum shows
an intense ligand based absorbance (π-π*) at around 200 nm with three less 
intense charge-transfer bounds at around 235, 270 and 300 nm. No d-d transitions
are seen in the 400 - 800 nm region. The spectrum is similar to the analogous
complex with N,N coordination (2.1a), the main difference being the presence of
an additional charge-transfer band at around 235 nm for complex 2.1b.1-3
Complex
Ligand
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Figure 2.14: UV/vis spectrum of complex 2.1b
2.3.2 X-Ray crystallography of cobalt tris-picolinamide complexes (mixed
coordination)
All complexes were crystallised in a triclinic cell and structural solutions were
performed in the P 1 space group with one (2.1b, 2.15b - 2.17b) or two (2.14b
and 2.18b) molecules in the asymmetric unit (Figure 2.15). Selected bond lengths
and angles are stated in Table 2.6, Table 2.7 and Table 2.8 respectively.
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2.15b 2.16b
2.17b 2.18b
Figure 2.15: Molecular structures of complexes 2.1b - 2.18b. Displacement
ellipsoids are at the 50 % probability level. Hydrogen atoms and co-
crystallising solvent molecules are omitted for clarity. For clarity, only
complex 2.1b is labelled, the remaining complexes follow the same atom
numbering scheme
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Table 2.6: Selected bond lengths for complexes 2.1b - 2.18b
Distance / Å
Co(1)-N(1) Co(1)-N(3) Co(1)-N(4) Co(1)-N(5) Co(1)-N(6) Co(1)-O(1)
2.1b 1.959(2) 1.924(2) 1.922(2) 1.927(2) 1.921(2) 1.9154(17)
2.14b 1.927(4) 1.929(4) 1.926(4) 1.932(3) 1.949(4) 1.920(3)
2.15b 1.964(7) 1.947(9) 1.943(7) 1.929(8) 1.937(8) 1.906(6)
2.16b 1.967(4) 1.944(4) 1.929(4) 1.928(4) 1.938(4) 1.921(3)
2.17b 1.919(2) 1.933(2) 1.933(2) 1.925(2) 1.960(2) 1.9233(18)
2.18b 1.9348(19) 1.9362(19) 1.9386(19) 1.9423(19) 1.9497(19) 1.9257(16)
Table 2.7: Carbon-nitrogen bond lengths for complexes 2.1b - 2.18b
Distance / Å
2.1b 2.14b 2.15b 2.16b 2.17b 2.18b
C(6)-N(2) 1.297(3) 1.290(6) 1.278(12) 1.284(7) 1.292(3) 1.300(3)
Table 2.8: Selected bond angles for complexes 2.1b - 2.18b
Angle / °
N(1)-Co(1)-O(1) O(1)-Co(1)-N(3) O(1)-Co(1)-N(4)
2.1b 83.48(8) 88.48(8) 89.06(8)
2.14b 83.11(14) 91.05(15) 89.01(15)
2.15b 83.0(3) 89.0(3) 88.5(3)
2.16b 83.02(15) 90.78(17) 88.43(16)
2.17b 83.61(8) 90.19(9) 88.72(9)
2.18b 83.02(7) 91.53(7)) 89.69(7)
As with the related tris-picolinamide complexes, all complexes show a distorted
octahedral geometry around the central cobalt atom with the relevant bond angles
in the range 82.6 - 91.3°, deviating from the expected 90° (Table 2.8). The
cobalt-pyridyl nitrogen bond lengths are in the range 1.92 - 1.98 Å and the
cobalt-amide nitrogen bond lengths are in the range 1.92 - 1.94 Å, these are
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consistent with the related tris-picolinamide complexes with N,N coordination
(Chapter 2.2). Within the N,O coordinated ligand, the imine carbon-nitrogen bond
distance is in the range 1.26 - 1.30 Å (Table 2.7) and the cobalt-oxygen bond
distance in the range 1.91 - 1.93 Å, these are consistent with a carbon-nitrogen
double bond and a low spin cobalt(III)-oxygen single bond.3, 27-29 There is evidence
from the crystal structure for intermolecular hydrogen bonds, these tend to be
between a solvent molecule and the amide oxygen or imine nitrogen, with bond
distances in the range 2.93 - 3.37 Å (Figure 2.16). Other interactions include π-π 
stacking or T-stacking interactions between aryl rings in neighbouring molecules,
with bond distances in the range 3.46 - 3.74 Å (Figure 2.16).
a)
b)
Figure 2.16: Intermolecular interactions a) hydrogen bonding between complex
and solvent molecules and T-stacking between complexes b) π-π stacking 
between complexes
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2.4 Conclusions
A range of picolinamide ligands with different electronic and steric properties have
been synthesised. Utilising these ligands, a series of novel cobalt(III)
tris-picolinamide complexes have been synthesised. The first set of complexes
contain ligands which all display N,N coordination to the central cobalt, whereas in
the second set of complexes one of the ligands instead displays N,O coordination.
This second set of complexes is only formed with electron donating group
substituents on the aryl ring and under particular solvent conditions. These two
sets of complexes represent non-interconverting coordination isomers. Complexes
show a distorted octahedral structure with bond lengths in keeping with a
cobalt(III) species. No intramolecular bonds are observed, however intermolecular
hydrogen bonds, π-π stacking and T-stacking interactions are observed between 
neighbouring molecules. The efficacy of the complexes as anti-cancer agents will be
discussed in Chapter 5.
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Synthesis and characterisation of cobalt (II) bis-picolinamide
complexes
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3. Cobalt (II) bis-picolinamide complexes
Cobalt(II) bis-picolinamide complexes have been sparingly studied so far, with only
a handful of structural studies published in the literature. The first study was
carried out by Mamedov, investigating how the position of the amide group from
the pyridine ring influences the structure of the corresponding metal complexes.1
Structural data showed dicationic octahedral cobalt(II) complexes with two
picolinamide ligands which coordinate in the neutral N,O mode, with two aqua
ligands arranged in the trans geometry and two acetate counterions (Figure 3.1a).
Further studies with chloride or squarate acting as the counterion confirmed this
trans geometry.2, 3 Corresponding nickel(II) and zinc(II) aqua complexes also display
the trans geometry.4 Alteration of the axial aqua ligand to thiocyanate produced a
neutral cobalt complex and altered the geometry with the thiocyanate ligands
arranged in the cis geometry, although the pyridyl rings remain trans to each other
(Figure 3.1b).5 Density functional theory (DFT) calculations found that the lowest
energy form of this complex involved the picolinamide ligands in the cis geometry
and the thiocyanate ligands coordinating through the nitrogen, as opposed to the
sulfur atom. Corresponding nickel(II) and zinc(II) thiocyanate complexes also display
the cis geometry. However, the analogous copper(II) complex contains the two
thiocyanate ligands in the trans geometry and coordinated to the central copper
through the sulfur atom. The biological activity of such cobalt(II), copper(II),
nickel(II) and zinc(II) bis-picolinamide complexes has not been investigated.
However, the corresponding zinc(II) complex with axial aqua ligands and nitrate
counterions showed a small tendency to decrease monocyte and neutrophil
intracellular killing capacity by approximately 5 %.4
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Figure 3.1: Previously published cobalt(II) picolinamide complexes displaying
varying cis and trans geometries
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3.1 Cobalt bis-picolinamide thiocyanate complexes
The cobalt picolinamide complexes synthesised within this section are shown in
Figure 3.2. Complexes were synthesised via the complexation reaction of
picolinamide ligand with cobalt nitrate in the presence of potassium thiocyanate,
based on the synthesis reported by Đaković et al. (Scheme 3.1).5
Figure 3.2: Cobalt picolinamide complexes synthesised within this section
Scheme 3.1: Synthetic route for cobalt bis-picolinamide complexes in this section
In this synthesis, the two ligands coordinate through the pyridyl nitrogen and
amide oxygen, acting as neutral donors to help stabilise the 2+ oxidation state of
the central cobalt ion, as has been reported previously.1, 2, 5 The axial thiocyanate
ligands coordinate to the cobalt through the nitrogen atom, as opposed to through
the sulfur atom; this result is consistent with the previous complexes and DFT
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calculations performed by Đaković et al.5 The synthesis was only successful when
there were no electron withdrawing groups as substituents on the aryl ring. This
may be explained by the increased acidity of the amide proton when electron
withdrawing groups are present which may hinder N,O coordination to the metal
centre. This is consistent with previous results for cobalt(III) tris-picolinamide
complexes where the nature of the aryl ring substituents impacted on the
coordination modes of the picolinamide ligand (Chapter 2).
Each cobalt bis-picolinamide complex may form five potential geometric isomers
(Error! Reference source not found.). However, only the trans-trans-trans and cis-
trans-cis isomers were observed. In general, when the aryl ring is unsubstituted or
substituted in the meta position, the thiocyanate molecules are positioned trans to
each other; whereas substitution in the ortho or para positions on the aryl ring
result in the corresponding cis complexes. However, complex 3.8, containing the
3,5-dimethyoxy picolinamide ligand, does not obey this general rule and is
observed in the cis geometry rather than the expected trans geometry. The
geometry of complex 3.6 is unknown, however it is hypothesised to adopt the cis
geometry due to the presence of an ortho substituent on the picolinamide aryl ring.
If substitution in the ortho position has a greater effect than substitution in the
meta position this may explain why attempts to synthesise the cobalt(II)
bis-picolinamide complex with the anthracene picolinamide ligand (1.22) were
unsuccessful. The bulky nature of this ligand presumably would prevent the
formation of the cis geometry due to steric hindrance. The majority of cobalt(II)
bis-picoliamide complexes previously reported contain axial ligands in the trans
position. Differences in cis/trans geometry have been noted with alterations in the
axial ligand (aqua1 to thiocyanate5) and the metal ion (cobalt to copper5), though
the nature of the axial ligand appears to be the more important factor. All previous
studies have involved the picolinamide ligand with no N-aryl substitutions and thus
this represents the first report on the geometric effects of changing the
picolinamide ligand substituents. This work implies that the effect of ligand
substituents on geometry is greater than the effect of the type of axial ligand. It is
suggested that differing geometries have differing thermodynamic stabilities
depending upon the N-aryl substitution, although the reason for these differences
is unclear. The fact that altering the position of the same group, e.g. methyl, alters
the geometry perhaps implies that steric effects are of greater importance than
electronic effects. Perhaps α, β, γ C-H interactions between the aryl ring and the 
axial ligands are important during the transition phase to help stabilise one
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geometry over the other.6 Alternatively, intra-ligand n to π* transitions or 
hydrogen bonding may also assist the stabilisation of one particular geometry.7, 8
Figure 3.3: Potential isomers of cobalt bis-picolinamide thiocyanate complexes.
Geometric (cis / trans) descriptors are designated in the order: thiocyanate
ligand, picolinamide pyridyl ring, picolinamide amide group
3.1.1 Characterisation of cobalt bis-picolinamide thiocyanate complexes
The cobalt bis-picolinamide complexes contain a central cobalt(II) ion which is
paramagnetic (d7). Therefore the 1H NMR spectra of complexes 3.1 - 3.8 show a
number a broad peaks; however the pattern of peaks is the same for the
complexes as for the free ligands and thus assignment is possible. The 1H NMR
spectra of these complexes are all very similar with the amide proton in the region
10.54 - 10.20 ppm and the pyridyl protons (8.70 - 7.45 ppm) typically having slightly
higher chemical shifts than the aryl protons (7.96 - 6.21 ppm). All pyridyl and aryl
protons are shifted slightly upfield in the complex compared to in the free ligand.
Examples of the 1H NMR chemical shifts for complex 3.4 compared to the ligand
are shown in Figure 3.4 and Table 3.1.
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Figure 3.4: 1H NMR of complex 3.4 and ligand 1.15
Table 3.1: 1H NMR chemical shifts for complex 3.4 and ligand 1.15
Proton
environment
1H NMR chemical shift / ppm
Ligand Complex
Amide 10.26 10.21
Pyridyl 8.75
8.17
8.08
7.70
8.70
8.12
8.03
7.64
Aryl 7.86
7.27
7.12
7.82
7.22
7.07
The IR spectra of complexes 3.1 - 3.8 all display a broad NH stretch at
3200 - 3300 cm-1, a weak aryl CH stretch at 3050 - 3100 cm-1, a strong CN (from
NCS) at 2070 - 2100 cm-1 and a strong CO stretch at 1610 - 1635 cm-1. There are
also several bands of varying intensities in the region 500 - 1600 cm-1. The CO
stretch is shifted to a lower wavenumber in the complex compared to the free
ligand as is expected due to the weakening of the CO bond following coordination
to the metal centre. The CN stretch from the thiocyanate ligand is diagnostic for
the formation of the cobalt bis-picolinamide thiocyanate complex.2, 3, 5
The UV/vis spectrum of complex 3.1 is shown in Figure 3.5. The spectrum shows an
intense ligand based absorbance (π-π*) at around 200 nm with two less intense 
Complex
Ligand
Cobalt bis-picolinamide complexes Chapter 3
87
charge-transfer bounds at around 220 and 280 nm and finally a weak d-d transition
at around 640 nm.2, 3
Figure 3.5: UV/vis spectrum of complex 3.1
3.1.2 X-Ray crystallography of cobalt bis-picolinamide thiocyanate
complexes
Complexes in the trans geometry (3.1 - 3.3) were crystallised in a monoclinic (3.1,
3.2) or triclinic cell (3.3) and structural solutions were performed in the P 1 (3.1,
3.3) or P 21/c (3.2) space group with half (3.1, 3.2, 3.3) a molecule in the
asymmetric unit (Figure 3.6). Selected bond lengths and angles are stated in Table
3.2 and Table 3.3 respectively.
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3.3
Figure 3.6: Molecular structures of complexes 3.1 - 3.3. Displacement ellipsoids are
at the 50 % probability level. Hydrogen atoms are omitted for clarity. For
clarity, only complex 3.1 is labelled, the remaining complexes follow the same
atom numbering scheme
Table 3.2: Selected bond lengths for complexes 3.1 - 3.3. a = symmetry generated
Distance / Å Complex
3.1 3.2 3.3
Co(1)-N(1) 2.1064(15) 2.117(2) 2.114(3)
Co(1)-N(1)’ 2.1064(15)a 2.117(2)a 2.114(3)a
Co(1)-O(1) 2.1021(12) 2.0934(17) 2.124(2)
Co(1)-O(1)’ 2.1021(12)a 2.0934(17)a 2.124(2)a
Co(1)-N(2) 2.0827(17) 2.070(2) 2.060(3)
Co(1)-N(2)’ 2.0827(17)a 2.070(2)a 2.060(3)a
Table 3.3: Selected bond angles for complexes 3.1 - 3.3
Angle / °
N(1)-Co(1)-O1 N(1)-Co(1)-N(2) O(1)-Co(1)-N(1)’
3.1 77.28(5) 89.32(6) 102.72(5)
3.2 76.86(7) 91.32(9) 103.14(7)
3.3 76.81(9) 86.37(10) 103.19(9)
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All complexes show a distorted octahedral geometry around the central cobalt
atom with the relevant bond angles in the range 76.8 - 91.3°, deviating from the
expected 90° (Table 3.3). This distortion can be ascribed to the restrictions imposed
by the bidentate picolinamide ligand. The cobalt-pyridyl nitrogen bond lengths are
in the range 2.10 - 2.12 Å, the cobalt-oxygen bond lengths are in the range
2.09 - 2.12 Å and the cobalt-thiocyanate nitrogen bond lengths are in the range
2.06 - 2.08 Å. This is consistent with related high spin Co(II) compounds which have
reported Co-Npyridyl bond lengths of 2.07 - 2.12 Å and Co-Oamide bond lengths of
2.06 - 2.12 Å and the one related Co(II) thiocyanate compound which has a
reported Co-Nthiocyanate bond length of 2.07 Å.1-3, 5 These are also longer than in
related Co(III) compounds which have reported Co-Npyridyl bond lengths of
1.91 - 1.96 Å.9-12 There is evidence from the crystal structure for an intramolecular
hydrogen bond between the amide oxygen and the aryl ortho-CH group of the
same ligand, with the bond distance in the range 2.83 - 2.86 Å. There is also
evidence for an intermolecular hydrogen bond between the thiocyanate sulfur and
the neighbouring amide NH group, with the bond distance in the range
3.55 - 3.61 Å. Other interactions observed include π-π stacking interactions 
between aryl rings and pyridyl rings in neighbouring molecules, with π-π 
interaction distances in the range 3.65 - 3.87 Å, and in the case of complex 3.1
alignment of the thiocyanate groups (Figure 3.7).
Figure 3.7: Intermolecular hydrogen bonding and π-π stacking interactions
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Complexes in the cis geometry (3.4 - 3.8) were crystallised in a monoclinic (3.4, 3.5,
3.7) or triclinic (3.8) cell and structural solutions were performed in the P 21/c (3.4),
Cc (3.5, 3.7) or P 1 (3.8) space group with one (3.4, 3.5, 3.7) or four (3.8)
molecules in the asymmetric unit (Figure 3.8). Selected bond lengths and angles
are stated in Table 3.4 and respectively Table 3.5.
3.4 3.5
3.7 3.8
Figure 3.8: Molecular structures of complexes 3.4 - 3.8. Displacement ellipsoids are
at the 50 % probability level. Hydrogen atoms are omitted for clarity. For
clarity, only complex 3.4 is labelled, the remaining complexes follow the same
atom numbering scheme
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Table 3.4: Selected bond lengths for complexes 3.4 - 3.8
Distance / Å Complex
3.4 3.5 3.7 3.8
Co(1)-N(1) 2.135(3) 2.127(3) 2.129(2) 2.112(4)
Co(1)-N(2) 2.141(3) 2.110(3) 2.102(2) 2.127(4)
Co(1)-O(1) 2.122(3) 2.133(2) 2.144(2) 2.231(4)
Co(1)-O(2) 2.138(3) 2.155(2) 2.165(2) 2.194(4)
Co(1)-N(3) 2.069(4) 2.071(3) 2.080(3) 2.061(5)
Co(1)-N(4) 2.048(4) 2.046(3) 2.048(3) 2.054(5)
Table 3.5: Selected bond angles for complexes 3.4 - 3.8
Angle / °
N(1)-Co(1)-O(1) O(1)-Co(1)-N(3) N(3)-Co(1)-N(4)
3.4 75.90(12) 89.42(14) 94.87(15)
3.5 75.94(11) 87.46(11) 99.13(13)
3.7 76.10(9) 87.38(10) 99.49(11)
3.8 75.32(15) 89.47(18) 101.7(2)
All complexes show a distorted octahedral geometry around the central cobalt
atom with the relevant bond angles in the range 75.3 - 99.5°, deviating from the
expected 90° (Table 3.5). This distortion can be ascribed to the restrictions imposed
by the bidentate picolinamide ligand. The cis geometry complexes show greater
distortion from an octahedral compared to the trans geometry complexes,
evidenced by the distortion of the bond angle between the two thiocyanate
nitrogen atoms from the expected 90° by up to 9.5°. This distortion is similar to the
previous cobalt bis-picolinamide thiocyanate complex in the cis geometry, where
the bond angle between the two thiocyanate nitrogen atoms was reported as
96.9°.5 The cobalt-pyridyl nitrogen bond lengths are in the range 2.10 - 2.14 Å, the
cobalt-oxygen bond lengths are in the range 2.12 - 2.23 Å and the
cobalt-thiocyanate nitrogen bond lengths are in the range 2.04 - 2.08 Å. There is
evidence from the crystal structure for an intermolecular hydrogen bond between
the thiocyanate sulfur and the neighbouring amide NH group, with bond distances
in the range 3.32 - 3.50 Å. Other interactions observed include π-π stacking 
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interactions between aryl rings and pyridyl rings in neighbouring molecules, with
π-π interaction distances in the range 3.55 - 3.83 Å (Figure 3.9).
Figure 3.9: Intermolecular π-π stacking interactions
3.1.3 Powder X-ray diffraction of cobalt bis-picolinamide thiocyanate
complexes
Powder X-ray diffraction patterns of complexes 3.1 - 3.8 were recorded to allow
comparison with the single crystal data. In the solid state, complexes 3.1 - 3.3
adopt the trans geometry whereas complexes 3.4 - 3.8 adopt the cis geometry.
Experimental powder diffraction data can be compared to powder diffraction data
simulated from the single crystal structure to determine whether the bulk sample is
consistent with the single crystals i.e. whether a single isomer or a mixture of
isomers is present. Powder diffraction data for complexes 3.1 - 3.8 is displayed in
Figure 3.10. Due to the lack of a suitable crystal structure of complex 3.6, no
simulated powder diffraction data is presented.
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Figure 3.10: X-ray powder diffraction patterns for complexes 3.1 - 3.3 (trans) and 3.4 - 3.8 (cis)
Key: Black = simulated, blue = experimental
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All the trans complexes (3.1 - 3.3) show good agreement between the
experimental and the simulated powder diffraction patterns, with all the high
intensity peaks from the simulated pattern present at similar 2θ positions in the 
experimental patterns. This confirms that the bulk samples of complexes 3.1 - 3.3
consist of only the trans isomer. For the cis complexes with simulated data (3.4,
3.5, 3.7, 3.8) there are some similarities but also some differences between the
experimental and the simulated powder diffraction patterns. The high intensity
peaks from the simulated pattern do appear in the experimental patterns, but
some other peaks are also present in the experimental diffraction pattern which
cannot be matched to the corresponding simulated pattern. This could be ascribed
to the presence of a mixture of isomers in the bulk powder sample compared to
the single crystals analysed or could be due to differences in the solvent content
between the crystal and powder samples. If the observed differences are due to
the presence of a mixture of isomers, as this is only observed for cis complexes, this
may imply that the trans complex is the thermodynamic product and the cis
complex (or mixture) is the kinetic product of the complex synthesis.
3.1.4 Magnetic studies of cobalt bis-picolinamide thiocyanate complexes
Cobalt(II) has d7 electron configuration and can exist in either a low spin or a high
spin state (Figure 3.11). The calculated spin only magnetic moment for low spin
Co(II) is 1.73 μB with the observed values generally in the range 1.8 - 2.2 μB; the
calculated spin only magnetic moment for a high spin Co(II) is 3.88 μB with the
observed values generally in the range 4.3 - 5.2 μB.13 The chemical environment
around the central cobalt ion affects which spin state is adopted. Octahedral
cobalt(II) complexes tend to be high spin but transitions between the two spin
states are known to occur, this phenomenon is known as spin crossover (SCO). SCO
in cobalt(II) complexes is uncommon and often gradual or incomplete; however
there are examples of ligand systems which display abrupt SCO with thermal
hysteresis, these ligands tend to be based upon the terpyridine ligand system.14-19
Figure 3.11: Low and high spin states of cobalt(II)
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Cobalt(II) bis-picolinamide complexes have previously been shown to be high spin
(μeff = 4.1 μB).3 The magnetic behaviour of complex 3.4 was investigated in both the
solution and solid states. Complex 3.4 was selected as it displays the highest
solubility. In the solution state, the magnetic moment is measured via the Evans
NMR method.20 In the solid state, the magnetic moment as a function of
temperature is measured by a superconducting quantum interference device
(SQUID).21 In the solution state, the magnetic moment for complex 3.4 was found
to be 4.01 μB at 300 K in d3-acetonitrile. Due to limited solubility the Evans NMR
method was only performed at a single temperature. This is consistent with a high
spin central cobalt(II) ion in solution. The magnetic moment is lower than may be
expected due to the low solubility of the complex; if the concentration of the
solution was altered before the measurement performed (due to some of the
complex precipitating out of solution) this would affect the magnetic moment
calculation. The solid state magnetic moment measurements for complex 3.4,
collected by Dr. Rafal Kulmaczewski at The University of Leeds using a SQUID
magnetometer in a field of 5 kG, are shown in Figure 3.12. The magnetic moment is
shown to be 4.36 μB from 300 - 75 K before dropping at lower temperatures due to
the effect of zero field splitting. This supports the solution state data and again
shows a high spin cobalt(II) ion which does not undergo spin transitions.
Figure 3.12: Variable temperature magnetic moment measurements of complex
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3.2 Adaptations of cobalt bis-picolinamide complexes
The cobalt picolinamide complexes synthesised within this section are shown in
Figure 3.13. Complexes were synthesised via the complexation reaction of
picolinamide ligand either with cobalt chloride or with cobalt nitrate in the
presence of potassium iodide, adapted from the synthesis reported by Đaković et
al. (Scheme 3.2).5
Figure 3.13: Cobalt picolinamide complexes synthesised within this section
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Scheme 3.2: Synthetic route for cobalt bis-picolinamide complexes in this section
Similar to the cobalt bis-picolinamide thiocyanate complexes (3.1 - 3.8), these
cobalt complexes contain two ligands coordinated through the pyridyl nitrogen and
amide oxygen to stabilise the 2+ oxidation state of the central cobalt ion.1, 2, 5
Complex 3.9 contains two axial chloride ligands and complex 3.10 contains two
axial aqua ligands resulting in a dicationic complex with two iodide counterions.
Complex 3.10 shows that unlike thiocyanate, iodide is unable to displace the aqua
ligands from the axial ligand positions. Both complexes adopt the trans geometry
similar to complex 3.1 which contains the same picolinamide ligand and with
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previous cobalt bis-picolinamide aqua complexes.1-3 This supports the previous
conclusion that the effect of ligand substituents on geometry is greater than the
effect of the type of axial ligand. In addition, complex 3.9 was synthesised from a
different cobalt starting material compared to all the other cobalt(II)
bis-picolinamide complexes (cobalt chloride as opposed to cobalt nitrate) implying
that the nature of the cobalt starting material has no bearing on the geometry of
the final complex.
The synthesis of further cobalt bis-picolinamide complexes with imidazoles as the
axial ligands using the same synthetic method as previously described was
attempted; however these were mainly unsuccessful. A cobalt(II) bis-picolinamide
thiocyanate imidazole complex was shown to form by mass spectrometry but could
not be isolated (Figure 3.14a). In addition, the synthesis of monoanionic complexes
containing one picolinamide ligand in the N,O coordination mode and the other
picolinamide ligand in the N,N coordination mode was attempted. There was some
evidence that the desired complex had formed by mass spectrometry, however this
complex could not be isolated (Figure 3.14b). Further characterisation data is also
required to determine whether the desired complex was formed, as opposed to
the cobalt bis-picolinamide thiocyanate complex containing both picolinamide
ligands in either the N,N or N,O coordination mode.
Figure 3.14: Cobalt bis-picolinamide complex with a) thiocyanate and imidazole
ligands b) picolinamide ligands with mixed N,O and N,N coordination modes
3.2.1 X-Ray crystallography of cobalt bis-picolinamide complexes
Complexes were crystallised in a monoclinic (3.9 and 3.10) cell and structural
solutions were performed in the P 21/c (3.9 and 3.10) space group with half (3.9
and 3.10) molecules in the asymmetric unit (Figure 3.15). Selected bond lengths
and angles are stated in Table 3.6 and Table 3.7 respectively.
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3.9 3.10
Figure 3.15: Molecular structures of complexes 3.9 and 3.10. Displacement
ellipsoids are at the 50 % probability level. Hydrogen atoms are omitted for
clarity
Table 3.6: Selected bond lengths for complexes 3.9 and 3.10. a = symmetry
generated
Distance / Å Complex
3.9 3.10
Co(1)-N(1) 2.0887(18) 2.094(3)
Co(1)-N(1)’ 2.0887(18)a 2.094(3)
Co(1)-O(1) 2.0937(15) 2.046(2)
Co(1)-O(1)’ 2.0937(15)a 2.046(2)
Co(1)-Cl(1) 2.4462(7) -
Co(1)-Cl(1)’ 2.4462(7)a -
Co(1)-O(2) - 2.121(3)
Co(1)-O(2)’ - 2.121(3)
Table 3.7: Selected bond angles for complexes 3.9 and 3.10
Angle / °
N(1)-Co(1)-O(1) O(1)-Co(1)-Cl(1) O(1)-Co(1)-O(2) O(1)-Co(1)-N(1)’
3.9 77.42(7) 90.13(5) - 102.58(7)
3.10 77.88(10) - 91.71(10) 102.12(10)
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Both complexes show a distorted octahedral geometry around the central cobalt
atom with the relevant bond angles in the range 77.4 - 91.7°, deviating from the
expected 90°. This distortion can be ascribed to the restrictions imposed by the
bidentate picolinamide ligand. The cobalt-pyridyl nitrogen bond lengths are in the
range 2.08 - 2.09 Å and the cobalt-oxygen bond lengths are in the range
2.04 - 2.09 Å. This is consistent with complex 3.1 which showed a Co-Npyridyl bond
length of 2.11 Å and a Co-Oamide bond length of 2.10 Å. For complex 3.10, the
cobalt-aqua oxygen bond length is 2.12 Å which is consistent with reported cobalt
bis-picolinamide aqua complexes which show Co-Oaqua bond lengths in the range
2.10 - 2.12 Å.1-3 For complex 3.9 there is evidence from the crystal structure for an
intramolecular hydrogen bond between the amide oxygen and the aryl ortho-CH
group of the same ligand, however this hydrogen bond is not observed in complex
3.10 due to twisting of the aryl ring. Complex 3.9 also displays an intermolecular
hydrogen bond between the chloride and the neighbouring amide NH group which
is again absent in complex 3.10. Other interactions observed include π-π stacking 
interactions between aryl rings and pyridyl rings in neighbouring molecules for
complex 3.9 and bridging of complexes of 3.10 through the aqua ligands and iodide
counterions (Figure 3.16). Overall, the planar nature of the picolinamide ligands in
complex 3.9 permits similar intra- and intermolecular bonding interactions to
complex 3.1 which also contains planar picolinamide ligands. The aryl rings of the
picolinamide ligands in complex 3.10 are twisted and therefore the ligand is not
planar, presumably this is due to the presence of the iodide counterion. This
intra-ligand torsion alters the nature of the intermolecular interactions and thus
complex 3.10 does not display any π-π stacking interactions. 
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a)
b)
Figure 3.16: Intermolecular interactions a) π-π stacking b) bridging of complexes 
through aqua ligands and iodide counterion
3.3 Conclusions
A series of novel high spin cobalt(II) bis-picolinamide complexes has been
synthesised with the two picolinamide ligands coordinating in the N,O mode and
the two axial ligands either thiocyanate, chloride or aqua. The substituent on the
aryl ring of the ligands determines the trans or cis geometry of the final complexes.
In general, no substituents or meta substituents lead to the trans geometry,
whereas ortho or para substituents bestow the cis geometry. Complexes show a
distorted octahedral structure with bond lengths in keeping with a cobalt(II)
species. Intramolecular hydrogen bonds are observed for trans complexes but not
for cis complexes. Intermolecular hydrogen bonds and π-π stacking interactions are 
observed between neighbouring molecules. Trans complexes are hypothesised to
be the thermodynamic product of the reaction. The efficacy of the complexes as
anti-cancer, anti-bacterial and anti-fungal agents will be discussed in Chapter 5.
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Synthesis and characterisation of cobalt (III) mixed ligand complexes
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4. Cobalt (III) mixed ligand complexes
There are a number of examples of cobalt mixed ligand complexes in the literature,
however none of these complexes contain picolinamide ligands. In terms of anti-
cancer cobalt mixed ligand complexes, the majority of these contain a known
cytotoxic ligand with the cobalt and additional ligands present either to act as a
chaperone or for tunability purposes, to allow the more selective targeting of
cancer cells. Cobalt(II) conjugates containing pyridyl based ligands, e.g. pyridine,
bipyridine and phenanthroline, and nonsteroidal anti-inflammatory drugs
e.g. naproxen, mefenamic acid and tolfenamic acid have shown strong DNA binding
properties and high antioxidant activities but have not been investigated for
cytotoxicity (Figure 4.1a).1-3 A cobalt(III) cyclam complex with naproxen was found
to be toxic to both cancer cells and cancer stem cells.4 Cobalt(III) mixed ligand
complexes with acetylacetonate and nitrogen mustard ligands have shown to be
cytototoxic with improved targeting of cancerous cells over non-cancerous cells.
This targeting is due to hypoxia selectivity, as in a hypoxic environment the central
cobalt(III) is reduced to cobalt(II) with the concurrent loss of the nitrogen mustard
ligand which is a known therapeutic agent (Figure 4.1b).5, 6 Cobalt(III) mixed ligand
complexes with tris(2-methylpyridyl)amine (tpa) with marimastat, a matrix
metalloproteinase, was found to suppress tumour growth. Complexation of
marimastat through the hydroxamic acid moiety, thought to be the cause of low
bioavailability due to binding to other biomolecules, imparted hypoxic selectivity
allowing the specific targeting of cancer cells (Figure 4.1c).7, 8 Aside from tpa, cyclen
ligands are commonly used in the preparation of cobalt(III) chaperones.9, 10
Figure 4.1: The structures of a) cobalt-mefenamic acid conjugate b) cobalt acac
nitrogen mustard c) cobalt tpa marimastat
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4.1 β-Diketonate and ferrocenyl β-diketonate ligands 
Ferrocene is a metallocene consisting of a central iron(II) ion “sandwiched”
between two cyclopentadiene (Cp) rings. Ferrocene has good aqueous solubility,
with highly tunable properties and is easily derivatised, leading to the widespread
investigation of ferrocene bioconjugates and ferrocenyl drug-derivatives.11 To date,
the only ferrocenyl drug derivative to have entered the clinic is the anti-malarial
drug ferroquine (Figure 4.2a).12 In terms of chemotherapy, ferrocifen: the
ferrocene adduct of hydroxytamoxifen (the active metabolite of the breast cancer
drug tamoxifen) (Figure 4.2b), showed improved bioavailability and activity against
both hormone-dependent and hormone-independent tumours.13, 14
Figure 4.2: The structures of a) ferroquine b) ferrocifen
The successes of ferrocenyl derivatives in clinical research has led to the
investigation of a number of ferrocenyl derivatives of compounds which can act as
ligands for metal complexes. For example, β-diketonate ligands are non-cytotoxic 
but ferrocenyl β-diketonate ligands have shown promising cytotoxic activity, these 
are currently under investigation within the McGowan group.15 Within the series of
ferrocenyl β-diketonate ligands, higher reduction potentials and lower pKa values
are associated with greater toxicity.16 Metal complexes with these ferrocenyl
β-diketonate ligands have also proven cytotoxic, but less cytotoxic than the free 
ligand.17
β-Diketonate ligands were synthesised via the Claisen condensation reaction of
ethyl acetate with the respective acetophenone in presence of sodium ethoxide
(Scheme 4.1a).18 All ligands have been synthesised previously in the literature and
are not discussed further.19-21 Ferrocenyl β-diketonate ligands were synthesised via
the Claisen condensation reaction of acetyl ferrocene with the respective benzoate
or acetate in the presence of sodium ethoxide (Scheme 4.1b).16, 22 All ferrocenyl
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β-diketonate ligands were synthesised by Matthew Allison at The University of 
Leeds.
Scheme 4.1: Synthetic routes for β-diketonate ligands
The 1H NMR spectra of the β-diketonate and ferrocenyl β-diketonate ligands show 
a characteristic methine proton singlet peak between 5.63 - 7.01 ppm depending
upon the nature of the substitution on the ligand; this signal is the most
characteristic for ligand formation.
4.2 Cobalt bis-picolinamide β-diketonate complexes 
The cobalt picolinamide complexes synthesised within this section are shown in
Figure 4.3. Complexes were synthesised via the complexation reaction of
picolinamide and β-diketonate ligands with cobalt carbonate in the presence of 
hydrogen peroxide, similar to the synthesis used for the preparation of cobalt
β-diketonate complexes (Scheme 4.2).23-25 Complex 4.1 was prepared and partially
characterised by Bilal Saloo at The University of Leeds following the procedure
determined by the author.
Scheme 4.2: Synthetic route for cobalt picolinamide β-diketonate complexes in this 
section
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Figure 4.3: Cobalt picolinamide complexes synthesised within this section
In this synthesis, cobalt is oxidised from Co(II) in the metal carbonate precursor to
Co(III) in the metal complex which then permits the complexation of three ligands
to the metal centre. The β-diketonate ligand coordinates through the two keto 
oxygen atoms and the two picolinamide ligands coordinate through the pyridyl
nitrogen and amide nitrogen, acting as monoanionic donors to stabilise the 3+
oxidation state of the central cobalt ion. This N,N coordination of the picolinamide
ligands is ensured with the use of an electron withdrawing group substituent on
the aryl ring and the use of a 2:1 ethanol-water mixture as the reaction solvent.
The same picolinamide ligand is used throughout and the β-diketonate ligand 
varied; the 3,5-di(trifluoromethyl) picolinamide ligand (1.14) was selected as the
analogous cobalt(III) tris-picolinamide complex with this ligand was found to be
cytotoxic (Chapter 5). The presence of hydrogen peroxide in the reaction is
responsible for the oxidation of cobalt in an aerobic atmosphere. Cobalt may also
be oxidised with bases such as triethylamine or sodium hydrogen carbonate,
however these result in poorer conversion of the metal precursor to the final
complex or the formation of a greater percentage of side products.
The formation of complexes 4.1 - 4.9, with two picolinamide ligands and one
β-diketonate ligand, is permitted through stoichiometric control of the reaction. 
Despite this a number of side products are also formed resulting in lower yields.
The two major side products formed are the cobalt(III) tris-picolinamide complex
and the cobalt(III) picolinamide β-diketonate complex with one picolinamide ligand 
and two β-diketonate ligands, as shown by thin layer chromatography (TLC) and 
mass spectrometry.
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The synthesis was successful with the majority of β-diketonate ligands apart from 
curcumin (Figure 4.4). The cobalt picolinamide curcumin complex was shown to
form by mass spectrometry but could not be isolated. Curcumin is a natural
product present in turmeric which has been found to have anti-tumourigenic,
anti-angiogenic and anti-inflammatory properties and is thus under investigation as
a potential anti-cancer drug.26-29 However, curcumin undergoes rapid metabolism
and is poorly soluble in water (especially at physiological pH) leading to poor
bioavailability.30, 31 Various methods are under investigation to improve
bioavailability, protect against degradation and target cancer cells including the use
of chaperones and nanoparticles as delivery mechanisms. A few cobalt curcumin
complexes have been evaluated for their potential to act as curcumin chaperones
with promising results.32-38
Figure 4.4: The structure of curcumin
4.2.1 Characterisation of cobalt picolinamide β-diketonate complexes 
The cobalt(III) picolinamide β-diketonate complexes are low spin d6 and thus
diamagnetic. The 1H NMR spectra of these complexes are all very similar with the
pyridyl protons (8.19 - 7.13 ppm) typically having higher chemical shifts than the
aryl protons of both the picolinamide and β-diketonate ligands (7.90 - 6.91 ppm) 
and the methine proton in the region 6.79 - 5.43 ppm. All pyridyl and aryl protons
from both ligand types are shifted upfield in the complex compared to in the free
ligand; the methine proton also undergoes a slight upfield shift. Examples of the
1H NMR chemical shifts for complex 4.8 compared to the ligands are shown in
Figure 4.5 and Table 4.1. Two distinct or overlapping sets of signals for the
picolinamide protons are seen in the final complex as the two ligands are
inequivalent due to the slightly distorted octahedral geometry of the complex.
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Figure 4.5: 1H NMR spectra of complex 4.8 and the constituent picolinamide and β-
diketonate ligands
Table 4.1: 1H NMR chemical shifts for complex 4.8 and the constituent picolinamide
and β-diketonate ligands
Proton
environment
1H NMR chemical shift / ppm
Ligand Complex
Pyridyl 8.66
8.30
7.97
7.48
8.16
7.91
7.73
7.15
Aryl
(picolinamide)
8.32
7.68
7.73
7.52
Aryl
(β-diketonate) 
7.76
7.60
7.52
7.24
Methine 6.15 6.08
Complex
Picolinamide
β-diketonate 
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The IR spectra of complexes 4.1 - 4.9 all display a weak aryl CH stretch at
3080 - 3100 cm-1, a medium intensity CO (picolinamide) stretch at 1635 - 1640 cm-1
and a medium intensity CO (β-diketonate) stretch at 1600 - 1605 cm-1. There are
also several bands of varying intensities in the region 500 - 1600 cm-1. The
disappearance of the broad NH stretches (3250 - 3400 cm-1) is characteristic of
complex formation with the picolinamide ligand adopting the N,N coordination
mode. The CO stretches for the picolinamide and β-diketonate ligand are shifted to 
a lower wavenumber in the complex compared to the free ligand as is expected
due to the weakening of the CO bond following coordination of the ligand to the
metal centre.39, 40
The UV/vis spectrum of complex 4.3 is shown in Figure 4.6. The spectrum shows an
intense ligand based absorbance (π-π*) at around 200 nm with three less intense 
charge-transfer bounds at around 265, 290 and 360 nm. No d-d transitions are seen
in the 400 - 800 nm region.39, 40
Figure 4.6: UV/vis spectrum of complex 4.3
4.2.2 X-Ray crystallography of cobalt picolinamide β-diketonate complexes 
Complexes crystallised in either a monoclinic (4.3, 4.4, 4.6, 4.8, 4.9), triclinic (4.2) or
tetragonal (4.1) cell and structural solutions were performed in the P 21/n (4.3),
P 21/c (4.4, 4.6), P 1 (4.2), C c (4.8, 4.9) or I 41cd (4.1) space group with half (4.1),
one (4.2, 4.4, 4.6, 4.8, 4.9) or two (4.3) molecules in the asymmetric unit (Figure
4.7). Selected bond lengths and angles are stated in Table 4.2 and Table 4.3
respectively.
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Figure 4.7: Molecular structures of complexes 4.1 - 4.9. Displacement ellipsoids are
at the 50 % probability level. Hydrogen atoms and co-crystallising solvents are
omitted for clarity. For clarity, only complexes 4.1 and 4.3 are labelled, the
remaining complexes follow the same atom numbering scheme
Table 4.2: Selected bond lengths for complexes 4.1 - 4.9. a = symmetry generated
Distance / Å
Co(1)-N(1) Co(1)-N(2) Co(1)-N(3) Co(1)-N(4) Co(1)-O(1) Co(1)-O(2)
4.1 1.939(5) 1.939(5)a 1.938(6) 1.938(6)a 1.903(5) 1.903(5)a
4.2 1.944(15) 1.898(17) 1.947(14) 1.942(12) 1.909(15) 1.908(9)
4.3 1.923(4) 1.928(4) 1.926(4) 1.941(4) 1.903(3) 1.908(3)
4.4 1.9340(16) 1.9353(16) 1.9322(16) 1.9330(17) 1.9030(14) 1.9043(14)
4.6 1.9311(17) 1.9381(17) 1.9291(17) 1.9317(18) 1.9041(15) 1.9063(15)
4.8 1.928(6) 1.943(6) 1.937(6) 1.947(5) 1.906(5) 1.922(5)
4.9 1.958(14) 1.910(14) 1.947(11) 1.924(12) 1.873(11) 1.947(10)
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Table 4.3: Selected bond angles for complexes 4.1 - 4.9
Angle / °
N(1)-Co(1)-N(3) N(3)-Co(1)-O(2) O(1)-Co(1)-O(2)
4.1 83.5(2) 85.67(19) 95.0(3)
4.2 83.8(7) 87.3(5) 93.6(5)
4.3 83.23(15) 87.56(15) 94.41(14)
4.4 82.55(7) 86.16(6) 94.35(6)
4.6 82.61(7) 86.74(7) 93.97(6)
4.8 82.6(2) 89.5(2) 93.9(2)
4.9 82.5(5) 90.7(5) 95.7(5)
All complexes show a distorted octahedral geometry around the central cobalt
atom with the relevant bond angles in the range 82.5 - 95.7°, deviating from the
expected 90° (Table 4.3). This distortion can be ascribed to the restrictions imposed
by the bidentate picolinamide and β-diketonate ligand. The cobalt-pyridyl nitrogen 
bond lengths are in the range 1.94 - 1.96 Å, the cobalt-amide nitrogen bond lengths
are in the range 1.92 - 1.95 Å and the cobalt-oxygen bond lengths in the range
1.87 - 1.95 Å. This is consistent with related low spin Co(III) compounds which have
reported Co-Npyridyl bond lengths of 1.91 - 1.96 Å and Co-Namide bond lengths of
1.90 - 1.99 Å.41-44 These are also shorter than in related Co(II) compounds which
have reported Co-Npyridyl bond lengths of 2.07 - 2.15 Å.45-47 The Co-Odiketonate bond
lengths are also consistent with literature values which are in the range
1.84 - 1.91 Å.48-50 There is evidence from the crystal structure for long range
intermolecular hydrogen bonds, with bond distances in the range 3.12 - 3.38 Å.
These hydrogen bonds tend to be either between the amide oxygen and a
neighbouring pyridyl or aryl CH group or between the trifluoromethyl group and a
neighbouring aryl CH group (Figure 4.8).
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Figure 4.8: Intermolecular hydrogen bonding interactions between complexes
4.3 Cobalt bis-picolinamide ferrocenyl β-diketonate complexes 
The cobalt picolinamide complexes synthesised within this section are shown in
Figure 4.9. Complexes were synthesised via the complexation reaction of
picolinamide and β-diketonate ligands with cobalt carbonate in the presence of 
hydrogen peroxide, similar to the synthesis in the previous section (Scheme 4.3).
N
N
H
O R'
O O
+ + CoCO3
CF3
CF3
H2O2
EtOH / H2O
Co
N
N O
O
N
N
Fe
Scheme 4.3: Synthetic route for cobalt picolinamide ferrocenyl β-diketonate 
complexes in this section
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Figure 4.9: Cobalt picolinamide complexes synthesised within this section
As in the previous synthesis, cobalt is oxidised from Co(II) to Co(III) which then
permits the complexation of three ligands to the metal centre. The β-diketonate 
ligand coordinates through the two keto oxygen atoms and the two picolinamide
ligands coordinate through the pyridyl nitrogen and amide nitrogen. This
N,N coordination of the picolinamide ligands is ensured with the use of an electron
withdrawing group substituent on the aryl ring and the use of a 2:1 ethanol-water
mixture as the reaction solvent.
The formation of the desired complex with two picolinamide ligands and one
ferrocenyl β-diketonate ligand is permitted through stoichiometric control of the 
reaction. As for the previous synthesis, a number of side products are also formed,
however these are more easily separated resulting in improved yields compared to
the cobalt(III) picolinamide β-diketonate complexes. The two major side products 
formed are the cobalt(III) tris-picolinamide complex and the cobalt(III) picolinamide
ferrocenyl β-diketonate complex with one picolinamide ligand and two ferrocenyl 
β-diketonate ligands, as shown by TLC and mass spectrometry. 
4.3.1 Characterisation of cobalt picolinamide ferrocenyl β-diketonate 
complexes
The cobalt(III) picolinamide ferrocenyl β-diketonate complexes are low spin d6 and
thus diamagnetic. The 1H NMR spectra of these complexes are all very similar to
each other and to the cobalt complexes containing the non-ferrocenyl β-diketonate 
ligand. The pyridyl protons (8.34 - 7.13 ppm) typically have higher chemical shifts
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than the aryl protons of both the picolinamide and β-diketonate ligands  
(7.85 - 6.99 ppm), with the methine proton in the region 6.29 - 5.61 ppm and the
ferrocenyl protons in the region 4.99 - 2.10 ppm. As for the equivalent
non-ferrocenyl complexes, all pyridyl and aryl protons from both ligand types are
shifted upfield in the complex compared to in the free ligand; the methine proton
and ferrocenyl protons also undergo an upfield shift. Examples of the
1H NMR chemical shifts for complex 4.16 compared to the ligands are shown in
Figure 4.10 and Table 4.4. Two distinct or overlapping sets of signals for the
picolinamide protons are seen in the final complex as the two ligands are
inequivalent due to the slightly distorted octahedral geometry of the complex. The
ferrocenyl protons (substituted Cp ring) also split from two to four peaks showing
the breaking of symmetry and inequivalence of these protons upon complexation.
Figure 4.10: 1H NMR spectra of complex 4.16 and the constituent picolinamide and
ferrocenyl β-diketonate ligands
Complex
Picolinamide
β-diketonate 
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Table 4.4: 1H NMR chemical shifts for complex 4.16 and the constituent
picolinamide and β-diketonate ligands
Proton
environment
1H NMR chemical shift / ppm
Ligand Complex
Pyridyl 8.66
8.30
7.97
7.48
8.28 and 8.18
7.98 and 7.91
7.83
7.23 and 7.16
Aryl
(picolinamide)
8.32
7.68
7.57
7.53
Aryl
(β-diketonate) 
7.56
7.12
7.32
6.99
Methine 6.72 6.17
Ferrocenyl 4.97
4.55
4.13
4.99 and 4.76
4.67 and 4.59
3.77
The IR spectra of complexes 4.10 - 4.19 all display a weak aryl CH stretch at
3050 - 3090 cm-1, a medium intensity CO (picolinamide) stretch at 1635 - 1640 cm-1
and a medium intensity CO (ferrocenyl β-diketonate) stretch at 1600 - 1605 cm-1.
There are also several bands of varying intensities in the region 500 - 1600 cm-1.
The IR spectra of these complexes are similar to the equivalent non-ferrocenyl
complexes (4.1 - 4.9). The disappearance of the broad NH stretches
(3250 - 3400 cm-1) is characteristic of complex formation with the picolinamide
ligand adopting the N,N coordination mode. The CO stretches of both the
picolinamide and ferrocenyl β-diketonate ligand are shifted to a lower 
wavenumber in the complex compared to the free ligand due to the weakening of
the CO bond following coordination of the ligand to the metal centre.16, 51
The UV/vis spectrum of complex 4.13 is shown in Figure 4.11. The spectrum shows
an intense ligand based absorbance (π-π*) at around 200 nm with three less 
intense charge-transfer bounds at around 265, 300 and 370 nm and finally a weak
d-d transition at around 515 nm. The absorbance bands are similar to in the
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equivalent non-ferrocenyl complex 4.3 (Figure 4.6) aside from the d-d transition.
Complex 4.3 shows no d-d transition whereas complex 4.13 shows a clear
absorbance band, therefore this d-d transition can be assigned to the iron(II) of the
ferrocenyl β-diketonate rather than the central cobalt(III) ion.16, 51
Figure 4.11: UV/vis spectrum of complex 4.13
4.3.2 X-Ray crystallography of cobalt picolinamide ferrocenyl β-diketonate 
complexes
Complexes crystallised in either a monoclinic (4.13, 4.14, 4.15, 4.16, 4.18) or
orthorhombic (4.11, 4.17, 4.19) cell and structural solutions were performed in the
P 21 (4.16), P 21/c (4.13, 4.18), P 2/c (4.14), P na21 (4.11, 4.17, 4.19) or I a (4.15)
space group with half (4.14), one (4.11, 4.14, 4.17, 4.18, 4.19) or two (4.13, 4.16)
molecules in the asymmetric unit (Figure 4.12). Selected bond lengths and angles
are stated in Table 4.5 and Table 4.6 respectively.
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Figure 4.12: Molecular structures of complexes 4.11 - 4.19. Displacement ellipsoids
are at the 50 % probability level. Hydrogen atoms and co-crystallising solvents
are omitted for clarity. For clarity, only complex 4.11 is labelled, the
remaining complexes follow the same atom numbering scheme
Table 4.5: Selected bond lengths for complexes 4.11 - 4.19. a = symmetry
generated
Distance / Å
Co(1)-N(1) Co(1)-N(2) Co(1)-N(3) Co(1)-N(4) Co(1)-O(1) Co(1)-O(2)
4.11 1.916(3) 1.920(3) 1.932(4) 1.922(4) 1.917(3) 1.914(3)
4.13 1.919(7) 1.935(7) 1.923(7) 1.928(6) 1.904(5) 1.893(6)
4.14 1.938(7) 1.933(8) 1.938(7)a 1.933(8)a 1.896(7) 1.896(7)a
4.15 1.935(7) 1.936(7) 1.939(7) 1.925(7) 1.878(6) 1.890(5)
4.16 1.92(3) 1.92(3) 1.91(3) 1.90(3) 1.90(3) 1.91(2)
4.17 1.927(6) 1.915(6) 1.931(6) 1.944(5) 1.917(5) 1.901(5)
4.18 1.925(2) 1.930(3) 1.919(2) 1.933(3) 1.886(2) 1.900(2)
4.19 1.928(8) 1.906(9) 1.933(8) 1.938(9) 1.881(8) 1.909(8)
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Table 4.6: Selected bond angles for complexes 4.11 - 4.19
Angle / °
N(1)-Co(1)-N(2) N(2)-Co(1)-O(1) O(1)-Co(1)-O(2)
4.11 83.13(15) 87.56(16) 94.95(14)
4.13 83.2(3) 87.4(3) 95.1(2)
4.14 83.7(3) 86.6(3) 95.8(4)
4.15 83.2(3) 87.0(3) 94.9(2)
4.16 82.8(12) 88.3(13) 92.2(12)
4.17 82.5(2) 87.5(2) 94.3(2)
4.18 82.77(11) 85.89(10) 94.89(10)
4.19 83.6(4) 86.6(4) 95.4(3)
All complexes show a distorted octahedral geometry around the central cobalt
atom with the relevant bond angles in the range 82.5 - 95.8°, deviating from the
expected 90° (Table 4.6). This distortion can be ascribed to the restrictions imposed
by the bidentate picolinamide and β-diketonate ligand. The bond lengths are 
similar to those observed with the previous cobalt picolinamide β-diketonate 
complexes (4.1 - 4.9). The cobalt-pyridyl nitrogen bond lengths are in the range
1.90 - 1.93 Å, the cobalt-amide nitrogen bond lengths are in the range 1.90 - 1.94 Å
and the cobalt-oxygen bond lengths in the range 1.87 - 1.92 Å. The Co-Odiketonate
bond lengths are consistent with literature values for complexes containing
ferrocenyl β-diketonate ligands, with values in the range 1.84 - 1.91 Å.48-50 There is
evidence from the crystal structure for long range intermolecular hydrogen bonds,
with bond distances in the range 3.06 - 3.23 Å. These hydrogen bonds tend to be
either between the amide oxygen and a neighbouring pyridyl or aryl CH group or
between the trifluoromethyl group and a neighbouring aryl CH group (Figure 4.13).
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Figure 4.13: Intermolecular hydrogen bonding interactions between complexes
4.4 Conclusions
A series of novel cobalt(III) picolinamide β-diketonate complexes have been 
synthesised, with two picolinamide ligands (with N,N coordination) and a
β-diketonate ligand. Within this series, two types of β-diketonate ligand have been 
utilised: aryl β-diketonate and ferrocenyl β-diketonate ligands. The synthesis is 
controlled stoichiometrically, however a number of side products limits the yields
obtained. Complexes show a distorted octahedral structure with bond lengths in
keeping with a cobalt(III) species. No intramolecular bonds are observed, however
intermolecular hydrogen bonds are observed between neighbouring molecules.
The efficacy of the complexes as anti-cancer, anti-bacterial and anti-fungal agents
will be discussed in Chapter 5.
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5. Biological investigation
Drug discovery is the process by which new potential drugs are identified. Large
chemical libraries of small molecules, natural products etc., are screened against a
known biological target to identify lead molecules with the desired therapeutic
effect. Further development of lead compounds is then required to optimise effects
such as potency, selectivity and stability. Following lead optimisation, these drugs
may progress to preclinical trials which investigate aspects such as the
pharmacokinetics, pharmacodynamics and toxicity. A successful preclinical study
may lead to the drug entering clinical trials. The majority of drugs which fail in clinical
trials are either ineffective (or no more effective than current treatments) or are
unsafe. Therefore the non-clinical phases of drug discovery and lead validation are
crucial. A number of techniques are used in the screening and validation process
including high throughput screening of compounds, secondary in vitro investigation
into mechanisms of action and selectivity followed by in vivo analysis examining
efficacy and toxicity.1-4
5.1 Cytotoxicity
The first stage of anti-cancer drug discovery is in vitro cytotoxicity screening. Cell
based assays are used to measure cytotoxicity and are commonly used to screen
compounds to determine their effect on target cells and thus identify any lead
compounds.3 Cytotoxicity assays determine the IC50 value of a compound, which is
defined as the concentration of drug required to inhibit 50 % of cell proliferation. A
variety of methods are used to determine the number of viable eukaryotic cells, one
being tetrazolium reduction assays which are widely used due to their utility in high
throughput screening.5
The MTT assay is a colorimetric tetrazolium reduction assay, developed by
Mossman,6 and was the first cell viability assay suitable for high throughput
screening and is widely used. Viable, metabolically active cells reduce yellow MTT
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) to purple formazan
which is monitored spectrophotometrically (Figure 5.1).5 Reduction of tetrazolium
dyes such as MTT is dependent on NAD(P)H dependent reductases within the cell,
with the concurrent oxidation of NAD(P)H to NAD(P)+. The specific reductase
enzymes were originally thought to be specific to the mitochondria, but now these
enzymes are thought to be mainly cytosolic. Formazan accumulates within the cell
as in insoluble precipitate and is deposited near the cell surface.5, 7
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Figure 5.1: Reduction of MTT to formazan
The three series of cobalt picolinamide complexes described in Chapter 2, Chapter
3 and Chapter 4 were screened for cytotoxicity against two cancerous cell lines and
a non-cancerous cell line: MIA PaCa-2 (human pancreatic carcinoma), BE (human
colon carcinoma) and ARPE-19 (human retinal pigment epithelial cells) by the author
and Samantha Shepherd under the supervision of Professor Roger Phillips at The
University of Huddersfield. Initially, complexes were screened against all three cell
lines, but as similar trends were noticed across the different cell lines it was decided
to screen the remainder of the complexes against Mia PaCa-2 cells only. The
complexes, at a variety of concentrations, were incubated with the cell lines at 37 °C
for five days. All cytotoxicity assays were performed in triplicate. Inhibition of cell
survival was determined by measuring absorbance at 540 nm following the addition
of MTT and incubation at 37 °C for a further three hours. IC50 values are determined
from graphs of percentage cell survival versus drug concentration.
Cytotoxicity screening results for cobalt(III) tris-picolinamide complexes, cobalt(II)
bis-picolinamide complexes and cobalt(III) mixed ligand complexes are summarised
in Table 5.1, Table 5.2 and Table 5.3 respectively. Active complexes are highlighted
in green (IC50 < 20 μM) and partially active complexes are highlighted in orange  
(IC50 = 20 - 50 μM). Results for the active and partially active complexes only are 
summarised in Figure 5.2. Complexes 4.1, 4.18 and 4.19 were insufficiently soluble
in DMSO and cell culture medium used for the MTT assay and therefore no results
could be obtained.
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Table 5.1: IC50 values of cobalt(III) tris-picolinamide complexes
Complex IC50 / μM 
MIA PaCa-2 BE ARPE-19
cisplatin 2.84 ± 2.05 0.66 ± 0.33 6.41 ± 0.95
2.1a > 100 > 100 > 100
2.2 > 100 > 100 > 100
2.3 > 100 > 100 > 100
2.4 > 100 > 100 > 100
2.5 > 100 > 100 > 100
2.6 > 97.5 > 100 > 100
2.7 > 86.4 > 100 > 65.5
2.8 > 100 > 93.2 > 100
2.9 > 68.5 > 100 > 100
2.10 37.4 ± 18.9 > 74.9 > 65.4
2.11 > 62.3 > 100 > 100
2.12 > 100 > 100 > 100
2.13 17.53 ± 13.33 3.77 ± 1.98 7.57 ± 3.92
2.14a > 100 > 100 > 100
2.15a > 100 > 100 > 100
2.16a > 98.1 > 100 > 100
2.17a > 100 - -
2.18a > 100 - -
2.1b > 67.0 > 100 > 82.4
2.14b 36.73 ± 13.97 52.61 ± 6.99 29.12 ± 14.25
2.15b 55.82 ± 1.63 37.45 ± 13.04 38.67 ± 19.86
2.16b 7.38 ± 2.17 19.31 ± 1.38 6.53 ± 4.27
2.17b > 100 - -
2.18b > 100 - -
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Table 5.2: IC50 values of cobalt(II) bis-picolinamide complexes
Complex IC50 / μM 
MIA PaCa-2 BE ARPE-19
3.1 > 100 - -
3.2 > 100 - -
3.3 > 100 - -
3.4 > 100 - -
3.5 > 100 - -
3.6 > 100 - -
3.7 > 100 - -
3.8 > 100 - -
3.9 > 100 - -
3.10 > 100 - -
Figure 5.2: IC50 values of active and partially active cobalt picolinamide complexes
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Table 5.3: IC50 values of cobalt(III) mixed ligand complexes
Complex IC50 / μM 
MIA PaCa-2 BE ARPE-19
4.2 > 100 - -
4.3 > 100 - -
4.4 > 100 - -
4.5 > 100 - -
4.6 > 100 - -
4.7 > 100 - -
4.8 > 100 - -
4.9 > 100 - -
4.10 32.9 ± 6.8 - -
4.11 > 100
4.12 > 100 - -
4.13 > 100 - -
4.14 > 100 - -
4.15 > 100 - -
4.16 > 100 - -
4.17 > 100 - -
A number of complexes have cytotoxic effects against the selected cell lines,
however the majority of complexes display no cytotoxic effects. This in itself is an
interesting observation as cobalt ions and especially cobalt(II) chloride are known to
be cytotoxic through induction of DNA damage and oxidative stress leading to
apoptosis.8-11 Three series of cobalt picolinamide complexes have been screened;
five cobalt(III) tris-picolinamide complexes, no cobalt(II) bis-picolinamide complexes
and one cobalt(III) mixed ligand complex show activity or partial activity. All of these
complexes, with one exception, display activity against all three of the different cell
lines; the implication being that complexes which are active have broad spectrum
cytotoxicity against a range of different cell types and as such are not selective for
cancerous cells over non-cancerous cells.
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Within the series of cobalt tris-picolinamide complexes (2.1a - 2.18b), complexes
2.13 and 2.16b were active and complexes 2.10, 2.14b and 2.15b were partially
active, with potencies in the micromolar range. The general trend is that the
complexes with N,O coordination are more active than the analogous complexes
with N,N coordination (Figure 5.3). For example, complex 2.16b with N,O
coordination is active against all three cell lines (IC50 = 7.38 μM against MIA PaCa-2 
cells) but its N,N isomer complex 2.16a is completely inactive (IC50 > 98 μM against 
MIA PaCa-2 cells). The cobalt tris-picolinamide complexes represent true
coordination isomers with no change in molecular formula, molecular weight, charge
or metal oxidation state and therefore the differences in cytotoxicity derive from the
differences in ligand coordination mode. This helps provide insight into the
underlying mechanisms of activity for these type of complexes as previously any
metal picolinamide complexes with N,O coordination have been associated with
changes in molecular formula, molecular weight and charge due to the different
ways in which the amide oxygen can coordinate to the metal centre (either in a
neutral or anionic manner). The reason for this stark difference in potency between
coordination isomers is unknown, possible reasons include differences in stability,
hydrolysis rates, target binding etc.
This work represents the first example of metal picolinamide complexes where N,O
coordination is associated with improved activity compared to N,N coordination. In
fact, this is in contrast to the trend noted within a series ruthenium and osmium
p-cymene picolinamide complexes.12, 13 In these complexes N,N coordination was
associated with potent activity, rapid hydrolysis and binding to guanine residues,
whereas N,O coordination was associated with a lack of toxicity, slow hydrolysis and
no binding to guanine residues.12, 13 However, in these series of complexes the amide
oxygen acts as a neutral donor resulting in a monocationic complex, this differs from
the cobalt tris-picolinamide series in this work where amide oxygen acts as an
anionic donor resulting in a neutral complex. It is therefore unclear whether the
effects described previously are due to the change in ligand coordination mode, the
change in charge of the complex or a combination of both.
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Figure 5.3: IC50 values of 2.14b, 2.15b and 2.16b with their analogous inactive
isomers 2.14a, 2.15a and 2.16a
The two most active complexes, designated as the lead complexes, are both doubly
substituted at the meta position on the aryl ring with trifluoromethyl group (2.13) or
a methyl group (2.16b) (Figure 5.4). The fact that these two similar molecules are
the most active suggests that perhaps molecular shape plays an important role,
where these two molecules are able to more specifically bind a target molecule;
however, this would not explain why complex 2.16a, which also has a similar shape,
is inactive.
Figure 5.4: Two most active (lead) complexes
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In contrast to the cobalt(III) tris-picolinamide complexes, all of the cobalt(II)
bis-picolinamide complexes (3.1 - 3.10) were inactive. This implies that either the
cobalt oxidation state or presence of three picolinamide ligands is important in
relation to activity. It is thought that the shape of the molecule may be important for
activity as the majority of intracellular targets are proteins which have specific
structures to provides specificity to molecular interactions and reactions.14, 15
Therefore the presence of only two picolinamide ligands may explain the non-toxic
nature of the cobalt bis-picolinamide complexes as they may not be able to bind to
the specific target due to the differences in shape.
The cobalt(III) mixed ligand complexes contain two 3,5-di(trifluoromethyl)
picolinamide ligands (1.14) with the third ligand a β-diketonate or ferrocenyl  
β-diketonate ligand and are thus analogous to lead complex 2.13. All of these
complexes were inactive except for complex 4.10, which was partially active but was
less active than complex 2.13. This implies that having the three picolinamide ligands
around the central cobalt(III) ion is important for activity as substitution of just one
3,5-di(trifluoromethyl) picolinamide ligand for a β-diketonate ligand led to 
inactivation of the complex. This supports the suggestion that the shape of the
molecule is important for activity. The partially active complex 4.10 contains a CHF2
group as the ferrocenyl β-diketonate substituent. Complexes 4.11 and 4.12, with a
trifluoromethyl or methyl group respectively in the same position as the CHF2 group
in complex 4.10, are inactive which suggests that for this molecule electronics rather
than sterics plays a role in activity. The lack of activity for complex 4.11 is surprising
as the ferrocenyl β-diketonate ligand which constitutes part of this complex is 
cytotoxic as the free ligand.16 Other than this example, there is no improvement in
activity with addition of the ferrocene group which is different to several examples
in organometallic chemistry where addition of ferrocene improves drug activity.17, 18
Cobalt picolinamide complexes are quite sparse within the literature and only a few
have been tested for their anti-cancer potential. Only a series of cobalt(III)
heterobimetallic complexes (with cadmium, mercury or zinc) containing tridentate
picolinamide ligands have been screened against cancerous U87 (human
glioblastoma) and non-cancerous HEK (human embryonic kidney) cell lines.19 These
complexes displayed moderate activity, in the micromolar or millimolar range,
against both the cancerous and non-cancerous cell lines. These cytotoxicities are less
potent than for the cobalt picolinamide complexes investigated in this chapter,
however the trend of broad spectrum toxicity rather than cancer cell selectivity is
consistent with that observed for these cobalt picolinamide complexes.
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5.2 Hypoxia studies
The ability to preserve oxygen (O2) homeostasis is essential for cell survival. Hypoxia
defines an environment of reduced oxygen concentration. Mammalian cells typically
exist at 2 - 9 % oxygen (normoxia) with hypoxia defined as ≤ 2 % oxygen and severe 
hypoxia (anoxia) as ≤ 0.02 % oxygen.20 Hypoxia is present in many diverse
pathologies such as infarction, ischaemia, stroke and cancer.
Tumours which are larger than 1 mm3 contain hypoxic regions due to insufficient
vascularisation of the rapidly growing tumour. Cancer cells are able to survive their
hypoxic state through activation of hypoxia-inducible factor-1 (HIF-1). HIF-1 is a
heterodimeric transcription factor consisting of an α and β-subunit. In normoxia, the 
α-subunits are hydroxylated, allowing ubiquitination and degradation by the 
proteasome. In hypoxia, the specific hydroxylase enzyme is inhibited and thus the
α-subunits are not degraded.20-24 The intact HIF-1 can bind to the hypoxia responsive
element (HRE) and upregulate transcription of a number of genes involved in cell
survival such as genes encoding for proteins involved in glycolysis, angiogenesis and
the inflammatory response.23, 25, 26 HIF-1 is implicated in a number of cancers and
there is also a strong correlation between HIF-1 overexpression and the tumour
grade and vascularisation.22, 27
Tumour hypoxia is a strong prognostic factor in many cancers; extensive hypoxia
results in reduced chemotherapeutic drug delivery, intrinsic resistance to
radiotherapy, neovascularisation, greater metastatic capacity and increased
apoptotic resistance.20, 22, 28 Therapies which destroy normoxic but not hypoxic
cancer cells are more likely to result in recurrence. The hypoxic environment of these
cells may also lead to upregulation of genes involved in drug resistance and
promotion of cell growth.29, 30 Hypoxic cancer cells also present a more reducing
environment, thought to help stabilise HIF-α, compared to normoxic non-cancerous 
cells, providing the potential for selective targeting of hypoxic cancer cells.
A novel approach to overcome the resistance of hypoxic cells to cancer therapies is
to employ bio-reductive prodrugs. Metal complexes are well suited to such
strategies due to the variations in coordination number, geometry and accessible
oxidation states.31 Cobalt(III) prodrugs have already been discussed in Chapter 1.
These tend to consist of a central cobalt(III) ion with one known cytotoxic ligand
which is released upon reduction to cobalt(II). Other transition metal prodrugs under
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investigation include platinum(IV),32 ruthenium(III),33, 34 copper(II)35 and iron(III)36
prodrugs.
Cobalt(III) tris-picolinamide complexes were screened for cytotoxicity under hypoxic
conditions against MIA PaCa-2 cells by the author and Samantha Shepherd under the
supervision of Professor Roger Phillips at The University of Huddersfield. The MTT
assay was performed as previously described (Chapter 5.1) except all cell culturing
and cell incubation was performed in an environment of 0.1 % oxygen. The
cytotoxicity results in normoxia (21 % oxygen) and hypoxia are summarised in Table
5.4. Results for complexes which are active or partially active are also displayed in
Figure 5.5.
Figure 5.5: IC50 values of active and partially active complexes under normoxic and
hypoxic conditions
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Table 5.4: IC50 values of cobalt(III) tris-picolinamide complexes under normoxic and
hypoxic conditions
Complex IC50 / μM 
Normoxia Hypoxia
cisplatin 2.84 ± 2.05 > 100
2.1a > 100 > 100
2.2 > 100 > 100
2.3 > 100 > 100
2.4 > 100 > 100
2.5 > 100 > 78.3
2.6 > 97.5 > 100
2.7 > 86.4 > 100
2.8 > 100 > 100
2.9 > 68.5 > 95.3
2.10 37.4 ± 18.9 > 100
2.11 > 62.3 > 100
2.12 > 100 > 100
2.13 17.53 ± 13.33 > 100
2.14a > 100 > 100
2.15a > 100 > 100
2.16a > 98.1 > 100
2.1b > 67.0 > 100
2.14b 36.73 ± 13.97 74.25 ± 3.68
2.15b 55.82 ± 1.63 > 100
2.16b 7.38 ± 2.17 29.68 ± 2.18
All complexes were less toxic to MIA PaCa-2 cells under hypoxic conditions compared
to normoxic conditions. Three of the five active or partially active complexes, 2.10,
2.13 and 2.15b, became completely inactive (IC50 > 100 μM) in hypoxia. Complex 
2.16b remained at least partially active (IC50 = 29.68 μM) even under the low oxygen 
conditions. Cells under hypoxic conditions have a more reducing intracellular
Biological investigation Chapter 5
139
environment than when under normoxic conditions and thus there is the potential
for the intracellular bioreduction of cobalt(III) to cobalt(II) with the concurrent
release of one ligand. If the cobalt(III) tris-picolinamide complexes are being reduced
to cobalt(II) bis-picolinamide complexes, this explains the decrease in potency. All of
the synthesised cobalt(II) bis-picolinamide complexes were non-toxic, therefore
reduction of the cobalt(III) complexes to similar species would be accompanied by a
reduction in the cytotoxicity. A number of cobalt(III) prodrugs utilise this reduction
to target cancer cells, however these all tend to contain a known cytotoxic ligand
which is released upon reduction to cobalt(II).37-39 Interestingly, complex 2.16b
retains activity even in hypoxic conditions despite the fact that it does not contain a
ligand which is known to be cytotoxic. This perhaps implies that this compound is
not fully intracellularly reduced from cobalt(III) to cobalt(II), due to a reduction
potential outside of the biological range, thus retaining some of the active complex.
5.3 Cell viability and cell cycle analysis
Once a lead compound has been identified, the next step in the drug development
process involves elucidating the mechanism of action.3, 4 Anti-cancer drugs may act
through induction of cancer cell death (cytotoxic drugs) e.g. cisplatin, or through
inhibition of cancer cell proliferation (cytostatic drugs) e.g. tamoxifen. Biological
assays coupled to cell imaging techniques, such as flow cytometry, can discriminate
between these two different types of effect. Following determination of cytotoxic or
cytostatic action, further investigations include apoptosis assays or cell cycle
analysis.5, 40, 41
Cytostatic drugs inhibit the cell cycle to halt cell proliferation. The cell cycle is the
sequence of events that occur during the lifetime of a cell leading to cell division. In
eukaryotic cells, the cell cycle is divided into four phases: mitosis (M phase), gap-1
(G1 phase), synthesis (S phase) and gap-2 (G2 phase) (Figure 5.6). Normal
non-dividing cells are quiescent (G0 phase); when cells enter the cell cycle they enter
in G1 phase, the growth phase when the cell increases in size, followed by S phase
when DNA is replicated. This is followed by G2 phase, a further short period of cell
growth, and finally M phase when mitosis occurs, separating the chromosomes and
dividing the cell to produce two daughter cells. The cell cycle is very tightly regulated
by a number of different pathways which controls progression through the cell cycle,
these are frequently disrupted during the oncogenic transformation of a cell.42-46
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Figure 5.6: The eukaryotic cell cycle47
Different drugs inhibit different phases of the cell cycle but tend to operate during S
phase, M phase or all phases. Alkylating agents, e.g. cisplatin and other platinum
drugs, nitrogen mustards and nitrosoureas, directly damage DNA and operate at all
phases of the cell cycle. Cytotoxic antibiotics, e.g doxorubicin, mitomycin-C and
bleomycin, also directly alter DNA and operate at all phases of the cell cycle.
Anti-metabolites, e.g. 5-fluorouracil, 6-mercaptopurine and methotrexate,
substitute for normal metabolites to interfere with DNA replication and thus operate
at S phase. Topoisomerase inhibitors, e.g. topotecan, etoposide and mitoxantrone,
inhibit enzymes involved in DNA unwinding for replication and thus operate at S
phase. Mitotic inhibitors, e.g. taxanes, vincristine and vinblastine, prevent formation
of the mitotic spindle often through binding to tubulin subunits and therefore act
during M phase.44, 45, 48, 49
The two lead complexes (2.13 and 2.16b) were tested for their effects on cell viability
and the cell cycle of MIA PaCa-2 cells by the author and Samantha Shepherd under
the supervision of Professor Roger Phillips at The University of Huddersfield. The
complexes, at a variety of concentrations, were incubated with MIA PaCa-2 cells at
37 °C for five days. For cell viability assay, single cell suspensions were prepared and
stained with acridine orange and 4’,6-diamidino-2-phenylindole (DAPI) to enable
counting of the entire cell population and non-viable cells by an automated cell
counter. For cell cycle analysis, single cell suspensions were washed with
phosphate-buffered saline (PBS), treated with lysis buffer and DAPI and cellular
fluorescence quantified using an image cytometer. Markers of cellular content and
DNA content are used to demarcate cells in different stages of the cell cycle.50
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The cell viability results for complexes 2.13 and 2.16b are shown in Table 5.5 and
Table 5.6 and in Figure 5.7. The cell cycle analyses for complexes 2.13 and 2.16b are
shown in Table 5.7 and Figure 5.8.
Table 5.5: Cell viability summary for complex 2.13
Concentration / μM 
0 5 10 20
Total cells 3.7 × 106 3.9 × 106 3.6 × 106 2.54 × 106
Cell viability / % 81.8 79.5 85.4 85
Cell diameter / μm 18.3 ± 11.3 17.5 ± 10.8 16.7 ± 10.7 17.8 ± 11.9
Aggregates of > 5 cells 65 61 59 54
Table 5.6: Cell viability summary for complex 2.16b
Concentration / μM 
0 5 10 20
Total cells 3.7 × 106 3.82 × 106 3.6 × 106 2.63 × 106
Cell viability / % 81.8 76 76 86
Cell diameter / μm 18.3 ± 11.3 16.5 ± 10.1 17.2 ± 10.8 17.6 ± 10.8
Aggregates of > 5 cells 65 57 51 54
For both complexes there is a reduction in the number of total cells but only at
concentrations above the respective IC50 values (20 μM) and there is no reduction in 
the percentage of viable cells. There are also no readily observable changes in cell
morphology, with cell shape and structure remaining consistent throughout (Figure
5.7). Cytotoxic drugs cause cell death and thus decrease the number of total cells
and the percentage of viable cells. Cytostatic drugs halt cell proliferation and thus do
not change the total number of cells (over a short time frame) or the percentage of
viable cells. These results suggest that complexes 2.13 and 2.16b act as cytostatic
agents through interruption of the cell cycle.
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Complex 2.13 Complex 2.16b
a)
b)
c)
d)
Figure 5.7: Representative optical microscopy images (× 2) of MIA PaCa-2 cells in
the presence of complexes 2.13 and 2.16b at various concentrations a) 0 μM 
b) 5 μM c) 10 μM d) 20 μM 
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Table 5.7: Cell cycle analysis for complexes 2.13 and 2.16b
Cell cycle
phase
Cell population / %
Concentration of complex
2.13 / μM 
Concentration of complex
2.16b / μM 
0 5 10 20 0 5 10 20
Sub G1 10 11 10 10.5 10 9 8 11.2
G1 83 83.4 83.3 74.2 83 84.3 85.3 76
S 4 3.6 3.4 6.3 4 3.4 3.4 6.3
M 3 2 3.3 9 3 3.3 3.3 6.5
Figure 5.8: Graphical representation of cell cycle analysis for complexes 2.13 and
2.16b
Cell cycle analysis shows that at high concentrations of both complexes (20 μM) 
there is a small increase in the population of cells in S phase and a larger increase in
the percentage of cells in M phase. Even small changes in the percentage of cells in
these phases is significant as the majority of cells are in G1 phase. The percentage of
cells in M phase has tripled (3 % to 9 %) for complex 2.13 and doubled (3 % to 6.5 %)
for complex 2.16b. This is coupled with a reduction of cells which are in G1 phase.
This demonstrates that both complexes initiate a level of cell cycle arrest during M
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phase. M phase is divided into two processes: mitosis and cytokinesis. In mitosis, the
replicated chromosomes condense and attach to mitotic spindle fibres which pull
each set of chromosomes to different sides of the cell. This is immediately followed
by cytokinesis in which a contractile ring forms and contracts inwardly to divide the
cell (with its constituent chromosomes, organelles, cytoplasm and cell membrane)
into two to produce two identical daughter cells.14, 42 There are two classes of
anti-cancer drugs which target M phase: taxanes and vinca alkaloids, which are both
natural product derivatives. These M phase inhibitors act through disruption of
mitotic spindle formation through interference with tubulin polymerisation.44, 48
There are a few examples of inorganic complexes, mainly ruthenium arenes or
ferrocenyl analogues of known inhibitors, which cause M phase arrest either through
interruption of signalling pathways or inhibition of tubulin polymerisation.51-54
As there is only a low proportion of cells in M phase at a given time point any changes
in this population of cells are inherently small. Therefore, further investigation of
these complexes at the higher concentration of 50 μM was performed, following 
incubation for five days, in order to determine if the M phase arrest is replicated and
if the effect is dose dependent. The cell viability results for complexes 2.13 and 2.16b
at a concentration of 50 μM are shown in Table 5.8 and in Figure 5.9. The cell cycle
analysis for complex 2.13 at a concentration of 50 μM is shown in Table 5.9 and
Figure 5.10.
Table 5.8: Cell viability summary for complexes 2.13 and 2.16b at 50 μM.  
* = unable to determine due to low total cell count
Complex
Control 2.13 2.16b
Total cells 3.13 × 105 2.34 × 105 2.52 × 103
Cell viability / % 91.3 67.5 87.5
Cell diameter / μm 18.4 ± 9.8 18.0 ± 12.0 *
Aggregates of > 5 cells 4 7 0
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Control
2.13
2.16b
Figure 5.9: Representative optical microscopy images (× 5) of MIA PaCa-2 cells with
no complex and in with complexes 2.13 and 2.16b at 50 μM
Table 5.9: Cell cycle analysis for complex 2.13 at 50 μM
Cell cycle
phase
Cell population / %
Concentration / μM 
0 50
Sub G1 9 6
G1 64 44
S 15 24
M 12 23
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Figure 5.10: Graphical representation of cell cycle analysis for control and complex
2.13 at 50 μM
At the higher concentration of 50 μM, complex 2.13 shows a small reduction in the
number total cells with a 25 % reduction in the percentage of viable cells. Complex
2.16b shows a 100-fold reduction in the total number of cells with no reduction in
the percentage of viable cells, however this may be due to the low cell count. There
are also no readily observable changes in cell morphology for complex 2.13
compared to the control; however for complex 2.16b not only is there an obvious
change in cell morphology to smaller more spherical cells but the decrease in cell
population is also readily observable. For complex 2.13 the results are similar to
when lower concentrations were analysed, implying that this complex remains a
cytostatic agent which acts through interruption of the cell cycle. However, for
complex 2.16b the results are different to when lower concentrations were
analysed. At higher concentrations complex 2.16b appears to induce cell death,
i.e. acts as a cytotoxic rather than a cytostatic agent.
Cell cycle analysis could only be performed for complex 2.13 due to the low number
of total cells present after incubation with complex 2.16b. There is an increase in the
population of cells in S phase and a larger increase in the percentage of cells in M
phase. In fact the percentage of cells in M phase doubled (12 % to 23 %), this is
coupled with a reduction of cells which are in G1 phase. This demonstrates that even
0
10
20
30
40
50
60
70
80
90
100
Control 2.13
Ce
ll
po
pu
la
tio
/%
Complex
M
S
G1
Sub G1
Biological investigation Chapter 5
147
at higher concentrations the mechanism of action of complex 2.13 appears to be the
induction cell cycle arrest during M phase.
5.4 Cancer stem cell studies
Cancer stem cells (CSCs) are a sub-type of tumour initiating cancer cells with stem
cell-like properties, such as the ability to self-renew and differentiate. The
origination of CSCs is under debate, but the two main hypotheses state either that
CSCs originate from the oncogenic transformation of normal stem cells or from
partially differentiated progenitor cells.55-58 Conventional cancer therapies are not
effective against CSCs as these target more rapidly growing cell types which make up
the bulk of the tumour. While tumour mass is reduced, the CSCs persist and are able
to generate new, often aggressive, tumours at the primary or secondary sites.58, 59 In
order for cancer treatment to be more effective and avoid relapse, it is crucial to be
able to remove CSCs in addition to the main tumour bulk. Potential drug targets for
CSCs include deregulated signalling pathways, cell surface markers and dysfunctional
organelles.60-63 Investigation into CSC-specific drugs has led to number of potential
drugs in clinical or pre-clinical trials such as salinomycin, the current gold standard
for CSC-selective agents.63, 64
Research into the anti-CSC potential of metal-based drugs is still in its infancy. To
date a limited number of cobalt,65 copper,66, 67 iron,68 vanadium,69 gold70 and
osmium71 complexes have been investigated. The only cobalt complexes so far
investigated are cobalt(III) cyclams, one of which contains two naproxen molecules
(a nonsteroidal anti-inflammatory drug (NSAID)) as axial ligands (Figure 5.11). The
cobalt(III) cyclam moiety acts as a prodrug which is activated by reduction to
cobalt(II) in hypoxic environments, such as a cancer cell or cancer stem cell.31 The
cobalt cyclam naproxen complex showed selective activity for breast CSC-enriched
cells and additionally inhibited the formation of the small tumour-like
mammospheres with concurrent reduction in viability.65
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Figure 5.11: Cobalt cyclam complexes investigated against CSCs
The two lead complexes (2.13 and 2.16b) were tested for their anti-CSC activity by
Paul Cressey under the supervision of Dr. Kogularamanan Suntharalingam at King’s
College London. The IC50 values were determined using the five day MTT assay as
previously described (Chapter 5.1) against two cancerous human mammary
epithelial cell lines: HMLER (stable CSC-like population of 5 - 8 %) and HMLER-shEcad
(stable CSC-like population of approximately 90 %).72 Additionally, IC50 values were
determined with mammospheres, which are three-dimensional tumour-like
structures which are able to form in non-adherent, serum-free media. The ability of
the complexes to inhibit the formation of mammospheres was determined.
Single-cell suspensions of CSC-enriched HMLER-shEcad cells were incubated with the
complexes, at their IC20 values, for five days and mammosphere formation
determined microscopically. The ability to inhibit mammosphere formation in single
cell suspensions is used as a marker for anti-CSC potency.65, 73
The IC50 values of complexes 2.13 and 2.16b are shown in Table 5.10 and the results
from the mammosphere formation assay are shown in Figure 5.12 and Figure 5.13.
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Table 5.10: IC50 values of lead complexes against CSCs
Complex IC50 / μM 
HMLER HMLER-shEcad Mammosphere
2.13 0.49 ± 0.06 0.52 ± 0.05 1.57
2.16b 1.3 ± 0.1 0.88 ± 0.02 8.39
Complexes 2.13 and 2.16b are active against both the CSC enriched and non-CSC
enriched cancer cells with micromolar or sub-micromolar potencies. Complex 2.13
has greater potency against both cell types compared to complex 2.16b; however,
complex 2.16b is moderately selective for CSC enriched cancer cells (IC50 = 0.88 μM) 
over the bulk cancer cells (IC50 = 1.3 μM). In addition, both complexes effectively 
reduce the viability of mammospheres at micromolar concentrations, with complex
2.13 the more active of the two (IC50 = 1.57 μM) (Table 5.10). These results are
similar to the cobalt cyclam complex with naproxen (Figure 5.11) which also displays
submicromolar IC50 values, however this complex displays greater selectivity for CSC
enriched cancer cells over bulk cancer cells than either complex 2.13 or 2.16b.65
Figure 5.12: Mammosphere formation in absence or presence of complexes 2.13
and 2.16b
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Figure 5.13: Representative bright-field microscopy images (× 10) of
mammospheres in absence or presence of complexes 2.13 and 2.16b
Both complexes reduced the number of mammospheres formed from single cell
suspensions of HMLER-shEcad cells compared to untreated cells (Figure 5.12).
Complexes 2.13 and 2.16b both resulted in a 25 - 40 % decrease in the number of
mammospheres formed. In addition, mammosphere size decreased upon incubation
with both complexes (Figure 5.13). As the ability to inhibit mammosphere formation
is a marker for CSC potency, these results confirm that both complexes are active
against CSCs. The decrease in the number and size of mammospheres is again
consistent with the previously studied cobalt complex, however this displayed a
greater reduction in the number of mammospheres of 65 %.65
5.5 Anti-bacterial activity
Antibiotic resistance is one of the key challenges facing modern day medicine.74
There is growing resistance amongst both Gram-negative and Gram-positive
bacteria, including a group of pathogens which constitute the majority of hospital
based infections- the ESKAPE pathogens. The ESKAPE pathogens are Enterococcus
faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii,
Pseudomonas aeruginosa and Enterobacter species, a number of which are resistant
to multiple drugs.75, 76 Bacteria are able to acquire resistance through various
mechanisms such as drug inactivation, modification of drug binding sites, changes in
cell permeability and biofilm formation.77 Resistance can spread rapidly due to the
ability of bacteria to transfer genes both vertically (between generations) and
horizontally (within the same generation).78 New antibiotics with wide ranging action
against multi-drug resistant pathogens are needed; however, the number of new
approved antibiotics has dramatically slowed.79, 80 Most of these new drugs are
improved versions of drugs from pre-existing antibiotic drug classes which merely
delays the problem of resistance rather than offering a solution. Therefore it is
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important to develop whole new classes of antibiotic with novel modes of action,
this has led to the investigation of organometallic and coordination complexes as
potential drugs.
A number of cobalt complexes with anti-bacterial activity have been reported in the
literature, starting with the bacteriostatic and bactericidal activity of a cobalt(III)
cationic coordination complex reported by Dwyer in 1950s.81 A variety of cobalt(II)
and cobalt(III) complexes with a number of diverse ligands have been investigated.82
Cobalt(III) complexes with bidentate and tridentate picolinamide including a set of
heterobimetallic complexes have been investigated by Mishra (Figure 5.14). The
bidentate and tridentate complexes showed activity against resistant strains of
Pseudomonas and E. coli and against standard strains of Shigella and Klebsiella
(MIC = 5 - 350 μg ml-1). It is suggested that the presence of uncoordinated pyridyl
rings is responsible for the anti-bacterial activity.83 Some of the heterobimetallic
complexes were effective against P. vulgaris, E. coli and P. aeruginosa (MIC = 5 - 350
μg ml-1). The authors suggest that the anti-bacterial activity may be due to the
presence of labile sites on the second metal ion.19
Figure 5.14: Cobalt picolinamide complexes investigated as anti-bacterial agents a)
cobalt bidentate complexes b) cobalt tridentate complexes c)
heterobimetallic complexes
Complexes were screened for their anti-bacterial activity against Escherichia coli
(E. coli), Klebsiella pneumoniae (K. pneumoniae), Acinetobacter baumannii
(A. baumannii), Pseudomonas aeruginosa (P. aeruginosa) and Staphylococcus aureus
(S. aureus) by The Community for Antimicrobial Drug Discovery (CO-ADD) at The
University of Queensland. The complexes, at a single concentration of 32 μg mL-1,
were incubated with the bacterial strains at 37 °C for 18 hours without shaking. All
growth inhibition assays were performed in duplicate. Growth inhibition was
determined by measuring absorbance at 600 nm. Complexes with growth inhibition
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values greater than 80 % are classed as active and complexes with growth inhibition
values in the range 50- 80 % are classed as partially active.
Anti-bacterial activity screening results for cobalt(III) tris-picolinamide complexes,
cobalt(II) bis-picolinamide complexes and cobalt(III) mixed ligand complexes are
summarised in Table 5.11, Table 5.12 and Table 5.13 respectively. Partially active
complexes are highlighted in orange. Complexes 4.1, 4.18 and 4.19 were
insufficiently soluble in DMSO and cell culture medium used for the growth inhibition
assays and therefore no results could be obtained.
Only one complex displayed any notable activity against any of the bacterial strains
screened; all other complexes were inactive. Complex 2.8, a cobalt(III)
tris-picolinamide complex (N,N coordination) with a para-chloro substituent on the
aryl ring, was partially active against S. aureus with growth inhibition of 65.9 %.
Interestingly, complex 2.8 shows selective activity against S. aureus and is inactive
against the other four bacterial strains. Alteration of the position of the chloro
substitution to the meta position resulted in inactivation of the complex and
conversion of the chloro to a fluoro or bromo also resulted in loss of activity. The
para-chloro substituent appears to be crucial for the selective toxicity to S. aureus.
These results contrast with the previous bidentate cobalt picolinamide complexes
studied (Figure 5.14a) which were all active against E. coli, Klebsiella and
Pseudomonas.83 The related tridentate cobalt complexes and related
heterobimetallic complexes also displayed broad anti-bacterial activity.19, 83 With
regards to the bidentate and tridentate complexes, it is hypothesised that the
uncoordinated pyridyl rings present in these complexes is responsible for their
activity, due to the ability of these pyridyl rings to form strong interactions with
cations.83 These results tend to support this hypothesis as none of the complexes
tested contained coordinating groups within or attached to the aryl ring and all
besides one complex were inactive. In addition, the previously tested complexes
were active against a number of different bacterial strains, whereas in contrast
complex 2.8 was selectively active against one strain. This implies that specific
substitutions onto the aryl ring may lead to selective activity, while substitutions into
the aryl ring (to create a pyridyl ring) lead to broad spectrum activity.
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Table 5.11: Growth inhibition of cobalt(III) tris-picolinamide complexes against
bacterial strains
Complex Inhibition / %
E. coli K.
pneumoniae
A.
baumannii
P.
aeruginosa
S. aureus
2.1a 0.0 8.3 1.6 0.0 0.0
2.2 2.4 13.4 7.6 0.0 2.2
2.3 9.8 17.6 13.4 0.0 18.7
2.4 7.2 18.8 11.2 0.0 14.9
2.5 3.5 19.2 14.8 0.0 23.8
2.6 6.0 19.4 12.1 0.0 16.7
2.7 0.0 17.2 13.6 0.0 6.5
2.8 0.0 17.7 9.6 0.0 65.9
2.9 5.4 17.5 11.3 0.0 13.0
2.10 0.9 17.9 8.1 0.0 16.0
2.11 0.0 17.6 6.9 0.0 15.1
2.12 5.2 15.2 7.6 1.5 12.0
2.13 4.4 12.4 7.2 3.1 8.6
2.14a 8.7 18.2 10.3 0.0 18.6
2.15a 6.8 17.3 10.2 0.0 15.0
2.16a 0.4 18.1 13.1 0.0 20.9
2.17a 1.3 16.7 9.3 0.0 13.9
2.18a 1.3 19.6 8.5 0.0 14.8
2.1b 11.4 18.0 13.7 0.0 16.8
2.14b 4.3 19.2 13.1 0.0 14.2
2.15b 5.4 17.5 12.9 0.0 18.5
2.16b 6.3 17.7 10.7 0.0 15.4
2.17b 6.3 14.8 12.0 0.0 5.3
2.18b 4.3 15.8 9.5 0.0 6.9
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Table 5.12: Growth inhibition of cobalt(II) bis-picolinamide complexes against
bacterial strains
Complex Inhibition / %
E. coli K.
pneumoniae
A.
baumannii
P.
aeruginosa
S. aureus
3.1 4.4 19.1 16.7 0.0 9.1
3.2 0.0 19.2 12.5 0.0 13.3
3.3 0.0 14.7 8.6 0.0 10.0
3.4 5.2 15.6 11.7 0.0 6.6
3.5 3.5 14.2 12.8 0.0 8.4
3.6 0.0 16.2 12.8 0.0 6.7
3.7 2.1 17.3 11.7 0.0 2.3
3.8 0.0 17.5 7.8 0.0 5.8
3.9 0.0 16.1 11.8 0.0 0.5
3.10 3.1 11.2 6.9 0.0 0.0
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Table 5.13: Growth inhibition of cobalt(III) mixed ligand complexes against
bacterial strains
Complex Inhibition / %
E. coli K.
pneumoniae
A.
baumannii
P.
aeruginosa
S. aureus
4.2 0.0 13.1 4.7 0.0 0.0
4.3 0.0 8.5 0.0 0.0 0.0
4.4 0.0 10.0 1.6 0.0 0.0
4.5 0.0 11.7 0.0 0.0 3.9
4.6 0.0 12.1 7.1 0.0 0.5
4.7 0.0 2.2 0.0 0.0 0.9
4.8 0.0 4.2 0.0 0.0 0.0
4.9 0.0 2.0 0.0 0.0 1.1
4.10 0.0 0.0 0.0 0.0 0.0
4.11 0.0 0.0 0.0 0.0 4.6
4.12 0.0 0.0 0.0 0.0 2.7
4.13 0.0 5.0 0.0 0.0 0.0
4.14 0.0 8.1 0.0 0.0 0.0
4.15 0.0 5.4 0.0 0.0 0.0
4.16 0.0 3.5 0.0 0.0 4.2
4.17 0.0 3.1 0.0 6.0 0.0
5.6 Anti-fungal activity
The incidence of fungal infections has increased in recent years and these are often
associated with significant mortality rates.84 This is partly due to the increase in
immunocompromised patients, for example patients with HIV or patients
undergoing organ transplantation or aggressive chemotherapy, for which
opportunistic fungal or bacterial infections are particularly worrisome.85 Clinical
outcomes are often poor and drug resistant strains of common organism such as
Candida albicans are emerging.86 In the USA, C. albicans is now the fourth most
common iatrogenic bloodstream infection87 and in developing healthcare systems
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infection with fungi of the Cryptococcus genus causes more deaths in HIV patients
than tuberculosis.88 There are currently only four main classes of anti-fungal drugs:
polyenes, azoles, allylamines and echinocandins; and thus there is a crucial
requirement for the development of new anti-fungal drugs.85
Despite the need for new drugs, there has been relatively little investigation into the
anti-fungal potential of organometallic or coordination complexes. There are only a
few publications which examine the anti-fungal activity of cobalt complexes and
these exclusively examine cobalt(II) complexes. Schiff base complexes, some based
on amino acids, have shown promising activity against C. albicans or Aspergillus
genus fungi or general broad spectrum activity.89-92 Other ligands investigated
include azoles,93 cephalexins,94 sulphonamides,95 dithiones,96 thiolenes,97 diols98 and
8-hydroxyquinoline99 which tend to show broad spectrum activity against a variety
of fungi. In cases where analogous copper(II) complexes are investigated, these show
improved activity compared to the cobalt(II) complexes.92, 98
Complexes were screened for their anti-fungal activity against Candida albicans
(C. albicans) and Cryptococcus neoformans (C. neoformans) by CO-ADD at The
University of Queensland. The complexes, at a single concentration of 32 μg mL-1,
were incubated with the fungal strains at 35 °C for 24 hours without shaking. All
growth inhibition assays were performed in duplicate. Growth inhibition of
C. albicans was determined by measuring absorbance at 530 nm. Growth inhibition
of C. neoformans was determined by measuring the difference in absorbance
between 580 and 600 nm following the addition of resazurin and incubation at 35 °C
for a further two hours. Complexes with growth inhibition values greater than 80 %
are classed as active and complexes with growth inhibition values in the range
50 - 80 % are classed as partially active.
Anti-fungal activity screening results for cobalt(III) tris-picolinamide complexes,
cobalt(II) bis-picolinamide complexes and cobalt(III) mixed ligand complexes are
summarised in Table 5.14, Table 5.15 and Table 5.16 respectively. Active complexes
are highlighted in green and partially active complexes are highlighted in orange.
Results for active and partially active complexes are also displayed in Figure 5.15.
Complexes 4.1, 4.18 and 4.19 were insufficiently soluble in DMSO and cell culture
medium used for the growth inhibition assays and therefore no results could be
obtained.
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Table 5.14: Growth inhibition of cobalt(III) tris-picolinamide complexes against
fungal strains
Complex Inhibition / %
C. albicans C. neoformans
2.1a 0.8 0.0
2.2 1.0 0.0
2.3 3.3 0.0
2.4 1.7 0.0
2.5 2.1 0.0
2.6 4.2 0.0
2.7 1.9 0.0
2.8 2.2 0.0
2.9 0.8 0.0
2.10 3.6 0.0
2.11 2.6 0.0
2.12 0.8 0.0
2.13 9.7 0.0
2.14a 3.2 0.0
2.15a 1.4 0.0
2.16a 3.9 0.0
2.17a 0.8 0.0
2.18a 5.3 0.0
2.1b 5.3 0.0
2.14b 7.7 0.0
2.15b 6.6 0.0
2.16b 4.3 0.0
2.17b 6.7 7.7
2.18b 2.5 0.0
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Table 5.15: Growth inhibition of cobalt(II) bis-picolinamide complexes against
fungal strains
Complex Inhibition / %
C. albicans C. neoformans
3.1 86.8 0.0
3.2 81.0 0.0
3.3 85.9 0.0
3.4 78.6 0.0
3.5 72.8 0.0
3.6 73.5 0.0
3.7 63.5 0.0
3.8 72.0 0.0
3.9 44.0 0.0
3.10 26.0 0.0
Figure 5.15: Growth inhibition of C. albicans by cobalt(II) bis-picolinamide
thiocyanate complexes
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Table 5.16: Growth inhibition of cobalt(III) mixed ligand complexes against fungal
strains
Complex Inhibition / %
C. albicans C. neoformans
4.2 5.2 0.0
4.3 9.9 0.0
4.4 20.6 0.0
4.5 7.4 0.0
4.6 3.7 0.0
4.7 9.9 0.0
4.8 6.0 0.0
4.9 14.6 0.0
4.10 30.3 0.0
4.11 1.2 0.0
4.12 6.4 0.0
4.13 9.2 16.8
4.14 9.1 0.0
4.15 6.3 0.0
4.16 5.9 7.2
4.17 6.2 7.0
Only eight complexes displayed any notable activity against one of the fungal strains
screened, all other complexes were inactive. All of the cobalt(II) bis-picolinamide
thiocyanate complexes 3.1 - 3.8 were selectively active or partially active against
C. albicans, with growth inhibition in the range 63.5 - 86.8 %. The analogous cobalt(II)
complex with chlorides as the axial ligands (3.9) and the analogous dicationic
cobalt(II) complex with aquas as the axial ligands (3.10) are inactive. The analogous
cobalt(III) tris-picolinamide complexes are also inactive. Therefore, the axial
thiocyanate ligands are essential for the anti-fungal activity of the complexes.
Potentially, within the cell, the thiocyanate ligands are either released or exchanged,
resulting in free thiocyanate ions which are known to be toxic.100 In the saliva,
salivary peroxidase catalyses the oxidation of thiocyanate (SCN-) by hydrogen
peroxide to hypothiocyanite (NCSO-) and hypothiocyanous acid (NCSOH).101, 102
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These compounds have been shown to inhibit the viability of C. albicans.103 As
toxicity to C. albicans is seen in these experiments, similar peroxidase enzymes
within C. albicans may allow the formation of these toxic compounds leading to
inhibition of growth. If these peroxidase enzymes are present at a higher
concentration, or are more active or specific to C. albicans compared to
C. neoformans, this may explain why these complexes are selectively toxic.
While all of the cobalt(II) bis-picolinamide thiocyanate complexes are at least
partially active, the three active complexes (3.1 - 3.3) all contain the axial
thiocyanates in the trans configuration; although the differences in percentage
growth inhibition are fairly small. It is unknown if the positioning of the thiocyanate
ligands has a causative effect on the anti-fungal activity. However, thiocyanate is a
known trans-directing ligand104 and different kinetics have been noted previously for
trans and cis complexes with cobalt105, 106 and a number of other metals.107-109
Therefore, in the trans configuration the thiocyanates are released more readily,
leading to greater concentrations of intracellular thiocyanate and its metabolites,
hence a greater percentage of growth inhibition. Alternatively, the cis geometry may
be more thermodynamically stable compared to the trans geometry, again favouring
ligand substitution in the trans positions.110
Direct comparison of these results for cobalt picolinamide complexes with similar
cobalt(II) Schiff base complexes in the literature is not possible due to use of different
methods to quantify anti-fungal activity (percentage growth inhibition versus zone
of inhibition). However, these Schiff base complexes display broad spectrum activity
against a number of other fungal strains, whereas the cobalt picolinamide complexes
show selectivity for C. albicans.89, 90
Complexes with sufficient activity (3.1 - 3.7) underwent hit confirmation to
determine their minimum inhibitory concentration (MIC). MIC is the lowest drug
concentration which prevents visible growth of the pathogen, in this case a fungus.
The MIC values for complexes 3.1 - 3.7 were determined against C. albicans and
C. neoformans by CO-ADD at The University of Queensland. The complexes, at eight
concentrations, were incubated with the cell suspensions of the fungal strains at
35 °C for 36 hours without shaking. All growth inhibition assays were performed in
duplicate. Growth inhibition of C. albicans was determined by measuring absorbance
at 630 nm. Growth inhibition of C. neoformans was determined by measuring the
difference in absorbance between 570 and 600 nm following the addition of
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resazurin and incubation at 35 °C for a further two hours. The MIC was defined as
the lowest concentration at which the growth was fully inhibited, set at ≥ 80% for  
C. albicans and inhibition ≥ 70% for C. neoformans (due to higher variance in growth
and inhibition of C. neoformans compared to C. albicans). Complexes with MIC less
than 16 μg ml-1 are classed as confirmed active hits. The cytotoxicity of these
complexes was also determined against the HEK293 (human embryonic kidney) cell
line. The complexes, at eight concentrations, were incubated with the cells at 37 °C
for three hours in 5 % CO2. Cytotoxicity was measured by fluorescence, with
excitation at 560 nm and emission at 590 nm, following the addition of resazurin.
Cytotoxicity is expressed in terms of CC50, which is defined as the concentration of
drug required to produce 50 % of cell death.
Anti-fungal MICs and cytotoxicity results for complexes 3.1 - 3.6 and 3.8 are
summarised in Table 5.17. Despite displaying growth inhibition of C. albicans in the
initial screen, none of the complexes displayed sufficient activity against C. albicans
(MIC ≤ 16 μg ml-1) to be classified as active hits. Perhaps the kinetics of ligand
substitution resulting in free thiocyanate or the conversion of thiocyanate to
hypothiocyanite is insufficiently rapid to allow sufficient anti-fungal activity.
Complexes were also shown to be non-toxic to HEK293 cells, these results are in
agreement with the previous cytotoxicity studies performed which also showed
these complexes to be non-toxic to three different cell lines (Chapter 5.1).
Table 5.17: The anti-fungal toxicity and cytotoxicity of complexes 3.1 - 3.6 and 3.8
Complex MIC / μg ml-1 CC50 / μg ml-1
C. albicans C. neoformans HEK293
3.1 > 32 > 32 > 32
3.2 > 32 > 32 > 32
3.3 > 32 > 32 > 32
3.4 > 32 > 32 > 32
3.5 > 32 > 32 > 32
3.6 > 32 > 32 > 32
3.8 > 32 > 32 > 32
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5.7 Conclusions
Three series of cobalt picolinamide complexes were screened for their anti-cancer
activity. Six complexes, mainly from the cobalt(III) tris-picolinamide series, were
cytotoxic to pancreatic carcinoma, colon carcinoma and retinal epithelial cells.
Within the cobalt(III) tris-picolinamide series, coordination isomers with N,O
coordination were more active than the analogous N,N coordination complexes. This
work represents the first time that coordination isomers of metal picolinamide
complexes have been investigated and the first time that this trend in potency has
been observed. Cobalt tris-picolinamide complexes were tested in a low oxygen
(hypoxic) environment and found to be less active compared to in a normal oxygen
(normoxic environment). Two complexes (2.13 and 2.16b) with high potency were
designated as lead compounds and underwent mechanistic investigation. Both
complexes inhibited cell proliferation rather than induced cell death at
physiologically relevant concentrations and were found to act through interruption
of M phase of the cell cycle. Both lead complexes were active against cancer stem
cell enriched breast cancer cells and were able to inhibit mammosphere formation
and viability.
The three series of cobalt picolinamide complexes were also screened for their
anti-bacterial and anti-fungal activity. Complex 2.8 showed selective activity against
the bacterium S. aureus, but all other complexes were inactive. All of the cobalt(II)
bis-picolinamide thiocyanate complexes were selectively active against the fungus
C. albicans. The thiocyanate axial ligands are essential for toxicity, possibly due to
their ability to undergo ligand substitution to release free thiocyanate intracellularly.
However, despite activity against C. albicans in the primary anti-fungal screen, the
MIC values for these complexes were deemed insufficiently active to define the
cobalt(II) bis-picolinamide thiocyanate complexes as active hits or to continue
further study.
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6. Chemical investigation
After the identification of promising (lead) drugs during initial biological screening it
is necessary to investigate aspects such as the distribution of the drug within the
body, the drug metabolism and any drug toxicity to non-target cells.1, 2 These in
depth investigations are essential to identify the potential pitfalls or adverse effects
of new drugs. Several promising leads fail at this stage of development e.g. the
titanium containing anti-cancer drug budotitane which was removed from clinical
trials due to problems with solubility, stability and non-target toxicity.3-6 If such
problems can be identified in the preclinical phase, they can inform further rounds
of lead development and optimisation. The understanding of the relationship
between the molecular structure of a drug and activity through structure-activity
relationships (SAR) allows the modification of drugs to improve various biologically
relevant characteristics.7-9
6.1 Hydrolysis studies
The proposed mechanism of action for several metal based anti-cancer drugs,
including cisplatin, involves activation by hydrolysis.10, 11 Initially such drugs are inert
when administered and do not undergo ligand substitution, but upon transfer across
the cell membrane, the change in chloride concentration permits ligand substitution
reactions to occur leading to activation of the drug.12-14 In other metal picolinamide
complexes, the rate of hydrolysis was related to the cytotoxicity.15 For example,
within the McGowan group a greater degree of hydrolysis of ruthenium(III)
bis-picolinamide dichloride complexes was associated with improved cytotoxicity
whereas a lesser degree of hydrolysis of ruthenium(III) bis-picolinamide diiode
complexes was associated with improved cytotoxicity.16 Possible hydrolysis
pathways for the cobalt picolinamide complexes involve the formation of cationic
monoaqua or diaqua intermediates under physiological conditions (Figure 6.1).17-20
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Figure 6.1: Potential hydrolysis pathways for cobalt picolinamide complexes
Hydrolysis studies were performed using both 1H NMR and UV/vis spectroscopy.
NMR samples were prepared in 4:1 d3-acetonitrile/D2O to give a final concentration
of 8 mg ml-1. UV/vis samples were prepared in 4:1 acetonitrile/water to give a final
concentration of 50 μM. Attempts to increase the concentration of water in these 
samples resulted in poor solubility. Samples were analysed using NMR and UV/vis
spectroscopy every 24 hours over a period of five days, to correlate with the MTT
assay. Following the final analyses, samples were analysed by electrospray mass
spectrometry.
Hydrolysis was not investigated for all complexes; only for complexes with activity
or partial activity against cancer cell lines (2.13, 2.16b and 4.10), their closest
analogous inactive complex (2.16a and 4.11) and an example of an unsubstituted
complex from the series of cobalt picolinamide complexes synthesised (2.1a, 2.1b,
4.3 and 4.13). Cobalt(II) bis-picolinamide complexes (3.1 - 3.10) were insufficiently
soluble in the acetonitrile/water mixture used in these investigations and therefore
no results could be obtained. The changes in wavelengths of absorption bands from
the UV/vis spectra are summarised in Table 6.1 and UV/vis spectra of complexes
which undergo changes over time are displayed in Figure 6.2. All complexes are
stable in acetonitrile over the same time period with no concurrent changes to the
NMR, UV/vis or mass spectra over time.
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Table 6.1: Wavelengths of absorption bands of cobalt picolinamide complexes
Complex Wavelength / nm
Day 0 Day 5
2.1a 204, 263, 298 (sh) 204, 263, 298 (sh)
2.13 207, 256, 299 (sh) 207, 256, 299 (sh)
2.16a 205, 262, 303 (sh) 205, 262, 303 (sh)
2.1b 202, 266, 300 (sh), 355 (sh) 202, 266, 300 (sh), 355 (sh)
2.16b 206, 256 (sh), 340 (sh) 206, 256 (sh), 340 (sh)
4.3 202, 266, 287 (sh), 354 202, 266, 287 (sh), 354
4.10 204, 258, 293, 369 (sh), 522 200, 231 (sh), 272
4.11 201, 259, 302, 384 (sh), 527 200, 229 (sh), 273
4.13 203, 267, 299, 373, 511 203, 270, 388 (sh), 419 (sh)
There is no change in the UV/vis, NMR or mass spectra for complexes 2.1a, 2.13,
2.16a, 2.1b, 2.16b or 4.3 over the five day time period. This shows that the cobalt(III)
tris-picolinamide complexes and cobalt(III) mixed ligand complexes with
β-diketonate ligands are stable in solution and do not undergo hydrolysis. There is 
no difference in the degree of hydrolysis between the active and inactive complexes
(from the same and different cobalt picolinamide series) and therefore the
differences in anti-cancer activity are not due to differences in either the degree or
rate of hydrolysis. This is in contrast to previously studied ruthenium(III)
picolinamide complexes where hydrolysis was correlated with activity,15, 16 the
implication being that the mechanism of action of these complexes is different to
those previously studied. This lack of a requirement for hydrolysis for activation of
the drug is also different to a number of well-established and promising metal
anti-cancer drugs such as cisplatin, KP1019 and NAMI-A.10, 11, 21 However, the
hydrolytic activation of these drugs has disadvantages; for example the rapid
hydrolysis of cisplatin leads to reduced bioavailability due to binding to thiol
containing proteins which is thought to be a key mechanism in cisplatin toxicity to
non-target cells.22-24 It is possible that the difference in mechanism for these cobalt
picolinamide complexes, which do not seem to require hydrolytic activation, will
limit some of these potential drug pitfalls.
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Complex 4.10 Complex 4.11 Complex 4.13
Figure 6.2: UV/vis spectra for the hydrolysis of complexes 4.10, 4.11 and 4.13
Key: Black = day 0, pale blue = day 1, dark blue = day 2, pink = day 3, purple = day 4, dark red = day 5
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Distinct changes in the UV/vis spectra for complexes 4.10, 4.11 and 4.13 are
observed over the five day time period. These spectral changes are associated with
changes in the colour of the samples themselves; the UV/vis solutions changing from
red/purple on day 0 to brown by day 5. This shows that the cobalt(III) mixed ligand
complexes with ferrocenyl β-diketonate ligands undergo hydrolysis over time. This 
susceptibility to hydrolysis is due to the presence of the ferrocenyl group as in the
absence of ferrocene no hydrolysis is observed. On day 0, these complexes show an
intense ligand based absorbance (π-π*) at approximately 200 nm with three less 
intense ligand based charge-transfer bands at 255 - 270 nm, 290 - 305 nm and
370 - 385 nm and finally a weak d-d transition at 510 - 530 nm. By day 5, the intense
absorbance at around 200 nm remains but all of the weaker charge-transfer bands
and d-d transition have disappeared and instead a distinct charge-transfer band at
270 - 275 nm has appeared. The spectra seen at day 5 are remarkably similar to the
UV/vis spectra of the cobalt bis-picolinamide complexes, which also display an
intense ligand based absorbance at around 200 nm and a distinct charge-transfer
band at 275 - 285 nm. This suggests that during the hydrolysis experiment, the
ferrocenyl β-diketonate ligand dissociates from the complex resulting in a cobalt  
bis-picolinamide complex with the axial ligands either aqua or acetonitrile molecules
(Figure 6.1c).
Relative hydrolysis rates (4.11 > 4.10 > 4.13) can be inferred from the UV/vis spectra
as by day 1 complex 4.11 is completely converted, by day 2 complex 4.10 is
completely converted and by day 5 complex 4.13 is still undergoing conversion.
Complex 4.11 in particular undergoes rapid hydrolysis as the colour change of the
UV/vis solution is observed within 1 - 2 hours, and with only 20 % water component
in the solution. The relative hydrolysis rates correlate with the ferrocenyl
β-diketonate substituents present in the complexes. Complex 4.11 contains the most
electron withdrawing substituent (CF3) and has the most rapid hydrolysis rate,
complex 4.10 contains a slightly less electron withdrawing substituent (CHF2) and
has a rapid hydrolysis rate and complex 4.13 contains an electron donating
substituent (Ph) and has the slowest rate of hydrolysis.
The changes to the NMR and mass spectra during hydrolysis can be used to uncover
the fate of complexes 4.10, 4.11 and 4.13. Example NMR spectra over time are
shown for complex 4.11 (Figure 6.3) and the changes in the mass spectra for
complexes 4.10, 4.11 and 4.13 over time are summarised in Table 6.2.
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Figure 6.3: 1H NMR spectra of complex 4.11 over time (4:1 CD3CN/D2O)
Table 6.2: Mass spectrometry peaks and assignments for complexes 4.10, 4.11 and
4.13. pica = picolinamide, keto = β-diketonate
Complex Day 0 Day 5
Peak Assignment Peak Assignment
4.10 1031.04 (100 %) [Co(pica)2(keto)]+ 725.02 (5 %)
335.06 (95 %)
[Co(pica)2]+
pica+
4.11 1049.04 (100 %) [Co(pica)2(keto)]+ 725.02 (5 %)
335.06 (95 %)
[Co(pica)2]+
pica+
4.13 1057.08 (100 %) [Co(pica)2(keto)]+ 725.02 (5 %)
335.06 (95 %)
[Co(pica)2]+
pica+
In the NMR spectra, complexes 4.10, 4.11 and 4.13 all show broadening of peaks
over time, revealing that either a charged or a paramagnetic species is being
produced in solution. This could be consistent with the substitution of one of the
bidentate ligands for two water molecules producing a cationic species (Figure 6.1c).
In addition, the methine β-diketonate peak at 6.11 ppm disappears over time and 
new peaks at 6.45, 6.54, 6.80 and 8.45 ppm appear (Figure 6.3). The loss of the
methine peak may indicate the dissociation of the ferrocenyl β-diketonate ligand 
from the complex with the new peaks either the result of the formation of a cobalt
bis-picolinamide complex or degradation of the cobalt picolinamide complex.18 This
Day 0
Day 1
Day 2
Day 3
Day 4
Day 5
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supports the evidence from the UV/vis spectra, which suggests the formation of a
cobalt bis-picolinamide complex. The new peaks at 6.45 - 6.80 may be explained by
the shifting and splitting of the methine peak if new species are formed in solution
from the free ferrocenyl β-diketonate ligands. The formation of new species in 
solution is supported by the fact that the ferrocenyl β-diketonate ligand with a 
trifluoromethyl group was cytotoxic as the free ligand.25 But as the complex
containing this ligand is non-cytotoxic the implication is that any ferrocenyl
β-diketonate ligand released is either released in a modified form or can rapidly form 
new species in solution.
The mass spectra of complexes 4.10, 4.11 and 4.13 also show changes over time.
Initially the major peak is for the intact cobalt mixed ligand complex, but by day 5
the major peaks can be assigned to free picolinamide ligand and a cobalt
bis-picolinamide complex. This supports evidence from NMR spectroscopy which
suggests that the ferrocenyl β-diketonate ligand is substituted during hydrolysis. 
Unfortunately, no cobalt aqua species could be identified from the mass spectra
which may imply that the complexes may simply undergo degradation rather than
aquation over time.
In order to probe the behaviour of the complexes in solution, the ferrocenyl
β-diketonate ligand component of complex 4.11 was studied in isolation under the
same conditions as previously described (Figure 6.4). The UV/vis spectra showed
distinct changes over time but the absorption bands observed did not correlate with
complex 4.11. The NMR spectra also showed peak broadening over time with the
disappearance of the methine peak and appearance of two new peaks at 6.45 and
6.53 ppm, which may be due to shifting and splitting of the methine peak. The mass
spectra also showed changes over time but none of the peaks after day 0 could be
assigned due to the complex nature of the spectra. The ligand is stable in acetonitrile
over the same time period with no concurrent changes to the NMR, UV/vis or mass
spectra over time.26
Figure 6.4: Ferrocenyl β-diketonate ligand component of complex 4.11
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During these hydrolysis experiments, dark brown crystals formed in the NMR tube
containing the ferrocenyl β-diketonate ligand in 4:1 d3-acetonitrile/D2O. This
hydrolysis product crystallised in a monoclinic cell and structural solutions were
performed in the P 21/c space group with a single molecule in the asymmetric unit
(Figure 6.5).
Figure 6.5: Molecular structure of the ferrocenyl β-diketonate ligand hydrolysis 
product. Displacement ellipsoids are at the 50 % probability level. Hydrogen
atoms are omitted for clarity
This hydrolysis product is a metal complex with a central iron(III) surrounded by
three ferrocenyl β-diketonate ligands (Figure 6.6). This is a surprising result as
ferrocene has high stability and previous ferrocenyl β-diketonate ligands have 
proven stable in solution, however these were not investigated in water or for
extended time periods.27-30 The iron at the centre of this complex can only originate
from the ferrocene of the ferrocenyl ligand as there are no other species initially
present. This implies that either the presence of water (or D2O) or some unknown
contaminant can cause the breakdown of some of the ferrocene to release free iron.
Ferrocene contains iron(II) whereas this complex contains iron(III), therefore an
oxidation step is also required. The iron may be oxidised following release from
ferrocene or ferrocene may convert to ferrocenium which then releases iron(III).
Other hydrolysis products from the ferrocenyl β-diketonate ligand are likely to be 
present in solution but these have not been identified.
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Figure 6.6: Hydrolysis of ferrocenyl β-diketonate ligand component of complex 4.11
6.2 Hydrophobicity studies
The relative hydrophilicity or lipophilicity (hydrophobicity) of a drug is a key factor in
determining its pharmacokinetic profile. Hydrophobicity is determined by calculating
the partition coefficient (log P) of a drug. The importance of hydrophobicity is
highlighted by the fact that one of the Lipinski rules states that log P should not be
greater than 5.31, 32 Further investigation of “drug-likeness” states that log P should
be between -0.4 and 5.6.33, 34 These intermediate log P values are desired as a drug
which is administered orally needs to be sufficiently soluble in both hydrophilic
(aqueous) and lipophilic (organic) environments to allow for absorbance across the
intestinal lumen into the blood followed by target delivery across a cell membrane.
Hydrophobicity was determined by measuring the octanol-water partition
coefficient of selected complexes the using the shake flask-type method, with
1-octanol serving as a model of the lipophilic component. Complexes were dissolved
in water-saturated octanol and shaken with an equal volume of octanol-saturated
water for 2 hours at 1000 g min-1. The concentration of each complex in the octanol
layer, both before and after partitioning, was measured using UV/vis spectroscopy
with comparison to previously prepared individual calibration curves. A hydrophobic
or lipophilic complex has a positive log P value whereas a hydrophilic complex has a
negative log P value.35, 36
Hydrophobicity was not investigated for all complexes; only for complexes with
activity or partial activity against cancer cell lines (2.13, 2.14b, 2.15b, 2.16b and
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4.10), their closest analogous inactive complex (2.14a, 2.15a, 2.16a and 4.11) and an
example of a complex from each of the three series of cobalt picolinamide complexes
synthesised (2.1a, 2.1b, 3.2, 4.3 and 4.13). The log P values of the investigated
complexes are summarised in Table 6.3 and Figure 6.7.
Table 6.3: Log P values of selected cobalt picolinamide complexes
Complex log P
2.1a 0.10 ± 0.01
2.13 1.54 ± 0.09
2.14a 0.82 ± 0.03
2.15a 1.05 ± 0.03
2.16a 1.57 ± 0.03
2.1b 1.04 ± 0.02
2.14b 0.93 ± 0.01
2.15b 0.72 ± 0.05
2.16b 0.73 ± 0.04
3.1 0.45 ± 0.03
4.3 1.30 ± 0.04
4.10 1.35 ± 0.05
4.11 0.91 ± 0.03
4.13 0.78 ± 0.01
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Figure 6.7: Graph of log P values of selected cobalt picolinamide complexes
All complexes have positive log P values in the range 0.1 - 1.57 and hence are all
hydrophobic and within the limits stipulated in the Lipinski rules. The hydrophobic
nature of the complexes is unsurprising since the picolinamide ligands contain both
pyridyl and aryl rings. In addition, for the cobalt(III) tris-picolinamide complexes and
cobalt(III) mixed ligand complexes there are three bulky aromatic ligands effectively
surrounding the central cobalt ion, thus reducing the hydrophilicity even further.
Hydrophobic molecules have a greater potential to cross the lipophilic cell
membrane and enter the cell by passive diffusion, implying that these molecules
have the potential to enter the cell and that their mode of action is not limited by
poor distribution into the cells.37 However, there are no obvious trends between
cytotoxicities and log P values suggesting that hydrophobicity is unrelated to anti-
cancer potential. Complex 2.13, one of the two lead complexes, is one of the most
hydrophobic complexes (log P = 1.54), however complex 2.16a with a very similar
hydrophobicity (log P = 1.57) is completely inactive against the cancer cell lines.
Complex 2.16b, the other lead complex, has one of the lower hydrophobicity values
(log P = 0.73) but again this is very similar to other complexes such as 2.14a
(log P = 0.82) which are completely inactive.
Furthermore, there are no obvious trends either within or between the different
series of cobalt picolinamide complexes. For example, within the cobalt(III)
tris-picolinamide series of complexes, for complexes which may adopt either N,N or
N,O coordination, sometimes the N,N coordination isomer is more hydrophobic and
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sometimes the N,O coordination isomer is more hydrophobic. The most interesting
hydrophobicity data is for complex 2.1a (log P = 0.10) as this is only slightly
hydrophobic with a considerably lower log P value than for any of the other
complexes. The reason for this is unclear, especially as the analogous complex 2.1b
has an intermediate hydrophobicity (log P = 1.04).
6.3 Biomembrane studies
A drug must be able to cross many biological membranes following administration
to reach its site of action. Drug distribution, in terms of both concentration and rate,
is thus strongly determined by the interactions of a drug with various
biomembranes.38 Therefore, the study of drug-biomembrane interactions is crucial
during the preclinical phase to allow compatible drugs to enter clinical trials. Artificial
membrane models have been used extensively to study particular aspects of
drug-biomembrane interactions due to the highly complex and fragile nature of
natural membranes rendering their use labour-intensive.39, 40 Three types of
membrane model are used: monolayers (Langmuir monolayers), vesicle forming
bilayers (liposomes) and supported bilayers.38, 39
Phospholipid monolayers supported on a mercury on platinum electrode are
powerful membrane models with the application of studying the phospholipid
monolayer properties in an applied electric field.41 This sensing electrode is
connected to a to a high throughput flow system which uses rapid cyclic voltammetry
(RCV) to monitor changes in capacitance current with voltage and allow rapid
screening of large numbers of compounds (Figure 6.8). The mercury support allows
the formation of defect-free, self-healing phospholipid monolayers which allows for
the detection of any alterations to monolayer integrity. The monolayers are formed
from the phospholipid dioleoyl phosphatidylcholine (DOPC) which acts as the model
biomembrane.40, 42-45
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Figure 6.8: Scheme of the model biomembrane system46
This unique system, developed by Nelson over the past decade, acts as a model
biomembrane to allow the study of drug-biomembrane interactions, ion channel
function and the electron transport chain; with the main application as a sensor for
biomembrane active molecules.41, 43, 44 Biomembrane active molecules can interact
with the phospholipid monolayer leading to selective membrane damage which is
detected electrochemically. This system has been used to detect biomembrane
disruption with organic molecules (flavonoids, steroids, polycyclic aromatic
hydrocarbons, tricyclic anti-depressants and tricyclic phenothiazines),46, 47
peptides,48-51 nanoparticles52, 53 and ionic liquids.54 The first use of this system with
organometallic compounds was reported recently to detect the membrane
disrupting properties of a series of silver(I) non-heterocyclic carbene (NHC)
complexes.55
The DOPC monolayer undergoes various potential induced phase transitions
visualised as sharp peaks in the capacitance current (Figure 6.9). In a flow system,
such as in this system, two phase transitions are seen as two capacitance current
peaks in the RCV plot (Figure 6.10). These two peaks correspond to the permeation
of electrolyte into the monolayer and the reorganisation of the monolayer into a
bilayer.42, 56
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Figure 6.9: a) Typical RCV plot of DOPC monolayer with b) associated phase
transitions56
Figure 6.10: Typical RCV plot of DOPC monolayer in a flow cell42
Alterations to the organisation or fluidity of the DOPC monolayer alters the phase
transitions and thus the characteristic peak shapes, positions and heights in the RCV
plot. Reduction in height and broadening of peaks with no change in the baseline
current represents adsorption of a molecule onto the monolayer surface. Reduction
in the peak heights with an increase in the baseline current represents disruption of
the monolayer due to permeation of a molecule.53
Complexes were tested for their potential to interact with the artificial biomembrane
by Danielle Marriott and Dr. Shahrzad Mohamadi supervised by Professor Andrew
Nelson at The University of Leeds. Biomembrane studies of cobalt picolinamide
a)
b)a)
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complexes first requires the deposition of DOPC onto the electrode. A potential
excursion from -0.4 to -3.0 V at a scan rate of 100 V s-1 is applied, DOPC introduced
into the flow cell and the potential excursion altered to -0.4 to -1.2 V. By repetitive
cycling, the typical RCV plot are obtained. The complex is then introduced into the
flow cell and the RCV plot monitored while cycling the electrode potential from
-0.4 to -3.0 V.
Biomembrane interaction was not investigated for all complexes, only cobalt(III)
tris-picolinamide complexes were investigated as this was the only series of
complexes to contain a number of complexes which displayed activity or partial
activity against cancer cell lines. Complexes which displayed cytotoxicity (2.13 and
2.16b), their closest analogous inactive complex (2.11 and 2.14b) and a range of
other complexes within this series, encompassing complexes with substituents in the
ortho, meta and para positions and complexes with N,N and N,O coordination (2.2,
2.6, 2.7, 2.14a, 2.15a and 2.1b). The RCV plots of the interaction of the complexes
with the artificial biomembrane are shown in Figure 6.11.
186
-50
-40
-30
-20
-10
0
10
20
30
40
50
60
0.4 0.6 0.8 1 1.2
I/
μ
A
-E / V
-50
-40
-30
-20
-10
0
10
20
30
40
50
60
0.4 0.6 0.8 1 1.2
I/
μ
A
-E / V
-50
-40
-30
-20
-10
0
10
20
30
40
50
60
0.4 0.6 0.8 1 1.2
I/
μ
A
-E / V
-50
-40
-30
-20
-10
0
10
20
30
40
50
60
0.4 0.6 0.8 1 1.2
I/
μ
A
-E / V
-50
-40
-30
-20
-10
0
10
20
30
40
50
60
0.4 0.6 0.8 1 1.2
I/
μ
A
-E / V
-50
-40
-30
-20
-10
0
10
20
30
40
50
60
0.4 0.6 0.8 1 1.2
I/
μ
A
-E / V
2.2 2.6 2.7
2.11 2.13 2.14a
Chem
icalinvestigation
Chapter6
187
Figure 6.11: RCV plots for the interaction of complexes with the DOPC artificial biomembrane
Key: Black = DOPC membrane in the absence of complex, blue = DOPC membrane in the presence of complex
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The only complexes to show distortion of the DOPC membrane RCV plots are 2.13
and 2.16b. All other complexes show no changes in RCV plots meaning that these
complexes are not able to perturb the artificial biomembrane and as such are unable
to passively diffuse across the membrane. The implication is that if these complexes
enter a cell this can only be achieved through active transport with the aid of
membrane channels or transporter proteins. Complexes 2.13 and 2.16b are able to
interact with the biomembrane as visualised by alterations to the RCV plots, namely
reduction in the heights and broadening of the peaks with no change in baseline
current; these effects are more pronounced for complex 2.16b compared to 2.13.
These characteristic changes suggest that these complexes are able to adsorb onto
the membrane surface rather than being able to permeate the membrane.53 These
results suggest that these complexes also enter a cell through active transport rather
than passive diffusion.
The differences in biomembrane interaction between these two complexes and the
others tested may be due to the specific shape of these complexes as, for instance
complex 2.11 with the 3-(trifluoromethyl) picolinamide ligand shows no membrane
interaction whereas complex 2.13 with the 3,5-di(trifluoromethyl) picolinamide
ligand does show membrane interaction. Surface charge appears to not have an
effect as complexes with electronegative substituents, such as fluoro groups,
providing an area of negative surface charge do not perturb the biomembrane
despite their potential to interact with the positively charged DOPC head group. In
addition, the relative hydrophobicities of the complexes (Chapter 5.2) appears to not
have an effect as there is no correlation between the hyrdrophobicity data and the
ability to interact with the artificial biomembrane.
In addition to being the only complexes tested to display interaction with the
biomembrane, complexes 2.13 and 2.16b are also the lead anti-cancer complexes.
This correlation reveals a potential rationale for the activity of these two complexes,
perhaps their cytotoxicity is due to a higher degree of passage across the cell
membrane leading to improved accumulation within the cell compared to the
non-cytotoxic complexes. Complexes 2.13 and 2.16b are unable to passively diffuse
across the biomembrane but are able to adsorb onto the surface, once absorbed
onto a cell membrane surface there is the potential for the transfer of these
complexes into the cell. This mechanism of internalisation via energy-dependent
pathways has been previously observed in peptidomimetics and nanoparticles.57, 58
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6.4 Conclusions
Cobalt(III)-tris picolinamide, cobalt(II) bis-picolinamide and cobalt(III) mixed ligand
complexes with β-diketonate ligands were not observed to undergo hydrolysis. 
Cobalt(III) mixed ligand complexes with ferrocenyl β-diketonate ligands were 
observed to hydrolyse through the release of the ferrocenyl β-diketonate ligand 
resulting in a cobalt bis-picolinamide complex. An isolated ferrocenyl β-diketonate 
ligand has been shown to form an iron(III) tris-ferrocenyl β-diketonate complex 
following hydrolysis, where the iron is hypothesised to originate from the
breakdown of ferrocene. The rate of hydrolysis was found to be dependent upon the
nature of the substitution of the ferrocenyl β-diketonate ligand with more rapid 
hydrolysis rates observed with electron withdrawing groups compared to electron
donating groups. There was not found to be any correlation between the
hydrophobicities of various cobalt picolinamide complexes and cytotoxicity. The
interaction of cobalt tris-picolinamide complexes with an artificial biomembrane
revealed that most complexes were unable to interact with the phospholipid
membrane. However, the two lead complexes were able to interact with the
biomembrane through adsorption onto the membrane surface. The implication
being that these two complexes can undergo more facile entry into a cell through
the cell membrane which is the cause of the improved anti-cancer activity.
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7. Conclusions and further work
7.1 Conclusions
Picolinamide ligands have proven to be effective ligands for the formation of
complexes with a number of different metals.1-6 One of the interesting features of
these ligands is that there are three potential coordination modes to a metal centre:
neutral N,O-donors or monoanionic N,O- or N,N-donors (Figure 7.1).
Figure 7.1: Coordination modes for picolinamide ligand a) neutral N,O-donor
b) monoanionic N,O-donor c) monoanionic N,N-donor
Previous work within the McGowan group has uncovered the anti-cancer potential
of picolinamide complexes of ruthenium, rhodium, iridium and titanium.7-11 The
coordination mode of the picolinamide ligand has also been shown to impact the
chemical and biological properties of the complex.12 The aim of this thesis was the
exploration of the anti-cancer potential of a range of cobalt picolinamide complexes.
Three series of cobalt picolinamide complexes have been synthesised and
characterised in order to explore their potential biological applications. The first
series of complexes are octahedral cobalt(III) tris-picolinamide complexes (Figure
7.2). Two non-interconverting coordination isomers of these complexes are noted,
the major isomer with all three picolinamide ligands displaying N,N coordination and
the minor isomer with one of these ligands displaying monoanionic N,O coordination
instead. The minor isomer can only be isolated under certain reaction conditions
when the substituent on the aryl ring of the ligand is an electron donating group. The
synthetic route for the formation of the major isomer was optimised. However
optimisation of the synthetic route for the formation of the minor isomer was
unsuccessful.
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Figure 7.2: Cobalt(III) tris-picolinamide complexes with a) N,N coordination
b) mixed N,N and N,O coordination
The second series of complexes are octahedral cobalt(II) bis-picolinamide complexes
(Figure 7.3). These complexes contain two picolinamide ligands with neutral N,O
coordination and two axial ligand sites which have been occupied with thiocyanate,
chloride and aqua ligands. The axial thiocyanate ligands in the cobalt
bis-picolinamide thiocyanate complexes display either trans or cis geometry
depending upon the substituent on the picolinamide aryl ring. No substituents or
substituents in the meta position tend to give rise to the trans geometry, whereas
ortho or para substituents tend to give rise to complexes with the cis geometry. It is
hypothesised that the trans complex is the thermodynamic product of the synthesis.
Figure 7.3: Cobalt(II) bis-picolinamide complexes with a) trans thiocyanate b) cis
thiocyanate c) trans chloride d) trans aqua axial ligands
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The third series of complexes are octahedral cobalt(III) mixed ligand complexes
(Figure 7.4). These complexes contain two 3,5-di(trifluoromethyl) picolinamide
ligands with N,N coordination and one β-diketonate or ferrocenyl β-diketonate 
ligand. The synthesis of these complexes is controlled stoichiometrically, however a
number of side products reduces the experimental yields. The main side products
are the cobalt(III) tris-picolinamide complex and the cobalt(III) mixed ligand complex
with one picolinamide ligand and two β-diketonate ligands. 
Figure 7.4: Cobalt(III) mixed ligand complexes with a) β-diketonate b) ferrocenyl β-
diketonate ligand
The cobalt picolinamide complexes were screened for their anti-cancer, anti-
bacterial and anti-fungal properties. Complexes with anti-cancer activity tended to
belong to the cobalt(III) tris-picolinamide series and complexes with N,O
coordination were more active than the analogous N,N coordination complexes.
Cobalt tris-picolinamide complexes were tested under hypoxic conditions and found
to have lower cytotoxicity compared to when tested under normoxic conditions,
implying that these complexes do not undergo activation by reduction. Two lead
complexes (Figure 7.5) were identified and at physiologically relevant concentrations
were found to inhibit cell proliferation through interruption of M phase of the cell
cycle. Both complexes were also active against cancer stem cells and were able to
inhibit mammosphere formation and viability. The cobalt(II) bis-picolinamide
thiocyanate complexes were selectively toxic to the fungus C. albicans, however
activities were only moderate and thus no lead complexes were selected for further
study. The thiocyanate ligands were essential for activity; it is theorised that this is
due to their ability to undergo ligand substitution leading to the release of free
thiocyanate.
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Figure 7.5: Lead anti-cancer cobalt picolinamide complexes
Hydrolysis is often an important mechanism for activation of metal based drugs.13, 14
The cobalt(III)-tris picolinamide, cobalt(II) bis-picolinamide and cobalt(III) mixed
ligand complexes with β-diketonate ligands did not undergo hydrolysis over a five 
day period. Cobalt(III) mixed ligand complexes with ferrocenyl β-diketonate ligands 
underwent hydrolysis, thought to be due to the release of the ferrocenyl
β-diketonate ligand, resulting in a cobalt bis-picolinamide complex. The rate of
hydrolysis was found to be dependent upon the nature of the substitution of the
ferrocenyl β-diketonate ligand, with electron withdrawing groups associated with 
more rapid hydrolysis rates compared to electron donating groups. The
hydrophobicities of various cobalt picolinamide complexes was also determined but
there was no correlation between log P and cytotoxicity. The interaction of cobalt
tris-picolinamide complexes with an artificial biomembrane was studied. Most
complexes were unable to interact with the phospholipid membrane suggesting no
role for passive diffusion in the uptake mechanism, whereas the two lead complexes
did show an association with the membrane through adsorption onto the membrane
surface. The implication is that the two lead complexes may undergo more facile
entry into a cell through the cell membrane via ATP-dependent mechanisms which
is the cause of the improved anti-cancer activity.
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7.2 Further work
A variety of substituents on the aryl ring of the picolinamide ligand have been
investigated. However a greater number and variety of substituents would provide
a greater number of complexes for investigation. This can be performed in a targeted
manner following on from the initial results presented in this thesis. For example, a
greater number of fluorinated ligands or ligands with substituents in both meta
positions may be synthesised as both these types of ligand furnished cobalt
complexes with anti-cancer activity. Coordinating groups on the picolinamide aryl
ring provide the potential to coordinate secondary metal ions, which is thought to
be responsible for the anti-cancer and anti-bacterial activity of previous cobalt(III)
complexes with bidentate or tridentate picolinamide ligands.15, 16 The synthesis of
similar picolinamide ligands with coordinating groups, e.g. hydroxyl or amine would
test this hypothesis in these systems. No investigation into the effect of substitution
of the pyridyl ring has been performed, however the high price and limited
availability of substituted picolinic acids precludes a detailed investigation via the
current synthetic route. Alternatively, different heterocycles such as quinaldamides,
pyrrolidines or azoles could replace the pyridyl ring.
Another area of the picolinamide ligand which can be modified is the carbonyl group
which could be varied as for example an amidine or thioester (Figure 7.6) to
investigate the impact of changing the inner coordination sphere. Only a brief
investigation has been carried out so far with thiopicolinamide ligands which did not
result in the formation of any cobalt thiopicolinamide complexes. The methylation
of the picolinamide amide group (Figure 7.6) would limit the potential binding modes
of the ligand to only N,O coordination and thus could be used for the formation of
further cobalt picolinamide isomers and the investigation into any further
differences in biological activity between isomers.
Figure 7.6: Examples of potential picolinamide ligand modifications
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Only bidentate picolinamide ligands have been investigated in this thesis; there is
also the capacity to investigate both tridentate and tetradentate picolinamide
ligands (Figure 7.7).
Figure 7.7: General structure of a) tridentate b) tetradentate picolinamide ligands
The cobalt(III) tris-picolinamide complexes were only able to form both the N,N and
N,O coordination isomers when the aryl substituent was an electron donating group.
However, the number of synthesised ligands containing electron donating groups
was limited. The synthesis of further complexes with more electron donating groups,
such as tert-butyl or amines, would help reveal trends between the strength of
electron donation and sterics with the proportion of N,O isomer formed and any
associated cytotoxicity. The N,O coordination isomers showed improved cytotoxicity
compared to the analogous N,N coordination complexes, however the N,O isomer is
the minor isomer. The synthesis was not successfully optimised to maximise the
formation of this isomer. Previous work with ruthenium(III) picolinamide complexes
found that the N,N isomer was the thermodynamic product of the synthetic route
whereas the N,O isomer was the kinetic product and the equilibrium between the
formation of these two isomers was temperature and pH dependent.12 It would be
worth investigating whether alterations in time, temperature or pH affect the
formation of the N,O coordination isomer in this cobalt picolinamide system. In
addition, the formation of monocationic cobalt(III) tris-picolinamide complexes
involving one picolinamide ligand with neutral N,O coordination (Figure 7.8) with
subsequent anti-cancer investigation would allow the full comparison of the
different coordination modes in these types of cobalt(III) tris-picolinamide
complexes.
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Figure 7.8: General structure of monocationic cobalt(III) tris-picolinamide with
neutral N,O coordination
The cobalt(II) bis-picolinamide complexes were only able to form when the aryl ring
substituent was an electron donating group. The series could be expanded following
the synthesis of a greater number of ligands with a diverse range of electron
donating groups attached. Investigations into the synthetic route for complex
formation may also allow the formation of complexes with electron withdrawing
groups as the aryl substituent, a feat which has yet to be accomplished. It would be
interesting to note if the relationship between the aryl substituent position and the
cis/trans geometry of the cobalt bis-picolinamide complex remains the same if
electron withdrawing groups are present. The evidence so far suggests that the
nature of the cobalt starting material has no effect on the geometry of the final
complex, however further syntheses with a greater variety of cobalt salts is needed
to confirm this hypothesis. Computational studies into the stability of cis and trans
complexes may reveal the reasons behind the differing geometries adopted and
whether one constitutes the thermodynamic product and the other the kinetic
product of the reaction.12
It is theorised that trans and cis cobalt(II) bis-picolinamide thiocyanate complexes
may have different rates of exchange of the axial thiocyanate ligands. Computational
studies can calculate the bond dissociation energies for the cobalt-nitrogen
(thiocyanate) bond to discern if there is a difference which may lead to different
rates of exchange in solution. Experimental 1H NMR studies with deuterium oxide or
labelled groups may also permit investigation of this theory. Adaptations of cobalt(II)
bis-picolinamide complexes with alternative axial ligands have been synthesised,
however there are only a couple of examples of these with the unsubstituted
picolinamide ligand. The next step would be the expansion of these series with a
greater number of both picolinamide ligands and axial ligands. Alternative axial
ligands such as imidazole groups have been synthesised but could not be isolated,
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further effort is needed in the investigation into the synthesis and purification of
such complexes.
The cobalt(III) mixed ligand complexes synthesised contain two picolinamide ligands
with a 3,5-di(trifluoromethyl) group as the aryl substituent and a variable
β-diketonate or ferrocenyl β-diketonate ligand. The 3,5-di(trifluoromethyl) 
picolinamide ligand was selected as the associated cobalt(III) tris-picolinamide
complex showed activity against various cancerous cell lines. However, the series
could be expanded with a number of the other picolinamide ligands synthesised. A
greater range of aryl substituents on the β-diketonate ligand can also be 
investigated, for instance there were no examples of β-diketonate ligands with the 
aryl substituent in the ortho position.
The synthesis of the mixed ligand complex where the β-diketonate ligand was 
curcumin, was shown to be successful by mass spectrometry but the complex could
not be isolated. Further attempts to synthesise and purify this complex are desirable
as curcumin is under investigation as a potential anti-cancer drug, thus a cobalt
curcumin complex may act as a chaperone to improve the biological properties
e.g. bioavailability of curcumin.
Yields of mixed ligand complexes were low due to the formation of a number of side
products; optimisation of the synthetic route is required for improvement. One of
the side products produced is the cobalt(III) mixed ligand complex with one
picolinamide ligand and two β-diketonate ligands (Figure 7.9). Synthesis of a series
of these compounds would provide an interesting comparison with the series of
cobalt(III) picolinamide β-diketonate mixed ligand complexes synthesised so far. In 
this work only cobalt(III) picolinamide mixed ligand complexes with β-diketonate 
ligands have been synthesised, but other additional ligands may also be used
e.g. β-ketoiminate or amino acid based ligands. The ability to attach diverse ligand 
types to the mixed ligand complexes would open the opportunity to attach a variety
of known drugs to the structure to investigate whether the cobalt(III) picolinamide
mixed ligand can act as chaperones.
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Figure 7.9: Cobalt(III) mixed ligand complex with one picolinamide ligand and two
β-diketonate ligands 
The anti-cancer activity of the cobalt picolinamide complexes was evaluated against
two cancerous cell lines and one non-cancerous cell line. From these investigations,
two lead complexes were identified. The evaluation of these two leads against a
number of further cancerous cell lines is necessary to examine their potential as anti-
cancer drugs against specific cancers. These studies may also uncover underlying
targets or mechanisms of action, allowing further cycles of informed drug
development. One of the main reason that a potential drug does not progress
through clinical trials is toxicity to non-target cells leading to adverse drug
reactions.17 Toxicity to hepatocytes is frequently seen as the liver is the main organ
responsible for the metabolism of drugs. Investigation into the potential toxicity of
the two lead complexes to hepatocytes can be investigated with various in vitro
studies, for example using cultured hepatocytes or liver slices.18
The investigation into the performance of complexes in a hypoxic environment was
only performed with the cobalt(III) tris-picolinamide complexes, the behaviour of the
cobalt(III) mixed ligand complexes under hypoxia should also be investigated.
Hypoxic studies of cobalt(III) tris-picolinamide complexes suggests that these
complexes may undergo bioreduction to inactive cobalt(II) bis-picolinamide
complexes. The reduction potential of this Co(III)/Co(II) couple could be determined
for the cobalt(III) tris-picolinamide complexes using cyclic voltammetry to ascertain
whether this reduction is biologically feasible.
At physiologically relevant concentrations, the two lead complexes were found to
induce cell cycle arrest at M phase. However, due to the low proportion of cells in
M phase at any given time point any changes in population are small. Therefore,
further investigation of these complexes at higher concentrations and shorter
exposure times would be beneficial as these conditions should reduce the amount
of natural cell death and reduce the number of aggregated cells, thus more
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accurately presenting the effects of the complexes on the cell cycle. Most drugs
which act at M phase of the cell cycle inhibit the polymerisation of tubulin, which is
essential for spindle formation; the ability of the two lead complexes to bind tubulin
and inhibit tubulin polymerisation should be investigated. Further investigations to
uncover the mechanism of action of these lead complexes are essential, for example
investigations into any anti-metastatic properties, the ability to bind to DNA,
induction of changes in protein expression or interaction with various intracellular
targets.
The cobalt(II) bis-picolinamide thiocyanate complexes were shown to have
moderate anti-fungal activity. Previous cobalt complexes in the literature with
anti-fungal properties have shown decreased activity compared to their copper
analogues.19, 20 Therefore the synthesis of the analogous copper(II) bis-picolinamide
thiocyanate complexes and evaluation of their anti-fungal properties would be of
interest.
Investigation into the chemical properties of a range of cobalt picolinamide
complexes found that cobalt(III) tris-picolinamide complexes and cobalt(III) mixed
ligand complexes with β-diketonate ligands did not undergo hydrolysis. However, 
these investigations were performed with 20 % water, due to the lack of solubility of
some complexes at higher percentages of water. For complexes which are soluble at
higher concentrations of water it should be confirmed that the behaviour of the
complexes does not alter. Cobalt(III) mixed ligand complexes with ferrocenyl
β-diketonate ligands underwent hydrolysis with 20 % water. If these complexes are 
sufficiently soluble, this behaviour should be confirmed with different
concentrations of water, to determine if a particular threshold level of water is
required or if the behaviour or resultant hydrolytic products differ with changes in
concentration. For complexes which undergo hydrolysis, the rates of hydrolysis and
the amount of hydrolysis should be quantified as previous work within the McGowan
group with ruthenium(III) bis-picolinamide complexes has shown a correlation
between the amount of hydrolysis and cytotoxicity. The current rates of hydrolysis
appear to depend upon the nature of the ligand substituent, with more electron
withdrawing groups leading to more rapid hydrolysis compared to electron donating
groups. This hypothesis should be confirmed by monitoring the hydrolysis of all of
the cobalt(III) mixed ligand complexes with ferrocenyl β-diketonate ligands. The 
determination of the hydrolytic products of the complexes would be informative, at
present only one product from the hydrolysis of a ferrocenyl β-diketonate ligand as 
opposed to the complex itself has been identified through X-ray crystallography.
Conclusions Chapter 7
205
Through artificial biomembrane studies, it was found that the two lead complexes
could interact with the membrane whereas the inactive complexes did not show any
interaction. This implies that the uptake of the lead complexes into the cell is
improved compared to the inactive complexes. This result with the artificial
biomembrane should be confirmed with in vitro studies using inductively coupled
plasma mass spectrometry (ICP-MS) to determine the intracellular cobalt
concentration (and distribution) before and after incubation with the two lead
complexes. Only cobalt(III) tris-picolinamide complexes were investigated, therefore
investigation of the other series of cobalt picolinamide complexes would be
instructive to determine if these are inactive due to poor membrane interaction.
Cobalt(III) tris-picolinamide complexes have previously been noted to be active and
selective catalysts for the oxidation of ethylbenzene to acetophenone with oxygen
as the oxidant.21 No catalytic studies have been performed on any of the cobalt
picolinamide complexes in this work. The evaluation of all the cobalt picolinamide
complexes as potential catalysts for the oxidation of ethylbenzene and other organic
compounds is highly desirable.
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8. Experimental section
8.1 General experimental procedures
All ligands and complexes were synthesised under aerobic conditions. All chemicals
were supplied by Sigma-Aldrich Chemical Co., Acros Organics, Alfa Aesar and BOC
gases. Deuterated NMR solvents were purchased from Sigma-Aldrich Chemical Co.
or Acros Organics.
8.2 Instrumentation
All NMR spectra were acquired using a Bruker Avance 300, 400 or 500 MHz
spectrometer. Chemical shifts (δ) are expressed in parts per million (ppm) and 
referred to the solvent signal, used as an internal reference. Mass spectra were
recorded at the University of Leeds Mass Spectrometry Service on a Bruker Daltonics
MicroTOF instrument with electrospray ionisation (ESI) and a photodiode array
analyser. Microanalyses were acquired either by Ms. Tanya Marinko-Covell at the
University of Leeds Microanalytical Service using a Carlo Erba 1108 Elemental
Analyser or by Mr. Stephen Boyer at the London Metropolitan University Elemental
Analysis Service. Infrared spectra were acquired on a Perkin-Elmer SpectrumOne
FT-IR spectrometer. UV/vis absorption spectra were acquired on a Cary Series
UV-Vis spectrophotometer using 1 cm path length quartz cuvettes. Magnetic
susceptibility measurements were performed by Dr. Rafal Kulmaczewski at the
University of Leeds on a Quantum Design VSM SQUID magnetometer in an applied
field of 500 G.
8.3 X-Ray crystallography
Single crystal X-ray diffraction data were collected by the author or Dr. Christopher
Pask using an Agilent (Rigaku) SuperNova X-ray diffractometer fitted with an Atlas
area detector using mirror monochromated Mo-Kα (λ = 0.71073 Å) or Cu-Kα
(λ = 1.54184 Å) radiation. The crystal was cooled to 120 K using an Oxford Cryosystem 
low temperature device.1 The full dataset was collected and the images processed
using CrysAlisPro program.2 Structure solution by direct methods was achieved
through the use of SHELXS86,3 SHELXL-20144 or SHELXT,5 and the structural model
was refined by full matrix least squares on F2 using SHELX976 interfaced through the
program Olex2.7 Molecular graphics were plotted, editing of CIFs and construction
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of tables of bond lengths and angles were achieved using Olex2. Unless otherwise
stated, hydrogen atoms were placed using idealised geometric positions (with free
rotation for methyl groups), allowed to move in a “riding model” along with the
atoms to which they were attached, and refined isotropically. The SQUEEZE routine
of Platon was used to refine structures where diffuse electron density could not be
adequately modelled as solvent of crystallisation.8
8.4 X-Ray powder diffraction
X-ray powder diffraction data were collected by the author or Dr. Christopher Pask
using a Bruker AXS D2Phaser diffractometer. Data collection was carried out at room
temperature using Cu-Kα (λ = 1.54184 Å) radiation. Diffraction patterns were 
recorded in step-scan mode with a step size of 0.2° from 5° to 50° (5 s per step) using
a 0.1 mm divergent slit. Experimental data was processed using Diffrac.Suite Eva9
and Chekcell.10 Mercury was used to simulate the powder diffraction pattern from
the single crystal structures.11
8.5 Syntheses of N-aryl picolinamide ligands
Ligands 1.1 - 1.21 have been previously reported in the literature;12-17 only the
characterisation of novel ligand 1.22 is reported in detail. Ligands 1.2 - 1.8 and 1.10
were synthesised and characterised by Dr. Carlo Sambiagio, Dr. Aida Basri or Dr.
Christopher Pask (University of Leeds).
8.5.1 General synthetic procedure for N-aryl picolinamide ligands
Ligands 1.1 - 1.10 and 1.12 - 1.22 were synthesised via a literature method.18 The
required aniline (1 equivalent) was added to a solution of pyridine-2-carboxylic acid
(1 equivalent) in pyridine and warmed to 50 °C for 15 minutes. To this mixture,
triphenylphosphite (1 equivalent) was added and heated at 110 °C for 18 hours. After
cooling to room temperature, addition of distilled water precipitated out the crude
product (for ligands 1.2 - 1.10 and 1.12 - 1.14) which was isolated by filtration,
washed with distilled water and purified by recrystallisation from hot methanol. For
ligands 1.1 and 1.15 - 1.22, addition of distilled water instead yielded an oil,
dichloromethane was added to the mixture and the organic layer separated from the
aqueous layer. The product in the organic layer was extracted three times with
1:1 (v/v) aqueous hydrochloric acid. To neutralise the acid extract, sodium
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bicarbonate was added until pH 7 was reached. The crude product was isolated by
filtration, washed with distilled water and purified by recrystallisation from hot
methanol.
8.5.2 General synthetic procedure for ligand 1.11
Ligand 1.11 was synthesised via an alternative literature method.19 Pyridine-2-
carboxylic acid (1 equivalent), the required aniline (1 equivalent) and triethylamine
(2 equivalents) were dissolved in dichloromethane and stirred at 0 °C. To this
mixture, phosphorus(V) oxychloride (2 equivalents) was added dropwise and stirred
at 0 °C for 15 minutes. The mixture was gradually warmed to room temperature
while stirring for 2 hours. Excess phosphorus(V) oxychloride was quenched by slow
addition of distilled water, then the product in the organic layer was extracted with
dichloromethane. Organic fractions were combined and the evaporated to give the
crude product which was purified by recrystallisation from hot pentane.
8.5.3 Synthesis of C20H14N2O (1.22)
Brown solid (0.962 g, 3.225 mmol, 64 %). Recrystallisation by vapour diffusion
(chloroform/pentane) at room temperature yielded yellow crystals suitable for
single crystal X-ray diffraction.
1H NMR (CDCl3, 500.23 MHz, 300.0 K) δ 10.93 (br. s, 1H, 
NH), 8.81 (d, 1H, Ha, 3J (1H-1H) = 4.6 Hz), 8.64 (s, 1H, Hl),
8.50 (s, 1H, Hs), 8.43 (d, 1H, Hh, 3J (1H-1H) = 2.5 Hz), 8.42
(d, 1H, Hd, 3J (1H-1H) = 3.2 Hz), 8.13 (m, 1H, Hn or Hq), 8.04
(m, 1H, Hn or Hq), 8.00 (td, 1H, Hc, 3J (1H-1H) = 7.7 Hz and
3J (1H-1H) = 1.6 Hz), 7.89 (d, 1H, Hj, 3J (1H-1H) = 8.5 Hz), 7.59 (ddd, 1H, Hb, 3J (1H-1H) =
7.7 Hz, 3J (1H-1H) = 4.9 Hz and 4J (1H-1H) = 1.1 Hz), 7.52 (m, 3H, Hi, Ho and Hp) 13C{1H}
NMR (CDCl3, 125.9 MHz, 299.3 K) δ 162.4 (quaternary C-O, Cf), 150.2 (quaternary
aniline C, Ce), 148.2 (aniline CH, Ca), 137.8 (aniline CH, Cc), 132.2 (quaternary
aromatic C, Ck), 132.1 (quaternary aromatic C, Ct), 131.6 (aromatic CH, Co and Cp),
128.5 (aromatic CH, Cn or Cq), 128.0 (aromatic CH, Cn or Cq), 127.3 (aromatic CH, Cs),
126.6 (aniline CH, Cb), 125.8 (quaternary aromatic C, Cm), 125.7 (quaternary aromatic
C, Cr), 125.5 (quaternary aromatic C, Cg), 125.4 (aromatic CH, Cj), 125.3 (aromatic CH,
Ci), 122.6 (aniline CH, Cd), 119.1 (aromatic CH, Cl), 117.5 (aromatic CH, Ch) Analysis
calculated C 80.52, H 4.73, N 9.39 % Analysis found C 80.20, H 4.60, N 9.20 % ES MS
(+) (CH3OH) m/z 299.12 [MH+] IR (cm-1) ν 3352 (m, NH), 3048 (w, Ar CH), 1683 (m, 
CO), 1540 (m), 1516 (s), 1460 (m), 1400 (m), 1347 (m), 1210 (w), 1136 (w), 1014 (w),
843 (s), 728 (s), 632 (s), 531 (s)
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8.6 Syntheses of β-diketonate ligands 
β-Diketonate ligands have been previously reported in the literature20-22 and thus
the characterisation data is not reported here. Aside from the 4-(trifluoromethyl)
β-diketonate ligand, all ligands were synthesised and characterised by Dr. Felix 
Janeway or Dr. Andrew Hebden (University of Leeds).
8.6.1 General synthetic procedure for β-diketonate ligands 
Ligands were synthesised via a literature method.23 Sodium ethoxide (1 equivalent)
was added to a solution of the required acetophenone (1 equivalent) in ethyl acetate
and heated at 80 °C for 4 hours. After cooling to room temperature, ice cold sulfuric
acid was added dropwise until the mixture was just acidic. The crude product was
extracted three times into diethyl ether, dried over magnesium sulfate, filtered and
the solvent removed under reduced pressure to yield the pure product.
8.7 Syntheses of cobalt(III) tris-picolinamide complexes (N,N
coordination)
The required picolinamide ligand (3 equivalents) in ethanol (10 mL) was added to a
solution of cobalt(II) chloride hexahydrate (1 equivalent) in distilled water (10 mL).
Triethylamine (3 equivalents) was added and the mixture was heated at 85 °C for
2 hours to give a brown solution. The solvent was removed under reduced pressure
and the product purified by column chromatography (methanol/diethyl ether).
Product was dissolved in dichloromethane or chloroform, filtered through a sinter
and the pure product was precipitated with the addition of hexane.
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8.7.1 Synthesis of CoC36H27N6O3 (2.1a)
Purified by column chromatography (methanol/diethyl ether 9:1) to give a red solid
(0.225 g, 0.346 mmol, 82 %). Recrystallisation by vapour diffusion
(acetonitrile/diethyl ether) at 5 °C yielded red crystals suitable for single crystal X-
ray diffraction.
1H NMR (CDCl3, 500.23 MHz, 300.2 K) δ 9.17 (d, 1H, Ha,
Ha’ or Ha’’, 3J (1H-1H) = 5.5 Hz), 8.59 (d, 1H, Ha, Ha’ or Ha’’,
3J (1H-1H) = 5.7 Hz), 8.37 (d, 1H, Hd, Hd’ or Hd’’, 3J (1H-1H) =
7.6 Hz), 8.12 (t, 1H, Hc, Hc’ or Hc’’, 3J (1H-1H) = 7.4 Hz), 7.97
(d, 1H, Hd, Hd’ or Hd’’, 3J (1H-1H) = 7.3 Hz), 7.78 (t, 1H, Hc,
Hc’ or Hc’’, 3J (1H-1H) = 7.1 Hz), 7.73 (m, 2H, Hc, Hc’ or Hc’’
and Hd, Hd’ and Hd’’), 7.66 (ddd, 1H, Hb, Hb’ or Hb’’, 3J (1H-
1H) = 7.0 Hz, 3J (1H-1H) = 5.7 Hz and 4J (1H-1H) = 1.3 Hz), 7.26 (m, 2H, Hh and Hl, Hh’
and Hl’ or Hh’’ and Hl’’), 7.17 (m, 2H, Ha, Ha’ or Ha’’ and Hb, Hb’ or Hb’’), 7.14 (ddd, 1H,
Hb, Hb’ or Hb’’, 3J (1H-1H) = 7.0 Hz, 3J (1H-1H) = 5.7 Hz and 4J (1H-1H) = 1.2 Hz), 6.95 (m,
6H, Hh and Hl, Hh’ and Hl’ or Hh’’ and Hl’’, Hi and Hk, Hi’ and Hk’ or Hi’’ and Hk’’, Hj, Hj’ or
Hj’’ and Hj, Hj’ or Hj’’), 6.81 (t, 1H, Hj, Hj’ or Hj’’, 3J (1H-1H) = 7.3 Hz), 6.71 (t, 2H, Hi and
Hk, Hi’ and Hk’ or Hi’’ and Hk’’, 3J (1H-1H) = 7.7 Hz), 6.49 (br. s, 2H, Hh and Hl, Hh’ and Hl’
or Hh’’ and Hl’’), 6.12 (br. s, 2H, Hi and Hk, Hi’ and Hk’ or Hi’’ and Hk’’) 13C {1H} NMR
(CDCl3, 125.8 MHz, 300.1 K) δ 170.4 (quaternary C-O, Cf, Cf’ or Cf’’), 169.5 (quaternary
C-O, Cf, Cf’ or Cf’’), 168.9 (quaternary C-O, Cf, Cf’ or Cf’’), 158.5 (quaternary aniline C,
Ce, Ce’ or Ce’’), 157.2 (quaternary aniline C, Ce, Ce’ or Ce’’), 156.7 (quaternary aniline C,
Ce, Ce’ or Ce’’), 149.7 (aniline CH, Ca, Ca’ or Ca’’), 149.0 (aniline CH, Ca, Ca’ or Ca’’), 148.4
(aniline CH, Ca, Ca’ or Ca’’), 145.9 (quaternary aromatic C, Cg, Cg’ or Cg’’), 144.3
(quaternary aromatic C, Cg, Cg’ or Cg’’), 143.7 (quaternary aromatic C, Cg, Cg’ or Cg’’),
140.5 (aniline CH, Cc, Cc’ or Cc’’), 139.5 (aniline CH, Cc, Cc’ or Cc’’), 139.4 (aniline CH, Cc,
Cc’ or Cc’’), 129.3 (aromatic CH, Ch and Cl, Ch’ and Cl’ or Ch’’ and Cl’’, and Ch and Cl, Ch’
and Cl’ or Ch’’ and Cl’’), 128.8 (aromatic CH, Ch and Cl, Ch’ and Cl’ or Ch’’ and Cl’’), 128.1
(aniline CH, Cb, Cb’ or Cb’’ and Cb, Cb’ or Cb’’), 127.7 (aniline CH, Cb, Cb’ or Cb’’), 126.7
(aromatic CH, Ci and Ck, Ci’ and Ck’ or Ci’’ and Ck’’, and Ci and Ck, Ci’ and Ck’ or Ci’’ and
Ck’’), 126.6 (aromatic CH, Ci and Ck, Ci’ and Ck’ or Ci’’ and Ck’’), 125.9 (aniline CH, Cd, Cd’
or Cd’’), 125.8 (aniline CH, Cd, Cd’ or Cd’’ and Cd, Cd’ or Cd’’), 125.5 (aromatic CH, Cj, Cj’
or Cj’’), 125.1 (aromatic CH, Cj, Cj’ or Cj’’), 124.8 (aromatic CH, Cj, Cj’ or Cj’’) Analysis
calculated (+ 2 H2O) C 62.97, H 4.55, N 12.24 % Analysis found C 63.40, H 4.00, N
11.90 % ES MS (+) (CH3OH) m/z 651.16 [MH+] IR (cm-1) ν 3051 (w, ArCH), 1620 (s, 
CO), 1585 (s, CO), 1567 (s, CO), 1487 (m), 1364 (m), 1289 (w), 1145 (w), 759 (m), 685
(m), 503 (m)
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8.7.2 Synthesis of CoC36H24N6O3F3 (2.2)
Purified by column chromatography (methanol/diethyl ether 9:1) to give a brown
solid (0.220 g, 0.313 mmol, 75 %). Recrystallisation by slow evaporation
(ethanol/water) at room temperature yielded red crystals suitable for single crystal
X-ray diffraction.
1H NMR (CDCl3, 500.23 MHz, 300.1 K) δ 9.24 (br. s, 1H, 
Ha, Ha’ or Ha’’), 8.78 (t, 1H, Ha, Ha’ or Ha’’, 3J (1H-1H) = 6.2
Hz), 8.31 (d, 1H, Hd, Hd’ or Hd’’, 3J (1H-1H) = 7.6 Hz), 8.07 (t,
1H, Hc, Hc’ or Hc’’, 3J (1H-1H) = 7.2 Hz), 8.02 (d, 1H, Hd, Hd’
or Hd’’, 3J (1H-1H) = 7.3 Hz), 7.84 (t, 1H, Hc, Hc’ or Hc’’, 3J (1H-
1H) = 7.7 Hz), 7.75 (m, 2H, Hc, Hc’ or Hc’’and Hd, Hd’ or Hd’’),
7.66 (ddd, 1H, Hb, Hb’ or Hb’’, 3J (1H-1H) = 7.4 Hz, 3J (1H-1H)
= 5.9 Hz and 4J (1H-1H) = 1.4 Hz), 7.58 (ddd, 1H, Hb, Hb’ or Hb’’, 3J (1H-1H) = 7.2 Hz, 3J
(1H-1H) = 5.7 Hz and 4J (1H-1H) = 1.3 Hz), 7.50 (br. s, 1H, Ha, Ha’ or Ha’’), 7.23 (m, 3H,
Hi, Hi’ or Hi’’, Hk, Hk’ or Hk’’ and Hl, Hl’ or Hl’’), 7.12 (ddd, 1H, Hb, Hb’ or Hb’’, 3J (1H-1H) =
7.0 Hz, 3J (1H-1H) = 5.7 Hz and 4J (1H-1H) = 1.3 Hz), 6.95 (m, 2H, Hk, Hk’ or Hk’’ and Hl,
Hl’ or Hl’’), 6.86 (m, 2H, Hi, Hi’ or Hi’’ and Hl, Hl’ or Hl’’), 6.50 (m, 3H, Hi, Hi’ or Hi’’, Hj, Hj’
or Hj’’ and Hk, Hk’ or Hk’’), 5.42 (t, 1H, Hj, Hj’ or Hj’’, 3J (1H-1H) = 7.7 Hz), 5.27 (t, 1H, Hj,
Hj’ or Hj’’, 3J (1H-1H) = 7.7 Hz) 13C {1H} NMR (CDCl3, 125.8 MHz, 300.1 K) δ 169.9 
(quaternary C-O, Cf, Cf’ or Cf’’), 169.5 (quaternary C-O, Cf, Cf’ or Cf’’), 169.1 (quaternary
C-O, Cf, Cf’ or Cf’’), 158.0 (quaternary aniline C, Ce, Ce’ and Ce’’), 150.0 (aniline CH, Ca,
Ca’ or Ca’’), 149.9 (aniline CH, Ca, Ca’ or Ca’’), 149.6 (aniline CH, Ca, Ca’ or Ca’’), 151.1
(quaternary aromatic C, Ch, Ch’ or Ch’’), 150.9 (quaternary aromatic C, Ch, Ch’ or Ch’’
and Ch, Ch’ or Ch’’), 140.4 (aniline CH, Cc, Cc’ or Cc’’), 139.8 (aniline CH, Cc, Cc’ or Cc’’),
139.3 (aniline CH, Cc, Cc’ or Cc’’), 133.2 (quaternary aromatic C, Cg, Cg’ or Cg’’), 131.8
(quaternary aromatic C, Cg, Cg’ or Cg’’), 130.9 (quaternary aromatic C, Cg, Cg’ or Cg’’),
127.8 (aromatic CH, Cj, Cj’ or Cj’’), 127.3 (aromatic CH, Cj, Cj’ or Cj’’ and Cj, Cj’ or Cj’’),
127.2 (aniline CH, Cb, Cb’ or Cb’’), 126.9 (aniline CH, Cb, Cb’ or Cb’’), 126.8 (aniline CH,
Cb, Cb’ or Cb’’), 126.3 (aniline CH, Cd, Cd’ or Cd’’), 126.0 (aniline CH, Cd, Cd’ or Cd’’ and Cd,
Cd’ or Cd’’), 125.3 (aromatic CH, Ck, Ck’ or Ck’’), 125.2 (aromatic CH, Ck, Ck’ or Ck’’ and Ck,
Ck’ or Ck’’), 124.9 (aromatic CH, Cl, Cl’ or Cl’’), 123.8 (aromatic CH, Cl, Cl’ or Cl’’ and Cl, Cl’
or Cl’’), 115.7 (aromatic CH, Ci, Ci’ or Ci’’), 115.5 (aromatic CH, Ci, Ci’ or Ci’’), 115.3
(aromatic CH, Ci, Ci’ or Ci’’) Analysis calculated (+ 1 H2O) C 59.84, H 3.63, N 11.63 %
Analysis found C 59.70, H 3.40, N 11.48 % ES MS (+) (CH3OH) m/z 705.13 [MH+] IR
(cm-1) ν 3080 (w, ArCH), 1625 (m, CO), 1590 (m, CO), 1489 (m), 1362 (m), 1096 (w), 
762 (s), 687 (m), 508 (m)
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8.7.3 Synthesis of CoC36H24N6O3F3 (2.3)
Purified by column chromatography (methanol/diethyl ether 9:1) to give a brown
solid (0.192 g, 0.272 mmol, 65 %). Recrystallisation by vapour diffusion
(methanol/diethyl ether) at 5 °C yielded red crystals suitable for single crystal X-ray
diffraction.
1H NMR (CDCl3, 500.23 MHz, 299.9 K) δ 9.03 (d, 1H, Ha,
Ha’ or Ha’’, 3J (1H-1H) = 5.3 Hz), 8.55 (d, 1H, Ha, Ha’ or Ha’’,
3J (1H-1H) = 5.3 Hz), 8.38 (d, 1H, Hd, Hd’ or Hd’’, 3J (1H-1H)
= 7.3 Hz), 8.16 (td, 1H, Hc, Hc’ or Hc’’, 3J (1H-1H) = 7.2 Hz
and 3J (1H-1H) = 1.1 Hz), 7.99 (d, 1H, Hd, Hd’ or Hd’’, 3J
(1H-1H) = 7.8 Hz), 7.86 (td, 1H, Hc, Hc’ or Hc’’, 3J (1H-1H) =
7.2 Hz and 3J (1H-1H) = 1.1 Hz), 7.78 (m, 2H, Hc, Hc’ or
Hc’’and Hd, Hd’ or Hd’’), 7.69 (ddd, 1H, Hb, Hb’ or Hb’’, 3J (1H-1H) = 6.8 Hz, 3J (1H-1H) = 5.5
Hz and 4J (1H-1H) = 1.1 Hz), 7.24 (m, 5H, Ha, Ha’ or Ha’’, Hb, Hb’ or Hb’’, Hb, Hb’ or Hb’’, Hh,
Hh’ or Hh’’ and Hj, Hj’ or Hj’’), 6.98 (m, 3H, Hh, Hh’ or Hh’’, Hj, Hj’ or Hj’’ and Hk, Hk’ or Hk’’),
6.69 (m, 2H, Hj, Hj’ or Hj’’ and Hk, Hk’ or Hk’’), 6.54 (t, 1H, Hl, Hl’ or Hl’’, 3J (1H-1H) = 8.0
Hz), 6.46 (br. s, 1H, Hh, Hh’ or Hh’’), 6.19 (br. s, 2H, Hk, Hk’ or Hk’’ and Hl, Hl’ or Hl’’), 5.64
(br. s, 1H, Hl, Hl’ or Hl’’) 13C {1H} NMR (d6-DMSO, 100.6 MHz, 300.0 K) δ 169.5 
(quaternary C-O, Cf, Cf’ or Cf’’), 169.0 (quaternary C-O, Cf, Cf’ or Cf’’), 168.5 (quaternary
C-O, Cf, Cf’ or Cf’’), 156.5 (quaternary aniline C, Ce, Ce’ or Ce’’ and Ce, Ce’ or Ce’’), 155.3
(quaternary aniline C, Ce, Ce’ or Ce’’), 151.5 (quaternary aromatic C, Ci, Ci’ and Ci’’),
150.0 (aniline CH, Ca, Ca’ or Ca’’ and Ca, Ca’ or Ca’’), 149.5 (aniline CH, Ca, Ca’ or Ca’’),
146.3 (quaternary aromatic C, Cg, Cg’ and Cg’’), 141.4 (aniline CH, Cc, Cc’ or Cc’’), 140.5
(aniline CH, Cc, Cc’ or Cc’’), 140.4 (aniline CH, Cc, Cc’ or Cc’’), 129.7 (aniline CH, Cb, Cb’ or
Cb’’), 129.4 (aniline CH, Cb, Cb’ or Cb’’), 128.4 (aniline CH, Cb, Cb’ or Cb’’), 128.2 (aniline
CH, Cd, Cd’ or Cd’’ and Cd, Cd’ or Cd’’), 128.1 (aniline CH, Cd, Cd’ or Cd’’), 126.1 (aromatic
CH, Cl, Cl’ or Cl’’ and Cl, Cl’ or Cl’’), 125.3 (aromatic CH, Cl, Cl’ or Cl’’), 124.3 (aromatic
CH, Ck, Ck’ or Ck’’ and Ck’ or Ck’’), 123.4 (aromatic CH, Ck, Ck’ or Ck’’), 114.7 (aromatic
CH, Cj, Cj’ or Cj’’), 114.4 (aromatic CH, Cj, Cj’ or Cj’’ and Cj, Cj’ or Cj’’), 111.2 (aromatic
CH, Ch, Ch’ or Ch’’), 111.1 (aromatic CH, Ch, Ch’ or Ch’’), 111.0 (aromatic CH, Ch, Ch’ or
Ch’’) Analysis calculated C 61.37, H 3.43, N 11.93 % Analysis found C 61.19, H 3.51,
N 11.73 % ES MS (+) (CH3OH) m/z 705.13 [MH+] IR (cm-1) ν 3079 (w, ArCH), 1625 (m, 
CO), 1592 (s, CO), 1483 (m), 1366 (m), 1262 (w), 1187 (w), 1118 (w), 1005 (w), 764
(m), 680 (m)
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8.7.4 Synthesis of CoC36H24N6O3F3 (2.4)
Purified by column chromatography (methanol/diethyl ether 9:1) to give a red solid
(0.255 g, 0.362 mmol, 86 %). Recrystallisation by vapour diffusion (methanol/diethyl
ether) at room temperature yielded red crystals suitable for single crystal X-ray
diffraction.
1H NMR (CDCl3, 500.23 MHz, 300.1 K) δ 9.09 (d, 1H, 
Ha, Ha’ or Ha’’, 3J (1H-1H) = 5.5 Hz), 8.52 (d, 1H, Ha, Ha’ or
Ha’’, 3J (1H-1H) = 5.5 Hz), 8.36 (d, 1H, Hd, Hd’ or Hd’’, 3J
(1H-1H) = 7.6 Hz), 8.16 (td, 1H, Hc, Hc’ or Hc’’, 3J (1H-1H)
= 7.5 Hz and 3J (1H-1H) = 1.1 Hz), 8.00 (d, 1H, Hd, Hd’ or
Hd’’, 3J (1H-1H) = 7.6 Hz), 7.87 (td, 1H, Hc, Hc’ or Hc’’, 3J
(1H-1H) = 7.5 Hz and 3J (1H-1H) = 1.2 Hz), 7.80 (m, 2H,
Hc, Hc’ or Hc’’ and Hd, Hd’ or Hd’’), 7.69 (ddd, 1H, Hb, Hb’
or Hb’’, 3J (1H-1H) = 6.8 Hz, 3J (1H-1H) = 5.5 Hz and 4J (1H-1H) = 1.5 Hz), 7.23 (ddd, 2H,
Hb, Hb’ or Hb’’ and Hb, Hb’ or Hb’’, 3J (1H-1H) = 6.8 Hz, 3J (1H-1H) = 5.2 Hz and 4J (1H-1H) =
1.2 Hz), 7.15 (d, 1H, Ha, Ha’ or Ha’’, 3J (1H-1H) = 5.5 Hz), 6.97 (t, 2H, Hi and Hk, Hi’ and
Hk’ or Hi’’ and Hk’’, 3J (1H-1H) = 8.0 Hz), 6.90 (br. s, 2H, Hh and Hl, Hh’ and Hl’ or Hh’’ and
Hl’’), 6.66 (br. s, 2H, Hh and Hl, Hh’ and Hl’ or Hh’’ and Hl’’), 6.46 (t, 2H, Hi and Hk, Hi’ and
Hk’ or Hi’’ and Hk’’, 3J (1H-1H) = 8.6 Hz), 6.09 (br. s, 2H, Hh and Hl, Hh’ and Hl’ or Hh’’ and
Hl’’) 13C {1H} NMR (CDCl3, 125.8 MHz, 300.0 K) δ 170.6 (quaternary C-O, Cf, Cf’ or Cf’’),
169.8 (quaternary C-O, Cf, Cf’ or Cf’’), 169.1 (quaternary C-O, Cf, Cf’ or Cf’’), 158.1
(quaternary aniline C, Ce, Ce’ or Ce’’), 156.8 (quaternary aniline C, Ce, Ce’ or Ce’’), 156.4
(quaternary aniline C, Ce, Ce’ or Ce’’), 149.4 (aniline CH, Ca, Ca’ or Ca’’), 148.8 (aniline
CH, Ca, Ca’ or Ca’’), 148.3 (aniline CH, Ca, Ca’ or Ca’’), 141.7 (quaternary aromatic C, Cj,
Cj’ or Cj’’), 140.7 (quaternary aromatic C, Cj, Cj’ or Cj’’ and Cj, Cj’ or Cj’’), 139.9 (aniline
CH, Cc, Cc’ or Cc’’), 139.7 (aniline CH, Cc, Cc’ or Cc’’), 139.5 (aniline CH, Cc, Cc’ or Cc’’),
128.9 (aniline CH, Cb, Cb’ or Cb’’), 128.1 (aniline CH, Cb, Cb’ or Cb’’), 127.1 (aniline CH,
Cb, Cb’ or Cb’’), 126.8 (aniline CH, Cd, Cd’ or Cd’’), 126.6 (aniline CH, Cd, Cd’ or Cd’’), 125.7
(aniline CH, Cd, Cd’ or Cd’’), 116.4 (aromatic CH, Ch and Cl, Ch’ and Cl’ or Ch’’ and Cl’’, and
Ch and Cl, Ch’ and Cl’ or Ch’’ and Cl’’), 116.2 (aromatic CH, Ch and Cl, Ch’ and Cl’ or Ch’’
and Cl’’), 115.8 (quaternary aromatic C, Cg, Cg’ and Cg’’), 115.1 (aromatic CH, Ci and Ck,
Ci’ and Ck’ and Ci’’ and Ck’’), 114.9 (aromatic CH, Ci and Ck, Ci’ and Ck’ and Ci’’ and Ck’’,
and Ci and Ck, Ci’ and Ck’ and Ci’’ and Ck’’) Analysis calculated (+ 1 ½ CH2Cl2) C 54.14, H
3.27, N 10.10 % Analysis found C 54.60, H 3.40, N 10.20 % ES MS (+) (CH3OH) m/z
705.13 [MH+] IR (cm-1) ν 3064 (w, ArCH), 1620 (m, CO), 1585 (s, CO), 1567 (m), 1499 
(s), 1367 (m), 1211 (m), 1151 (m), 1094 (w), 826 (m), 788 (m), 682 (m), 529 (m)
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8.7.5 Synthesis of CoC36H21N6O3F6 (2.5)
Purified by column chromatography (methanol/diethyl ether 9:1) to give a brown
solid (0.245 g, 0.323 mmol, 77 %). Recrystallisation by vapour diffusion
(chloroform/diethyl ether) at room temperature yielded red crystals suitable for
single crystal X-ray diffraction.
1H NMR (CDCl3, 500.23 MHz, 299.9 K) δ 9.17 (m, 1H, 
Ha, Ha’ or Ha’’), 8.74 (t, 1H, Ha, Ha’ or Ha’’, 3J (1H-1H) = 6.0
Hz), 8.32 (d, 1H, Hd, Hd’ or Hd’’, 3J (1H-1H) = 7.3 Hz), 8.10
(td, 1H, Hc, Hc’ or Hc’’, 3J (1H-1H) = 7.3 Hz and 3J (1H-1H)
= 1.2 Hz), 8.04 (d, 1H, Hd, Hd’ or Hd’’, 3J (1H-1H) = 7.6 Hz),
7.94 (t, 1H, Hc, Hc’ or Hc’’, 3J (1H-1H) = 7.3 Hz and 3J (1H-
1H) = 1.0 Hz), 7.83 (m, 2H, Hc, Hc’ or Hc’’and Hd, Hd’ or
Hd’’), 7.59 (m, 2H, Ha, Ha’ or Ha’’ and Hb, Hb’ or Hb’’), 7.47
(m, 1H, Hk, Hk’ or Hk’’), 7.29 (ddd, 1H, Hb, Hb’ or Hb’’, 3J (1H-1H) = 7.0 Hz, 3J (1H-1H) = 5.8
Hz and 4J (1H-1H) = 1.2 Hz), 7.21 (ddd, 1H, Hb, Hb’ or Hb’’, 3J (1H-1H) = 7.0 Hz, 3J (1H-1H)
= 5.7 Hz and 4J (1H-1H) = 1.2 Hz), 6.98 (ddd, 1H, Hi, Hi’ or Hi’’, 3J (1H-1H) = 11.1 Hz, 3J
(1H-1H) = 8.4 Hz and 4J (1H-1H) = 2.7 Hz), 6.70 (td, 1H, Hk, Hk’ or Hk’’, 3J (1H-1H) = 8.2 Hz
and 3J (1H-1H) = 2.1 Hz), 6.62 (td, 1H, Hk, Hk’ or Hk’’, 3J (1H-1H) = 8.2 Hz and 3J (1H-1H) =
2.4 Hz), 6.31 (m, 3H, Hi, Hi’ or Hi’’, Hi, Hi’ or Hi’’ and Hk, Hk’ or Hk’’), 5.37 (m, 2H, Hl, Hl’
or Hl’’ and Hl, Hl’ or Hl’’) 13C {1H} NMR (CDCl3, 125.8 MHz, 300.1 K) δ 169.6 (quaternary 
C-O, Cf, Cf’ and Cf’’), 157.6 (quaternary aniline C, Ce, Ce’ or Ce’’), 156.1 (quaternary
aniline C, Ce, Ce’ or Ce’’), 155.2 (quaternary aniline C, Ce, Ce’ or Ce’’), 150.7 (quaternary
aromatic C, Ch, Ch’ or Ch’’), 150.6 (quaternary aromatic C, Ch, Ch’ or Ch’’ and Ch, Ch’ or
Ch’’), 149.9 (aniline CH, Ca, Ca’ or Ca’’), 149.8 (aniline CH, Ca, Ca’ or Ca’’), 149.7 (aniline
CH, Ca, Ca’ or Ca’’), 140.6 (aniline CH, Cc, Cc’ or Cc’’), 140.2 (aniline CH, Cc, Cc’ or Cc’’),
139.7 (aniline CH, Cc, Cc’ or Cc’’), 133.6 (quaternary aromatic C, Cj, Cj’ or Cj’’), 131.5
(quaternary aromatic C, Cj, Cj’ or Cj’’), 130.0 (quaternary aromatic C, Cj, Cj’ or Cj’’),
128.4 (quaternary aromatic C, Cg, Cg’ or Cg’’), 128.3 (quaternary aromatic C, Cg, Cg’ or
Cg’’), 128.2 (quaternary aromatic C, Cg, Cg’ or Cg’’), 127.5 (aniline CH, Cb, Cb’ or Cb’’),
127.3 (aniline CH, Cb, Cb’ or Cb’’), 126.7 (aniline CH, Cb, Cb’ or Cb’’), 126.2 (aniline CH,
Cd, Cd’ or Cd’’), 125.5 (aniline CH, Cd, Cd’ or Cd’’), 125.2 (aniline CH, Cd, Cd’ or Cd’’), 112.4
(aromatic CH, Cl, Cl’ or Cl’’), 112.2 (aromatic CH, Cl, Cl’ or Cl’’ and Cl, Cl’ or Cl’’), 111.0
(aromatic CH, Ck, Ck’ or Ck’’ and Ck, Ck’ or Ck’’), 110.9 (aromatic CH, Ck, Ck’ or Ck’’), 103.9
(aromatic CH, Ci, Ci’ or Ci’’), 103.7 (aromatic CH, Ci, Ci’ or Ci’’ and Ci, Ci’ or Ci’’) Analysis
calculated (+ ½ CH2Cl2) C 54.73, H 2.77, N 10.49 % Analysis found C 54.93, H 2.48, N
10.60 % ES MS (+) (CH3OH) m/z 759.10 [MH+] IR (cm-1) ν 3048 (w, ArCH), 1626 (m, 
CO), 1592 (s, CO), 1497 (s), 1355 (m), 1260 (m), 1143 (m), 966 (m), 847 (m), 807 (m),
765 (m), 682 (m), 541 (m), 511 (m)
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8.7.6 Synthesis of CoC36H21N6O3F6 (2.6)
Purified by column chromatography (methanol/diethyl ether 9:1) to give a red solid
(0.269 g, 0.355 mmol, 84 %). Recrystallisation by slow evaporation (ethanol/water)
at room temperature yielded orange crystals suitable for single crystal X-ray
diffraction.
1H NMR (CDCl3, 400.13 MHz, 300.0 K) δ 9.17 (m, 1H, 
Ha, Ha’ or Ha’’), 8.86 (t, 1H, Ha, Ha’ or Ha’’, 3J (1H-1H) = 6.0
Hz), 8.33 (d, 1H, Hd, Hd’ or Hd’’, 3J (1H-1H) = 7.5 Hz), 8.11
(td, 1H, Hc, Hc’ or Hc’’, 3J (1H-1H) = 7.6 Hz and 3J (1H-1H)
= 1.3 Hz), 8.01 (d, 1H, Hd, Hd’ or Hd’’, 3J (1H-1H) = 7.7 Hz),
7.94 (m, 2H, Hc, Hc’ or Hc’’ and Hd, Hd’ or Hd’’), 7.83 (td,
1H, Hc, Hc’ or Hc’’, 3J (1H-1H) = 7.7 Hz and 3J (1H-1H) = 1.2
Hz), 7.60 (ddd, 1H, Hb, Hb’ or Hb’’, 3J (1H-1H) = 7.0 Hz, 3J
(1H-1H) = 5.5 Hz and 4J (1H-1H) = 1.1 Hz), 7.52 (ddd, 1H, Hb, Hb’ or Hb’’, 3J (1H-1H) = 6.7
Hz, 3J (1H-1H) = 5.3 Hz and 4J (1H-1H) = 1.2 Hz), 7.28 (m, 4H, Ha, Ha’ or Ha’’, Hb, Hb’ or
Hb’’, Hl, Hl’ or Hl’’ and Hl, Hl’ or Hl’’), 6.98 (m, 1H, Hi, Hi’ or Hi’’), 6.69 (m, 1H, Hi, Hi’ or
Hi’’), 6.52 (m, 3H, Hi, Hi’ or Hi’’, Hj, Hj’ or Hj’’ and Hl, Hl’ or Hl’’), 5.26 (ddd, 1H, Hj, Hj’ or
Hj’’, 3J (1H-1H) = 9.6 Hz, 3J (1H-1H) = 6.4 Hz and 4J (1H-1H) = 2.9 Hz), 4.99 (ddd, 1H, Hj,
Hj’ or Hj’’, 3J (1H-1H) = 9.1 Hz, 3J (1H-1H) = 6.1 Hz and 4J (1H-1H) = 3.0 Hz) 13C {1H} NMR
(d6-DMSO, 100.6 MHz, 300.0 K) δ 169.6 (quaternary C-O, Cf, Cf’ or Cf’’), 169.0
(quaternary C-O, Cf, Cf’ or Cf’’), 168.4 (quaternary C-O, Cf, Cf’ or Cf’’), 158.8 (quaternary
aniline C, Ce, Ce’ or Ce’’), 157.1 (quaternary aniline C, Ce, Ce’ or Ce’’), 156.0 (quaternary
aniline C, Ce, Ce’ or Ce’’), 154.8 (quaternary aromatic C, Ck, Ck’ or Ck’’), 153.7
(quaternary aromatic C, Ck, Ck’ or Ck’’ and Ck, Ck’ or Ck’’), 149.9 (aniline CH, Ca, Ca’ and
Ca’’), 149.6 (quaternary aromatic C, Ch, Ch’ or Ch’’), 141.7 (aniline CH, Cc, Cc’ or Cc’’),
141.3 (aniline CH, Cc, Cc’ or Cc’’), 141.0 (aniline CH, Cc, Cc’ or Cc’’), 128.6 (aniline CH, Cb,
Cb’ or Cb’’), 128.4 (aniline CH, Cb, Cb’ or Cb’’), 128.1 (aniline CH, Cb, Cb’ or Cb’’), 126.1
(aniline CH, Cd, Cd’ or Cd’’), 125.3 (aniline CH, Cd, Cd’ or Cd’’), 124.6 (aniline CH, Cd, Cd’
or Cd’’), 116.5 (aromatic CH, Ci, Ci’ or Ci’’), 115.6 (aromatic CH, Ci, Ci’ or Ci’’ and Ci, Ci’ or
Ci’’), 114.6 (quaternary aromatic C, Cg, Cg’ or Cg’’ and Cg, Cg’ or Cg’’), 114.3 (quaternary
aromatic C, Cg, Cg’ or Cg’’), 113.1 (quaternary aromatic C, Cj, Cj’ or Cj’’), 112.8
(quaternary aromatic C, Cj, Cj’ or Cj’’ and Cj, Cj’ or Cj’’), 111.3 (aromatic CH, Cl, Cl’ and
Cl’’) Analysis calculated (+ ½ CH2Cl2) C 54.73, H 2.77, N 10.49 % Analysis found C
54.63, H 3.17, N 10.16 % ES MS (+) (CH3OH) m/z 759.10 [MH+] IR (cm-1) ν 3067 (w, 
ArCH), 1633 (s, CO), 1597 (s, CO), 1490 (s), 1357 (s), 1242 (m), 1178 (m), 973 (m), 859
(m), 749 9 (s), 684 (m), 592 (w)
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8.7.7 Synthesis of CoC36H24N6O3Cl3 (2.7)
Purified by column chromatography (methanol/diethyl ether 9:1) to give a brown
solid (0.129 g, 0.170 mmol, 41 %). Recrystallisation by vapour diffusion
(methanol/diethyl ether) at room temperature yielded red crystals suitable for single
crystal X-ray diffraction.
1H NMR (CDCl3, 500.23 MHz, 300.1 K) δ 9.04 (d, 1H, 
Ha, Ha’ or Ha’’, 3J (1H-1H) = 5.5 Hz), 8.57 (d, 1H, Ha, Ha’
or Ha’’, 3J (1H-1H) = 5.5 Hz), 8.38 (d, 1H, Hd, Hd’ or Hd’’,
3J (1H-1H) = 7.6 Hz), 8.17 (t, 1H, Hc, Hc’ or Hc’’, 3J (1H-
1H) = 7.4 Hz), 8.02 (d, 1H, Hd, Hd’ or Hd’’, 3J (1H-1H) =
7.6 Hz), 7.89 (t, 1H, Hc, Hc’ or Hc’’, 3J (1H-1H) = 7.4 Hz),
7.82 (t, 1H, Hc, Hc’ or Hc’’, 3J (1H-1H) = 7.4 Hz), 7.77 (d,
1H, Hd, Hd’ or Hd’’, 3J (1H-1H) = 7.6 Hz), 7.71 (ddd, 1H, Hb, Hb’ or Hb’’, 3J (1H-1H) = 6.8 Hz,
3J (1H-1H) = 5.7 Hz and 4J (1H-1H) = 1.2 Hz), 7.36 (ddd, 1H, Hb, Hb’ or Hb’’, 3J (1H-1H) =
6.8 Hz, 3J (1H-1H) = 5.7 Hz and 4J (1H-1H) = 1.2 Hz), 7.31 (ddd, 1H, Hb, Hb’ or Hb’’, 3J (1H-
1H) = 6.8 Hz, 3J (1H-1H) = 5.7 Hz and 4J (1H-1H) = 1.2 Hz), 7.26 (d, 1H, Hj, Hj’ or Hj’’, 3J
(1H-1H) = 8.0 Hz), 7.23 (d, 1H, Ha, Ha’ or Ha’’, 3J (1H-1H) = 5.5 Hz), 7.17 (m, 2H, Hh, Hh’
or Hh’’ and Hk, Hk’ or Hk’’), 7.02 (t, 1H, Hk, Hk’ or Hk’’, 3J (1H-1H) = 7.8 Hz), 6.95 (d, 1H, Hj,
Hj’ or Hj’’, 3J (1H-1H) = 8.0 Hz), 6.84 (d, 1H, Hl, Hl’ or Hl’’, 3J (1H-1H) = 7.8 Hz), 6.75 (t, 1H,
Hk, Hk’ or Hk’’, 3J (1H-1H) = 8.0 Hz), 6.58 (br. s, 2H, Hh, Hh’ or Hh’’ and Hj, Hj’ or Hj’’), 6.37
(br. s, 1H, Hl, Hl’ or Hl’’), 6.18 (br. s, 1H, Hh, Hh’ or Hh’’), 5.89 (br. s, 1H, Hl, Hl’ or Hl’’) 13C
{1H} NMR (CDCl3, 125.8 MHz, 300.0 K) δ 170.3 (quaternary C-O, Cf, Cf’ or Cf’’), 169.6
(quaternary C-O, Cf, Cf’ or Cf’’), 168.7 (quaternary C-O, Cf, Cf’ or Cf’’), 157.6 (quaternary
aniline C, Ce, Ce’ or Ce’’), 156.5 (quaternary aniline C, Ce, Ce’ or Ce’’), 156.2 (quaternary
aniline C, Ce, Ce’ or Ce’’), 149.3 (aniline CH, Ca, Ca’ or Ca’’), 148.9 (aniline CH, Ca, Ca’ or
Ca’’), 148.4 (aniline CH, Ca, Ca’ or Ca’’), 147.1 (quaternary aromatic C, Cg, Cg’ or Cg’’),
145.3 (quaternary aromatic C, Cg, Cg’ or Cg’’), 145.0 (quaternary aromatic C, Cg, Cg’ or
Cg’’), 140.9 (aniline CH, Cc, Cc’ or Cc’’), 140.1 (aniline CH, Cc, Cc’ or Cc’’), 139.9 (aniline
CH, Cc, Cc’ or Cc’’), 134.9 (quaternary aromatic C, Ci, Ci’ or Ci’’), 133.8 (quaternary
aromatic C, Ci, Ci’ or Ci’’), 133.6 (quaternary aromatic C, Ci, Ci’ or Ci’’), 130.4 (aromatic
CH, Cj, Cj’ or Cj’’ and Cj, Cj’ or Cj’’), 130.2 (aromatic CH, Cj, Cj’ or Cj’’), 129.0 (aniline CH,
Cb, Cb’ or Cb’’), 128.3 (aniline CH, Cb, Cb’ or Cb’’), 127.8 (aniline CH, Cb, Cb’ or Cb’’), 127.2
(aromatic CH, Ck, Ck’ or Ck’’ and Ck, Ck’ or Ck’’), 127.1 (aromatic CH, Ck, Ck’ or Ck’’), 126.9
(aniline CH, Cd, Cd’ or Cd’’), 126.3 (aniline CH, Cd, Cd’ or Cd’’ and Cd, Cd’ or Cd’’), 125.8
(aromatic CH, Ch, Ch’ and Ch’’), 125.3 (aromatic CH, Cl, Cl’ or Cl’’), 125.1 (aromatic CH,
Cl, Cl’ or Cl’’ and Cl, Cl’ or Cl’’) Analysis calculated (+ ½ CHCl3) C 53.88, H 3.04, N 10.33
% Analysis found C 53.95, H 3.09, N 10.36 % ES MS (+) (CH3OH) m/z 755.04 [MH+] IR
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(cm-1) ν 3067 (w, ArCH), 1624 (s, CO), 1598 (s, CO), 1471 (m), 1362 (m), 1151 (w), 999 
(w), 881 (w), 763 (m), 685 (m), 506 (w)
8.7.8 Synthesis of CoC36H24N6O3Cl3 (2.8)
Purified by column chromatography (methanol/diethyl ether 9:1) to give a red solid
(0.239 g, 0.317 mmol, 75 %). Recrystallisation by vapour diffusion
(chloroform/pentane) at 5 °C yielded orange crystals suitable for single crystal X-ray
diffraction.
1H NMR (CDCl3, 500.23 MHz, 299.9 K) δ 9.08 (d, 1H, 
Ha, Ha’ or Ha’’, 3J (1H-1H) = 4.8 Hz), 8.53 (d, 1H, Ha, Ha’
or Ha’’, 3J (1H-1H) = 4.8 Hz), 8.39 (d, 1H, Hd, Hd’ or Hd’’,
3J (1H-1H) = 7.3 Hz), 8.18 (t, 1H, Hc, Hc’ or Hc’’, 3J (1H-
1H) = 7.3 Hz), 8.03 (d, 1H, Hd, Hd’ or Hd’’, 3J (1H-1H) =
7.3 Hz), 7.90 (t, 1H, Hc, Hc’ or Hc’’, 3J (1H-1H) = 7.3 Hz),
7.82 (m, 2H, Hc, Hc’ or Hc’’ and Hd, Hd’ or Hd’’), 7.70
(ddd, 1H, Hb, Hb’ or Hb’’, 3J (1H-1H) = 7.0 Hz, 3J (1H-1H)
= 5.7 Hz and 4J (1H-1H) = 1.3 Hz), 7.25 (m, 4H, Hb, Hb’ or Hb’’, Hb, Hb’ or Hb’’, and Hi and
Hk, Hi’ and Hk’ or Hi’’ and Hk’’), 7.17 (d, 1H, Ha, Ha’ or Ha’’, 3J (1H-1H) = 4.8 Hz), 6.93 (m,
4H, Hh and Hl, Hh’ and Hl’or Hh’’ and Hl’’, and Hi and Hk, Hi’ and Hk’ or Hi’’ and Hk’’), 6.74
(d, 2H, Hh and Hl, Hh’ and Hl’ or Hh’’ and Hl’’, 3J (1H-1H) = 8.2 Hz), 6.42 (br. s, 2H, Hi and
Hk, Hi’ and Hk’ or Hi’’ and Hk’’), 6.07 (br. s, 2H, Hh and Hl, Hh’ and Hl’ or Hh’’ and Hl’’) 13C
{1H} NMR (CDCl3, 125.8 MHz, 300.1 K) δ 170.4 (quaternary C-O, Cf, Cf’ or Cf’’), 169.6
(quaternary C-O, Cf, Cf’ or Cf’’), 168.9 (quaternary C-O, Cf, Cf’ or Cf’’), 157.9 (quaternary
aniline C, Ce, Ce’ or Ce’’), 157.3 (quaternary aniline C, Ce, Ce’ or Ce’’), 156.7 (quaternary
aniline C, Ce, Ce’ or Ce’’), 149.4 (aniline CH, Ca, Ca’ or Ca’’), 148.9 (aniline CH, Ca, Ca’ or
Ca’’), 148.3 (aniline CH, Ca, Ca’ or Ca’’), 142.6 (quaternary aromatic C, Cj, Cj’ or Cj’’), 142.2
(quaternary aromatic C, Cj, Cj’ or Cj’’ and Cj, Cj’ or Cj’’), 140.8 (aniline CH, Cc, Cc’ or Cc’’),
140.0 (aniline CH, Cc, Cc’ or Cc’’), 139.8 (aniline CH, Cc, Cc’ or Cc’’), 131.5 (quaternary
aromatic C, Cg, Cg’ and Cg’’), 129.6 (aromatic CH, Ch and Cl, Ch’ and Cl’ or Ch’’ and Cl’’),
129.0 (aromatic CH, Ch and Cl, Ch’ and Cl’ or Ch’’ and Cl’’, and Ch and Cl, Ch’ and Cl’ or Ch’’
and Cl’’), 128.3 (aromatic CH, Ci and Ck, Ci’ and Ck’ and Ci’’ and Ck’’), 127.3 (aniline CH,
Cb, Cb’ or Cb’’ and Cb, Cb’ or Cb’’), 126.9 (aniline CH, Cb, Cb’ or Cb’’), 126.3 (aniline CH, Cd,
Cd’ or Cd’’ and Cd, Cd’ or Cd’’), 125.9 (aniline CH, Cd, Cd’ or Cd’’) Analysis calculated (+
CH2Cl2) C 52.98, H 3.12, N 10.02 % Analysis found C 52.70, H 2.75, N 9.50 % ES MS
(+) (CH3OH) m/z 755.04 [MH+] IR (cm-1) ν 3085 (w, ArCH), 1617 (m, CO), 1593 (s, CO), 
1566 (s, CO), 1482 (s), 1370 (m), 1084 (m), 1008 (m), 816 (m), 764 (m), 705 (m), 508
(m)
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8.7.9 Synthesis of CoC36H24N6O3Br3 (2.9)
Purified by column chromatography (methanol/diethyl ether 9:1) to give a brown
solid (0.157 g, 0.177 mmol, 42 %). Recrystallisation by vapour diffusion
(methanol/diethyl ether) at 5 °C yielded red crystals suitable for single crystal X-ray
diffraction.
1H NMR (CDCl3, 500.23 MHz, 299.9 K) δ 9.03 (d, 1H, 
Ha, Ha’ or Ha’’, 3J (1H-1H) = 5.5 Hz), 8.57 (d, 1H, Ha, Ha’
or Ha’’, 3J (1H-1H) = 5.5 Hz), 8.39 (d, 1H, Hd, Hd’ or Hd’’,
3J (1H-1H) = 7.6 Hz), 8.17 (td, 1H, Hc, Hc’ or Hc’’, 3J (1H-
1H) = 7.6 Hz and 3J (1H-1H) = 1.0 Hz), 8.01 (d, 1H, Hd,
Hd’ or Hd’’, 3J (1H-1H) = 7.6 Hz), 7.90 (td, 1H, Hc, Hc’ or
Hc’’, 3J (1H-1H) = 7.7 Hz and 3J (1H-1H) = 0.9 Hz), 7.83
(td, 1H, Hc, Hc’ or Hc’’, 3J (1H-1H) = 7.6 Hz and 3J (1H-1H) = 1.0 Hz), 7.77 (d, 1H, Hd, Hd’
or Hd’’, 3J (1H-1H) = 7.6 Hz), 7.71 (ddd, 1H, Hb, Hb’ or Hb’’, 3J (1H-1H) = 7.0 Hz, 3J (1H-1H)
= 5.8 Hz and 4J (1H-1H) = 1.4 Hz), 7.39 (m, 2H, Hb, Hb’ or Hb’’ and Hj, Hj’ or Hj’’), 7.34
(ddd, 1H, Hb, Hb’ or Hb’’, 3J (1H-1H) = 7.0 Hz, 3J (1H-1H) = 5.8 Hz and 4J (1H-1H) = 1.4 Hz),
7.24 (m, 2H, Ha, Ha’ or Ha’’ and Hk, Hk’ or Hk’’), 7.10 (m, 2H, Hh, Hh’ or Hh’’ and Hk, Hk’ or
Hk’’), 6.98 (m, 2H, Hj, Hj’ or Hj’’ and Hl, Hl’ or Hl’’), 6.72 (m, 3H, Hh, Hh’ or Hh’’, Hj, Hj’ or
Hj’’ and Hk, Hk’ or Hk’’), 6.47 (br. s, 1H, Hl, Hl’ or Hl’’), 6.22 (br. s, 1H, Hh, Hh’ or Hh’’), 6.06
(br. s, 1H, Hl, Hl’ or Hl’’) 13C {1H} NMR (CDCl3, 125.8 MHz, 300.0 K) δ 170.3 (quaternary 
C-O, Cf, Cf’ or Cf’’), 169.1 (quaternary C-O, Cf, Cf’ or Cf’’), 168.7 (quaternary C-O, Cf, Cf’
or Cf’’), 157.6 (quaternary aniline C, Ce, Ce’ or Ce’’), 156.6 (quaternary aniline C, Ce, Ce’
or Ce’’), 156.2 (quaternary aniline C, Ce, Ce’ or Ce’’), 149.3 (aniline CH, Ca, Ca’ or Ca’’),
148.9 (aniline CH, Ca, Ca’ or Ca’’), 148.4 (aniline CH, Ca, Ca’ or Ca’’), 147.4 (quaternary
aromatic C, Cg, Cg’ or Cg’’), 145.5 (quaternary aromatic C, Cg, Cg’ or Cg’’), 145.3
(quaternary aromatic C, Cg, Cg’ or Cg’’), 140.9 (aniline CH, Cc, Cc’ or Cc’’), 140.1 (aniline
CH, Cc, Cc’ or Cc’’), 140.0 (aniline CH, Cc, Cc’ or Cc’’), 131.2 (aromatic CH, Cj, Cj’ or Cj’’),
130.7 (aromatic CH, Cj, Cj’ or Cj’’), 130.5 (aromatic CH, Cj, Cj’ or Cj’’), 129.4 (aromatic
CH, Ch, Ch’ or Ch’’), 129.2 (aromatic CH, Ch, Ch’ or Ch’’ and Ch, Ch’ or Ch’’), 128.4 (aniline
CH, Cb, Cb’ or Cb’’), 128.2 (aniline CH, Cb, Cb’ or Cb’’), 128.0 (aniline CH, Cb, Cb’ or Cb’’),
127.3 (aromatic CH, Ck, Ck’ or Ck’’ and Ck, Ck’ or Ck’’), 127.2 (aromatic CH, Ck, Ck’ or Ck’’),
126.9 (aromatic CH, Cl, Cl’ and Cl’’), 126.4 (aniline CH, Cd, Cd’ or Cd’’), 126.0 (aniline CH,
Cd, Cd’ or Cd’’), 125.8 (aniline CH, Cd, Cd’ or Cd’’), 123.0 (quaternary aromatic C, Ci, Ci’ or
Ci’’ and Ci, Ci’ or Ci’’), 121.7 (quaternary aromatic C, Ci, Ci’ or Ci’’) Analysis calculated C
48.73, H 2.73, N 9.47 % Analysis found C 48.64, H 2.69, N 9.57 % ES MS (+) (CH3OH)
m/z 888.88 [MH+] IR (cm-1) ν 3063 (w, ArCH), 1624 (s, CO), 1593 (s, CO), 1468 (m), 
1363 (m), 1293 (w), 1148 (w), 1069 (w), 953 (w), 861 (m), 763 (s), 722 (m), 682 (s),
560 (m)
N
j
i''
hg''
l''
k''
c''b
a''
N e''
d''
f O
Co
N
N
N
N
e
d
c
b
a
a'
b'
c
d'
e'O
f
f'
O
k
j i h
gl
i'
j' k l'
g'
h
Br
Br
Br ''
'
'
''
''
''
'
Experimental Chapter 8
222
8.7.10 Synthesis of CoC36H24N6O3Br3 (2.10)
Purified by column chromatography (methanol/diethyl ether 9:1) to give a red solid
(0.250 g, 0.282 mmol, 67 %). Recrystallisation by vapour diffusion (methanol/diethyl
ether) at room temperature yielded red crystals suitable for single crystal X-ray
diffraction.
1H NMR (CDCl3, 500.23 MHz, 300.2 K) δ 9.07 (d, 1H, 
Ha, Ha’ or Ha’’, 3J (1H-1H) = 4.7 Hz), 8.52 (d, 1H, Ha, Ha’
or Ha’’, 3J (1H-1H) = 4.8 Hz), 8.39 (d, 1H, Hd, Hd’ or Hd’’,
3J (1H-1H) = 7.6 Hz), 8.18 (t, 1H, Hc, Hc’ or Hc’’, 3J (1H-
1H) = 7.3 Hz), 8.03 (d, 1H, Hd, Hd’ or Hd’’, 3J (1H-1H) =
7.3 Hz), 7.91 (t, 1H, Hc, Hc’ or Hc’’, 3J (1H-1H) = 7.4 Hz),
7.83 (m, 2H, Hb, Hb’ or Hb’’ and Hc, Hc’ or Hc’’), 7.71 (m,
2H, Hb, Hb’ or Hb’’ and Hb, Hb’ or Hb’’), 7.51 (d, 1H, Hd,
Hd’ or Hd’’, 3J (1H-1H) = 7.9 Hz), 7.39 (d, 2H, Hi and Hk, Hi’ and Hk’ or Hi’’ and Hk’’, 3J (1H-
1H) = 8.0 Hz), 7.17 (d, 1H, Ha, Ha’ or Ha’’, 3J (1H-1H) = 4.6 Hz), 7.08 (m, 2H, Hh and Hl,
Hh’ and Hl’or Hh’’ and Hl’’), 6.89 (d, 2H, Hh and Hl, Hh’ and Hl’or Hh’’ and Hl’’, 3J (1H-1H) =
8.0 Hz), 6.82 (br. s, 2H, Hi and Hk, Hi’ and Hk’ or Hi’’ and Hk’’), 6.36 (br. s, 2H, Hi and Hk,
Hi’ and Hk’ or Hi’’ and Hk’’), 6.00 (br. s, 2H, Hh and Hl, Hh’ and Hl’ or Hh’’ and Hl’’) 13C {1H}
NMR (CDCl3, 125.8 MHz, 299.9 K) δ 170.4 (quaternary C-O, Cf, Cf’ or Cf’’), 169.7
(quaternary C-O, Cf, Cf’ or Cf’’), 169.5 (quaternary C-O, Cf, Cf’ or Cf’’), 157.9 (quaternary
aniline C, Ce, Ce’ or Ce’’), 157.1 (quaternary aniline C, Ce, Ce’ or Ce’’), 156.3 (quaternary
aniline C, Ce, Ce’ or Ce’’), 149.4 (aniline CH, Ca, Ca’ or Ca’’), 148.9 (aniline CH, Ca, Ca’ or
Ca’’), 148.3 (aniline CH, Ca, Ca’ or Ca’’), 140.8 (aniline CH, Cc, Cc’ or Cc’’), 140.0 (aniline
CH, Cc, Cc’ or Cc’’), 139.9 (aniline CH, Cc, Cc’ or Cc’’), 132.5 (quaternary aromatic C, Cj,
Cj’ and Cj’’), 132.0 (aromatic CH, Ch and Cl, Ch’ and Cl’ or Ch’’ and Cl’’), 131.9 (aromatic
CH, Ch and Cl, Ch’ and Cl’ or Ch’’ and Cl’’), 131.3 (aromatic CH, Ch and Cl, Ch’ and Cl’ or
Ch’’ and Cl’’), 129.3 (aromatic CH, Ci and Ck, Ci’ and Ck’ and Ci’’ and Ck’’, and Ci and Ck, Ci’
and Ck’ and Ci’’ and Ck’’), 128.32 (aromatic CH, Ci and Ck, Ci’ and Ck’ and Ci’’ and Ck’’),
127.3 (aniline CH, Cb, Cb’ or Cb’’ and Cb, Cb’ or Cb’’), 126.9 (aniline CH, Cb, Cb’ or Cb’’),
126.4 (aniline CH, Cd, Cd’ or Cd’’ and Cd, Cd’ or Cd’’), 125.9 (aniline CH, Cd, Cd’ or Cd’’),
121.2 (quaternary aromatic C, Cg, Cg’ or Cg’’), 119.4 (quaternary aromatic C, Cg, Cg’ and
Cg’’, and Cg, Cg’ and Cg’’) Analysis calculated (+ 1 CH2Cl2) C 45.71, H 2.70, N 8.64 %
Analysis found C 45.55, H 2.72, N 8.83 % ES MS (+) (CH3OH) m/z 888.88 [MH+] IR
(cm-1) ν 3069 (w, ArCH), 1615 (m, CO), 1592 (s, CO), 1566 (m), 1478 (m), 1362 (m), 
1260 (m), 1070 (w), 1004 (w), 811 (m), 763 (m), 685 (m), 507 (m)
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8.7.11 Synthesis of CoC39H24N6O3F9 (2.11)
Purified by column chromatography (methanol/diethyl ether 4:1) to give a red solid
(0.190 g, 0.222 mmol, 53 %). Recrystallisation by vapour diffusion
(chloroform/pentane) at room temperature yielded orange crystals suitable for
single crystal X-ray diffraction.
1H NMR (CDCl3, 500.23 MHz, 300.0 K) δ 9.09 (d, 
1H, Ha, Ha’ or Ha’’, 3J (1H-1H) = 5.5 Hz), 8.67 (d, 1H,
Ha, Ha’ or Ha’’, 3J (1H-1H) = 5.5 Hz), 8.45 (d, 1H, Hd,
Hd’ or Hd’’, 3J (1H-1H) = 7.6 Hz), 8.23 (t, 1H, Hc, Hc’ or
Hc’’, 3J (1H-1H) = 7.6 Hz), 7.94 (d, 1H, Hd, Hd’ or Hd’’,
3J (1H-1H) = 7.3 Hz), 7.89 (t, 1H, Hc, Hc’ or Hc’’, 3J (1H-
1H) = 7.4 Hz), 7.78 (m, 3H, Hb, Hb’ or Hb’’, Hc, Hc’ or
Hc’’ and Hd, Hd’ or Hd’’), 7.63 (d, 1H, Hj, Hj’ or Hj’’, 3J (1H-1H) = 7.5 Hz), 7.52 (d, 1H, Hj, Hj’
or Hj’’, 3J (1H-1H) = 7.8 Hz), 7.31 (m, 7H, Ha, Ha’ or Ha’’, Hb, Hb’ or Hb’’, Hb, Hb’ or Hb’’, Hh,
Hh’ or Hh’’, Hk, Hk’ or Hk’’, Hk, Hk’ or Hk’’ and Hl, Hl’ or Hl’’), 7.12 (d, 1H, Hl, Hl’ or Hl’’, 3J
(1H-1H) = 7.6 Hz), 7.03 (t, 1H, Hk, Hk’ or Hk’’, 3J (1H-1H) = 7.8 Hz), 6.86 (m, 2H, Hh, Hh’ or
Hh’’ and Hl, Hl’ or Hl’’), 6.68 (br. s, 1H, Hh, Hh’ or Hh’’), 6.21 (br. s, 1H, Hl, Hl’ or Hl’’) 13C
{1H} NMR (CDCl3, 125.8 MHz, 300.1 K) δ 170.3 (quaternary C-O, Cf, Cf’ or Cf’’), 169.7
(quaternary C-O, Cf, Cf’ or Cf’’), 168.8 (quaternary C-O, Cf, Cf’ or Cf’’), 157.7 (quaternary
aniline C, Ce, Ce’ or Ce’’), 156.6 (quaternary aniline C, Ce, Ce’ or Ce’’), 156.2 (quaternary
aniline C, Ce, Ce’ or Ce’’), 149.0 (aniline CH, Ca, Ca’ or Ca’’), 148.3 (aniline CH, Ca, Ca’ or
Ca’’), 146.4 (aniline CH, Ca, Ca’ or Ca’’), 144.6 (quaternary aromatic C, Cg, Cg’ or Cg’’ and
Cg, Cg’ or Cg’’), 144.3 (quaternary aromatic C, Cg, Cg’ or Cg’’), 141.1 (aniline CH, Cc, Cc’
or Cc’’), 140.1 (aniline CH, Cc, Cc’ or Cc’’), 140.0 (aniline CH, Cc, Cc’ or Cc’’), 132.9
(aromatic CH, Cj, Cj’ or Cj’’), 132.1 (aromatic CH, Cj, Cj’ or Cj’’), 131.6 (aromatic CH, Cj,
Cj’ or Cj’’), 130.8 (CF3), 130.0 (CF3 and CF3), 128.8 (aniline CH, Cb, Cb’ or Cb’’), 128.3
(aniline CH, Cb, Cb’ or Cb’’), 128.0 (aniline CH, Cb, Cb’ or Cb’’), 127.6 (aromatic CH, Ck, Ck’
or Ck’’ and Ck, Ck’ or Ck’’), 127.1 (aromatic CH, Ck, Ck’ or Ck’’), 126.4 (aniline CH, Cd, Cd’
or Cd’’ and Cd, Cd’ or Cd’’), 126.0 (aniline CH, Cd, Cd’ or Cd’’), 124.6 (aromatic CH, Cl, Cl’
or Cl’’), 123.6 (aromatic CH, Cl, Cl’ or Cl’’), 122.8 (aromatic CH, Cl, Cl’ or Cl’’), 122.3
(aromatic CH, Ch, Ch’ or Ch’’ and Ch, Ch’ or Ch’’), 122.1 (aromatic CH, Ch, Ch’ or Ch’’), 121.9
(quaternary aromatic C, Ci, Ci’ or Ci’’ and Ci, Ci’ or Ci’’), 121.6 (quaternary aromatic C,
Ci, Ci’ or Ci’’) Analysis calculated (+ ½ CH2Cl2) C 52.89, H 2.81, N 9.37 % Analysis found
C 52.96, H 2.73, N 9.33 % ES MS (+) (CH3OH) m/z 855.12 [MH+] IR (cm-1) ν 3081 (w, 
ArCH), 1629 (m, CO), 1596 (m, CO), 1434 (m), 1362 (m), 1323 (s), 1117 (s), 1092 (m),
1066 (m), 797 (m), 776 (m), 684 (m), 657 (m)
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8.7.12 Synthesis of CoC39H24N6O3F9 (2.12)
Purified by column chromatography (methanol/diethyl ether 4:1) to give a red solid
(0.183 g, 0.214 mmol, 51 %). Recrystallisation by vapour diffusion (DCM/diethyl
ether) at room temperature yielded orange crystals suitable for single crystal X-ray
diffraction.
1H NMR (CDCl3, 500.23 MHz, 300.1 K) δ 9.10 (d, 1H, 
Ha, Ha’ or Ha’’, 3J (1H-1H) = 5.5 Hz), 8.56 (d, 1H, Ha, Ha’
or Ha’’, 3J (1H-1H) = 5.4 Hz), 8.44 (d, 1H, Hd, Hd’ or Hd’’,
3J (1H-1H) = 7.1 Hz), 8.23 (t, 1H, Hc, Hc’ or Hc’’, 3J (1H-
1H) = 7.0 Hz), 8.00 (d, 1H, Hd, Hd’ or Hd’’, 3J (1H-1H) =
6.9 Hz), 7.88 (t, 1H, Hc, Hc’ or Hc’’, 3J (1H-1H) = 7.1 Hz),
7.83 (1H, t, Hc, Hc’ or Hc’’, 3J (1H-1H) = 7.1 Hz), 7.76
(m, 2H, Ha, Ha’ or Ha’’ and Hb, Hb’ or Hb’’), 7.56 (d, 2H,
Hi, Hi’ or Hi’’ and Hk, Hk’ or Hk’’), 7.29 (m, 5H, Hb, Hb’ or Hb’’, Hb, Hb’ or Hb’’, Hd, Hd’ or Hd’’,
Hi, Hi’ or Hi’’ and Hk, Hk’ or Hk’’), 7.09 (br. s, 2H, Hh and Hl, Hh’ and Hl’ or Hh’’ and Hl’’),
7.00 (d, 2H, Hi and Hk, Hi’ and Hk’ or Hi’’ and Hk’’, 3J (1H-1H) = 8.0 Hz), 6.66 (br. s, 2H, Hh
and Hl, Hh’ and Hl’ or Hh’’ and Hl’’), 6.20 (br. s, 2H, Hh and Hl, Hh’ and Hl’ or Hh’’ and Hl’’)
13C {1H} NMR (d6-DMSO, 100.6 MHz, 300.0 K) δ 169.3 (quaternary C-O, Cf, Cf’ or Cf’’),
169.2 (quaternary C-O, Cf, Cf’ or Cf’’), 168.5 (quaternary C-O, Cf, Cf’ or Cf’’), 166.2
(quaternary aniline C, Ce, Ce’ or Ce’’), 161.0 (quaternary aniline C, Ce, Ce’ or Ce’’), 156.0
(quaternary aniline C, Ce, Ce’ or Ce’’), 155.1 (quaternary aromatic C, Cg, Cg’ or Cg’’),
154.9 (quaternary aromatic C, Cg, Cg’ or Cg’’), 151.4 (quaternary aromatic C, Cg, Cg’ or
Cg’’), 150.1 (aniline CH, Ca, Ca’ or Ca’’), 150.0 (aniline CH, Ca, Ca’ or Ca’’), 149.8 (aniline
CH, Ca, Ca’ or Ca’’), 148.9 (quaternary aromatic C, Cj, Cj’ and Cj’’), 148.5 (quaternary
aromatic C, Cj, Cj’ and Cj’’ and Cj, Cj’ and Cj’’), 141.7 (aniline CH, Cc, Cc’ or Cc’’), 140.7
(aniline CH, Cc, Cc’ or Cc’’), 140.6 (aniline CH, Cc, Cc’ or Cc’’), 129.6 (aniline CH, Cb, Cb’ or
Cb’’), 129.0 (aniline CH, Cb, Cb’ or Cb’’ and Cb, Cb’ or Cb’’), 128.7 (CF3, CF3 and CF3), 128.4
(aromatic CH, Ch and Cl, Ch’ and Cl’ or Ch’’ and Cl’’), 128.0 (aromatic CH, Ch and Cl, Ch’
and Cl’ or Ch’’ and Cl’’, and Ch and Cl, Ch’ and Cl’ or Ch’’ and Cl’’), 126.4 (aniline CH, Cd, Cd’
or Cd’’), 125.6 (aniline CH, Cd, Cd’ or Cd’’), 125.5 (aniline CH, Cd, Cd’ or Cd’’), 124.9
(aromatic CH, Ci and Ck, Ci’ and Ck’ or Ci’’ and Ck’’), 124.3 (aromatic CH, Ci and Ck, Ci’
and Ck’ or Ci’’ and Ck’’), 124.2 (aromatic CH, Ci and Ck, Ci’ and Ck’ or Ci’’ and Ck’’) Analysis
calculated (+ ½ H2O + 2 ½ CH2Cl2) C 46.68, H 2.08, N 7.87 % Analysis found C 46.50,
H 2.00, N 7.80 % ES MS (+) (CH3OH) m/z 855.12 [MH+] IR (cm-1) ν 3042 (w, ArCH), 
1631 (m, CO), 1598 (m, CO), 1362 (m), 1321 (s), 1107 (m), 1066 (m), 825 (w), 760(w),
686 (w), 506 (w)
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8.7.13 Synthesis of CoC42H21N6O3F18 (2.13)
Purified by column chromatography (methanol/diethyl ether 4:1) to give a red solid
(0.272 g, 0.257 mmol, 61 %). Recrystallisation by vapour diffusion
(chloroform/pentane) at 5 °C yielded orange crystals suitable for single crystal X-ray
diffraction.
1H NMR (CDCl3, 400.13 MHz, 300.0 K) δ 8.98 (d, 
1H, Ha, Ha’ or Ha’’, 3J (1H-1H) = 5.5 Hz), 8.80 (d, 1H,
Ha, Ha’ or Ha’’, 3J (1H-1H) = 5.7 Hz), 8.51 (d, 1H, Hd,
Hd’ or Hd’’, 3J (1H-1H) = 7.2 Hz), 8.31 (td, 1H, Hc, Hc’
or Hc’’, 3J (1H-1H) = 7.2 Hz and 3J (1H-1H) = 1.1 Hz),
8.00 (td, 1H, Hc, Hc’ or Hc’’, 3J (1H-1H) = 7.5 Hz and
3J (1H-1H) = 1.1 Hz), 7.87 (m, 3H, Hc, Hc’ or Hc’’, and
Hh and Hl, Hh’ and Hl’ or Hh’’ and Hl’’), 7.80 (ddd,
1H, Hb, Hb’ or Hb’’, 3J (1H-1H) = 7.0 Hz, 3J (1H-1H) = 5.7 Hz and 4J (1H-1H) = 1.2 Hz), 7.70
(s, 1H, Hj, Hj’ or Hj’’), 7.50 (m, 5H, Hb, Hb’ or Hb’’, Hb, Hb’ or Hb’’, Hd, Hd’ or Hd’’, Hd, Hd’ or
Hd’’ and Hj, Hj’ or Hj’’), 7.37 (m, 2H, Ha, Ha’ or Ha’’ and Hj, Hj’ or Hj’’), 6.94 (s, 2H, Hh and
Hl, Hh’ and Hl’ or Hh’’ and Hl’’), 6.87 (br.s, 2H, Hh and Hl, Hh’ and Hl’ or Hh’’ and Hl’’) 13C
{1H} NMR (d6-DMSO, 100.6 MHz, 300.0 K) δ 169.8 (quaternary C-O, Cf, Cf’ or Cf’’ and
Cf, Cf’ or Cf’’), 168.9 (quaternary C-O, Cf, Cf’ or Cf’’), 154.9 (quaternary aniline C, Ce, Ce’
or Ce’’), 154.0 (quaternary aniline C, Ce, Ce’ or Ce’’), 153.9 (quaternary aniline C, Ce, Ce’
or Ce’’), 150.5 (aniline CH, Ca, Ca’ or Ca’’ and Ca, Ca’ or Ca’’), 150.3 (aniline CH, Ca, Ca’ or
Ca’’), 149.1 (quaternary aromatic C, Cg, Cg’ or Cg’’), 146.3 (quaternary aromatic C, Cg,
Cg’ or Cg’’ and Cg, Cg’ or Cg’’), 142.2 (aniline CH, Cc, Cc’ or Cc’’), 141.4 (aniline CH, Cc, Cc’
or Cc’’), 141.2 (aniline CH, Cc, Cc’ or Cc’’), 130.4 (aniline CH, Cb, Cb’ or Cb’’), 130.3 (aniline
CH, Cb, Cb’ or Cb’’), 129.9 (aniline CH, Cb, Cb’ or Cb’’), 128.7 (aniline CH, Cd, Cd’ or Cd’’ and
Cd, Cd’ or Cd’’), 127.9 (aniline CH, Cd, Cd’ or Cd’’), 126.9 (CF3, CF3 and CF3), 125.8
(aromatic CH, Cj, Cj’ or Cj’’ and Cj, Cj’ or Cj’’), 125.4 (aromatic CH, Cj, Cj’ or Cj’’), 124.2
(quaternary aromatic C, Ci and Ck, Ci’ and Ck’ or Ci’’ and Ck’’), 123.3 (quaternary
aromatic C, Ci and Ck, Ci’ and Ck’ or Ci’’ and Ck’’), 121.4 (quaternary aromatic C, Ci and
Ck, Ci’ and Ck’ or Ci’’ and Ck’’), 118.5 (aromatic CH, Ch and Cl, Ch’ and Cl’ or Ch’’ and Cl’’),
117.6 (aromatic CH, Ch and Cl, Ch’ and Cl’ or Ch’’ and Cl’’), 117.3 (aromatic CH, Ch and
Cl, Ch’ and Cl’ or Ch’’ and Cl’’) Analysis calculated (+ ½ CHCl3) C 45.65, H 1.94, N 7.52 %
Analysis found C 45.69, H 1.66, N 7.52 % ES MS (+) (CH3OH) m/z 1059.08 [MH+] IR
(cm-1) ν 3087 (w, ArCH), 1635 (m, CO), 1601 (m, CO), 1465 (w), 1369 (m), 1273 (s), 
1058 (s), 967 (w), 897 (w), 762 (w), 682 (m)
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8.7.14 Synthesis of CoC39H33N6O3 (2.14a)
Purified by column chromatography (methanol/diethyl ether 9:1) to give a red solid
(0.206 g, 0.297 mmol, 71 %). Recrystallisation by vapour diffusion (methanol/diethyl
ether) at 5 °C yielded red crystals suitable for single crystal X-ray diffraction.
1H NMR (CDCl3, 400.13 MHz, 298.0 K) δ 9.17 (d, 1H, 
Ha, Ha’ or Ha’’, 3J (1H-1H) = 5.4 Hz), 8.57 (d, 1H, Ha, Ha’
or Ha’’, 3J (1H-1H) = 5.4 Hz), 8.34 (d, 1H, Hd, Hd’ or Hd’’,
3J (1H-1H) = 7.6 Hz), 8.11 (t, 1H, Hc, Hc’ or Hc’’, 3J (1H-1H)
= 7.5 Hz), 8.00 (d, 1H, Hd, Hd’ or Hd’’, 3J (1H-1H) = 7.6
Hz), 7.75 (m, 3H, Ha, Ha’ or Ha’’, Hc, Hc’ or Hc’’ and Hd,
Hd’ or Hd’’), 7.66 (ddd, 1H, Hb, Hb’ or Hb’’, 3J (1H-1H) =
6.7 Hz, 3J (1H-1H) = 5.7 Hz and 4J (1H-1H) = 1.2 Hz), 7.12 (m, 6H, Hb, Hb’ or Hb’’, Hb, Hb’
or Hb’’, Hc, Hc’ or Hc’’, Hh, Hh’ or Hh’’, Hh, Hh’ or Hh’’ and Hj, Hj’ or Hj’’), 6.86 (br. s, 2H, Hk,
Hk’ or Hk’’ and Hj, Hj’ or Hj’’), 6.75 (m, 2H, Hh, Hh’ or Hh’’ and Hk, Hk’ or Hk’’), 6.62 (m, 2H,
Hj, Hj’ or Hj’’ and Hl, Hl’ or Hl’’), 6.12 (br. s, 2H, Hk, Hk’ or Hk’’ and Hl, Hl’ or Hl’’), 5.75 (br.
s, 1H, Hl, Hl’ or Hl’’), 2.25 (s, 3H, Hm, Hm’ or Hm’’), 2.08 (s, 3H, Hm, Hm’ or Hm’’), 1.95 (s,
3H, Hm, Hm’ or Hm’’) 13C {1H} NMR (CDCl3, 100.6 MHz, 300.0 K) δ 170.3 (quaternary C-
O, Cf, Cf’ or Cf’’), 169.4 (quaternary C-O, Cf, Cf’ or Cf’’), 168.7 (quaternary C-O, Cf, Cf’ or
Cf’’), 158.7 (quaternary aniline C, Ce, Ce’ or Ce’’), 157.2 (quaternary aniline C, Ce, Ce’ or
Ce’’), 156.8 (quaternary aniline C, Ce, Ce’ or Ce’’), 149.7 (aniline CH, Ca, Ca’ or Ca’’), 148.9
(aniline CH, Ca, Ca’ or Ca’’), 148.4 (aniline CH, Ca, Ca’ or Ca’’), 145.8 (quaternary aromatic
C, Cg, Cg’ or Cg’’), 144.1 (quaternary aromatic C, Cg, Cg’ or Cg’’), 143.6 (quaternary
aromatic C, Cg, Cg’ or Cg’’), 140.4 (aniline CH, Cc, Cc’ or Cc’’), 139.3 (aniline CH, Cc, Cc’ or
Cc’’), 139.2 (aniline CH, Cc, Cc’ or Cc’’), 138.7 (quaternary aromatic C, Ci, Ci’ or Ci’’), 137.3
(quaternary aromatic C, Ci, Ci’ or Ci’’ and Ci, Ci’ or Ci’’), 129.1 (aromatic CH, Ch, Ch’ or
Ch’’), 128.7 (aromatic CH, Ch, Ch’ or Ch’’), 128.4 (aromatic CH, Ch, Ch’ or Ch’’), 127.7
(aniline CH, Cb, Cb’ or Cb’’), 126.6 (aniline CH, Cb, Cb’ or Cb’’ and Cb, Cb’ or Cb’’), 126.6
(aniline CH, Cd, Cd’ or Cd’’), 126.4 (aniline CH, Cd, Cd’ or Cd’’), 126.3 (aniline CH, Cd, Cd’
or Cd’’), 126.1 (aromatic CH, Ck, Ck’ or Ck’’), 125.9 (aromatic CH, Ck, Ck’ or Ck’’ and Ck, Ck’
or Ck’’), 125.7 (aromatic CH, Cl, Cl’ or Cl’’), 125.5 (aromatic CH, Cl, Cl’ or Cl’’ and Cl, Cl’ or
Cl’’), 125.1 (aromatic CH, Cj, Cj’ or Cj’’ and Cj, Cj’ or Cj’’), 124.5 (aromatic CH, Cj, Cj’ or
Cj’’), 21.4 (CH3, Cm, Cm’ or Cm’’), 21.0 (CH3, Cm, Cm’ or Cm’’), 20.8 (CH3, Cm, Cm’ or Cm’’)
Analysis calculated (+ ½ CHCl3) C 63.06, H 4.49, N 11.17 % Analysis found C 63.22, H
4.66, N 11.34 % ES MS (+) (CH3OH) m/z 693.20 [MH+] IR (cm-1) ν 3036 (w, ArCH), 2916 
(w, MeCH), 1620 (m, CO), 1590 (s, CO), 1565 (s, CO), 1483 (m), 1365 (m), 1294 (w),
1093 (w), 764 (m), 682 (m)
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8.7.15 Synthesis of CoC39H33N6O3 (2.15a)
Purified by column chromatography (methanol/diethyl ether 3:2) to give a red solid
(0.141 g, 0.203 mmol, 48 %). Recrystallisation by vapour diffusion (methanol/diethyl
ether) at 5 °C yielded red crystals suitable for single crystal X-ray diffraction.
1H NMR (CDCl3, 400.13 MHz, 298.0 K) δ 9.15 (d, 1H, 
Ha, Ha’ or Ha’’, 3J (1H-1H) = 5.4 Hz), 8.58 (d, 1H, Ha, Ha’
or Ha’’, 3J (1H-1H) = 5.4 Hz), 8.35 (d, 1H, Hd, Hd’ or Hd’’,
3J (1H-1H) = 7.6 Hz), 8.11 (td, 1H, Hc, Hc’ or Hc’’, 3J (1H-
1H) = 7.7 Hz and 3J (1H-1H) = 1.1 Hz), 7.96 (d, 1H, Hd,
Hd’ or Hd’’, 3J (1H-1H) = 7.6 Hz), 7.75 (m, 3H, Ha, Ha’ or
Ha’’, Hc, Hc’ or Hc’’ and Hc, Hc’ or Hc’’), 7.65 (ddd, 1H, Hb,
Hb’ or Hb’’, 3J (1H-1H) = 6.7 Hz, 3J (1H-1H) = 5.6 Hz and 4J
(1H-1H) = 1.3 Hz), 7.14 (m, 3H, Hb, Hb’ or Hb’’, Hb, Hb’ or Hb’’ and Hd, Hd’ or Hd’’), 7.06 (d,
2H, Hi and Hk, Hi’ and Hk’ or Hi’’ and Hk’’, 3J (1H-1H) = 7.8 Hz), 6.84 (br. s, 2H, Hh and Hl,
Hh’ and Hl’ or Hh’’ and Hl’’), 6.75 (d, 2H, Hi and Hk, Hi’ and Hk’ or Hi’’ and Hk’’, 3J (1H-1H)
= 7.7 Hz), 6.52 (d, 2H, Hi and Hk, Hi’ and Hk’ or Hi’’ and Hk’’, 3J (1H-1H) = 8.1 Hz), 6.33
(br. s, 2H, Hh and Hl, Hh’ and Hl’ or Hh’’ and Hl’’), 6.02 (br. s, 2H, Hh and Hl, Hh’ and Hl’
or Hh’’ and Hl’’), 2.26 (s, 3H, Hm, Hm’ or Hm’’), 2.08 (s, 3H, Hm, Hm’ or Hm’’), 1.98 (s, 3H,
Hm, Hm’ or Hm’’) 13C {1H} NMR (CDCl3, 100.6 MHz, 300.0 K) δ 170.5 (quaternary C-O, 
Cf, Cf’ or Cf’’), 169.6 (quaternary C-O, Cf, Cf’ or Cf’’), 167.0 (quaternary C-O, Cf, Cf’ or
Cf’’), 158.6 (quaternary aniline C, Ce, Ce’ or Ce’’), 157.2 (quaternary aniline C, Ce, Ce’ or
Ce’’), 156.8 (quaternary aniline C, Ce, Ce’ or Ce’’), 149.7 (aniline CH, Ca, Ca’ or Ca’’), 149.0
(aniline CH, Ca, Ca’ or Ca’’), 148.3 (aniline CH, Ca, Ca’ or Ca’’), 143.1 (quaternary aromatic
C, Cg, Cg’ or Cg’’), 141.5 (quaternary aromatic C, Cg, Cg’ or Cg’’), 141.0 (quaternary
aromatic C, Cg, Cg’ or Cg’’), 140.3 (aniline CH, Cc, Cc’ or Cc’’), 139.2 (aniline CH, Cc, Cc’ or
Cc’’), 139.1 (aniline CH, Cc, Cc’ or Cc’’), 135.3 (quaternary aromatic C, Cj, Cj’ or Cj’’), 134.6
(quaternary aromatic C, Cj, Cj’ or Cj’’), 134.3 (quaternary aromatic C, Cj, Cj’ or Cj’’),
130.0 (aromatic CH, Ci and Ck, Ci’ and Ck’ or Ci’’ and Ck’’), 129.4 (aromatic CH, Ci and Ck,
Ci’ and Ck’ or Ci’’ and Ck’’), 128.7 (aromatic CH, Ci and Ck, Ci’ and Ck’ or Ci’’ and Ck’’), 127.6
(aniline CH, Cb, Cb’ or Cb’’), 127.2 (aniline CH, Cb, Cb’ or Cb’’ and Cb, Cb’ or Cb’’), 126.6
(aniline CH, Cd, Cd’ or Cd’’), 126.5 (aniline CH, Cd, Cd’ or Cd’’), 126.4 (aniline CH, Cd, Cd’
or Cd’’), 125.8 (aromatic CH, Ch and Cl, Ch’ and Cl’ or Ch’’ and Cl’’), 125.4 (aromatic CH,
Ch and Cl, Ch’ and Cl’ or Ch’’ and Cl’’, and Ch and Cl, Ch’ and Cl’ or Ch’’ and Cl’’), 21.1 (CH3,
Cm, Cm’ or Cm’’), 21.0 (CH3, Cm, Cm’ or Cm’’), 20.9 (CH3, Cm, Cm’ or Cm’’) Analysis
calculated (+ ⅔ CH2Cl2) C 63.58, H 4.62, N 11.22 % Analysis found C 63.10, H 4.50, N
10.90 % ES MS (+) (CH3OH) m/z 693.20 [MH+] IR (cm-1) ν 3052 (w, ArCH), 2920 (w, 
MeCH), 1622 (m, CO), 1589 (s, CO), 1565 (s, CO), 1506 (m), 1368 (m), 1294 (w), 1149
(w), 1095 (w), 808 (m), 757 (m), 681 (m), 524 (m)
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8.7.16 Synthesis of CoC42H39N6O3 (2.16a)
Purified by column chromatography (methanol/diethyl ether 4:1) to give a red solid
(0.210 g, 0.286 mmol, 68 %). Recrystallisation by vapour diffusion
(chloroform/pentane) at room temperature yielded orange crystals suitable for
single crystal X-ray diffraction.
1H NMR (CDCl3, 400.13 MHz, 300.0 K) δ 9.17 (d, 1H, 
Ha, Ha’ or Ha’’, 3J (1H-1H) = 5.5 Hz), 8.56 (d, 1H, Ha, Ha’
or Ha’’, 3J (1H-1H) = 5.3 Hz), 8.32 (d, 1H, Hd, Hd’ or Hd’’,
3J (1H-1H) = 7.5 Hz), 8.09 (t, 1H, Hc, Hc’ or Hc’’, 3J (1H-
1H) = 7.5 Hz), 8.02 (d, 1H, Hd, Hd’ or Hd’’, 3J (1H-1H) =
7.5 Hz), 7.75 (m, 4H, Ha, Ha’ or Ha’’, Hc, Hc’ or Hc’’, Hc,
Hc’ or Hc’’ and Hd, Hd’ or Hd’’), 7.65 (ddd, 1H, Hb, Hb’ or
Hb’’, 3J (1H-1H) = 7.0 Hz, 3J (1H-1H) = 5.5 Hz and 4J (1H-1H) = 1.1 Hz), 7.14 (m, 4H, Hb, Hb’
or Hb’’ and Hb, Hb’ or Hb’’, and Hh and Hl, Hh’ and Hl’ or Hh’’ and Hl’’), 6.90 (s, 1H, Hj, Hj’
or Hj’’), 6.56 (m, 3H, Hh and Hl, Hh’ and Hl’ or Hh’’ and Hl’’, and Hj, Hj’ or Hj’’), 6.44 (s, 1H,
Hj, Hj’ or Hj’’), 5.77 (br. s, 2H, Hh and Hl, Hh’ and Hl’ or Hh’’ and Hl’’), 2.19 (br. s, 6H, Hm
and Hn, Hm’ and Hn’ or Hm’’ and Hn’’), 2.05 (s, 6H, Hm and Hn, Hm’ and Hn’ or Hm’’ and
Hn’’), 1.93 (s, 6H, Hm and Hn, Hm’ and Hn’ or Hm’’ and Hn’’) 13C {1H} NMR (CDCl3, 100.6
MHz, 300.0 K) δ 170.2 (quaternary C-O, Cf, Cf’ or Cf’’), 169.5 (quaternary C-O, Cf, Cf’ or
Cf’’), 168.6 (quaternary C-O, Cf, Cf’ or Cf’’), 158.9 (quaternary aniline C, Ce, Ce’ or Ce’’),
157.3 (quaternary aniline C, Ce, Ce’ or Ce’’), 157.0 (quaternary aniline C, Ce, Ce’ or Ce’’),
149.8 (aniline CH, Ca, Ca’ or Ca’’), 148.9 (aniline CH, Ca, Ca’ or Ca’’), 148.4 (aniline CH,
Ca, Ca’ or Ca’’), 145.7 (quaternary aromatic C, Cg, Cg’ or Cg’’), 144.1 (quaternary
aromatic C, Cg, Cg’ or Cg’’), 143.6 (quaternary aromatic C, Cg, Cg’ or Cg’’), 140.3 (aniline
CH, Cc, Cc’ or Cc’’), 139.1 (aniline CH, Cc, Cc’ or Cc’’), 139.0 (aniline CH, Cc, Cc’ or Cc’’),
137.0 (quaternary aromatic C, Ci and Ck, Ci’ and Ck’, and Ci’’ and Ck’’), 127.6 (aniline CH,
Cb, Cb’ or Cb’’), 127.5 (aniline CH, Cb, Cb’ or Cb’’), 126.9 (aniline CH, Cb, Cb’ or Cb’’), 126.6
(aniline CH, Cd, Cd’ or Cd’’), 126.4 (aniline CH, Cd, Cd’ or Cd’’), 126.2 (aniline CH, Cd, Cd’
or Cd’’), 125.8 (aromatic CH, Ch and Cl, Ch’ and Cl’ or Ch’’ and Cl’’, and Ch and Cl, Ch’ and
Cl’ or Ch’’ and Cl’’), 125.4 (aromatic CH, Ch and Cl, Ch’ and Cl’ or Ch’’ and Cl’’), 124.8
(aromatic CH, Cj, Cj’ and Cj’’), 21.4 (CH3, Cm and Cn, Cm’ and Cn’ or Cm’’ and Cn’’), 21.0
(CH3, Cm and Cn, Cm’ and Cn’ or Cm’’ and Cn’’), 20.8 (CH3, Cm and Cn, Cm’ and Cn’ or Cm’’
and Cn’’) Analysis calculated (+ ½ CHCl3) C 64.26, H 5.01, N 10.58 % Analysis found C
64.30, H 5.50, N 10.80 % ES MS (+) (CH3OH) m/z 735.25 [MH+] IR (cm-1) ν 3083 (w, 
ArCH), 2914 (w, MeCH), 1616 (m, CO), 1595 (s, CO), 1581 (s, CO), 1470 (w), 1374 (m),
1278 (w), 1097 (w), 1026 (w), 840 (w), 765 (m), 681 (m)
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8.7.17 Synthesis of CoC39H33N6O6 (2.17a)
Purified by column chromatography (methanol/diethyl ether 4:1) to give a red solid
(0.149 g, 0.201 mmol, 48 %). Recrystallisation by slow evaporation from methanol at
room temperature yielded red crystals suitable for single crystal X-ray diffraction.
1H NMR (CDCl3, 400.13 MHz, 300.0 K) δ 9.12 (d, 
1H, Ha, Ha’ or Ha’’, 3J (1H-1H) = 5.5 Hz), 8.55 (d, 1H,
Ha, Ha’ or Ha’’, 3J (1H-1H) = 5.3 Hz), 8.36 (d, 1H, Hd,
Hd’ or Hd’’, 3J (1H-1H) = 7.5 Hz), 8.11 (td, 1H, Hc, Hc’
or Hc’’, 3J (1H-1H) = 7.6 Hz and 3J (1H-1H) = 1.1 Hz),
7.97 (d, 1H, Hd, Hd’ or Hd’’, 3J (1H-1H) = 7.3 Hz), 7.76
(m, 3H, Hb, Hb’ or Hb’’, Hc, Hc’ or Hc’’ and Hd, Hd’ or
Hd’’), 7.64 (ddd, 1H, Hb, Hb’ or Hb’’, 3J (1H-1H) = 7.5
Hz, 3J (1H-1H) = 5.1 Hz and 4J (1H-1H) = 1.2 Hz), 7.15 (m, 3H, Ha, Ha’ or Ha’’, Hb, Hb’ or
Hb’’ and Hc, Hc’ or Hc’’), 6.88 (br. s, 2H, Hh and Hl, Hh’ and Hl’ or Hh’’ and Hl’’), 6.81 (d,
2H, Hi and Hk, Hi’ and Hk’ or Hi’’ and Hk’’, 3J (1H-1H) = 8.4 Hz), 6.51 (d, 2H, Hi and Hk, Hi’
and Hk’ or Hi’’ and Hk’’, 3J (1H-1H) = 7.8 Hz), 6.40 (br. s, 2H, Hh and Hl, Hh’ and Hl’ or Hh’’
and Hl’’), 6.29 (d, 2H, Hi and Hk, Hi’ and Hk’ or Hi’’ and Hk’’, 3J (1H-1H) = 8.8 Hz), 6.09 (br.
s, 2H, Hh and Hl, Hh’ and Hl’ or Hh’’ and Hl’’), 3.76 (s, 3H, Hm, Hm’ or Hm’’), 3.66 (s, 3H,
Hm, Hm’ or Hm’’), 3.58 (s, 3H, Hm, Hm’ or Hm’’) 13C {1H} NMR (CDCl3, 100.6 MHz, 300.0
K) δ 170.6 (quaternary C-O, Cf, Cf’ or Cf’’), 169.7 (quaternary C-O, Cf, Cf’ or Cf’’), 169.2
(quaternary C-O, Cf, Cf’ or Cf’’), 158.5 (quaternary aniline C, Ce, Ce’ or Ce’’), 157.4
(quaternary aniline C, Ce, Ce’ or Ce’’), 157.2 (quaternary aniline C, Ce, Ce’ or Ce’’), 156.8
(quaternary aromatic C, Cj, Cj’ or Cj’’), 156.7 (quaternary aromatic C, Cj, Cj’ or Cj’’),
156.6 (quaternary aromatic C, Cj, Cj’ or Cj’’), 149.6 (aniline CH, Ca, Ca’ or Ca’’), 149.0
(aniline CH, Ca, Ca’ or Ca’’), 148.3 (aniline CH, Ca, Ca’ or Ca’’), 140.3 (aniline CH, Cc, Cc’ or
Cc’’), 139.4 (aniline CH, Cc, Cc’ or Cc’’), 139.2 (aniline CH, Cc, Cc’ or Cc’’), 138.5
(quaternary aromatic C, Cg, Cg’ or Cg’’), 137.1 (quaternary aromatic C, Cg, Cg’ or Cg’’),
136.4 (quaternary aromatic C, Cg, Cg’ or Cg’’), 128.3 (aniline CH, Cb, Cb’ or Cb’’ and Cb,
Cb’ or Cb’’), 127.6 (aniline CH, Cb, Cb’ or Cb’’), 126.6 (aromatic CH, Ci and Ck, Ci’ and Ck’
or Ci’’ and Ck’’), 126.5 (aromatic CH, Ci and Ck, Ci’ and Ck’ or Ci’’ and Ck’’, and Ci and Ck,
Ci’ and Ck’ or Ci’’ and Ck’’), 125.8 (aniline CH, Cd, Cd’ or Cd’’ and Cd, Cd’ or Cd’’), 125.3
(aniline CH, Cd, Cd’ or Cd’’), 114.6 (aromatic CH, Ch and Cl, Ch’ and Cl’ or Ch’’ and Cl’’),
114.2 (aromatic CH, Ch and Cl, Ch’ and Cl’ or Ch’’ and Cl’’), 113.5 (aromatic CH, Ch and
Cl, Ch’ and Cl’ or Ch’’ and Cl’’), 55.3 (CH3, Cm, Cm’ or Cm’’ and Cm, Cm’ or Cm’’), 55.2 (CH3,
Cm, Cm’ or Cm’’) Analysis calculated (+ CH2Cl2) C 58.19, H 4.27, N 10.18 % Analysis
found C 57.29, H 4.48, N 10.23 % ES MS (+) (CH3OH) m/z 741.19 [MH+] IR (cm-1) ν 
3065 (w, ArCH), 2939 (w, MeCH), 2835 (w), 1588 (s, CO), 1503 (s), 1370 (m), 1286
(m), 1240 (s), 1027 (m), 822 (m), 763 (m), 683 (m)
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8.7.18 Synthesis of CoC42H39N6O9 (2.18a)
Purified by column chromatography (methanol/diethyl ether 2:3) to give a red solid
(0.135 g, 0.162 mmol, 39 %).
1H NMR (CDCl3, 400.13 MHz, 300.0 K) δ 9.10 (d, 
1H, Ha, Ha’ or Ha’’, 3J (1H-1H) = 5.1 Hz), 8.63 (d, 1H,
Ha, Ha’ or Ha’’, 3J (1H-1H) = 5.1 Hz), 8.38 (d, 1H, Hd,
Hd’ or Hd’’, 3J (1H-1H) = 7.5 Hz), 8.13 (td, 1H, Hc, Hc’
or Hc’’, 3J (1H-1H) = 7.4 Hz and 3J (1H-1H) = 1.2 Hz),
7.93 (d, 1H, Hd, Hd’ or Hd’’, 3J (1H-1H) = 7.5 Hz),
7.82 (m, 2H, Hc, Hc’ or Hc’’ and Hd, Hd’ and Hd’’),
7.75 (td, 1H, Hc, Hc’ or Hc’’, 3J (1H-1H) = 7.4 Hz and
3J (1H-1H) = 1.2 Hz), 7.67 (ddd, 1H, Hb, Hb’ or Hb’’, 3J (1H-1H) = 7.0 Hz, 3J (1H-1H) = 5.5
Hz and 4J (1H-1H) = 1.3 Hz), 7.14 (m, 4H, Ha, Ha’ or Ha’’, Hb, Hb’ or Hb’’ and, Hh and Hl,
Hh’ and Hl’ or Hh’’ and Hl’’), 6.35 (s, 1H, Hj, Hj’ or Hj’’), 6.17 (br. s, 3H, Hb, Hb’ or Hb’’, and
Hh and Hl, Hh’ and Hl’ or Hh’’ and Hl’’), 6.08 (s, 1H, Hj, Hj’ or Hj’’), 5.98 (s, 1H, Hj, Hj’ or
Hj’’), 5.61 (br.s, 2H, Hh and Hl, Hh’ and Hl’ or Hh’’ and Hl’’), 3.63 (s, 6H, Hm and Hn, Hm’
and Hn’ or Hm’’ and Hn’’), 3.58 (s, 6H, Hm and Hn, Hm’ and Hn’ or Hm’’ and Hn’’), 3.51 (s,
6H, Hm and Hn, Hm’ and Hn’ or Hm’’ and Hn’’) 13C {1H} NMR (CDCl3, 100.6 MHz, 300.0 K)
δ 170.2 (quaternary C-O, Cf, Cf’ or Cf’’), 169.2 (quaternary C-O, Cf, Cf’ or Cf’’), 169.1
(quaternary C-O, Cf, Cf’ or Cf’’), 161.0 (quaternary aromatic C, Ci and Ck, Ci’ and Ck’ or
Ci’’ and Ck’’), 160.6 (quaternary aromatic C, Ci and Ck, Ci’ and Ck’ or Ci’’ and Ck’’), 160.2
(quaternary aromatic C, Ci and Ck, Ci’ and Ck’ or Ci’’ and Ck’’), 158.8 (quaternary aniline
C, Ce, Ce’ or Ce’’), 157.1 (quaternary aniline C, Ce, Ce’ or Ce’’), 156.9 (quaternary aniline
C, Ce, Ce’ or Ce’’), 150.0 (aniline CH, Ca, Ca’ or Ca’’), 149.1 (aniline CH, Ca, Ca’ or Ca’’),
148.9 (aniline CH, Ca, Ca’ or Ca’’), 147.8 (quaternary aromatic C, Cg, Cg’ or Cg’’), 146.3
(quaternary aromatic C, Cg, Cg’ or Cg’’), 145.6 (quaternary aromatic C, Cg, Cg’ or Cg’’),
140.5 (aniline CH, Cc, Cc’ or Cc’’), 139.4 (aniline CH, Cc, Cc’ or Cc’’), 139.2 (aniline CH, Cc,
Cc’ or Cc’’), 127.7 (aniline CH, Cb, Cb’ or Cb’’), 126.6 (aniline CH, Cb, Cb’ or Cb’’), 126.5
(aniline CH, Cb, Cb’ or Cb’’), 126.4 (aniline CH, Cd, Cd’ or Cd’’), 125.7 (aniline CH, Cd, Cd’
or Cd’’), 125.0 (aniline CH, Cd, Cd’ or Cd’’), 105.8 (aromatic CH, Ch and Cl, Ch’ and Cl’ or
Ch’’ and Cl’’, and Ch and Cl, Ch’ and Cl’ or Ch’’ and Cl’’), 105.3 (aromatic CH, Ch and Cl, Ch’
and Cl’ or Ch’’ and Cl’’), 99.8 (aromatic CH, Cj, Cj’ or Cj’’), 98.5 (aromatic CH, Cj, Cj’ or Cj’’),
98.0 (aromatic CH, Cj, Cj’ or Cj’’), 55.3 (CH3, Cm and Cn, Cm’ and Cn’ or Cm’’ and Cn’’), 55.2
(CH3, Cm and Cn, Cm’ and Cn’ or Cm’’ and Cn’’), 55.1 (CH3, Cm and Cn, Cm’ and Cn’ or Cm’’
and Cn’’) Analysis calculated (+ 3 CH2Cl2) C 49.79, H 4.18, N 7.74 % Analysis found C
50.45, H 4.57, N 7.72 % ES MS (+) (CH3OH) m/z 831.22 [MH+] IR (cm-1) ν 3084 (w, 
ArCH), 2938 (w, MeCH), 2837 (w), 1584 (s, CO), 1456 (m), 1283 (m), 1201 (m), 1149
(s), 1058 (m), 828 (w), 764 (m), 682 (m)
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8.8 Syntheses of cobalt(III) tris-picolinamide complexes (mixed
coordination)
The required picolinamide ligand (3 equivalents) in ethanol (10 mL) was added to a
solution of cobalt(II) chloride hexahydrate (1 equivalent) in ethanol (10 mL).
Triethylamine (3 equivalents) was added and the mixture was heated at 85 °C for 2
hours to give a brown solution. The solvent was removed under reduced pressure
and the product purified by column chromatography (methanol/diethyl ether).
Product was dissolved in dichloromethane or chloroform, filtered through a sinter
and the pure product was precipitated with the addition of hexane.
8.8.1 Synthesis of CoC36H27N6O3 (2.1b)
Purified by column chromatography (methanol/diethyl ether 9:1) to give a brown
solid (0.090 g, 0.138 mmol, 33 %). Recrystallisation by vapour diffusion
(chloroform/diethyl ether) at room temperature yielded red crystals suitable for
single crystal X-ray diffraction.
1H NMR (CDCl3, 500.23 MHz, 300.0 K) δ 8.99 (d, 1H, Ha,
Ha’ or Ha’’, 3J (1H-1H) = 5.5 Hz), 8.43 (d, 1H, Hd, Hd’ or Hd’’,
3J (1H-1H) = 7.8 Hz), 8.03 (m, 2H, Ha, Ha’ or Ha’’ and Hc, Hc’
or Hc’’), 7.95 (t, 2H, Hc, Hc’ or Hc’’ and Hc, Hc’ or Hc’’, 3J (1H-
1H) = 7.7 Hz), 7.76 (d, 2H, Hd, Hd’ or Hd’’ and Hd, Hd’ or Hd’’,
3J (1H-1H) = 7.8 Hz), 7.70 (m, 2H, Ha, Ha’ or Ha’’ and Hb, Hb’
and Hb’’), 7.65 (ddd, 1H, Hb, Hb’ or Hb’’, 3J (1H-1H) = 7.2 Hz,
3J (1H-1H) = 5.6 Hz and 4J (1H-1H) = 1.2 Hz), 7.35 (t, 2H, Hi
and Hk, Hi’ and Hk’ or Hi’’ and Hk’’, 3J (1H-1H) = 7.7 Hz), 7.10 (m, 3H, Hb, Hb’ or Hb’’, and
Hi and Hk, Hi’ and Hk’ or Hi’’ and Hk’’), 6.98 (m, 8H, Hh and Hl, Hh’ and Hl’ or Hh’’ and Hl’’,
Hh and Hl, Hh’ and Hl’ or Hh’’ and Hl’’, Hi and Hk, Hi’ and Hk’ or Hi’’ and Hk’’, Hj, Hj’ or Hj’’
and Hj, Hj’ or Hj’’), 6.92 (br. s, 3H, Hh and Hl, Hh’ and Hl’ or Hh’’ and Hl’’, and Hj, Hj’ or Hj’’)
13C {1H} NMR (CDCl3, 125.8 MHz, 300.1 K) δ 170.1 (quaternary C-O, Cf, Cf’ or Cf’’),
169.3 (quaternary C-O, Cf, Cf’ or Cf’’ and Cf, Cf’ or Cf’’), 160.1 (quaternary aniline C, Ce,
Ce’ or Ce’’), 158.3 (quaternary aniline C, Ce, Ce’ or Ce’’), 155.9 (quaternary aniline C, Ce,
Ce’ or Ce’’), 148.8 (aniline CH, Ca, Ca’ or Ca’’), 148.4 (aniline CH, Ca, Ca’ or Ca’’), 148.3
(aniline CH, Ca, Ca’ or Ca’’), 147.2 (quaternary aromatic C, Cg, Cg’ or Cg’’), 145.5
(quaternary aromatic C, Cg, Cg’ or Cg’’), 144.7 (quaternary aromatic C, Cg, Cg’ or Cg’’),
139.4 (aniline CH, Cc, Cc’ or Cc’’), 139.3 (aniline CH, Cc, Cc’ or Cc’’), 139.2 (aniline CH, Cc,
Cc’ or Cc’’), 128.9 (aromatic CH, Ch and Cl, Ch’ and Cl’ or Ch’’ and Cl’’), 128.8 (aromatic
CH, Ch and Cl, Ch’ and Cl’ or Ch’’ and Cl’’), 128.5 (aromatic CH, Ch and Cl, Ch’ and Cl’ or
Ch’’ and Cl’’), 127.2 (aniline CH, Cb, Cb’ or Cb’’ and Cb, Cb’ or Cb’’), 127.1 (aniline CH, Cb,
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Cb’ or Cb’’), 126.5 (aromatic CH, Ci and Ck, Ci’ and Ck’ or Ci’’ and Ck’’), 126.2 (aromatic
CH, Ci and Ck, Ci’ and Ck’ or Ci’’ and Ck’’), 126.1 (aromatic CH, Ci and Ck, Ci’ and Ck’ or Ci’’
and Ck’’), 125.5 (aniline CH, Cd, Cd’ or Cd’’), 125.4 (aniline CH, Cd, Cd’ or Cd’’), 125.3
(aniline CH, Cd, Cd’ or Cd’’), 125.1 (aromatic CH, Cj, Cj’ or Cj’’), 125.0 (aromatic CH, Cj, Cj’
or Cj’’), 124.3 (aromatic CH, Cj, Cj’ or Cj’’) Analysis calculated (+ 2 H2O) C 62.97, H 4.55,
N 12.24 % Analysis found C 63.20, H 4.40, N 12.20 % ES MS (+) (CH3OH) m/z 651.16
[MH+] IR (cm-1) ν 3056 (w, ArCH), 1638 (m, CO), 1624 (m, CO), 1600 (m, CO), 1575 (s), 
1487 (m), 1384 (m), 1348 (m) 1137 (w), 804 (w), 753 (s), 680 (s), 510 (m)
8.8.2 Synthesis of CoC39H33N6O3 (2.14b)
Purified by column chromatography (methanol/diethyl ether 7:3) to give a brown
solid (0.072 g, 0.104 mmol, 25 %). Recrystallisation by slow evaporation from
methanol at room temperature yielded brown crystals suitable for single crystal X-
ray diffraction.
1H NMR (CDCl3, 500.23 MHz, 299.9 K) δ 8.98 (d, 1H, 
Ha, Ha’ or Ha’’, 3J (1H-1H) = 5.5 Hz), 8.42 (d, 1H, Hd, Hd’
or Hd’’, 3J (1H-1H) = 7.8 Hz), 8.03 (m, 3H, Ha, Ha’ or Ha’’,
Hc, Hc’ or Hc’’ and Hd, Hd’ or Hd’’), 7.93 (d, 1H, Hd, Hd’ or
Hd’’, 3J (1H-1H) = 7.6 Hz), 7.66 (m, 5H, Ha, Ha’ or Ha’’,
Hb, Hb’ or Hb’’, Hb, Hb’ or Hb’’, Hc, Hc’ or Hc’’ and Hc, Hc’
or Hc’’), 7.24 (t, 1H, Hk, Hk’ or Hk’’, 3J (1H-1H) = 7.7 Hz),
6.96 (m, 6H, Hb, Hb’ or Hb’’, Hh, Hh’ or Hh’’, Hh, Hh’ or
Hh’’, Hj, Hj’ or Hj’’, Hj, Hj’ or Hj’’ and Hl, Hl’ or Hl’’), 6.87 (t, 1H, Hk, Hk’ or Hk’’, 3J (1H-1H) =
7.5 Hz), 6.77 (m, 3H, Hh, Hh’ or Hh’’, Hj, Hj’ or Hj’’ and Hk, Hk’ or Hk’’), 6.51 (br. s, 2H, Hl,
Hl’ or Hl’’ and Hl, Hl’ or Hl’’), 2.39 (s, 3H, Hm, Hm’ or Hm’’), 2.10 (s, 3H, Hm, Hm’ or Hm’’),
2.06 (br. s, 3H, Hm, Hm’ or Hm’’) 13C {1H} NMR (CDCl3, 125.6 MHz, 299.9 K) δ 170.0 
(quaternary C-O, Cf, Cf’ or Cf’’ and Cf, Cf’ or Cf’’), 169.2 (quaternary C-O, Cf, Cf’ or Cf’’),
160.2 (quaternary aniline C, Ce, Ce’ or Ce’’), 156.1 (quaternary aniline C, Ce, Ce’ or Ce’’
and Ce, Ce’ or Ce’’), 148.8 (aniline CH, Ca, Ca’ or Ca’’), 148.4 (aniline CH, Ca, Ca’ or Ca’’),
148.2 (aniline CH, Ca, Ca’ or Ca’’), 147.1 (quaternary aromatic C, Cg, Cg’ and Cg’’), 139.3
(aniline CH, Cc, Cc’ or Cc’’), 139.1 (aniline CH, Cc, Cc’ or Cc’’), 139.0 (aniline CH, Cc, Cc’ or
Cc’’), 138.6 (quaternary aromatic C, Ci, Ci’ or Ci’’), 138.4 (quaternary aromatic C, Ci, Ci’
or Ci’’), 138.1 (quaternary aromatic C, Ci, Ci’ or Ci’’), 128.7 (aromatic CH, Ch, Ch’ or Ch’’),
128.6 (aromatic CH, Ch, Ch’ or Ch’’), 128.4 (aromatic CH, Ch, Ch’ or Ch’’), 127.6 (aromatic
CH, Ck, Ck’ or Ck’’), 127.0 (aromatic CH, Ck, Ck’ or Ck’’ and Ck, Ck’ or Ck’’), 126.3 (aniline
CH, Cb, Cb’ or Cb’’), 126.1 (aniline CH, Cb, Cb’ or Cb’’ and Cb, Cb’ or Cb’’), 126.0 (aniline
CH, Cd, Cd’ or Cd’’), 125.8 (aniline CH, Cd, Cd’ or Cd’’ and Cd, Cd’ or Cd’’), 125.3 (aromatic
CH, Cj, Cj’ or Cj’’ and Cj, Cj’ or Cj’’), 125.1 (aromatic CH, Cj, Cj’ or Cj’’), 122.3 (aromatic
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CH, Cl, Cl’ and Cl’’), 21.6 (CH3, Cm, Cm’ or Cm’’), 21.1 (CH3, Cm, Cm’ or Cm’’), 21.0 (CH3, Cm,
Cm’ or Cm’’) Analysis calculated (+ ½ CH2Cl2) C 64.54, H 4.66, N 11.43 % Analysis found
C 64.22, H 4.46, N 11.41 % ES MS (+) (CH3OH) m/z 693.20 [MH+] IR (cm-1) 3398 (br.
w, NH), 3032 (w, ArCH), 2917 (w, MeCH), 1621 (m, CO), 1590 (s, CO), 1559 (s, CO),
1480 (m), 1375 (m), 1331 (m), 1261 (m), 1123 (w), 1089 (w), 761 (m), 681 (m)
8.8.3 Synthesis of CoC39H33N6O3 (2.15b)
Purified by column chromatography (methanol/diethyl ether 4:1) to give a brown
solid (0.073 g, 0.105 mmol, 25 %). Recrystallisation by vapour diffusion
(chloroform/pentane) at 5 °C yielded brown crystals suitable for single crystal X-ray
diffraction.
1H NMR (CDCl3, 400.13 MHz, 300.0 K) δ 8.97 (d, 1H, 
Ha, Ha’ or Ha’’, 3J (1H-1H) = 5.3 Hz), 8.41 (d, 1H, Hd, Hd’
or Hd’’, 3J (1H-1H) = 7.9 Hz), 7.98 (m, 5H, Ha, Ha’ or Ha’’,
Hb, Hb’ or Hb’’, Hb, Hb’ or Hb’’, Hc, Hc’ or Hc’’ and Hd, Hd’ or
Hd’’), 7.70 (m, 4H, Hb, Hb’ or Hb’’, Hc, Hc’ or Hc’’, Hc, Hc’ or
Hc’’ and Hd, Hd’ or Hd’’), 7.62 (ddd, 1H, Hb, Hb’ or Hb’’, 3J
(1H-1H) = 7.0 Hz, 3J (1H-1H) = 5.4 Hz and 4J (1H-1H) = 1.3
Hz), 7.15 (d, 2H, Hh and Hl, Hh’ and Hl’ or Hh’’ and Hl’’, 3J
(1H-1H) = 8.1 Hz), 6.96 (m, 6H, Hh and Hl, Hh’ and Hl’ or Hh’’ and Hl’’, Hi and Hk, Hi’ and
Hk’ or Hi’’ and Hk’’ and, Hi and Hk, Hi’ and Hk’ or Hi’’ and Hk’’), 6.76 (d, 2H, Hh and Hl, Hh’
and Hl’ or Hh’’ and Hl’’, 3J (1H-1H) = 7.9 Hz), 6.72 (br. s, 2H, Hi and Hk, Hi’ and Hk’ or Hi’’
and Hk’’), 2.35 (s, 3H, Hm, Hm’ or Hm’’), 2.07 (s, 6H, Hm, Hm’ or Hm’’ and Hm, Hm’ or Hm’’)
13C {1H} NMR (CDCl3, 100.6 MHz, 300.0 K) δ 169.3 (quaternary C-O, Cf, Cf’ and Cf’’),
160.2 (quaternary aniline C, Ce, Ce’ or Ce’’), 158.4 (quaternary aniline C, Ce, Ce’ or Ce’’),
156.0 (quaternary aniline C, Ce, Ce’ or Ce’’), 148.8 (aniline CH, Ca, Ca’ or Ca’’), 148.3
(aniline CH, Ca, Ca’ or Ca’’), 148.2 (aniline CH, Ca, Ca’ or Ca’’), 142.8 (quaternary aromatic
C, Cg, Cg’ or Cg’’ and Cg, Cg’ or Cg’’), 142.0 (quaternary aromatic C, Cg, Cg’ or Cg’’), 139.1
(aniline CH, Cc, Cc’ or Cc’’), 139.0 (aniline CH, Cc, Cc’ or Cc’’), 138.9 (aniline CH, Cc, Cc’ or
Cc’’), 134.8 (quaternary aromatic C, Cj, Cj’ or Cj’’), 134.5 (quaternary aromatic C, Cj, Cj’
or Cj’’), 134.0 (quaternary aromatic C, Cj, Cj’ or Cj’’), 129.5 (aromatic CH, Ci and Ck, Ci’
and Ck’ or Ci’’ and Ck’’), 129.4 (aromatic CH, Ci and Ck, Ci’ and Ck’ or Ci’’ and Ck’’), 129.2
(aromatic CH, Ci and Ck, Ci’ and Ck’ or Ci’’ and Ck’’), 126.9 (aniline CH, Cb, Cb’ or Cb’’ and
Cb, Cb’ or Cb’’), 126.7 (aniline CH, Cb, Cb’ or Cb’’), 126.3 (aniline CH, Cd, Cd’ or Cd’’), 126.1
(aniline CH, Cd, Cd’ or Cd’’), 126.0 (aniline CH, Cd, Cd’ or Cd’’), 125.5 (aromatic CH, Ch
and Cl, Ch’ and Cl’ or Ch’’ and Cl’’), 125.4 (aromatic CH, Ch and Cl, Ch’ and Cl’ or Ch’’ and
Cl’’), 125.0 (aromatic CH, Ch and Cl, Ch’ and Cl’ or Ch’’ and Cl’’), 21.1 (CH3, Cm, Cm’ or Cm’’),
21.0 (CH3, Cm, Cm’ or Cm’’ and Cm, Cm’ or Cm’’) Analysis calculated (+ 4/5 CH2Cl2) C 62.85,
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H 4.59, N 11.05 % Analysis found C 62.38, H 4.86, N 11.24 % ES MS (+) (CH3OH) m/z
693.20 [MH+] IR (cm-1) ν 3025 (w, ArCH), 2919 (w, MeCH), 1580 (s, CO), 1567 (s, CO), 
1505 (m), 1341 (w), 1251 (w), 1096 (w), 806 (m), 757 (m), 680 (m), 510 (s)
8.8.4 Synthesis of CoC42H39N6O3 (2.16b)
Purified by column chromatography (methanol/diethyl ether 3:2) to give a brown
solid (0.106 g, 0.145 mmol, 34 %). Recrystallisation by slow evaporation from
methanol at room temperature yielded brown crystals suitable for single crystal X-
ray diffraction.
1H NMR (CDCl3, 500.23 MHz, 300.0 K) δ 8.98 (d, 1H, 
Ha, Ha’ or Ha’’, 3J (1H-1H) = 5.0 Hz), 8.48 (br. s, 1H, Hd,
Hd’ or Hd’’), 8.06 (d, 1H, Ha, Ha’ or Ha’’, 3J (1H-1H) = 5.3
Hz), 8.01 (m, 2H, Hc, Hc’ or Hc’’ and Hd, Hd’ or Hd’’), 7.94
(d, 1H, Hd, Hd’ or Hd’’, 3J (1H-1H) = 7.6 Hz), 7.70 (m, 2H,
Hc, Hc’ or Hc’’ and Hc, Hc’ or Hc’’), 7.64 (ddd, 1H, Hb, Hb’
or Hb’’, 3J (1H-1H) = 7.0 Hz, 3J (1H-1H) = 5.5 Hz and 4J
(1H-1H) = 1.2 Hz), 7.50 (s, 2H, Hh and Hl, Hh’ and Hl’ or
Hh’’ and Hl’’), 7.15 (br. s, 1H, Hj, Hj’ or Hj’’), 6.97 (m, 3H, Ha, Ha’ or Ha’’, Hb, Hb’ or Hb’’ and
Hb, Hb’ or Hb’’ ), 6.78 (s, 1H, Hj, Hj’ or Hj’’), 6.63 (s, 2H, Hh and Hl, Hh’ and Hl’ or Hh’’ and
Hl’’), 6.57 (s, 2H, Hh and Hl, Hh’ and Hl’ or Hh’’ and Hl’’), 6.32 (br. s, 1H, Hj, Hj’ or Hj’’),
2.36 (s, 6H, Hm and Hn, Hm’ and Hn’ or Hm’’ and Hn’’), 2.19 (br. s, 6H, Hm and Hn, Hm’ and
Hn’ or Hm’’ and Hn’’), 2.08 (s, 6H, Hm and Hn, Hm’ and Hn’ or Hm’’ and Hn’’) 13C {1H} NMR
(CDCl3, 125.6 MHz, 300.1 K) δ 169.0 (quaternary C-O, Cf, Cf’ and Cf’’), 158.7
(quaternary aniline C, Ce, Ce’ and Ce’’), 148.7 (aniline CH, Ca, Ca’ or Ca’’), 148.4 (aniline
CH, Ca, Ca’ or Ca’’), 148.1 (aniline CH, Ca, Ca’ or Ca’’), 144.3 (quaternary aromatic C, Cg,
Cg’ and Cg’’), 139.3 (aniline CH, Cc, Cc’ or Cc’’), 139.1 (aniline CH, Cc, Cc’ or Cc’’), 138.9
(aniline CH, Cc, Cc’ or Cc’’), 137.9 (quaternary aromatic C, Ci and Ck, Ci’ and Ck’, and Ci’’
and Ck’’), 127.1 (aniline CH, Cb, Cb’ or Cb’’), 127.0 (aniline CH, Cb, Cb’ or Cb’’), 126.9
(aniline CH, Cb, Cb’ or Cb’’), 126.3 (aniline CH, Cd, Cd’ or Cd’’), 126.1 (aniline CH, Cd, Cd’
or Cd’’), 126.0 (aniline CH, Cd, Cd’ or Cd’’), 125.6 (aromatic CH, Ch and Cl, Ch’ and Cl’ or
Ch’’ and Cl’’), 125.1 (aromatic CH, Ch and Cl, Ch’ and Cl’ or Ch’’ and Cl’’), 124.6 (aromatic
CH, Ch and Cl, Ch’ and Cl’ or Ch’’ and Cl’’), 123.2 (aromatic CH, Cj, Cj’ and Cj’’), 21.6 (CH3,
Cm and Cn, Cm’ and Cn’ or Cm’’ and Cn’’ and Cm and Cn, Cm’ and Cn’ or Cm’’ and Cn’’), 21.0
(CH3, Cm and Cn, Cm’ and Cn’ or Cm’’ and Cn’’) Analysis calculated (+ ½ CHCl3) C 64.26,
H 5.01, N 10.58 % Analysis found C 64.30, H 5.50, N 10.80 % ES MS (+) (CH3OH) m/z
735.25 [MH+] IR (cm-1) ν 3066 (w, ArCH), 2914 (w, MeCH), 1620 (m, CO), 1583 (s, CO), 
1562 (s, CO), 1467 (m), 1376 (m), 1335 (m), 1260 (w), 1159 (w), 1123 (w), 1028 (w),
840 (m), 762 (m), 682 (m)
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8.8.5 Synthesis of CoC39H33N6O6 (2.17b)
Purified by column chromatography (methanol/diethyl ether 4:1) to give a brown
solid (0.055 g, 0.074 mmol, 18 %). Recrystallisation by slow evaporation from
methanol at room temperature yielded red crystals suitable for single crystal X-ray
diffraction.
1H NMR (CDCl3, 400.13 MHz, 300.0 K) δ 8.93 (d, 1H, 
Ha, Ha’ or Ha’’, 3J (1H-1H) = 5.5 Hz), 8.39 (d, 1H, Hd, Hd’
or Hd’’, 3J (1H-1H) = 7.9 Hz), 8.05 (d, 1H, Ha, Ha’ or Ha’’,
3J (1H-1H) = 5.5 Hz), 7.96 (m, 3H, Hc, Hc’ or Hc’’, Hd, Hd’
or Hd’’ and Hd, Hd’ or Hd’’), 7.82 (m, 2H, Ha, Ha’ or Ha’’
and Hc, Hc’ or Hc’’), 7.72 (m, 2H, Hb, Hb’ or Hb’’ and Hc,
Hc’ or Hc’’), 7.60 (ddd, 1H, Hb, Hb’ or Hb’’, 3J (1H-1H) =
7.3 Hz, 3J (1H-1H) = 5.7 Hz and 4J (1H-1H) = 1.5 Hz),
6.99 (m, 5H, Hb, Hb’ or Hb’’, Hh and Hl, Hh’ and Hl’ or
Hh’’ and Hl’’, and Hi and Hk, Hi’ and Hk’ or Hi’’ and Hk’’), 6.89 (d, 2H, Hh and Hl, Hh’ and
Hl’ or Hh’’ and Hl’’, 3J (1H-1H) = 9.0 Hz), 6.53 (d, 2H, Hh and Hl, Hh’ and Hl’ or Hh’’ and Hl’’,
3J (1H-1H) = 9.0 Hz), 6.48 (br. s, 4H, Hi and Hk, Hi’ and Hk’ or Hi’’ and Hk’’, and Hi and Hk,
Hi’ and Hk’ or Hi’’ and Hk’’), 3.82 (s, 3H, Hm, Hm’ or Hm’’), 3.65 (s, 3H, Hm, Hm’ or Hm’’),
3.64 (s, 3H, Hm, Hm’ or Hm’’) 13C {1H} NMR (CDCl3, 100.6 MHz, 300.0 K) δ 170.4 
(quaternary C-O, Cf, Cf’ or Cf’’ and Cf, Cf’ or Cf’’), 169.6 (quaternary C-O, Cf, Cf’ or Cf’’),
163.0 (quaternary aniline C, Ce, Ce’ or Ce’’), 160.3 (quaternary aniline C, Ce, Ce’ or Ce’’),
158.3 (quaternary aniline C, Ce, Ce’ or Ce’’), 156.9 (quaternary aromatic C, Cj, Cj’ or Cj’’),
156.5 (quaternary aromatic C, Cj, Cj’ or Cj’’), 155.9 (quaternary aromatic C, Cj, Cj’ or
Cj’’), 148.8 (aniline CH, Ca, Ca’ or Ca’’), 148.3 (aniline CH, Ca, Ca’ or Ca’’), 148.2 (aniline
CH, Ca, Ca’ or Ca’’), 140.7 (quaternary aromatic C, Cg, Cg’ or Cg’’), 139.2 (aniline CH, Cc,
Cc’ or Cc’’), 139.1 (aniline CH, Cc, Cc’ or Cc’’), 139.0 (aniline CH, Cc, Cc’ or Cc’’), 138.4
(quaternary aromatic C, Cg, Cg’ or Cg’’), 137.5 (quaternary aromatic C, Cg, Cg’ or Cg’’),
127.8 (aniline CH, Cb, Cb’ or Cb’’), 126.8 (aniline CH, Cb, Cb’ or Cb’’), 126.7 (aniline CH,
Cb, Cb’ or Cb’’), 126.4 (aromatic CH, Ci and Ck, Ci’ and Ck’ or Ci’’ and Ck’’, and Ci and Ck,
Ci’ and Ck’ or Ci’’ and Ck’’), 126.1 (aromatic CH, Ci and Ck, Ci’ and Ck’ or Ci’’ and Ck’’), 125.8
(aniline CH, Cd, Cd’ or Cd’’), 125.4 (aniline CH, Cd, Cd’ or Cd’’), 125.0 (aniline CH, Cd, Cd’
or Cd’’), 114.2 (aromatic CH, Ch and Cl, Ch’ and Cl’ or Ch’’ and Cl’’, and Ch and Cl, Ch’ and
Cl’ or Ch’’ and Cl’’), 113.7 (aromatic CH, Ch and Cl, Ch’ and Cl’ or Ch’’ and Cl’’), 55.4 (CH3,
Cm, Cm’ or Cm’’), 55.3 (CH3, Cm, Cm’ or Cm’’), 55.2 (CH3, Cm, Cm’ or Cm’’) Analysis
calculated (+ 1 CH2Cl2) C 60.58, H 4.62, N 10.73 % Analysis found C 60.48, H 4.65, N
10.79 % ES MS (+) (CH3OH) m/z 741.19 [MH+] IR (cm-1) ν 3054 (w, ArCH), 2929 (w, 
MeCH), 2829 (w, MeCH), 1582 (s, CO), 1502 (s), 1338 (m), 1281 (m), 1238 (s), 1168
(m), 1020 (m), 824 (m), 759 (m), 682 (m), 560 (m)
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8.8.6 Synthesis of CoC42H39N6O9 (2.18b)
Purified by column chromatography (methanol/diethyl ether 2:3) to give a brown
solid (0.075 g, 0.091 mmol, 22 %). Recrystallisation by slow evaporation from
methanol at room temperature yielded orange crystals suitable for single crystal X-
ray diffraction.
1H NMR (CDCl3, 400.13 MHz, 300.0 K) δ 8.94 (d, 
1H, Ha, Ha’ or Ha’’, 3J (1H-1H) = 5.3 Hz), 8.39 (d,
1H, Hd, Hd’ or Hd’’, 3J (1H-1H) = 7.5 Hz), 8.11 (d,
1H, Ha, Ha’ or Ha’’, 3J (1H-1H) = 5.3 Hz), 7.98 (m,
3H, Hc, Hc’ or Hc’’ Hc, Hc’ or Hc’’ and Hd, Hd’ and
Hd’’), 7.76 (m, 2H, Hc, Hc’ or Hc’’ and Hc, Hc’ or
Hc’’), 7.65 (ddd, 1H, Hb, Hb’ or Hb’’, 3J (1H-1H) =
7.2 Hz, 3J (1H-1H) = 5.5 Hz and 4J (1H-1H) = 1.3
Hz), 7.06 (m, 3H, Ha, Ha’ or Ha’’, Hb, Hb’ or Hb’’ and Hb, Hb’ or Hb’’), 6.88 (m, 2H, Hh and
Hl, Hh’ and Hl’ or Hh’’ and Hl’’), 6.64 (br. s, 1H, Hj, Hj’ or Hj’’), 6.27 (m, 2H, Hh and Hl, Hh’
and Hl’ or Hh’’ and Hl’’), 6.22 (m, 1H, Hj, Hj’ or Hj’’), 6.08 (m, 2H, Hh and Hl, Hh’ and Hl’ or
Hh’’ and Hl’’), 5.98 (br.s, 1H, Hj, Hj’ or Hj’’), 3.76 (s, 6H, Hm and Hn, Hm’ and Hn’ or Hm’’
and Hn’’), 3.62 (s, 6H, Hm and Hn, Hm’ and Hn’ or Hm’’ and Hn’’), 3.57 (s, 6H, Hm and Hn,
Hm’ and Hn’ or Hm’’ and Hn’’) 13C {1H} NMR (CDCl3, 100.6 MHz, 300.0 K) δ 169.9 
(quaternary C-O, Cf, Cf’ or Cf’’), 169.0 (quaternary C-O, Cf, Cf’ or Cf’’ and Cf, Cf’ or Cf’’),
164.4 (quaternary aromatic C, Ci and Ck, Ci’ and Ck’ or Ci’’ and Ck’’), 160.7 (quaternary
aromatic C, Ci and Ck, Ci’ and Ck’ or Ci’’ and Ck’’), 160.6 (quaternary aromatic C, Ci and
Ck, Ci’ and Ck’ or Ci’’ and Ck’’), 158.4 (quaternary aniline C, Ce, Ce’ or Ce’’ and Ce, Ce’ or
Ce’’), 156.1 (quaternary aniline C, Ce, Ce’ or Ce’’), 149.0 (aniline CH, Ca, Ca’ or Ca’’), 148.7
(aniline CH, Ca, Ca’ or Ca’’), 148.4 (aniline CH, Ca, Ca’ or Ca’’), 147.3 (quaternary aromatic
C, Cg, Cg’ or Cg’’ and Cg, Cg’ or Cg’’), 146.7 (quaternary aromatic C, Cg, Cg’ or Cg’’), 139.4
(aniline CH, Cc, Cc’ or Cc’’), 139.3 (aniline CH, Cc, Cc’ or Cc’’), 139.2 (aniline CH, Cc, Cc’ or
Cc’’), 127.2 (aniline CH, Cb, Cb’ or Cb’’), 126.3 (aniline CH, Cb, Cb’ or Cb’’), 126.1 (aniline
CH, Cb, Cb’ or Cb’’), 125.2 (aniline CH, Cd, Cd’ or Cd’’ and Cd, Cd’ or Cd’’), 125.0 (aniline
CH, Cd, Cd’ or Cd’’), 103.2 (aromatic CH, Ch and Cl, Ch’ and Cl’ and Ch’’ and Cl’’), 99.6
(aromatic CH, Cj, Cj’ or Cj’’), 98.2 (aromatic CH, Cj, Cj’ or Cj’’), 97.1 (aromatic CH, Cj, Cj’
or Cj’’), 55.3 (CH3, Cm and Cn, Cm’ and Cn’ or Cm’’ and Cn’’, and Cm and Cn, Cm’ and Cn’ or
Cm’’ and Cn’’), 55.2 (CH3, Cm and Cn, Cm’ and Cn’ or Cm’’ and Cn’’) Analysis calculated (+
2 CH2Cl2) C 52.82, H 4.33, N 8.40 % Analysis found C 53.14, H 4.25, N 8.74 % ES MS
(+) (CH3OH) m/z 831.22 [MH+] IR (cm-1) ν 3081 (w, ArCH), 2936 (w, MeCH), 2834 (w, 
MeCH), 1562 (s, CO), 1454 (m), 1330 (m), 1197 (m), 1145 (s), 1047 (m), 760 (m), 681
(m)
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8.9 Syntheses of cobalt(II) bis-picolinamide thiocyanate complexes
The required picolinamide ligand (2 equivalents) in ethanol (10 mL) was added to a
solution of cobalt(II) nitrate hexahydrate (1 equivalent) in distilled water (5 mL) and
stirred at 50 °C for 15 min. Potassium thiocyanate (2 equivalents) in distilled water
(5 mL) was added dropwise and the mixture was stirred at 50 °C for 2 hours to give
a dark pink solution. Slow evaporation of solvent from the reaction mixture yielded
pure product.
8.9.1 Synthesis of CoC26H20N6O2S2 (3.1)
Dark pink crystals suitable for single crystal X-ray diffraction (0.175 g, 0.337 mmol,
73 %).
1H NMR (d6-DMSO, 300.13 MHz, 300.0 K) δ 10.54 (2H, 
NH), 8.68 (2H, Ha), 8.01 (4H, Hc and Hd), 7.88 (4H, Hh and
Hl), 7.62 (2H, Hb), 7.26 (4H, Hi and Hk), 7.04 (2H, Hj)
Analysis calculated C 54.64, H 3.53, N 14.70 % Analysis
found C 54.45, H 3.50, N 15.10 % ES MS (+) (CH3CN) m/z
513.07 [M-NCS+] IR (cm-1) ν 3295 (br. w, NH), 3054 (w, 
ArCH), 2080 (s, CN), 1632 (m, CO), 1605 (m, CO), 1551
(m), 1341 (m), 1261 (m), 1019 (m), 903 (m), 747 (s), 706 (s), 508 (m)
8.9.2 Synthesis of CoC28H24N6O2S2 (3.2)
Pink crystals suitable for single crystal X-ray diffraction (0.246 g, 0.410 mmol, 98 %).
1H NMR (d6-DMSO, 300.13 MHz, 300.0 K) δ 10.46 
(2H, NH), 8.68 (2H, Ha), 8.03 (4H, Hc and Hd), 7.71
(2H, Hh), 7.64 (4H, Hb and Hj), 7.16 (2H, Hk), 6.89 (2H,
Hl), 2.24 (6H, Hm) Analysis calculated C 56.09, H 4.03,
N 14.02 % Analysis found C 55.97, H 4.02, N 13.95 %
ES MS (+) (CH3CN) m/z 541.10 [M-NCS+] IR (cm-1) ν 
3255 (br. w, NH), 3067 (w, ArCH), 2918 (w, MeCH),
2083 (s, CN), 1630 (s, CO), 1587 (m, CO), 1551 (s), 1438 (m), 1261 (w), 1020 (w), 781
(m), 682 (m), 645 (m)
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8.9.3 Synthesis of CoC30H28N6O2S2 (3.3)
Dark pink crystals suitable for single crystal X-ray diffraction (0.233 g, 0.372 mmol,
89 %).
1H NMR (d6-DMSO, 500.23 MHz, 300.1 K) δ 10.27 
(2H, NH), 8.60 (2H, Ha), 7.96 (4H, Hc and Hd), 7.45
(6H, Hb, Hh and Hl), 6.67 (2H, Hj), 2.12 (12H, Hm and
Hn) Analysis calculated C 57.41, H 4.50, N 13.39 %
Analysis found C 57.50, H 4.60, N 13.60 % ES MS (+)
(CH3CN) m/z 569.13 [M-NCS+] IR (cm-1) ν 3263 (br. 
w, NH), 3099 (w, ArCH), 2912 (w, MeCH). 2098 (s,
CN), 1632 (m, CO), 1557 (m, CO), 1433 (m), 1309 (w), 1020 (w), 824 (m), 746 (m), 678
(s)
8.9.4 Synthesis of CoC28H24N6O2S2 (3.4)
Pink crystals suitable for single crystal X-ray diffraction (0.228 g, 0.382 mmol, 91 %).
1H NMR (d6-DMSO, 300.13 MHz, 300.0 K) δ 10.21 (2H, 
NH), 8.70 (2H, Ha), 8.12 (2H, Hd), 8.03 (2H, Hc), 7.82 (2H,
Hl), 7.64 (2H, Hb), 7.22 (4H, Hi and Hj), 7.07 (2H, Hk), 2.28
(6H, Hm) Analysis calculated C 56.09, H 4.03, N 14.02 %
Analysis found C 55.98, H 4.21, N 13.97 % ES MS (+)
(CH3CN) m/z 541.10 [M-NCS+] IR (cm-1) ν 3225 (br. w, NH), 
3066 (w, ArCH), 2872 (w, MeCH), 2069 (s, CN), 1632 (m,
CO), 1589 (m, CO), 1523 (s), 1459 (m), 1304 (w), 997 (w), 917 (w), 747 (s), 692 (m),
595 (w)
8.9.5 Synthesis of CoC28H24N6O2S2 (3.5)
Pink crystals suitable for single crystal X-ray diffraction (0.174 g, 0.291 mmol, 69 %).
1H NMR (d6-DMSO, 300.13 MHz, 300.0 K) δ 10.47 (2H, 
NH), 8.68 (2H, Ha), 8.03 (4H, Hc and Hd), 7.75 (4H, Hh
and Hl), 7.61 (2H, Hb), 7.08 (4H, Hi and Hk), 2.20 (6H,
Hm) Analysis calculated (+ 1 H2O) C 54.45, H 4.24, N
13.79 % Analysis found C 54.79, H 4.01, N 13.79 % ES
MS (+) (CH3CN) m/z 541.10 [M-NCS+] IR (cm-1) ν 3261 
(br. w, NH), 3085 (w, ArCH), 2081 (s, CN), 1630 (m, CO),
1586 (m, CO), 1529 (m), 1260 (w), 1020 (w), 808 (m), 751 (m), 687 (m), 596 (m), 509
(s)
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8.9.6 Synthesis of CoC28H24N6O2S2 (3.6)
Purple solid (0.248 g, 0.395 mmol, 94 %).
1H NMR (d6-DMSO, 500.23 MHz, 300.1 K) δ 10.20 (2H, 
NH), 8.63 (2H, Ha), 8.05 (2H, Hd), 7.96 (2H, Hl), 7.55 (2H,
Hc), 7.48 (2H, Hb), 6.99 (2H, Hk), 6.95 (2H, Hj), 2.18 (6H,
Hn), 2.09 (6H, Hm) Analysis calculated C 57.41, H 4.50,
N 13.39 % Analysis found C 57.50, H 4.64, N 13.24 % ES
MS (+) (CH3CN) m/z 569.13 [M-NCS+] IR (cm-1) ν 3264 
(br. w, NH), 3068 (w, ArCH), 2915 (w, MeCH), 2070 (s,
CN), 1633 (m, CO), 1589 (m, CO), 1531 (s), 1471 (m), 1304 (w), 1264 (w), 1017 (w),
780 (m), 694 (m), 576 (w)
8.9.7 Synthesis of CoC28H24N6O4S2 (3.7)
Pink crystals suitable for single crystal X-ray diffraction (0.146 g, 0.231 mmol, 55 %).
1H NMR (d6-DMSO, 500.57 MHz, 299.3 K) δ 10.47 
(2H, NH), 8.68 (2H, Ha), 8.09 (2H, Hd), 8.01 (2H, Hc),
7.78 (4H, Hh and Hl), 7.61 (2H, Hb), 6.88 (4H, Hi and
Hk), 3.49 (6H, Hm) Analysis calculated C 53.25, H
3.83, N 13.31 % Analysis found C 53.33, H 3.70, N
13.24 % ES MS (+) (CH3CN) m/z 573.09 [M-NCS+] IR
(cm-1) ν 3300 (br. w, NH), 3092 (w, ArCH), 2837 (w, 
MeCH), 2081 (s, CN), 1626 (m, CO), 1585 (m, CO), 1537 (m), 1508 (m), 1186 (m), 1020
(m), 827 (m), 751 (m), 550 (m), 524 (m)
8.9.8 Synthesis of CoC30H28N6O6S2 (3.8)
Purple crystals suitable for single crystal X-ray diffraction (0.127 g, 0.184 mmol, 44
%).
1H NMR (d6-DMSO, 500.57 MHz, 299.3 K) δ 10.45 
(2H, NH), 8.66 (2H, Ha), 8.07 (2H, Hd), 8.01 (2H, Hc),
7.60 (2H, Hb), 7.19 (4H, Hh and Hl), 6.21 (2H, Hj), 3.60
(6H, Hm and Hn) Analysis calculated C 52.10, H 4.08,
N 12.15 % Analysis found C 51.97, H 4.09, N 12.01 %
ES MS (+) (CH3CN) m/z 633.11 [M-NCS+] IR (cm-1) ν 
3207 (br. w, NH), 3084 (w, ArCH), 2963 (w, MeCH),
2072 (s, CN), 1612 (m, CO), 1555 (m, CO), 1318 (m), 1158 (s), 1065 (m), 832 (m), 752
(m), 675 (m), 640 (m)
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8.10 Synthesis of cobalt(II) bis-picolinamide chloride complex
The required picolinamide ligand (2 equivalents) in ethanol (10 mL) was added to a
solution of cobalt(II) chloride hexahydrate (1 equivalent) in ethanol (10 mL) and
stirred at 50 °C for 2 hours min to give an orange suspension. The solid was filtered,
washed with ethanol and dried to yield pure product.
8.10.1 Synthesis of CoC24H20N4O2Cl2 (3.9)
Orange solid (0.212 g, 0.403 mmol, 96 %). Recrystallisation by slow evaporation from
acetonitrile yielded orange crystals suitable for single crystal X-ray diffraction.
1H NMR (d6-DMSO, 300.13 MHz, 300.0 K) δ 10.59 (2H, 
NH), 8.74 (2H, Ha), 8.10 (4H, Hc and Hd), 7.91 (4H, Hh and
Hl), 7.68 (2H, Hb), 7.33 (4H, Hi and Hk), 7.10 (2H, Hj)
Analysis calculated C 54.77, H 3.83, N 10.65 % Analysis
found C 54.86, H 3.65, N 10.62 % ES MS (+) (CH3CN) m/z
490.06 [M-Cl+] IR (cm-1) ν 3248 (w, NH), 3092 (w, ArCH), 
1630 (m, CO), 1609 (m, CO), 1586 (m), 1558 (m), 1502
(m), 1447 (m), 1347 (m), 1264 (w), 1022 (w), 904 (w), 758 (s), 681 (s), 515 (m)
8.11 Synthesis of cobalt(II) bis-picolinamide aqua complex
The required picolinamide ligand (2 equivalents) in ethanol (10 mL) was added to a
solution of cobalt(II) chloride hexahydrate (1 equivalent) in distilled water (5 mL) and
stirred at 50 °C for 15 min. Potassium iodide (2 equivalents) in distilled water (5 mL)
was added dropwise and the mixture was stirred at 50 °C for 2 hours to give an
orange solution. Slow evaporation of solvent from the reaction mixture yielded pure
product.
Co
Cl
Cl
O
N
NH
O
k
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h
j
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f
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i
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8.11.1 Synthesis of CoC24H24N4O4I2 (3.10)
Orange crystals suitable for single crystal X-ray diffraction (0.304 g, 0.408 mmol, 97
%).
1H NMR (d6-DMSO, 300.13 MHz, 300.0 K) δ 10.54 
(2H, NH), 8.68 (2H, Ha), 8.11 (4H, Hc and Hd), 7.86
(4H, Hh and Hl), 7.62 (2H, Hb), 7.25 (4H, Hi and Hk),
7.06 (2H, Hj) Analysis calculated (+ 3 H2O) C 36.07,
H 3.78, N 7.01 % Analysis found C 35.85, H 3.18, N
6.66 % ES MS (+) (CH3CN) m/z 582.00 [M-(2H2O+I)+]
IR (cm-1) ν 3315 (br. m, OH), 3254 (m, NH), 3084 (w, 
ArCH), 1626 (m, CO), 1602 (m, CO), 1582 (m), 1547 (m), 1447 (m), 1344 (w), 1262
(w), 1054 (w), 899 (w), 765 (s), 688 (s), 585 (s)
8.12 Synthesis of cobalt(III) bis-picolinamide β-diketonate complexes 
Complex 4.1 was synthesised and partially characterised by Mr. Bilal Saloo
(University of Leeds). Crystals suitable for single crystal X-ray diffraction of
complexes 4.1, 4.3, 4.8 and 4.9 were provided by Mr. Bilal Saloo (University of
Leeds).
The required picolinamide ligand (2 equivalents) and the required β-diketonate 
ligand (1 equivalent) in ethanol (10 mL) was added to a solution of cobalt(II) chloride
hydrate (1 equivalent) in distilled water (5 mL). Hydrogen peroxide (1 equivalent)
was added dropwise and the mixture was heated at 85 °C for 18 hours to give a
brown solution. The solvent was removed under reduced pressure and the product
purified by column chromatography (ethyl acetate/hexane) to give pure product.
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8.12.1 Synthesis of CoC33H21N4O4F12 (4.1)
Purified by column chromatography (ethyl acetate/hexane 7:3) to give a green solid
(0.095 g, 0.115 mmol, 27 %). Recrystallisation by vapour diffusion
(dichloromethane/hexane) at room temperature yielded green crystals suitable for
single crystal X-ray diffraction.
1H NMR (CDCl3, 500.23 MHz, 300.0 K) δ 8.14 (d, 2H, Hd
and Hd’, 3J (1H-1H) = 7.5 Hz), 7.92 (td, 2H, Hc and Hc’, 3J
(1H-1H) = 7.7 Hz and 3J (1H-1H) = 1.4 Hz), 7.67 (d, 2H, Ha
and Ha’, 3J (1H-1H) = 5.5 Hz), 7.50 (s, 2H, Hj and Hj’), 7.45
(br. s, 4H, Hh, Hh’, Hl and Hl’), 7.19 (ddd, 2H, Hb and Hb’,
3J (1H-1H) = 7.0 Hz, 3J (1H-1H) = 5.8 Hz and 4J (1H-1H) =
1.1 Hz), 5.43 (s, 1H, Ho), 2.06 (s, 6H, Hm and Hq) 13C {1H}
NMR (CDCl3, 125.8 MHz, 300.1 K) δ 190.4 (quaternary diketonate C, Cn and Cp), 169.3
(quaternary C-O, Cf and Cf’), 156.7 (quaternary aniline C, Ce and Ce’), 148.5
(quaternary aromatic C, Ci, Ci’, Ck and Ck’), 148.0 (aniline CH, Ca and Ca’), 140.0 (aniline
CH, Cc and Cc’), 131.8 (CF3), 128.3 (aromatic CH, Ch, Ch’, Cl and Cl’), 126.5 (aniline CH,
Cb and Cb’), 125.9 (aniline CH, Cd and Cd’), 124.0 (quaternary aromatic C, Cg and Cg’),
121.8 (aromatic CH, Cj or Cj’), 119.6 (aromatic CH, Cj or Cj’), 97.9 (diketonate CH, Co),
27.3 (CH3, Cm and Cq) Analysis calculated C 48.07, H 2.57, N 6.80 % Analysis found C
47.92, H 2.43, N 6.78 % ES MS (+) (CH3OH) m/z 825.07 [MH+] IR (cm-1) ν 3090 (w, 
ArCH), 2962 (w, MeCH), 1637 (m, CO), 1604 (m, CO), 1570 (m, CO), 1518 (m), 1376
(m), 1274 (s), 1056 (s), 919 (m), 770 (m), 681 (m), 617 (w)
8.12.2 Synthesis of CoC43H25N4O4F12 (4.2)
Purified by column chromatography (ethyl acetate/hexane 1:1) to give a green solid
(0.088 g, 0.093 mmol, 22 %). Recrystallisation by slow evaporation from methanol at
room temperature yielded green crystals suitable for single crystal X-ray diffraction.
1H NMR (CDCl3, 500.23 MHz, 300.2 K) δ 8.20 (d, 2H, 
Hd and Hd’, 3J (1H-1H) = 7.7 Hz), 7.90 (m, 6H, Hc, Hc’,
Hj, Hj’, Ht and Ht’), 7.81 (d, 2H, Ha and Ha’, 3J (1H-1H)
= 5.5 Hz), 7.59 (m, 6H, Hh, Hh’, Hl, Hl’, Hr and Hr’ or
Hv and Hv’), 7.50 (m, 6H, Hr and Hr’ or Hv and Hv’, Hs,
Hs’, Hu and Hu’), 7.13 (ddd, 2H, Hb and Hb’, 3J (1H-1H)
= 7.5 Hz, 3J (1H-1H) = 5.7 Hz and 4J (1H-1H) = 1.3 Hz),
6.79 (s, 1H, Ho) 13C {1H} NMR (CDCl3, 125.8 MHz, 300.1 K) δ 184.0 (quaternary 
diketonate C, Cn and Cp), 169.5 (quaternary C-O, Cf and Cf’), 156.6 (quaternary aniline
C, Ce or Ce’), 148.6 (quaternary aromatic C, Ci ,Ci’, Ck and Ck’), 147.9 (aniline CH, Ca and
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Ca’), 140.1 (aniline CH, Cc and Cc’), 136.5 (aromatic CH, Cr and Cv), 132.8 (aromatic CH,
Ct), 131.9 (CF3), 128.9 (aromatic CH, Cu and Cs), 127.1 (aromatic CH, Ch, Ch’, Cl and Cl’),
126.7 (aniline CH, Cb and Cb’), 126.2 (aniline CH, Cd and Cd’), 123.9 (quaternary
aromatic C, Cg), 121.8 (quaternary aromatic C, Cm and Cq), 118.5 (aromatic CH, Cj and
Cj’), 91.4 (diketonate CH, Co) Analysis calculated C 54.44, H 2.66, N 5.91 % Analysis
found C 54.31, H 2.55, N 5.95 % ES MS (+) (CH3OH) m/z 949.11 [MH+] IR (cm-1) ν 3086 
(w, ArCH), 1639 (m, CO), 1600 (m, CO), 1515 (m), 1373 (m), 1277 (s), 1119 (s), 978
(w), 878 (w), 761 (w), 684 (m). 616 (w)
8.12.3 Synthesis of CoC38H23N4O4F12 (4.3)
Purified by column chromatography (ethyl acetate/hexane 3:7) to give a green solid
(0.043 g, 0.048 mmol, 11 %). Recrystallisation by vapour diffusion
(dichloromethane/hexane) at room temperature yielded green crystals suitable for
single crystal X-ray diffraction.
1H NMR (CDCl3, 400.13 MHz, 300.0 K) δ 8.19 (d, 1H, 
Hd or Hd’, 3J (1H-1H) = 7.7 Hz), 8.15 (d, 1H, Hd or Hd’,
3J (1H-1H) = 7.6 Hz), 7.93 (td, 1H, Hc or Hc’, 3J (1H-1H)
= 7.5 Hz and 3J (1H-1H) = 1.2 Hz), 7.90 (td, 1H, Hc or
Hc’, 3J (1H-1H) = 7.5 Hz and 3J (1H-1H) = 1.2 Hz), 7.82
(s, 1H, Hj or Hj’), 7.80 (s, 1H, Hj or Hj’), 7.75 (d, 1H,
Ha or Ha’, 3J (1H-1H) = 5.3 Hz), 7.73 (d, 1H, Ha or Ha’,
3J (1H-1H) = 5.3 Hz), 7.55 (m, 3H, Hr, Ht and Hv), 7.52 (s, 2H, Hh and Hl or Hh’ and Hl’),
7.50 (s, 2H, Hh and Hl or Hh’ and Hl’), 7.44 (t, 2H, Hs and Hu, 3J (1H-1H) = 7.6 Hz), 7.18
(ddd, 1H, Hb or Hb’, 3J (1H-1H) = 7.5 Hz, 3J (1H-1H) = 5.9 Hz and 4J (1H-1H) = 1.5 Hz), 7.14
(ddd, 1H, Hb or Hb’, 3J (1H-1H) = 7.4 Hz, 3J (1H-1H) = 5.8 Hz and 4J (1H-1H) = 1.5 Hz), 6.10
(s, 1H, Ho), 2.21 (s, 3H, Hm) 13C {1H} NMR (CDCl3, 100.6 MHz, 300.0 K) δ 192.0 
(quaternary diketonate C, Cn), 182.4 (quaternary diketonate C, Cp), 169.4 (quaternary
C-O, Cf and Cf’), 156.7 (quaternary aniline C, Ce or Ce’), 156.6 (quaternary aniline C, Ce
or Ce’), 148.6 (quaternary aromatic C, Ci and Ck or Ci’ and Ck’), 148.5 (quaternary
aromatic C, Ci and Ck or Ci’ and Ck’), 148.0 (aniline CH, Ca or Ca’), 147.9 (aniline CH, Ca
or Ca’), 140.1 (aniline CH, Cc and Cc’), 135.9 (aromatic CH, Cr and Cv), 132.7 (aromatic
CH, Ct), 131.9 (CF3), 128.8 (aromatic CH, Cu and Cs), 127.0 (aromatic CH, Ch, Ch’, Cl and
Cl’), 126.7 (aniline CH, Cb or Cb’), 126.6 (aniline CH, Cb or Cb’), 126.1 (aniline CH, Cd and
Cd’), 124.2 (quaternary aromatic C, Cg), 121.5 (quaternary aromatic C, Cq), 118.4
(aromatic CH, Cj and Cj’), 94.5 (diketonate CH, Co), 28.1 (CH3, Cm) Analysis calculated
C 51.48, H 2.61, N 6.32 % Analysis found C 51.35, H 2.58, N 6.23 % ES MS (+) (CH3OH)
m/z 887.10 [MH+] IR (cm-1) ν 3079 (w, ArCH), 1634 (m, CO), 1601 (m, CO), 1551 (m, 
CO), 1512 (m), 1373 (s), 1273 (s), 1122 (s), 975 (m), 763 (m), 685 (s), 608 (w)
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8.12.4 Synthesis of CoC38H22N4O4F13 (4.4)
Purified by column chromatography (ethyl acetate/hexane 3:7) to give a green solid
(0.061 g, 0.068 mmol, 16 %). Recrystallisation by slow evaporation from methanol at
room temperature yielded green crystals suitable for single crystal X-ray diffraction.
1H NMR (CDCl3, 400.13 MHz, 300.0 K) δ 8.19 (d, 
1H, Hd or Hd’, 3J (1H-1H) = 7.7 Hz and 3J (1H-1H) =
0.8 Hz), 8.14 (d, 1H, Hd or Hd’, 3J (1H-1H) = 7.7 Hz
and 3J (1H-1H) = 0.9 Hz), 7.94 (td, 1H, Hc or Hc’, 3J
(1H-1H) = 7.7 Hz and 3J (1H-1H) = 1.4 Hz), 7.91 (td,
1H, Hc or Hc’, 3J (1H-1H) = 7.7 Hz and 3J (1H-1H) =
1.4 Hz), 7.82 (m, 2H, Hr and Ht), 7.75 (d, 1H, Ha
or Ha’, 3J (1H-1H) = 5.1 Hz), 7.69 (d, 1H, Ha or Ha’, 3J (1H-1H) = 5.1 Hz), 7.51 (m, 6H, Hh,
Hh’, Hj, Hj’, Hl and Hl’), 7.19 (ddd, 1H, Hb or Hb’, 3J (1H-1H) = 7.7 Hz, 3J (1H-1H) = 5.7 Hz
and 4J (1H-1H) = 1.6 Hz), 7.14 (ddd, 1H, Hb or Hb’, 3J (1H-1H) = 7.5 Hz, 3J (1H-1H) = 5.7 Hz
and 4J (1H-1H) = 1.4 Hz), 6.04 (s, 1H, Ho), 2.20 (s, 3H, Hm) 13C {1H} NMR (CDCl3, 100.6
MHz, 300.0 K) δ 192.2 (quaternary diketonate C, Cn), 181.0 (quaternary diketonate
C, Cp), 169.4 (quaternary C-O, Cf or Cf’), 156.7 (quaternary aniline C, Ce or Ce’), 156.6
(quaternary aniline C, Ce or Ce’), 148.5 (quaternary aromatic C, Ci, Ci’, Ck and Ck’), 147.9
(aniline CH, Ca or Ca’), 147.8 (aniline CH, Ca or Ca’), 140.1 (aniline CH, Cc and Cc’), 132.3
(CF3), 131.6 (aromatic CH, Cu and Cv), 129.4 (aromatic CH, Cr and Ct), 128.3 (aromatic
CH, Ch and Cl, or Ch’ and Cl’), 128.2 (aromatic CH, Ch and Cl, or Ch’ and Cl’), 126.7 (aniline
CH, Cb or Cb’), 126.6 (aniline CH, Cb or Cb’), 126.1 (aniline CH, Cd or Cd’), 126.0 (aniline
CH, Cd or Cd’), 124.2 (quaternary aromatic C, Cg), 121.5 (quaternary aromatic C, Cq),
118.5 (aromatic CH, Cs), 116.0 (aromatic CH, Cj or Cj’), 115.8 (aromatic CH, Cj or Cj’),
94.3 (diketonate CH, Co), 28.1 (CH3, Cm) Analysis calculated C 50.46, H 2.45, N 6.19
% Analysis found C 50.49, H 2.54, N 6.08 % ES MS (+) (CH3OH) m/z 905.08 [MH+] IR
(cm-1) ν 3098 (w, ArCH), 2962 (w, MeCH), 1637 (m, CO), 1602 (m, CO), 1498 (m), 1391 
(m), 1273 (s), 1118 (s), 977 (m), 846 (w), 764 (w), 686 (m), 524 (w)
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8.12.5 Synthesis of CoC38H22N4O4F13 (4.5)
Purified by column chromatography (ethyl acetate/hexane 3:7) to give a green solid
(0.077 g, 0.085 mmol, 20 %).
1H NMR (CDCl3, 400.13 MHz, 300.0 K) δ 8.16 
(overlapping d, 2H, Hd and Hd’), 7.92 (overlapping
td, 1H, Hc or Hc’), 7.76 (m, 3H, Ha, Ha’ and Hr or Hv),
7.51 (m, 6H, Hh, Hh’, Hj, Hj’, Hl and Hl’), 7.32 (m, 2H,
Hr or Hv and Hs or Hu), 7.14 (m, 3H, Hb, Hb’ and Hs or
Hu), 6.08 (s, 1H, Ho), 2.20 (s, 3H, Hm) 13C {1H} NMR
(CDCl3, 100.6 MHz, 300.0 K) δ 192.1 (quaternary 
diketonate C, Cn), 182.1 (quaternary diketonate C,
Cp), 169.3 (quaternary C-O, Cf and Cf’), 159.9 (aromatic CH, Ct), 156.6 (quaternary
aniline C, Ce and Ce’), 148.6 (quaternary aromatic C, Ci and Ck or Ci’ and Ck’), 148.5
(quaternary aromatic C, Ci and Ck or Ci’ and Ck’), 147.9 (aniline CH, Ca or Ca’), 147.8
(aniline CH, Ca or Ca’), 140.1 (aniline CH, Cc or Cc’), 140.0 (aniline CH, Cc or Cc’), 137.3
(aromatic CH, Cr and Cv), 132.0 (CF3), 129.8 (aromatic CH, Cu and Cs), 129.4 (aromatic
CH, Ch, Ch’, Cl and Cl’), 126.7 (aniline CH, Cb or Cb’), 126.6 (aniline CH, Cb or Cb’), 126.1
(aniline CH, Cd or Cd’), 126.0 (aniline CH, Cd or Cd’), 124.2 (quaternary aromatic C, Cg),
121.5 (quaternary aromatic C, Cq), 118.3 (aromatic CH, Cj and Cj’), 94.4 (diketonate
CH, Co), 28.1 (CH3, Cm) Analysis calculated C 50.46, H 2.45, N 6.19 % Analysis found
C 50.58, H 2.53, N 6.24 % ES MS (+) (CH3OH) m/z 905.08 [MH+] IR (cm-1) ν 3080 (w, 
ArCH), 2920 (w, MeCH), 1636 (m, CO), 1600 (m, CO), 1551 (m, CO), 1373 (m), 1273
(s), 1122 (s), 974 (m), 877 (w), 844 (w), 748 (w), 685 (m)
8.12.6 Synthesis of CoC39H22N4O4F15 (4.6)
Purified by column chromatography (ethyl acetate/hexane 3:7) to give a green solid
(0.058 g, 0.060 mmol, 14 %). Recrystallisation by slow evaporation from methanol at
room temperature yielded green crystals suitable for single crystal X-ray diffraction.
1H NMR (CDCl3, 500.23 MHz, 300.2 K) δ 8.20 (d, 
1H, Hd or Hd’, 3J (1H-1H) = 7.6 Hz), 8.16 (d, 1H, Hd
or Hd’, 3J (1H-1H) = 7.6 Hz), 7.94 (overlapping td,
2H, Hc and Hc’, 3J (1H-1H) = 7.6 Hz and 3J (1H-1H) =
1.2 Hz), 7.89 (s, 1H, Hj or Hj’), 7.87 (s, 1H, Hj or Hj’),
7.74 (d, 1H, Ha or Ha’, 3J (1H-1H) = 5.5 Hz), 7.69 (m,
3H, Ha or Ha’, Hs and Hu), 7.52 (m, 6H, Hh, Hh’, Hl,
Hl’, Hr and Hv), 7.20 (ddd, 1H, Hb or Hb’, 3J (1H-1H) =
7.4 Hz, 3J (1H-1H) = 5.8 Hz and 4J (1H-1H) = 1.4 Hz), 7.16 (ddd, 1H, Hb or Hb’, 3J (1H-1H)
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= 7.4 Hz, 3J (1H-1H) = 5.8 Hz and 4J (1H-1H) = 1.4 Hz), 6.12 (s, 1H, Ho), 2.24 (s, 3H, Hm)
13C {1H} NMR (CDCl3, 125.8 MHz, 300.1 K) δ 193.6 (quaternary diketonate C, Cn),
180.6 (quaternary diketonate C, Cp), 169.3 (quaternary C-O, Cf and Cf’), 156.6
(quaternary aniline C, Ce or Ce’), 156.5 (quaternary aniline C, Ce or Ce’),148.5
(quaternary aromatic C, Ci and Ck or Ci’ and Ck’), 148.4 (quaternary aromatic C, Ci and
Ck or Ci’ and Ck’), 147.8 (aniline CH, Ca or Ca’), 147.7 (aniline CH, Ca or Ca’), 140.2
(aniline CH, Cc and Cc’), 139.0 (aromatic CH, Ct), 134.0 (CF3), 132.9 (diketonate CF3),
128.3 (aromatic CH, Cr and Cv), 127.3 (aromatic CH, Cu and Cs), 126.8 (aromatic CH,
Ch and Cl or Ch’ and Cl’), 126.7 (aromatic CH, Ch and Cl or Ch’ and Cl’), 126.2 (aniline CH,
Cb or Cb’), 126.1 (aniline CH, Cb or Cb’), 125.8 (aniline CH, Cd or Cd’), 125.7 (aniline CH,
Cd or Cd’), 123.9 (quaternary aromatic C, Cg), 121.8 (quaternary aromatic C, Cq), 118.6
(aromatic CH, Cj and Cj’), 95.2 (diketonate CH, Co), 28.4 (CH3, Cm) Analysis calculated
C 49.07, H 2.32, N 5.87 % Analysis found C 49.15, H 2.17, N 5.90 % ES MS (+) (CH3OH)
m/z 955.08 [MH+] IR (cm-1) ν 3087 (w, ArCH), 1637 (m, CO), 1603 (m, CO), 1558 (m, 
CO), 1553 (m), 1390 (m), 1272 (s), 1115 (s), 976 (m), 775 (m), 686 (m), 632 (w)
8.12.7 Synthesis of CoC39H25N4O4F12 (4.7)
Purified by column chromatography (ethyl acetate/hexane 3:7) to give a green solid
(0.052 g, 0.047 mmol, 14 %).
1H NMR (CDCl3, 400.13 MHz, 300.0 K) δ 8.18 (dd, 
1H, Hd or Hd’, 3J (1H-1H) = 7.7 Hz and 3J (1H-1H) =
0.8 Hz), 8.14 (dd, 1H, Hd or Hd’, 3J (1H-1H) = 7.6 Hz
and 3J (1H-1H) = 0.9 Hz), 7.93 (td, 1H, Hc or Hc’, 3J
(1H-1H) = 7.6 Hz and 3J (1H-1H) = 1.3 Hz), 7.90 (td,
1H, Hc or Hc’, 3J (1H-1H) = 7.7 Hz and 3J (1H-1H) =
1.3 Hz), 7.74 (m, 2H, Ha and Ha’), 7.64 (s, 1H, Hj
or Hj’), 7.55 (m, 7H, Hj or Hj’, Hh, Hh’, Hl, Hl’, Hr and Ht), 7.33 (m, 2H, Hu and Hv), 7.16
(overlapping ddd, 2H, Hb and Hb’, 4J (1H-1H) = 1.5 Hz), 6.10 (s, 1H, Ho), 2.42 (s, 3H, Hw),
2.21 (s, 3H, Hm) 13C {1H} NMR (CDCl3, 100.6 MHz, 300.0 K) δ 191.7 (quaternary 
diketonate C, Cn), 182.6 (quaternary diketonate C, Cp), 169.4 (quaternary C-O, Cf or
Cf’), 169.3 (quaternary C-O, Cf or Cf’), 156.7 (quaternary aniline C, Ce or Ce’), 156.6
(quaternary aniline C, Ce or Ce’), 148.6 (quaternary aromatic C, Ci and Ck or Ci’ and
Ck’), 148.5 (quaternary aromatic C, Ci and Ck or Ci’ and Ck’), 148.0 (aniline CH, Ca or
Ca’), 147.9 (aniline CH, Ca or Ca’), 140.0 (aniline CH, Cc and Cc’), 138.8 (aromatic CH,
Cs), 133.5 (aromatic CH, Cr and Ct), 132.0 (aromatic CH, Cu), 131.9 (CF3), 128.6
(aromatic CH, Cv), 127.6 (aromatic CH, Ch, Ch’, Cl and Cl’), 126.6 (aniline CH, Cb or Cb’),
126.5 (aniline CH, Cb or Cb’), 126.0 (aniline CH, Cd and Cd’), 124.3 (quaternary aromatic
C, Cg), 121.5 (quaternary aromatic C, Cq), 118.4 (aromatic CH, Cj and Cj’), 94.5
Experimental Chapter 8
247
(diketonate CH, Co), 28.1 (CH3, Cm), 21.3 (CH3, Cw) Analysis calculated C 52.01, H 2.80,
N 6.22 % Analysis found C 51.85, H 2.63, N 6.13 % ES MS (+) (CH3OH) m/z 901.10
[MH+] IR (cm-1) ν 3081 (w, ArCH), 2923 (w, MeCH), 1636 (m, CO), 1601 (m, CO), 1551 
(m, CO), 1515 (m), 1371 (m), 1273 (s), 1125 (s), 973 (w), 877 (w), 764 (w), 685 (m),
608 (m)
8.12.8 Synthesis of CoC39H25N4O4F12 (4.8)
Purified by column chromatography (ethyl acetate/hexane 3:7) to give a green solid
(0.102 g, 0.113 mmol, 27 %). Recrystallisation by vapour diffusion
(dichloromethane/hexane) at room temperature yielded green crystals suitable for
single crystal X-ray diffraction.
1H NMR (CDCl3, 500.23 MHz, 300.0 K) δ 8.16 
(overlapping d, 2H, Hd and Hd’, 3J (1H-1H) = 7.8 Hz),
7.91 (overlapping td, 2H, Hc and Hc’, 3J (1H-1H) = 7.7
Hz and 3J (1H-1H) = 1.3 Hz), 7.73 (m, 4H, Ha, Ha’, Hj
and Hj’), 7.52 (m, 6H, Hh, Hh’, Hl, Hl’, Hr and Hv), 7.24
(m, 2H, Hu and Hs), 7.15 (overlapping ddd, 2H, Hb
and Hb’, 4J (1H-1H) = 1.3 Hz), 6.08 (s, 1H, Ho), 2.42 (s,
3H, Hw), 2.19 (s, 3H, Hm) 13C {1H} NMR (CDCl3, 125.8
MHz, 300.2 K) δ 191.4 (quaternary diketonate C, Cn), 182.3 (quaternary diketonate
C, Cp), 169.3 (quaternary C-O, Cf and Cf’), 156.7 (quaternary aniline C, Ce and Ce’),
148.6 (quaternary aromatic C, Ci and Ck or Ci’ and Ck’), 148.5 (quaternary aromatic C,
Ci and Ck or Ci’ and Ck’), 148.0 (aniline CH, Ca or Ca’), 147.9 (aniline CH, Ca or Ca’), 143.7
(aromatic CH, Ct), 140.0 (aniline CH, Cc and Cc’), 133.2 (aromatic CH, Cr and Cv), 131.9
(CF3), 129.5 (aromatic CH, Cu and Cs), 127.1 (aromatic CH, Ch, Ch’, Cl and Cl’), 126.6
(aniline CH, Cb or Cb’), 126.5 (aniline CH, Cb or Cb’), 126.0 (aniline CH, Cd and Cd’), 124.0
(quaternary aromatic C, Cg), 121.8 (quaternary aromatic C, Cq), 118.4 (aromatic CH,
Cj and Cj’), 94.1 (diketonate CH, Co), 28.0 (CH3, Cm), 21.5 (CH3, Cw) Analysis calculated
C 52.01, H 2.80, N 6.22 % Analysis found C 51.99, H 2.91, N 6.14 % ES MS (+) (CH3OH)
m/z 901.10 [MH+] IR (cm-1) ν 3083 (w, ArCH), 2965 (w, MeCH), 1635 (m, CO), 1602 
(m, CO), 1519 (m), 1499 (m), 1372 (m), 1273 (s), 1121 (s), 973 (m), 763 (m), 686
(m),608 (w)
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8.12.9 Synthesis of CoC39H25N4O5F12 (4.9)
Purified by column chromatography (ethyl acetate/hexane 3:7) to give a green solid
(0.102 g, 0.111 mmol, 26 %). Recrystallisation by vapour diffusion
(dichloromethane/hexane) at room temperature yielded green crystals suitable for
single crystal X-ray diffraction.
1H NMR (CDCl3, 500.23 MHz, 300.1 K) δ 8.17 (d, 1H, 
Hd or Hd’, 3J (1H-1H) = 7.2 Hz), 8.14 (d, 1H, Hd or Hd’,
3J (1H-1H) = 7.3 Hz), 7.91 (overlapping td, 2H, Hc and
Hc’, 3J (1H-1H) = 7.5 Hz and 3J (1H-1H) = 1.4 Hz), 7.81
(s, 1H, Hj or Hj’), 7.79 (s, 1H, Hj or Hj’), 7.75 (d, 1H,
Ha or Ha’, 3J (1H-1H) = 5.5 Hz), 7.71 (d, 1H, Ha or Ha’,
3J (1H-1H) = 5.3 Hz), 7.52 (m, 6H, Hh, Hh’, Hl, Hl’, Hr
and Hv), 7.15 (overlapping ddd, 2H, Hb and Hb’, 4J
(1H-1H) = 1.3 Hz), 6.91 (m, 2H, Hu and Hs), 6.03 (s, 1H, Ho), 3.88 (s, 3H, Hw), 2.18 (s,
3H, Hm) 13C {1H} NMR (CDCl3, 125.8 MHz, 300.1 K) δ 190.6 (quaternary diketonate C, 
Cn), 181.6 (quaternary diketonate C, Cp), 169.4 (quaternary C-O, Cf and Cf’), 163.4
(aromatic CH, Ct), 156.8 (quaternary aniline C, Ce or Ce’), 156.7 (quaternary aniline C,
Ce or Ce’),148.6 (quaternary aromatic C, Ci and Ck or Ci’ and Ck’), 148.5 (quaternary
aromatic C, Ci and Ck or Ci’ and Ck’), 148.0 (aniline CH, Ca or Ca’), 147.9 (aniline CH, Ca
or Ca’), 140.0 (aniline CH, Cc and Cc’), 132.0 (aromatic CH, Cr and Cv), 131.7 (CF3), 129.2
(aromatic CH, Cu and Cs), 128.4 (aromatic CH, Ch and Cl or Ch’ and Cl’), 128.3 (aromatic
CH, Ch and Cl or Ch’ and Cl’), 126.6 (aniline CH, Cb or Cb’), 126.5 (aniline CH, Cb or Cb’),
126.0 (aniline CH, Cd and Cd’), 124.0 (quaternary aromatic C, Cg), 121.8 (quaternary
aromatic C, Cq), 118.3 (aromatic CH, Cj and Cj’), 93.6 (diketonate CH, Co), 55.6 (CH3,
Cw), 28.0 (CH3, Cm) Analysis calculated C 51.11, H 2.75, N 6.11 % Analysis found C
50.99, H 2.67, N 5.98 % ES MS (+) (CH3OH) m/z 917.10 [MH+] IR (cm-1) ν 3082 (w, 
ArCH), 2964 (w, MeCH), 1743 (w), 1637 (m, CO), 1601 (m, CO), 1494 (m), 1371 (m),
1278 (m), 1200 (s), 1145 (s), 970 (m), 863 (m), 807 (m), 714 (m)
8.13 Synthesis of cobalt(III) bis-picolinamide ferrocenyl β-diketonate 
complexes
The required picolinamide ligand (2 equivalents) and the required ferrocenyl β-
diketonate ligand (1 equivalent) in ethanol (10 mL) was added to a solution of
cobalt(II) chloride hydrate (1 equivalent) in distilled water (5 mL). Hydrogen peroxide
(1 equivalent) was added dropwise and the mixture was heated at 85 °C for 2 hours
to give a dark red solution. The solvent was removed under reduced pressure and
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the product purified by column chromatography (ethyl acetate/hexane) to give pure
product.
8.13.1 Synthesis of CoC42H25N4O4F14Fe (4.10)
Purified by column chromatography (ethyl acetate/hexane 1:1) to give a purple solid
(0.146 g, 0.142 mmol, 34 %).
1H NMR (CDCl3, 500.23 MHz, 300.1 K) δ 8.22 (d, 
1H, Hd or Hd’, 3J (1H-1H) = 7.6 Hz), 8.18 (d, 1H, Hd
or Hd’, 3J (1H-1H) = 7.6 Hz), 7.96 (m, 3H, Hc, Hc’
and Ha or Ha’), 7.76 (d, 1H, Ha or Ha’, 3J (1H-1H) =
5.3 Hz), 7.52 (m, 6H, Hh, Hh’, Hj, Hj’, Hl and Hl’),
7.28 (overlapping ddd, 1H, Hb or Hb’), 7.18
(overlapping ddd, 1H, Hb or Hb’), 5.93 (s, 1H, Hr),
4.94 (s, 1H, Hn or Hn’), 4.72 (s, 2H, Hn or Hn’ and
Ho or Ho’), 4.62 (s, 1H, Ho or Ho’), 4.23 (s, 1H, Ht), 3.77 (s, 5H, Hp) 13C {1H} NMR (CDCl3,
125.8 MHz, 300.1 K) δ 193.7 (quaternary diketonate C, Cs), 174.0 (quaternary
diketonate C, Cq), 169.3 (quaternary C-O, Cf or Cf’), 169.2 (quaternary C-O, Cf or Cf’),
156.6 (quaternary aniline C, Ce or Ce’), 156.5 (quaternary aniline C, Ce or Ce’), 148.8
(quaternary aromatic C, Ci and Ck or Ci’ and Ck’), 148.5 (quaternary aromatic C, Ci and
Ck or Ci’ and Ck’), 147.7 (aniline CH, Ca and Ca’), 140.5 (aniline CH, Cc or Cc’), 140.3
(aniline CH, Cc or Cc’), 132.5 (CHF2, Ct), 132.1 (aromatic CH, Ch and Cl or Ch’ and Cl’),
131.8 (aromatic CH, Ch and Cl or Ch’ and Cl’), 128.5 (CF3), 128.2 (CF3), 127.0 (aniline
CH, Cb or Cb’), 126.7 (aniline CH, Cb or Cb’), 126.2 (aniline CH, Cd or Cd’), 126.0 (aniline
CH, Cd or Cd’), 123.9 (quaternary aromatic C, Cg or Cg’), 121.7 (quaternary aromatic C,
Cg or Cg’), 118.7 (aromatic CH, Cj and Cj’), 90.9 (diketonate CH, Cr), 78.3 (quaternary
Cp C, Cm), 74.0 (Cp CH, Co or Co’), 73.7 (Cp CH, Co or Co’), 70.4 (Cp CH, Cp), 69.7 (Cp CH,
Cn or Cn’), 68.9 (Cp CH, Cn or Cn’) Analysis calculated C 48.96, H 2.45, N 5.44 % Analysis
found C 49.03, H 2.50, N 5.30 % ES MS (+) (CH3OH) m/z 1031.05 [MH+] IR (cm-1) ν 
3080 (w, ArCH), 1636 (m, CO), 1601 (m, CO), 1557 (m, CO), 1376 (s), 1276 (s), 1111
(s), 966 (w), 879 (w), 687 (m), 608 (w), 588 (w), 509 (m)
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8.13.2 Synthesis of CoC42H24N4O4F15Fe (4.11)
Purified by column chromatography (ethyl acetate/hexane 1:1) to give a purple solid
(0.200 g, 0.191 mmol, 45 %). Recrystallisation by vapour diffusion
(chloroform/pentane) at room temperature yielded orange crystals suitable for
single crystal X-ray diffraction.
1H NMR (CDCl3, 400.13 MHz, 300.0 K) δ 8.34 (d, 
1H, Hd or Hd’, 3J (1H-1H) = 7.0 Hz), 8.25 (d, 1H, Hd
or Hd’, 3J (1H-1H) = 6.6 Hz), 8.00 (overlapping td,
2H, Hc and Hc’), 7.88 (d, 1H, Ha or Ha’, 3J (1H-1H) =
4.4 Hz), 7.75 (d, 1H, Ha or Ha’, 3J (1H-1H) = 4.0 Hz),
7.54 (s, 2H, Hj and Hj’), 7.48 (br. s, 4H, Hh, Hh’, Hl
and Hl’), 7.29 (overlapping ddd, 1H, Hb or Hb’),
7.20 (overlapping ddd, 1H, Hb or Hb’), 5.94 (s, 1H,
Hr), 4.93 (s, 1H, Hn or Hn’), 4.76 (s, 1H, Hn or Hn’), 4.72 (s, 1H, Ho or Ho’), 4.69 (s, 1H, Ho
or Ho’), 3.79 (s, 5H, Hp) 13C {1H} NMR (CDCl3, 100.6 MHz, 300.0 K) δ 195.1 (quaternary 
diketonate C, Cs), 185.3 (quaternary diketonate C, Cq), 167.8 (quaternary C-O, Cf and
Cf’), 157.0 (quaternary aniline C, Ce and Ce’), 148.5 (quaternary aromatic C, Ci and Ck
or Ci’ and Ck’), 148.4 (quaternary aromatic C, Ci and Ck or Ci’ and Ck’), 147.6 (aniline
CH, Ca or Ca’), 147.5 (aniline CH, Ca or Ca’), 140.6 (aniline CH, Cc or Cc’), 140.5 (aniline
CH, Cc or Cc’), 132.3 (aromatic CH, Ch and Cl or Ch’ and Cl’), 132.0 (aromatic CH, Ch and
Cl or Ch’ and Cl’), 131.8 (CF3, Ct), 128.7 (CF3), 128.4 (CF3), 127.1 (aniline CH, Cb or Cb’),
126.8 (aniline CH, Cb or Cb’), 126.4 (aniline CH, Cd or Cd’), 126.2 (aniline CH, Cd or Cd’),
124.1 (quaternary aromatic C, Cg or Cg’), 121.4 (quaternary aromatic C, Cg or Cg’),
118.7 (aromatic CH, Cj and Cj’), 91.2 (diketonate CH, Cr), 78.2 (quaternary Cp C, Cm),
74.5 (Cp CH, Co or Co’), 74.1 (Cp CH, Co or Co’), 70.6 (Cp CH, Cp), 69.8 (Cp CH, Cn or Cn’),
69.1 (Cp CH, Cn or Cn’) Analysis calculated (+ 1 H2O) C 47.30, H 2.46, N 5.25 % Analysis
found C 47.09, H 2.78, N 5.02 % ES MS (+) (CH3OH) m/z 1049.04 [MH+] IR (cm-1) ν 
3086 (w, ArCH), 2963 (w), 1636 (m, CO), 1572 (m, CO), 1462 (w), 1377 (s), 1277 (m),
1227 (s), 796 (w), 688 (m), 538 (m)
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8.13.3 Synthesis of CoC42H27N4O4F12Fe (4.12)
Purified by column chromatography (ethyl acetate/hexane 1:1) to give a red solid
(0.140 g, 0.141 mmol, 34 %).
1H NMR (CDCl3, 500.23 MHz, 300.1 K) δ 8.22 (d, 
1H, Hd or Hd’, 3J (1H-1H) = 7.3 Hz), 8.16 (d, 1H, Hd
or Hd’, 3J (1H-1H) = 7.6 Hz), 7.93 (overlapping td,
2H, Hc and Hc’, 3J (1H-1H) = 7.4 Hz and 3J (1H-1H) =
1.3 Hz), 7.81 (d, 1H, Ha or Ha’, 3J (1H-1H) = 5.5 Hz),
7.78 (d, 1H, Ha or Ha’, 3J (1H-1H) = 5.5 Hz), 7.53
(m, 6H, Hh, Hh’, Hj, Hj’, Hl, Hl’), 7.24 (ddd, 1H, Hb
or Hb’, 3J (1H-1H) = 7.5 Hz, 3J (1H-1H) = 5.7 Hz and
4J (1H-1H) = 1.3 Hz), 7.14 (ddd, 1H, Hb or Hb’, 3J (1H-1H) = 7.5 Hz, 3J (1H-1H) = 5.7 Hz and
4J (1H-1H) = 1.2 Hz), 5.61 (s, 1H, Hr), 4.88 (s, 1H, Hn or Hn’), 4.62 (s, 1H, Hn or Hn’), 4.55
(s, 1H, Ho or Ho’), 4.47 (s, 1H, Ho or Ho’), 3.73 (s, 5H, Hp), 2.10 (s, 3H, Ht) 13C {1H} NMR
(CDCl3, 125.8 MHz, 300.1 K) δ 188.0 (quaternary diketonate C, Cs), 187.4 (quaternary
diketonate C, Cq), 169.4 (quaternary C-O, Cf or Cf’), 169.2 (quaternary C-O, Cf or Cf’),
157.0 (quaternary aniline C, Ce or Ce’), 156.8 (quaternary aniline C, Ce or Ce’), 148.6
(quaternary aromatic C, Ci, Ci’, Ck and Ck’), 148.2 (aniline CH, Ca or Ca’), 148.0 (aniline
CH, Ca or Ca’), 140.1 (aniline CH, Cc or Cc’), 139.9 (aniline CH, Cc or Cc’), 132.0 (aromatic
CH, Ch and Cl or Ch’ and Cl’), 131.7 (aromatic CH, Ch and Cl or Ch’ and Cl’), 128.2 (CF3),
128.0 (CF3), 126.5 (aniline CH, Cb or Cb’), 126.3 (aniline CH, Cb or Cb’), 125.9 (aniline
CH, Cd and Cd’), 124.0 (quaternary aromatic C, Cg or Cg’), 121.8 (quaternary aromatic
C, Cg or Cg’), 118.3 (aromatic CH, Cj and Cj’), 94.1 (diketonate CH, Cr), 78.9 (quaternary
Cp C, Cm), 72.5 (Cp CH, Co or Co’), 72.1 (Cp CH, Co or Co’), 70.0 (Cp CH, Cp), 69.5 (Cp CH,
Cn or Cn’), 67.9 (Cp CH, Cn or Cn’), 27.5 (CH3, Ct) Analysis calculated C 50.73, H 2.74, N
5.63 % Analysis found C 50.64, H 2.63, N 5.71 % ES MS (+) (CH3OH) m/z 995.06 [MH+]
IR (cm-1) ν 3091 (w, ArCH), 1637 (m, CO), 1602 (m, CO), 1509 (m), 1368 (s), 1300 (s), 
1225 (s), 1140 (s), 964 (w), 878 (w), 828 (w), 748 (w), 688 (m), 513 (m)
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8.13.4 Synthesis of CoC47H29N4O4F12Fe (4.13)
Purified by column chromatography (ethyl acetate/hexane 1:1) to give a purple solid
(0.151 g, 0.143 mmol, 34 %). Recrystallisation by slow evaporation from methanol at
room temperature yielded red crystals suitable for single crystal X-ray diffraction.
1H NMR (CDCl3, 300.13 MHz, 300.0 K) δ 8.27 (dd, 
1H, Hd or Hd’, 3J (1H-1H) = 7.7 Hz and 3J (1H-1H) =
0.9 Hz), 8.16 (dd, 1H, Hd or Hd’, 3J (1H-1H) = 7.7 Hz
and 3J (1H-1H) = 0.8 Hz), 7.95 (td, 1H, Hc or Hc’, 3J
(1H-1H) = 7.6 Hz and 3J (1H-1H) = 1.3 Hz), 7.85 (m,
5H, Hc or Hc’, Ha, Ha’, Hj and Hj’), 7.57 (m, 7H, Hh,
Hh’, Hl, Hl’, Hu, Hw and Hy), 7.47 (t, 2H, Hv and Hx,
3J (1H-1H) = 7.0 Hz), 7.16 (overlapping ddd, 2H,
Hb and Hb’, 4J (1H-1H) = 1.5 Hz), 6.29 (s, 1H, Hr), 4.98 (m, 1H, Hn or Hn’), 4.75 (m, 1H,
Hn or Hn’), 4.62 (td, 1H, Ho or Ho’, 3J (1H-1H) = 2.6 Hz and 3J (1H-1H) = 1.2 Hz), 4.54 (td,
1H, Ho or Ho’, 3J (1H-1H) = 2.5 Hz and 3J (1H-1H) = 1.3 Hz), 3.76 (s, 5H, Hp) 13C {1H} NMR
(CDCl3, 100.6 MHz, 300.0 K) δ 189.8 (quaternary diketonate C, Cs), 179.6 (quaternary
diketonate C, Cq), 169.2 (quaternary C-O, Cf and Cf’), 156.8 (quaternary aniline C, Ce
or Ce’), 156.5 (quaternary aniline C, Ce or Ce’), 149.5 (quaternary aromatic C, Ci and Ck
or Ci’ and Ck’), 149.4 (quaternary aromatic C, Ci and Ck or Ci’ and Ck’), 149.1 (aniline
CH, Ca and Ca’), 141.0 (aniline CH, Cc or Cc’), 140.7 (aniline CH, Cc or Cc’), 137.2
(quaternary aromatic C, Ct), 131.9 (aromatic CH, Cv and Cx), 131.3 (aromatic CH, Cu
or Cy), 131.0 (aromatic CH, Cu or Cy), 128.6 (aromatic CH, Cw), 128.5 (CF3), 127.7
(aniline CH, Cb or Cb’), 127.3 (aniline CH, Cb or Cb’), 127.0 (aromatic CH, Ch, Ch’, Cl and
Cl’), 125.8 (aniline CH, Cd or Cd’), 125.6 (aniline CH, Cd or Cd’), 124.6 (quaternary
aromatic C, Cg or Cg’), 121.9 (quaternary aromatic C, Cg or Cg’), 117.5 (aromatic CH, Cj
and Cj’), 91.4 (diketonate CH, Cr), 80.1 (quaternary Cp C, Cm), 72.5 (Cp CH, Co or Co’),
72.2 (Cp CH, Co or Co’), 70.0 (Cp CH, Cp), 69.5 (Cp CH, Cn or Cn’), 68.4 (Cp CH, Cn or Cn’)
Analysis calculated C 53.43, H 2.77, N 5.30 % Analysis found C 53.38, H 2.84, N 5.33
% ES MS (+) (CH3OH) m/z 1057.08 [MH+] IR (cm-1) ν 3080 (w, ArCH), 2070 (w), 1997 
(br. w), 1639 (m, CO), 1601 (m, CO), 1530 (m), 1441 (m), 1335 (s), 1228 (s), 1173 (m),
1035 (m), 805 (m), 760 (m), 686 (s), 608 (w), 556 (w), 511 (s)
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8.13.5 Synthesis of CoC47H28N4O4F13Fe (4.14)
Purified by column chromatography (ethyl acetate/hexane 1:1) to give a purple solid
(0.245 g, 0.228 mmol, 54 %). Recrystallisation by vapour diffusion
(chloroform/pentane) at room temperature yielded red crystals suitable for single
crystal X-ray diffraction.
1H NMR (CDCl3, 400.13 MHz, 300.0 K) δ 8.27 (d, 
1H, Hd or Hd’, 3J (1H-1H) = 7.5 Hz), 8.17 (d, 1H, Hd
or Hd’, 3J (1H-1H) = 7.5 Hz), 7.96 (td, 1H, Hc or Hc’,
3J (1H-1H) = 7.7 Hz and 3J (1H-1H) = 1.1 Hz), 7.90
(td, 1H, Hc or Hc’, 3J (1H-1H) = 7.6 Hz and 3J (1H-
1H) = 1.1 Hz), 7.84 (m, 2H, Ha or Ha’ and Hu), 7.65
(d, 1H, Ha or Ha’, 3J (1H-1H) = 7.9 Hz), 7.52 (m, 8H,
Hh, Hh’, Hj, Hj’, Hl, Hl’, Hw and Hx), 7.24 (m, 1H, Hy),
7.20 (ddd, 1H, Hb and Hb’, 3J (1H-1H) = 7.5 Hz, 3J (1H-1H) = 5.7 Hz and 4J (1H-1H) = 1.4
Hz), 7.15 (ddd, 1H, Hb and Hb’, 3J (1H-1H) = 7.5 Hz, 3J (1H-1H) = 5.7 Hz and 4J (1H-1H) =
1.3 Hz), 6.23 (s, 1H, Hr), 4.98 (m, 1H, Hn or Hn’), 4.75 (m, 1H, Hn or Hn’), 4.65 (m, 1H,
Ho or Ho’), 4.56 (m, 1H, Ho or Ho’), 3.77 (s, 5H, Hp) 13C {1H} NMR (CDCl3, 100.6 MHz,
300.0 K) δ 190.3 (quaternary diketonate C, Cs), 178.0 (quaternary diketonate C, Cq),
169.4 (quaternary C-O, Cf or Cf’), 169.2 (quaternary C-O, Cf or Cf’), 163.9 (quaternary
aromatic C, Cv), 157.0 (quaternary aniline C, Ce or Ce’), 156.6 (quaternary aniline C, Ce
or Ce’), 148.6 (quaternary aromatic C, Ci, Ci’, Ck and Ck’), 148.0 (aniline CH, Ca or Ca’),
147.9 (aniline CH, Ca or Ca’), 140.3 (aniline CH, Cc or Cc’), 140.1 (aniline CH, Cc or Cc’),
138.9 (quaternary aromatic C, Ct), 132.1 (aromatic CH, Cu or Cw), 132.0 (aromatic CH,
Cu or Cw), 131.8 (aromatic CH, Ch, Ch’, Cl and Cl’), 130.5 (aromatic CH, Cx), 128.1 (CF3),
126.8 (aniline CH, Cb or Cb’), 126.5 (aniline CH, Cb or Cb’), 126.1 (aniline CH, Cd and
Cd’), 124.2 (quaternary aromatic C, Cg or Cg’), 122.6 (quaternary aromatic C, Cg or Cg’),
119.0 (aromatic CH, Cy), 113.7 (aromatic CH, Cj or Cj’), 113.5 (aromatic CH, Cj or Cj’),
91.4 (diketonate CH, Cr), 79.4 (quaternary Cp C, Cm), 73.0 (Cp CH, Co or Co’), 72.6 (Cp
CH, Co or Co’), 70.1 (Cp CH, Cp), 69.7 (Cp CH, Cn or Cn’), 68.1 (Cp CH, Cn or Cn’) Analysis
calculated C 52.54, H 2.63, N 5.21 % Analysis found C 52.47, H 2.56, N 5.20 % ES MS
(+) (CH3OH) m/z 1075.07 [MH+] IR (cm-1) ν 3084 (w, ArCH), 1633 (m, CO), 1601 (m, 
CO), 1529 (m), 1388 (m), 1309 (s), 1173 (m), 1120(s), 956 (w), 762 (w), 703 (m), 608
(m)
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8.13.6 Synthesis of CoC47H28N4O4F13Fe (4.15)
Purified by column chromatography (ethyl acetate/hexane 1:1) to give a purple solid
(0.273 g, 0.254 mmol, 61 %). Recrystallisation by vapour diffusion
(chloroform/pentane) at room temperature yielded orange crystals suitable for
single crystal X-ray diffraction.
1H NMR (CDCl3, 500.23 MHz, 300.1 K) δ 8.27 (d, 
1H, Hd or Hd’, 3J (1H-1H) = 7.3 Hz), 8.17 (d, 1H, Hd
or Hd’, 3J (1H-1H) = 7.6 Hz), 7.96 (td, 1H, Hc or Hc’,
3J (1H-1H) = 7.4 Hz and 3J (1H-1H) = 1.2 Hz), 7.90
(td, 1H, Hc or Hc’, 3J (1H-1H) = 7.4 Hz and 3J (1H-
1H) = 1.3 Hz), 7.85 (m, 4H, Ha, Ha’, Hv and Hx), 7.58
(br. s, 4H, Hh, Hh’, Hl and Hl’), 7.52 (s, 2H, Hj and
Hj’), 7.19 (ddd, 1H, Hb or Hb’, 3J (1H-1H) = 7.5 Hz,
3J (1H-1H) = 5.7 Hz and 4J (1H-1H) = 1.4 Hz), 7.14 (m, 3H, Hb or Hb’, Hu and Hy), 6.22 (s,
1H, Hr), 4.97 (s, 1H, Hn or Hn’), 4.74 (s, 1H, Hn or Hn’), 4.63 (s, 1H, Ho or Ho’), 4.54 (s,
1H, Ho or Ho’), 3.76 (s, 5H, Hp) 13C {1H} NMR (CDCl3, 125.8 MHz, 299.9 K) δ 188.6 
(quaternary diketonate C, Cs), 178.4 (quaternary diketonate C, Cq), 169.4 (quaternary
C-O, Cf and Cf’), 161.0 (quaternary aromatic C, Cw), 157.0 (quaternary aniline C, Ce
and Ce’), 148.6 (quaternary aromatic C, Ci, Ci’, Ck and Ck’), 148.1 (aniline CH, Ca and
Ca’), 140.3 (aniline CH, Cc or Cc’), 140.1 (aniline CH, Cc or Cc’), 132.6 (quaternary
aromatic C, Ct), 129.2 (aromatic CH, Cu and Cy), 129.0 (aromatic CH, Cv and Cx), 128.2
(CF3), 126.7 (aromatic CH, Ch, Ch’, Cl and Cl’), 126.4 (aniline CH, Cb and Cb’), 126.1
(aniline CH, Cd and Cd’), 124.0 (quaternary aromatic C, Cg or Cg’), 121.8 (quaternary
aromatic C, Cg or Cg’), 116.0 (aromatic CH, Cj or Cj’), 115.8 (aromatic CH, Cj or Cj’), 90.9
(diketonate CH, Cr), 79.6 (quaternary Cp C, Cm), 72.8 (Cp CH, Co or Co’), 72.4 (Cp CH,
Co or Co’), 70.1 (Cp CH, Cp), 69.6 (Cp CH, Cn or Cn’), 68.0 (Cp CH, Cn or Cn’) Analysis
calculated C 52.54, H 2.63, N 5.21 % Analysis found C 52.51, H 2.66, N 5.27 % ES MS
(+) (CH3OH) m/z 1075.07 [MH+] IR (cm-1) ν 3085 (w, ArCH), 1636 (m, CO), 1599 (m, 
CO), 1521 (m), 1497 (m), 1369 (m), 1274 (s), 1119 (s), 1101 (s), 1003 (m), 895 (m),
686 (m), 608 (w) 498 (s)
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8.13.7 Synthesis of CoC47H27N4O4F14Fe (4.16)
Purified by column chromatography (ethyl acetate/hexane 1:1) to give a purple solid
(0.263 g, 0.240 mmol, 57 %). Recrystallisation by slow evaporation from methanol at
room temperature yielded red crystals suitable for single crystal X-ray diffraction.
1H NMR (CDCl3, 500.23 MHz, 300.0 K) δ 8.28 (d, 
1H, Hd or Hd’, 3J (1H-1H) = 7.5 Hz), 8.18 (d, 1H, Hd
or Hd’, 3J (1H-1H) = 7.4 Hz), 7.98 (td, 1H, Hc or Hc’,
3J (1H-1H) = 7.7 Hz and 3J (1H-1H) = 1.1 Hz), 7.91
(td, 1H, Hc or Hc’, 3J (1H-1H) = 7.7 Hz and 3J (1H-
1H) = 1.1 Hz), 7.83 (overlapping d, 2H, Ha and Ha’,
3J (1H-1H) = 5.5 Hz), 7.57 (br. s, 4H, Hh, Hh’ and Hl
and Hl’), 7.53 (s, 2H, Hj and Hj’), 7.32 (m, 2H, Hu
and Hy), 7.23 (ddd, 1H, Hb or Hb’, 3J (1H-1H) = 7.4 Hz, 3J (1H-1H) = 5.9 Hz and 4J (1H-1H)
= 1.4 Hz), 7.16 (ddd, 1H, Hb or Hb’, 3J (1H-1H) = 7.4 Hz, 3J (1H-1H) = 5.8 Hz and 4J (1H-
1H) = 1.4 Hz), 6.99 (m, 1H, Hw), 6.17 (s, 1H, Hr), 4.99 (s, 1H, Hn or Hn’), 4.76 (s, 1H, Hn
or Hn’), 4.67 (s, 1H, Ho or Ho’), 4.59 (s, 1H, Ho or Ho’), 3.77 (s, 5H, Hp) 13C {1H} NMR
(CDCl3, 125.8 MHz, 299.9 K) δ 191.2 (quaternary diketonate C, Cs), 176.5 (quaternary
diketonate C, Cq), 169.3 (quaternary C-O, Cf or Cf’), 169.2 (quaternary C-O, Cf or Cf’),
164.5 (quaternary aromatic C, Cv and Cx), 156.9 (quaternary aniline C, Ce or Ce’), 156.6
(quaternary aniline C, Ce or Ce’), 148.5 (quaternary aromatic C, Ci, Ci’, Ck and Ck’), 147.9
(aniline CH, Ca or Ca’), 147.8 (aniline CH, Ca or Ca’), 140.4 (aniline CH, Cc or Cc’), 140.2
(aniline CH, Cc or Cc’), 134.2 (quaternary aromatic C, Ct), 128.2 (CF3), 126.8 (aromatic
CH, Ch, Ch’, Cl and Cl’), 126.6 (aniline CH, Cb and Cb’), 126.2 (aniline CH, Cd and Cd’),
123.9 (quaternary aromatic C, Cg or Cg’), 121.7 (quaternary aromatic C, Cg or Cg’),
116.0 (aromatic CH, Cj or Cj’), 120.8 (aromatic CH, Cj or Cj’), 118.5 (aromatic CH, Cj or
Cj’), 109.8 (aromatic CH, Cu and Cy), 109.6 (aromatic CH, Cu and Cy), 107.2 (aromatic
CH, Cw), 91.6 (diketonate CH, Cr), 79.2 (quaternary Cp C, Cm), 73.3 (Cp CH, Co or Co’),
72.9 (Cp CH, Co or Co’), 70.2 (Cp CH, Cp), 69.7 (Cp CH, Cn or Cn’), 68.2 (Cp CH, Cn or Cn’)
Analysis calculated C 51.67, H 2.49, N 5.13 % Analysis found C 51.52, H 2.56, N 5.18
% ES MS (+) (CH3OH) m/z 1093.06 [MH+] IR (cm-1) ν 3056 (w, ArCH), 1633 (m, CO), 
1602 (m, CO), 1529 (m), 1367 (m), 1276 (s), 1116 (s), 964 (m), 879 (w), 762 (w), 703
(m), 608 (w), 502 (m)
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8.13.8 Synthesis of CoC48H31N4O4F12Fe (4.17)
Purified by column chromatography (ethyl acetate/hexane 1:1) to give a red solid
(0.273 g, 0.254 mmol, 61 %). Recrystallisation by slow evaporation from ethyl acetate
at room temperature yielded red crystals suitable for single crystal X-ray diffraction.
1H NMR (CDCl3, 400.13 MHz, 300.0 K) δ 8.26 (dd, 
1H, Hd or Hd’, 3J (1H-1H) = 7.8 Hz and 3J (1H-1H) =
1.0 Hz), 8.15 (dd, 1H, Hd or Hd’, 3J (1H-1H) = 7.8 Hz
and 3J (1H-1H) = 1.0 Hz), 7.95 (td, 1H, Hc or Hc’, 3J
(1H-1H) = 7.7 Hz and 3J (1H-1H) = 1.3 Hz), 7.87 (m,
3H, Hc or Hc’, Ha and Ha’), 7.69 (s, 1H, Hu), 7.64 (d,
1H, Hy, 3J (1H-1H) = 7.3 Hz), 7.58 (br. s, 4H, Hh, Hh’,
Hl and Hl’), 7.51 (s, 2H, Hj and Hj’), 7.36 (m, 2H,
Hw and Hx), 7.19 (ddd, 1H, Hb and Hb’, 3J (1H-1H) = 7.4 Hz, 3J (1H-1H) = 5.8 Hz and 4J (1H-
1H) = 1.5 Hz), 7.13 (ddd, 1H, Hb and Hb’, 3J (1H-1H) = 7.4 Hz, 3J (1H-1H) = 5.8 Hz and 4J
(1H-1H) = 1.5 Hz), 6.29 (s, 1H, Hr), 4.99 (m, 1H, Hn or Hn’), 4.76 (m, 1H, Hn or Hn’), 4.62
(td, 1H, Ho or Ho’, 3J (1H-1H) = 2.5 Hz and 3J (1H-1H) = 1.1 Hz), 4.53 (td, 1H, Ho or Ho’, 3J
(1H-1H) = 2.5 Hz and 3J (1H-1H) = 1.1 Hz), 3.75 (s, 5H, Hp), 2.46 (s, 3H, Hz) 13C {1H} NMR
(CDCl3, 100.6 MHz, 300.0 K) δ 189.2 (quaternary diketonate C, Cs), 180.0 (quaternary
diketonate C, Cq), 169.4 (quaternary C-O, Cf or Cf’), 169.3 (quaternary C-O, Cf or Cf’),
157.0 (quaternary aniline C, Ce or Ce’), 156.7 (quaternary aniline C, Ce or Ce’), 148.7
(quaternary aromatic C, Ci and Ck or Ci’ and Ck’), 148.6 (quaternary aromatic C, Ci and
Ck or Ci’ and Ck’), 148.1 (aniline CH, Ca or Ca’), 148.0 (aniline CH, Ca or Ca’), 140.2
(aniline CH, Cc or Cc’), 140.0 (aniline CH, Cc or Cc’), 138.9 (quaternary aromatic C, Cv),
136.7 (quaternary aromatic C, Ct), 133.0 (aromatic CH, Cw), 132.0 (aromatic CH, Cu or
Cy), 131.7 (aromatic CH, Cu or Cy), 128.6 (aromatic CH, Cx), 128.1 (CF3), 127.4
(aromatic CH, Ch, Ch’, Cl and Cl’), 126.7 (aniline CH, Cb or Cb’), 126.4 (aniline CH, Cb or
Cb’), 126.0 (aniline CH, Cd and Cd’), 124.2 (quaternary aromatic C, Cg or Cg’), 121.6
(quaternary aromatic C, Cg or Cg’), 118.3 (aromatic CH, Cj and Cj’), 91.2 (diketonate
CH, Cr), 79.7 (quaternary Cp C, Cm), 72.7 (Cp CH, Co or Co’), 72.3 (Cp CH, Co or Co’), 70.1
(Cp CH, Cp), 69.6 (Cp CH, Cn or Cn’), 68.0 (Cp CH, Cn or Cn’), 21.4 (CH3, Cz) Analysis
calculated C 53.85, H 2.92, N 5.23 % Analysis found C 53.69, H 2.98, N 5.19 % ES MS
(+) (CH3OH) m/z 1071.09 [MH+] IR (cm-1) ν 3053 (w, ArCH), 2923 (w, MeCH), 1722 
(w), 1634 (m, CO), 1599 (m, CO), 1511 (m), 1365 (m), 1275 (s), 1170 (m), 1121 (s),
1002 (w), 843 (w), 766 (m), 688 (m), 608 (w), 514 (m)
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8.13.9 Synthesis of CoC48H31N4O4F12Fe (4.18)
Purified by column chromatography (ethyl acetate/hexane 1:1) to give a purple solid
(0.210 g, 0.197 mmol, 47 %). Recrystallisation by slow evaporation from methanol at
room temperature yielded red crystals suitable for single crystal X-ray diffraction.
1H NMR (CDCl3, 400.13 MHz, 300.0 K) δ 8.26 (dd, 
1H, Hd or Hd’, 3J (1H-1H) = 7.7 Hz and 3J (1H-1H) =
0.9 Hz), 8.15 (dd, 1H, Hd or Hd’, 3J (1H-1H) = 7.7 Hz
and 3J (1H-1H) = 0.9 Hz), 7.94 (td, 1H, Hc or Hc’, 3J
(1H-1H) = 7.7 Hz and 3J (1H-1H) = 1.3 Hz), 7.87 (m,
3H, Hc or Hc’, Ha and Ha’), 7.78 (d, 2H, Hu and Hy,
3J (1H-1H) = 8.3 Hz), 7.59 (br. s, 4H, Hh, Hh’, Hl and
Hl’), 7.51 (s, 2H, Hj and Hj’), 7.27 (d, 2H, Hv and
Hx, 3J (1H-1H) = 8.1 Hz), 7.17 (ddd, 1H, Hb and Hb’, 3J (1H-1H) = 7.4 Hz, 3J (1H-1H) = 5.8
Hz and 4J (1H-1H) = 1.5 Hz), 7.13 (ddd, 1H, Hb and Hb’, 3J (1H-1H) = 7.4 Hz, 3J (1H-1H) =
5.8 Hz and 4J (1H-1H) = 1.5 Hz), 6.28 (s, 1H, Hr), 4.97 (m, 1H, Hn or Hn’), 4.74 (m, 1H,
Hn or Hn’), 4.60 (td, 1H, Ho or Ho’, 3J (1H-1H) = 2.5 Hz and 3J (1H-1H) = 1.3 Hz), 4.52 (td,
1H, Ho or Ho’, 3J (1H-1H) = 2.5 Hz and 3J (1H-1H) = 1.3 Hz), 3.75 (s, 5H, Hp), 2.24 (s, 3H,
Hz) 13C {1H} NMR (CDCl3, 100.6 MHz, 300.0 K) δ 189.9 (quaternary diketonate C, Cs),
179.7 (quaternary diketonate C, Cq), 169.4 (quaternary C-O, Cf or Cf’), 169.3
(quaternary C-O, Cf or Cf’), 157.0 (quaternary aniline C, Ce or Ce’), 156.7 (quaternary
aniline C, Ce or Ce’), 148.7 (quaternary aromatic C, Ci and Ck or Ci’ and Ck’), 148.6
(quaternary aromatic C, Ci and Ck or Ci’ and Ck’), 148.1 (aniline CH, Ca or Ca’), 148.0
(aniline CH, Ca or Ca’), 143.2 (quaternary aromatic C, Cw), 140.2 (aniline CH, Cc or Cc’),
140.0 (aniline CH, Cc or Cc’), 134.0 (quaternary aromatic C, Ct), 132.0 (aromatic CH,
Cu or Cy), 131.7 (aromatic CH, Cu or Cy), 129.5 (aromatic CH, Cv and Cx), 128.1 (CF3),
126.9 (aromatic CH, Ch, Ch’, Cl and Cl’), 126.6 (aniline CH, Cb or Cb’), 126.4 (aniline CH,
Cb or Cb’), 126.0 (aniline CH, Cd and Cd’), 124.2 (quaternary aromatic C, Cg or Cg’), 121.6
(quaternary aromatic C, Cg or Cg’), 118.3 (aromatic CH, Cj and Cj’), 90.8 (diketonate
CH, Cr), 79.7 (quaternary Cp C, Cm), 72.6 (Cp CH, Co or Co’), 72.2 (Cp CH, Co or Co’), 70.0
(Cp CH, Cp), 69.6 (Cp CH, Cn or Cn’), 67.9 (Cp CH, Cn or Cn’), 21.5 (CH3, Cz) Analysis
calculated C 53.85, H 2.92, N 5.23 % Analysis found C 53.95, H 2.85, N 5.17 % ES MS
(+) (CH3OH) m/z 1071.09 [MH+] IR (cm-1) ν 3081 (w, ArCH), 2924 (w, MeCH), 2853 
(w), 1635 (M, CO), 1601 (m, CO), 1495 (m), 1365 (m), 1278 (s), 1229 (w), 1169 (s),
1116 (s), 947 (m), 688 (m), 512 (m)
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8.13.10 Synthesis of CoC49H33N4O4F12Fe (4.19)
Purified by column chromatography (ethyl acetate/hexane 1:1) to give a purple solid
(0.299 g, 0.276 mmol, 66 %). Recrystallisation by slow evaporation from methanol at
room temperature yielded red crystals suitable for single crystal X-ray diffraction.
1H NMR (CDCl3, 500.23 MHz, 299.9 K) δ 8.26 (d, 
1H, Hd or Hd’, 3J (1H-1H) = 7.1 Hz), 8.14 (d, 1H, Hd
or Hd’, 3J (1H-1H) = 7.1 Hz), 7.94 (td, 1H, Hc or Hc’,
3J (1H-1H) = 7.7 Hz and 3J (1H-1H) = 1.1 Hz), 7.91
(d, 1H, Ha or Ha’, 3J (1H-1H) = 5.5 Hz), 7.87 (td, 1H,
Hc or Hc’, 3J (1H-1H) = 7.6 Hz and 3J (1H-1H) = 1.1
Hz), 7.85 (d, 1H, Ha or Ha’, 3J (1H-1H) = 5.7 Hz),
7.58 (br. s, 4H, Hh, Hh’ and Hl and Hl’), 7.51 (s, 2H,
Hj and Hj’), 7.47 (s, 2H, Hu and Hy), 7.21 (s, 1H, Hw), 7.19 (ddd, 1H, Hb or Hb’, 3J (1H-1H)
= 7.4 Hz, 3J (1H-1H) = 5.8 Hz and 4J (1H-1H) = 1.1 Hz), 7.13 (ddd, 1H, Hb or Hb’, 3J (1H-
1H) = 7.5 Hz, 3J (1H-1H) = 5.8 Hz and 4J (1H-1H) = 1.1 Hz), 6.29 (s, 1H, Hr), 4.99 (s, 1H,
Hn or Hn’), 4.77 (s, 1H, Hn or Hn’), 4.61 (s, 1H, Ho or Ho’), 4.52 (s, 1H, Ho or Ho’), 3.74 (s,
5H, Hp), 2.41 (s, 6H, Hz and Hz’) 13C {1H} NMR (CDCl3, 125.8 MHz, 300.0 K) δ 189.0 
(quaternary diketonate C, Cs), 180.2 (quaternary diketonate C, Cq), 169.3 (quaternary
C-O, Cf and Cf’), 157.0 (quaternary aniline C, Ce or Ce’), 156.7 (quaternary aniline C, Ce
or Ce’), 148.8 (quaternary aromatic C, Ci and Ck or Ci’ and Ck’), 148.6 (quaternary
aromatic C, Ci and Ck or Ci’ and Ck’), 148.0 (aniline CH, Ca and Ca’), 140.2 (aniline CH,
Cc or Cc’), 139.9 (aniline CH, Cc or Cc’), 138.6 (quaternary aromatic C, Cv and Cx), 136.8
(quaternary aromatic C, Ct), 134.0 (aromatic CH, Cu and Cy), 131.7 (aromatic CH, Cw),
128.1 (CF3), 126.6 (aniline CH, Cb or Cb’), 126.4 (aniline CH, Cb or Cb’), 126.0 (aniline
CH, Cd and Cd’), 124.6 (aromatic CH, Ch, Ch’, Cl and Cl’), 124.0 (quaternary aromatic C,
Cg or Cg’), 121.8 (quaternary aromatic C, Cg or Cg’), 118.3 (aromatic CH, Cj and Cj’),
91.2 (diketonate CH, Cr), 79.7 (quaternary Cp C, Cm), 72.6 (Cp CH, Co or Co’), 72.2 (Cp
CH, Co or Co’), 70.0 (Cp CH, Cp), 69.6 (Cp CH, Cn or Cn’), 68.0 (Cp CH, Cn or Cn’), 21.2
(CH3, Cz and Cz’) Analysis calculated (+ 1 H2O) C 53.38, H 3.20, N 5.08 % Analysis
found C 53.06, H 3.02, N 5.18 % ES MS (+) (CH3OH) m/z 1085.11 [MH+] IR (cm-1) ν 
3051 (w, ArCH), 2923 (w, MeCH), 1722 (w), 1633 (m, CO), 1599 (m, CO), 1505 (m),
1462 (w), 1364 (m), 1274 (s), 1176 (m), 1122 (s), 1022 (w) 894 (w), 766 (m), 688 (m),
511 (m)
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8.14 Cytotoxic evaluation
Sterile techniques were used throughout this work. Chemicals were purchased from
Sigma-Aldrich Chemical Co. MIA PaCa-2 (human pancreatic carcinoma), BE (human
colon carcinoma) and ARPE-19 (human retinal pigment epithelial cells) cells were
obtained from Prof. Roger Phillips (University of Huddersfield). Stock cell cultures
were grown in T-25 or T-75 flasks containing RPMI-1640 complete cell medium
(20 mL) and incubated at 37 °C in an atmosphere of 5 % carbon dioxide. The complete
medium was prepared from RPMI-1640 incomplete medium (500 mL), sodium
pyruvate (5 mL, 0.5 mmol), L-glutamine (5 mL, 1.0 mmol) and foetal bovine serum
(FBS) (50 mL). Hank’s balanced salt solution (HBSS) was used to wash cells before use
and 0.25 % trypsin-EDTA solution was used to detach cells from the flask. MTT stock
solutions (5 mg mL-1) were prepared by dissolving MTT (250 μg) in distilled water  
(50 mL) followed by passage through a 0.2 μm sterile filter. RPMI-1640 incomplete 
medium, RPMI-1640 complete medium, sodium pyruvate, MTT and MTT stock
solutions were all stored at 4 °C. L-glutamine, FBS and 0.25 % trypsin-EDTA solution
were all stored at -20 °C. All chemicals except the MTT stock solution were incubated
at 37 °C prior to use.
Cells were washed with HBSS (3 × 10 mL) and HBSS carefully removed. 0.25 % trypsin-
EDTA solution (5 mL) was added and the flasks incubated at 37 °C for 5 minutes.
Following cellular detachment from the flask wall, cell media (10 mL) was added.
Cells were split into new flasks, diluted with cell media, the lids loosened and the
flasks transferred into the incubator at 37 °C. Each cell suspension (10 μL) was 
transferred to each side of the glass haemocytometer and cells were counted using
an optical microscope and an average taken with units of 104 cells mL-1.
8.14.1 The five-day MTT assay (normoxic conditions)
The cell suspension was diluted with RPMI-1640 complete media to give a
concentration of 2 × 104 cells mL-1. 100 μL of cell media was added to the first lane 
of the 96-well plate to act as a blank. 100 μL of diluted cell suspension were added 
to the other wells and the plate incubated at 37 °C overnight with 5 % CO2.
Complexes were prepared in DMSO and then further diluted with RPMI-1640 media
to give a final concentration of 250 μM (with a final DMSO concentration at 0.1 %). 
Further dilutions were carried out to give eight different drug concentrations. All
experiments were carried out in triplicate. Drug solutions were added to the cells
and the plate incubated for five days at 37 °C with 5 % CO2. After five days, 20 μL of 
a MTT stock solution (5 mg mL-1) was added to each well and incubated for a further
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3 hours at 37 °C with 5 % CO2. The media and MTT was removed and 150 μL of DMSO 
added to each well to dissolve any formazan crystals. The absorbance at 540 nm was
determined with a Thermo Scientific Multiskan EX microplate photometer. Cell
survival was determined at the absorbance of treated cells compared to the
absorbance of non-treated cells (negative control). IC50 values were determined
from plots of percentage survival against drug concentration.
8.14.2 The five-day MTT assay (hypoxic conditions)
The assay was conducted according to the protocol stated previously for normoxic
conditions. However, all the incubations periods, the addition of the drug and the
addition of the MTT solution were carried out inside a Don Whitley Scientific H35
Hypoxystation with the oxygen level set at 0.1 %. Cell culture media was conditioned
for 24 hours at 0.1 % O2 prior to the start of the experiment.
8.14.3 Cell viability assay
Cells were seeded at 1.66 × 105 cells ml-1 and incubated at 37 °C overnight with 5 %
CO2. Cells were washed with phosphate-buffered saline (PBS) (3 × 5 mL) and cell
media (5 mL) added following cellular detachment. Cell suspensions samples were
added to Via-1 cassettes preloaded with acridine orange and 4’,6-diamidino-2-
phenylindole (DAPI) and analysed with a Chemometec NucleoCounter NC-3000.
8.14.4 Cell cycle assay
Cell suspensions from the cell viability assay were diluted with PBS to 1 × 106 cells
ml-1 and centrifuged at 400 g min-1 for 5 minutes. The supernatant was removed,
washed with PBS, centrifuged at 400 g min-1 for 5 minutes and PBS removed. Cells
were resuspended in lysis buffer (250 μL) supplemented with DAPI (10 μg ml-1) and
incubated at 37 °C for 5 minutes. Stabilisation buffer (250 μL) was added and cells 
analysed with a Chemometec NucleoCounter NC-3000.
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8.15 Anti-bacterial evaluation
Anti-bacterial evaluation was performed by The Community for Antimicrobial Drug
Discovery (CO-ADD) at The University of Queensland, funded by The Wellcome Trust.
Complexes were prepared in DMSO and water to a give a final concentration of
32 μg mL-1 in 384-well non-binding surface (NBS) plate. The final DMSO
concentration was at a maximum of 1 % DMSO. All bacteria were cultured in Cation-
adjusted Mueller Hinton broth (CAMHB) at 37 °C overnight. A sample of each culture
was diluted 40-fold in fresh broth and incubated at 37 °C for 1.5 - 3 hours. The
resultant mid-log phase cultures were diluted (CFU mL-1 measured by OD600), then
added to each well of the compound containing plates, giving a cell density of
5 × 105 CFU mL-1 and a total volume of 50 μL. Colistin and vancomycin were used as 
positive bacterial inhibitor standards for Gram-negative and Gram-positive bacteria,
respectively. The antibiotics were provided at four concentrations, with two above
and two below the MIC value. All the plates were covered and incubated at 37 °C for
18 hours without shaking. All experiments were carried out in duplicate. Inhibition
of bacterial growth was determined measuring absorbance at 600 nm (OD600), using
a Tecan M1000 Pro monochromator plate reader. The percentage of growth
inhibition was calculated for each well, using the negative control (media only) and
positive control (bacteria without inhibitors) on the same plate as references. The
significance of the inhibition values was determined by modified Z-scores, calculated
using the median and MAD of the samples (no controls) on the same plate. Samples
with inhibition value above 80 % and Z-Score above 2.5 for either replicate were
classed as actives. Samples with inhibition values in the range 50 to 80 % and Z-Score
above 2.5 for either replicate were classed as partial actives.
8.16 Anti-fungal evaluation
Anti-fungal evaluation was performed by The Community for Antimicrobial Drug
Discovery (CO-ADD) at The University of Queensland, funded by The Wellcome Trust.
8.16.1 Anti-fungal screening procedure
Complexes were prepared in DMSO and water to a give a final concentration of
32 μg mL-1 in 384-well NBS plate. The final DMSO concentration was at a maximum
of 1 % DMSO. Fungal strains were cultured for three days on yeast extract-peptone
dextrose (YPD) agar at 30 °C. A yeast suspension of 1 x 106 to 5 x 106 CFU mL-1 (as
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determined by OD530) was prepared from five colonies. The suspension was diluted
and added to each well of the compound-containing plates giving a final cell density
of fungi suspension of 2.5 × 103 CFU mL-1 and a total volume of 50 μL. Fluconazole 
was used as a positive fungal inhibitor standard. All the plates were covered and
incubated at 35 °C for 24 hours without shaking. All experiments were carried out in
duplicate. Growth inhibition of C. albicans was determined measuring absorbance at
530 nm (OD530) and the growth inhibition of C. neoformans was determined
measuring the difference in absorbance between 600 and 570 nm (OD600-570), after
the addition of 0.001 % resazurin and incubation at 35 °C for an additional 2 hours.
The absorbance was measured using a Biotek Synergy HTX plate reader. The
percentage of growth inhibition was calculated for each well, using the negative
control (media only) and positive control (fungi without inhibitors) on the same
plate. The significance of the inhibition values was determined by modified Z-scores,
calculated using the median and MAD of the samples (no controls) on the same
plate. Samples with inhibition value above 80 % and Z-Score above 2.5 for either
replicate were classed as actives. Samples with inhibition values in the range 50 to
80 % and Z-Score above 2.5 for either replicate were classed as partial actives.
8.16.2 Anti-fungal hit confirmation procedure
Complexes were prepared in DMSO and water to a give a final concentration of
32 μg mL-1 and serially diluted two fold for eight times. Each sample concentration
was prepared in 384-well non-binding surface plate for each fungal strain or
tissue-culture treated plates for mammalian cell types. The final DMSO
concentration was at a maximum of 0.5 % DMSO. Fungal strains were cultured for
three days on YPD agar at 30 °C. A yeast suspension of 1 x 106 to 5 x 106 CFU mL-1 (as
determined by OD530) was prepared from five colonies. The suspension was
subsequently diluted and added to each well of the compound-containing plates
giving a final cell density of fungi suspension of 2.5 × 103 CFU mL-1 and a total volume
of 50 μL. Fluconazole was used as a positive fungal inhibitor standard. The anti-fungal 
was provided at four concentrations, with two above and two below the MIC value.
All plates were covered and incubated at 35 °C for 36 hours without shaking. All
experiments were performed in duplicate. Growth inhibition of C. albicans was
determined measuring absorbance at 630 nm (OD630) and the growth inhibition of
C. neoformans was determined measuring the difference in absorbance between
600 and 570 nm (OD600-570) after the addition of 0.001 % resazurin and incubation at
35 °C for 2 hours. The absorbance was measured using a Biotek Multiflo Synergy HTX
plate reader. The percentage of growth inhibition was calculated for each well, using
the negative control (media only) and positive control (fungi without inhibitors) on
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the same plate. The MIC was determined as the lowest concentration at which the
growth was fully inhibited, defined by an inhibition ≥ 80% for C. albicans and an
inhibition ≥ 70% for C. neoformans. Due to a higher variance in growth and inhibition,
a lower threshold was applied to the data for C. neoformans. In addition, the
maximal percentage of growth inhibition is reported as DMax, indicating any
compounds with marginal activity. Hits were classified by MIC ≤ 16 μg mL-1 or
MIC ≤ 10 μM in either replicate. 
To assess the cytotoxicity, HEK293 cells were counted manually in a Neubauer
haemocytometer and then plated in the 384-well plates containing the compounds
to give a density of 6000 cells well-1 in a final volume of 50 μL. Dulbecco’s modified 
eagle medium (DMEM) supplemented with 10 % FBS was used as growth media and
the cells were incubated together with the compounds for 20 hours at 37 °C in 5 %
CO2. Tamoxifen was used as a positive cytotoxicity standard. The cytotoxic drug was
provided at four concentrations, with two above and two below the CC50 value. All
experiments were performed in duplicate. Cytotoxicity was measured by
fluorescence with excitation at 560 nm and emission at 590 nm (F560/590), after
addition of 5 μL of resazurin (25 μg mL-1) and incubation for a further 3 hours at
37 °C in 5% CO2. The fluorescence intensity was measured using a Tecan M1000 Pro
monochromator plate reader, using automatic gain calculation CC50 were calculated
by curve fitting the inhibition values against log(concentration) using sigmoidal
dose-response function, with variable fitting values for bottom, top and slope. The
maximal percentage of cytotoxicity is reported as DMax, indicating any compounds
with partial cytotoxicity. The curve fitting was implemented using Pipeline Pilot's
dose-response component. Any value with > indicates a sample with no activity (low
DMax value) or samples with CC50 values above the maximum tested concentration.
Cytotoxic samples were classified by CC50 ≤ 32 μg mL-1 in either replicate.
8.17 Hydrolysis
Hydrolysis samples of complexes for investigation by NMR spectroscopy were
prepared from a 4:1 mixture of d3-acetonitrile/deuterium oxide to give a final
concentration of 8 mg mL-1. The NMR spectra of these samples were acquired every
24 hours over a five day period. Hydrolysis samples of complexes for investigation
by UV/vis spectroscopy were prepared from a 4:1 mixture of acetonitrile/water to
give a final concentration of 50 μM. The UV/vis spectra of these samples were 
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acquired every 24 hours over a five day period. After the five day period investigation
period, the mass spectra of the hydrolysis samples were acquired.
8.18 Hydrophobicity
Equal volumes of 1-octanol and sodium chloride saturated distilled water were
stirred for 16 hours and separated to give water-saturated octanol and
octanol-saturated water. Standard solutions of each complex (5, 10, 20, 40 and
60 μM) were prepared in water-saturated octanol. The calibration curve of 
absorbance against concentration was determined from the maximum absorbance
(λmax) of the standard solutions. Stock solutions of each complex (50 μM) in  
water-saturated octanol (25 mL) were prepared. Six independent samples were
prepared by the addition of the stock solution (3 mL) to a 15 mL Falcon tube followed
by layered addition of octanol-saturated water (3 mL). Samples were shaken at
1000 g min-1 for 2 hours using an IKA Vibrax VXC basic shaker. The layers were
separated and the water-saturated octanol layer retained. The concentration of each
sample in the water-saturated octanol layer was determined by UV/vis spectroscopy
with reference to the individual calibration curves to give an average concentration
for shaken samples ([C]final). The concentration of an unshaken sample of stock
solution was determined to give [C]initial. The partition coefficient (log P) was
determined with Equation 8.1.
Equation 8.1: Determination of partition coefficient (log P)logܲ = logଵ଴ቆ [ܥ]௙௜௡௔௟[ܥ]௜௡௜௧௜௔௟− [ܥ]௙௜௡௔௟ቇ
8.19 Biomembrane studies
The biomembrane studies were performed by Miss. Danielle Marriott and Dr.
Shahrzad Mohamadi (University of Leeds).
The micro fabricated electrode coated with DOPC lipid was contained in a closed
flow cell. A constant flow of phosphate-buffered saline (PBS) (pH 7.4) was passed
over the electrode using a peristaltic pump at a flow rate of 5 - 10 mL min-1. A
constant flow of DOPC dispersion in PBS was deposited on the electrode with the
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application of a potential excursion from -0.4 to -3.0 V at a scan rate of 100 Vs-1. The
electrode in the flow cell was connected to the PGSTATI2 potentiostat interfaced to
a Powerlab signal generator and controlled by Scope software. A flow of argon gas
is maintained over the electrolytes and the DOPC layer throughout. RCVs were
obtained by applying a saw-tooth waveform from -0.4 to -1.2 V (vs Ag/AgCl) with
ramp rate 40 V s-1 applied to the electrode surface. In the absence of faradaic
reactions, the current on the RCV plot was directly proportional to the capacitance
of the surface and is displayed as a function of voltage. All assays were carried out
with 15.6 μM solutions of each complex in acetone with a constant flow of 0.1 M 
PBS. The complexes are sampled for 400 seconds followed by PBS for 400 seconds
to allow in situ cleaning of the electrode.24, 25
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Complex 1.22 2.1a
Empirical formula C20H14N2O CoC37.33H29N6.67O3
Formula weight 298.33 677.94
Size / mm3 0.35 × 0.11 × 0.06 0.19 × 0.13 × 0.06
Temperature / K 120.01(10) 121(1)
Wavelength 0.71073 (Mo-Kα) 0.71073 (Mo-Kα)
Crystal system monoclinic triclinic
Space group P 21 P 1
a / Å 10.8320(15) 9.9033(4)
b / Å 5.9238(7) 20.5749(8)
c / Å 11.2014(19) 24.2666(11)
α / ° 90.00 81.265(4)
β / ° 99.771(14) 80.376(4)
γ / ° 90.00 80.584(3)
Volume / Å3 708.32(18) 4769.7(3)
Z 2 6
μ / mm-1 0.088 0.589
F(000) 312.0 2104.0
Data collection range / ° 7.38 ≤ θ ≤ 56.56 5.78 ≤ θ ≤ 52.74 
Index ranges -11 ≤ h ≤ 14 
-7 ≤ k ≤ 7 
-14 ≤ l ≤ 13 
-12 ≤ h ≤ 12 
-25 ≤ k ≤ 25 
-30 ≤ l ≤ 26 
Reflections collected 4234 68202
Independent reflections 3003 [Rint = 0.0472] 19506 [Rint = 0.1117]
Goodness of fit 1.165 1.117
Final R indices [I>2σ (I)] R1 = 0.0891, wR2 = 0.1922 R1 = 0.0958, wR2 = 0.1717
R indices (all data) R1 = 0.1095, wR2 = 0.2037 R1 = 0.1493, wR2 = 0.1935
Largest diff. / e Å-3 0.35 and -0.33 1.31 and -0.62
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Complex 2.2 2.3
Empirical formula CoC36H26F3N6O4 CoC36H24N6O3F3
Formula weight 722.56 704.54
Size / mm3 0.31 × 0.28 × 0.18 0.14 × 0.04 × 0.02
Temperature / K 120.00(10) 120.00(14)
Wavelength 0.71073 (Mo-Kα) 1.54184 (Cu-Kα)
Crystal system monoclinic monoclinic
Space group P 21/c P 21/n
a / Å 9.4536(3) 17.142(3)
b / Å 14.7729(5) 9.9817(16)
c / Å 22.8060(9) 20.332(5)
α / ° 90.00 90.00
β / ° 97.774(3) 107.39(2)
γ / ° 90.00 90.00
Volume / Å3 3155.8(2) 3319.9(13)
Z 4 4
μ / mm-1 0.614 4.590
F(000) 1480.0 1440.0
Data collection range / ° 5.802 ≤ θ ≤ 62.478 5.936 ≤ θ ≤ 150.194 
Index ranges -13 ≤ h ≤ 12 
-19 ≤ k ≤ 21 
-31 ≤ l ≤ 29 
-17 ≤ h ≤ 20 
-10 ≤ k ≤ 12 
-25 ≤ l ≤ 24 
Reflections collected 21520 13790
Independent reflections 8980 [Rint = 0.0377] 6520 [Rint = 0.0957]
Goodness of fit 1.024 1.398
Final R indices [I>2σ (I)] R1 = 0.0526, wR2 = 0.1246 R1 = 0.1569, wR2 = 0.4001
R indices (all data) R1 = 0.0723, wR2 = 0.1368 R1 = 0.2005, wR2 = 0.4365
Largest diff. / e Å-3 1.11 and -0.51 1.89 to -2.06
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Complex 2.4 2.5
Empirical formula CoC36H24F3N6O3 CoC38H26.75N6O3.88F6
Formula weight 704.54 802.33
Size / mm3 0.18 × 0.09 × 0.056 0.22 × 0.07 × 0.03
Temperature / K 120.01(12) 120.00(17)
Wavelength 0.71073 (Mo-Kα) 0.71073 (Mo-Kα)
Crystal system triclinic triclinic
Space group P 1 P 1
a / Å 10.2432(3) 10.1276(4)
b / Å 17.4043(6) 17.6691(8)
c / Å 19.9290(6) 20.7763(8)
α / ° 105.613(3) 104.972(4)
β / ° 98.051(2) 103.367(4)
γ / ° 101.322(3) 97.194(4)
Volume / Å3 3284.44(18) 3426.0(3)
Z 4 4
μ / mm-1 0.586 0.586
F(000) 1440.0 1635.0
Data collection range / ° 6.154 ≤ θ ≤ 62.508 6.08 ≤ θ ≤ 62.44 
Index ranges -14 ≤ h ≤ 14 
-23 ≤ k ≤ 23 
-29 ≤ l ≤ 25 
-13 ≤ h ≤ 14 
-22 ≤ k ≤ 25 
-30 ≤ l ≤ 26 
Reflections collected 48128 56214
Independent reflections 18850 [Rint = 0.0503] 19751 [Rint = 0.0967]
Goodness of fit 1.026 1.038
Final R indices [I>2σ (I)] R1 = 0.0601, wR2 = 0.1078 R1 = 0.0947, wR2 = 0.1600
R indices (all data) R1 = 0.0938, wR2 = 0.1204 R1 = 0.1961, wR2 = 0.2000
Largest diff. / e Å-3 0.41 to -0.51 0.72 and -0.53
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Complex 2.6 2.7
Empirical formula CoC36H21N6O3F6 CoC39H36N6O6Cl3
Formula weight 758.52 850.02
Size / mm3 0.34 × 0.11 × 0.08 0.25 × 0.09 × 0.047
Temperature / K 120.01(10) 120.01(12)
Wavelength 0.71073 (Mo-Kα) 0.71073 (Mo-Kα)
Crystal system monoclinic monoclinic
Space group P 21/n P 21/c
a / Å 17.2118(8) 10.1077(5)
b / Å 9.8701(4) 24.5768(12)
c / Å 21.7012(13) 15.3694(7)
α / ° 90.00 90.00
β / ° 111.685(6) 95.048(4)
γ / ° 90.00 90.00
Volume / Å3 3425.7(3) 3803.2(3)
Z 4 4
μ / mm-1 0.579 0.718
F(000) 1536.0 1752.0
Data collection range / ° 6.282 ≤ θ ≤ 62.394 6.27 ≤ θ ≤ 52.744 
Index ranges -25 ≤ h ≤ 22 
-13 ≤ k ≤ 13 
-30 ≤ l ≤ 29 
-12 ≤ h ≤ 10 
-30 ≤ k ≤ 30 
-14 ≤ l ≤ 19 
Reflections collected 28556 25381
Independent reflections 9755 [Rint = 0.0622] 7761 [Rint = 0.0540]
Goodness of fit 1.013 1.037
Final R indices [I>2σ (I)] R1 = 0.0560, wR2 = 0.1250 R1 = 0.0725, wR2 = 0.2423
R indices (all data) R1 = 0.0975, wR2 = 0.1430 R1 = 0.0982, wR2 = 0.2698
Largest diff. / e Å-3 1.33 and -0.60 1.88 and -0.98
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Complex 2.8 2.9
Empirical formula CoC41.6H35.6N6O3Cl9 CoC37H28N6O4Br3
Formula weight 1045.54 919.31
Size / mm3 0.18 × 0.11 × 0.07 0.21 × 0.15 × 0.09
Temperature / K 110.01(10) 110.01(10)
Wavelength 0.71073 (Mo-Kα) 0.71073 (Mo-Kα)
Crystal system triclinic triclinic
Space group P 1 P 1
a / Å 12.6110(10) 9.4660(4)
b / Å 13.4455(10) 11.0078(6)
c / Å 15.2414(13) 18.8301(10)
α / ° 99.379(7) 102.546(5)
β / ° 98.733(7) 93.541(4)
γ / ° 115.762(8) 112.143(4)
Volume / Å3 2223.1(3) 1751.46(16)
Z 2 2
μ / mm-1 0.974 3.962
F(000) 1062.0 912.0
Data collection range / ° 6.396 ≤ θ ≤ 52.742 5.966 ≤ θ ≤ 62.604 
Index ranges -14 ≤ h ≤ 15 
-16 ≤ k ≤ 16 
-19 ≤ l ≤ 19 
-11 ≤ h ≤ 13 
-15 ≤ k ≤ 11 
-26 ≤ l ≤ 26 
Reflections collected 23994 21757
Independent reflections 9084 [Rint = 0.1005] 9870 [Rint = 0.0517]
Goodness of fit 1.015 1.046
Final R indices [I>2σ (I)] R1 = 0.0824, wR2 = 0.1892 R1 = 0.0629, wR2 = 0.1476
R indices (all data) R1 = 0.1458, wR2 = 0.2304 R1 = 0.0908, wR2 = 0.1647
Largest diff. / e Å-3 1.37 and -0.82 1.44 and -1.04
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Complex 2.10 2.11
Empirical formula CoC37H30N6O5Br3 CoC41H26N6O3F9Cl6
Formula weight 937.33 1093.31
Size / mm3 0.27 × 0.21 × 0.12 0.17 × 0.04 × 0.02
Temperature / K 120.01(10) 120.02(17)
Wavelength 0.71073 (Mo-Kα) 0.71073 (Mo-Kα)
Crystal system monoclinic triclinic
Space group P 21/c P 1
a / Å 16.3898(5) 10.8889(4)
b / Å 12.4501(4) 13.3504(8)
c / Å 18.6887(6) 17.0160(12)
α / ° 90.00 67.229(6)
β / ° 109.585(3) 75.622(5)
γ / ° 90.00 76.343(4)
Volume / Å3 3592.9(2) 2182.1(2)
Z 4 2
μ / mm-1 3.867 0.847
F(000) 1864.0 1096.0
Data collection range / ° 5.734 ≤ θ ≤ 62.638 5.54 ≤ θ ≤ 56.56 
Index ranges -23 ≤ h ≤ 23 
-18 ≤ k ≤ 14 
-26 ≤ l ≤ 24 
-14 ≤ h ≤ 14 
-17 ≤ k ≤ 17 
-22 ≤ l ≤ 22 
Reflections collected 28543 30613
Independent reflections 10300 [Rint = 0.0425] 10824 [Rint = 0.0512]
Goodness of fit 1.038 1.035
Final R indices [I>2σ (I)] R1 = 0.0438, wR2 = 0.0816 R1 = 0.0707, wR2 = 0.1585
R indices (all data) R1 = 0.0739, wR2 = 0.0919 R1 = 0.1035, wR2 = 0.1771
Largest diff. / e Å-3 1.00 and -0.92 1.61 and -1.61
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Complex 2.12 2.13
Empirical formula CoC41.25H29.5N6O3.5F9Cl0.5 CoC43H22N6O3F18Cl3
Formula weight 912.86 1177.94
Size / mm3 0.28 × 0.05 × 0.02 0.18 × 0.06 × 0.03
Temperature / K 120.00(14) 120.01(19)
Wavelength 1.54184 (Cu-Kα) 0.71073 (Mo-Kα)
Crystal system triclinic monoclinic
Space group P 1 P 21/c
a / Å 14.3515(5) 15.525(2)
b / Å 16.6340(6) 16.581(2)
c / Å 18.2610(7) 18.791(3)
α / ° 104.315(3) 90.00
β / ° 98.187(3) 98.803(14)
γ / ° 108.532(3) 90.00
Volume / Å3 3887.3(3) 4780.2(11)
Z 4 4
μ / mm-1 4.613 0.644
F(000) 1854.0 2344.0
Data collection range / ° 6.508 ≤ θ ≤ 147.904 5.852 ≤ θ ≤ 52.848 
Index ranges -17 ≤ h ≤ 17 
-13 ≤ k ≤ 19 
-22 ≤ l ≤ 21 
-19 ≤ h ≤ 19 
-20 ≤ k ≤ 19 
-23 ≤ l ≤ 23 
Reflections collected 32517 17371
Independent reflections 14768 [Rint = 0.0771] 17371 [Rint= 0.168]
Goodness of fit 1.023 0.865
Final R indices [I>2σ (I)] R1 = 0.0935, wR2 = 0.2374 R1 = 0.0933, wR2 = 0.2084
R indices (all data) R1 = 0.1510, wR2 = 0.2862 R1 = 0.2201, wR2 = 0.2425
Largest diff. / e Å-3 1.56 and -1.02 0.96 and -0.84
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Complex 2.14a 2.15a
Empirical formula CoC40H38N6O4.5 CoC41.91H44.66N6O5.92
Formula weight 733.69 786.05
Size / mm3 0.27 × 0.19 × 0.09 0.18 × 0.10 × 0.09
Temperature / K 120.01(10) 120.0(3)
Wavelength 0.71073 (Mo-Kα) 0.71073 (Mo-Kα)
Crystal system triclinic triclinic
Space group P 1 P 1
a / Å 9.5494(3) 11.6389(4)
b / Å 13.7457(5) 13.5700(6)
c / Å 15.0145(5) 14.0659(7)
α / ° 78.179(3) 69.506(4)
β / ° 73.207(3) 72.633(4)
γ / ° 70.571(3) 83.743(3)
Volume / Å3 1766.40(12) 1986.08(16)
Z 2 2
μ / mm-1 0.539 0.486
F(000) 766.0 825.0
Data collection range / ° 6.186 ≤ θ ≤ 62.478 6.136 ≤ θ ≤ 62.426 
Index ranges -13 ≤ h ≤ 13 
-19 ≤ k ≤ 18 
-21 ≤ l ≤ 21 
-16 ≤ h ≤ 15 
-19 ≤ k ≤ 18 
-18 ≤ l ≤ 20 
Reflections collected 29518 25169
Independent reflections 10124 [Rint = 0.0412] 11192 [Rint = 0.0401]
Goodness of fit 1.048 1.058
Final R indices [I>2σ (I)] R1 = 0.0470, wR2 = 0.0993 R1 = 0.0571, wR2 = 0.1302
R indices (all data) R1 = 0.0609, wR2 = 0.1064 R1 = 0.0794, wR2 = 0.1419
Largest diff. / e Å-3 0.47 and -0.47 1.06 to -0.47
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Complex 2.16a 2.17a
Empirical formula CoC46.13H46.75N6O3.25Cl6.75 CoC40H33N6O7
Formula weight 1035.36 768.65
Size / mm3 0.37 × 0.14 × 0.04 0.25 × 0.08 × 0.06
Temperature / K 120.02(16) 120.01(18)
Wavelength 0.71073 (Mo-Kα) 1.54184 (Cu-Kα)
Crystal system triclinic triclinic
Space group P 1 P 1
a / Å 13.7483(6) 10.0253(4)
b / Å 17.0078(6) 13.0399(5)
c / Å 23.1559(9) 14.7478(5)
α / ° 78.587(3) 98.078(3)
β / ° 82.526(4) 108.411(4)
γ / ° 70.642(4) 105.152(4)
Volume / Å3 4995.2(4) 1712.53(12)
Z 4 2
μ / mm-1 0.750 4.459
F(000) 2133.0 796.0
Data collection range / ° 5.772 ≤ θ ≤ 46.512 6.52 ≤ θ ≤ 147.46 
Index ranges -15 ≤ h ≤ 15 
-18 ≤ k ≤ 18 
-25 ≤ l ≤ 25 
-12 ≤ h ≤ 11 
-16 ≤ k ≤ 15 
-18 ≤ l ≤ 15 
Reflections collected 61654 13889
Independent reflections 14319 [Rint = 0.1000] 6471 [Rint = 0.0295]
Goodness of fit 1.017 1.032
Final R indices [I>2σ (I)] R1 = 0.1076, wR2 = 0.2892 R1 = 0.0462, wR2 = 0.1207
R indices (all data) R1 = 0.1546, wR2 = 0.3320 R1 = 0.0513, wR2 = 0.1253
Largest diff. / e Å-3 2.29 to -1.25 0.99 and -1.43
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Complex 2.1b 2.14b
Empirical formula CoC36H29N6O4 CoC40H44N6O6
Formula weight 668.58 763.74
Size / mm3 0.11 × 0.08 × 0.05 0.14 × 0.11 × 0.04
Temperature / K 120.00(13) 120.0(2)
Wavelength 0.71073 (Mo-Kα) 1.54184 (Cu-Kα)
Crystal system triclinic triclinic
Space group P 1 P 1
a / Å 11.5229(13) 14.7347(4)
b / Å 11.9759(13) 15.5381(4)
c / Å 12.0279(8) 18.5489(5)
α / ° 78.077(7) 111.770(2)
β / ° 78.949(7) 93.953(2)
γ / ° 77.062(9) 106.249(2)
Volume / Å3 1564.3(3) 3714.61(15)
Z 2 4
μ / mm-1 0.600 4.080
F(000) 692.0 1604.0
Data collection range / ° 6.44 ≤ θ ≤ 52.74 6.36 ≤ θ ≤ 147.82 
Index ranges -14 ≤ h ≤ 14 
-14 ≤ k ≤ 14 
-15 ≤ l ≤ 13 
-18 ≤ h ≤ 14 
-19 ≤ k ≤ 17 
-23 ≤ l ≤ 22 
Reflections collected 16177 34545
Independent reflections 6368 [Rint = 0.0582] 14098 [Rint = 0.0447]
Goodness of fit 1.047 1.044
Final R indices [I>2σ (I)] R1 = 0.0512, wR2 = 0.1015 R1 = 0.0765, wR2 = 0.2180
R indices (all data) R1 = 0.0677, wR2 = 0.1096 R1 = 0.0988, wR2 = 0.2400
Largest diff. / e Å-3 0.70 and -0.38 1.74 and -0.84
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Complex 2.15b 2.16b
Empirical formula CoC40.85H36.85N5O4Cl2.55 CoC42H51.67N6O6.33
Formula weight 811.13 800.82
Size / mm3 0.19 × 0.12 × 0.06 0.09 × 0.05 × 0.04
Temperature / K 120.1(4) 120.5(9)
Wavelength 0.71073 (Mo-Kα) 1.54184 (Cu-Kα)
Crystal system triclinic triclinic
Space group P 1 P 1
a / Å 11.5554(11) 11.0281(6)
b / Å 12.0050(10) 13.7282(5)
c / Å 15.0864(15) 14.9976(7)
α / ° 95.392(7) 66.892(4)
β / ° 100.331(8) 74.161(4)
γ / ° 99.212(8) 77.568(4)
Volume / Å3 2016.1(3) 1994.03(16)
Z 2 2
μ / mm-1 0.641 0.486
F(000) 839.0 847.0
Data collection range / ° 6.148 ≤ θ ≤ 53.006 3.02 ≤ θ ≤ 50.24 
Index ranges -14 ≤ h ≤ 13 
-14 ≤ k ≤ 14 
-18 ≤ l ≤ 18 
-13 ≤ h ≤ 10 
-15 ≤ k ≤ 16 
-16 ≤ l ≤ 17 
Reflections collected 14935 14967
Independent reflections 14935 [Rint = 0.152] 6863 [Rint = 0.044]
Goodness of fit 0.985 1.082
Final R indices [I>2σ (I)] R1 = 0.1253, wR2 = 0.3307 R1 = 0.0889, wR2 = 0.2356
R indices (all data) R1 = 0.2379, wR2 = 0.3762 R1 = 0.1076, wR2 = 0.2493
Largest diff. / e Å-3 1.41 and -0.84 1.16 and -0.97
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Complex 2.17b 2.18b
Empirical formula CoC39H35N6O7 CoC42H50N6O14
Formula weight 758.66 921.81
Size / mm3 0.13 × 0.07 × 0.06 0.15 × 0.13 × 0.11
Temperature / K 120.01(16) 120.0(2)
Wavelength 1.54184 (Cu-Kα) 1.54184 (Cu-Kα)
Crystal system triclinic triclinic
Space group P 1 P 1
a / Å 10.5395(4) 13.8190(3)
b / Å 13.1143(5) 15.3377(4)
c / Å 13.5741(5) 22.5261(6)
α / ° 79.375(3) 76.712(2)
β / ° 69.846(3) 75.834(2)
γ / ° 85.467(3) 67.105(2)
Volume / Å3 1730.87(11) 4215.83(19)
Z 2 4
μ / mm-1 4.402 3.843
F(000) 788.0 1932.0
Data collection range / ° 6.86 ≤ θ ≤ 147.22 6.32 ≤ θ≤ 147.62 
Index ranges -13 ≤ h ≤ 9 
-16 ≤ k ≤ 14 
-16 ≤ l ≤ 15 
-17 ≤ h ≤ 16 
-18 ≤ k ≤ 18 
-27 ≤ l ≤ 27 
Reflections collected 13294 38898
Independent reflections 6533 [Rint = 0.0329] 15936 [Rint = 0.0319]
Goodness of fit 1.019 1.023
Final R indices [I>2σ (I)] R1 = 0.0475, wR2 = 0.1137 R1 = 0.0437, wR2 = 0.1127
R indices (all data) R1 = 0.0592, wR2 = 0.1226 R1 = 0.0570, wR2 = 0.1210
Largest diff. / e Å-3 0.71 and -0.61 0.66 and -0.65
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Complex 3.1 3.2
Empirical formula CoC26H20N6O2S2 CoC28H24N6O2S2
Formula weight 571.53 599.58
Size / mm3 0.21 × 0.15 × 0.11 0.13 × 0.11 × 0.04
Temperature / K 120.00(10) 120.00(13)
Wavelength 0.71073 (Mo-Kα) 0.71073 (Mo-Kα)
Crystal system triclinic monoclinic
Space group P 1 P 21/c
a / Å 8.1387(6) 8.0460(9)
b / Å 8.7460(5) 21.181(2)
c / Å 9.8413(7) 8.9024(11)
α / ° 85.840(6) 90.00
β / ° 75.883(6) 113.347(14)
γ / ° 66.742(7) 90.00
Volume / Å3 623.93(8) 1392.9(3)
Z 1 2
μ / mm-1 0.892 0.803
F(000) 293.0 618.0
Data collection range / ° 6.544 ≤ θ ≤ 56.556 5.84 ≤ θ ≤ 62.5 
Index ranges -10 ≤ h ≤ 10 
-11 ≤ k ≤ 11 
-13 ≤ l ≤ 13 
-9 ≤ h ≤ 11 
-28 ≤ k ≤ 29 
-12 ≤ l ≤ 7 
Reflections collected 1243 9421
Independent reflections 3094 [Rint = 0.0458] 3988 [Rint = 0.0477]
Goodness of fit 1.077 1.059
Final R indices [I>2σ (I)] R1 = 0.0354, wR2 = 0.0789 R1 = 0.0544, wR2 = 0.1123
R indices (all data) R1 = 0.0430, wR2 = 0.0838 R1 = 0.0929, wR2 = 0.1302
Largest diff. / e Å-3 0.36 and -0.29 0.66 and -0.58
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Complex 3.3 3.4
Empirical formula CoC30H28N6O2S2 CoC28H24N6O2S2
Formula weight 627.63 599.58
Size / mm3 0.2 × 0.14 × 0.09 0.16 × 0.12 × 0.08
Temperature / K 120.01(10) 119.99(17)
Wavelength pink block 0.71073 (Mo-Kα)
Crystal system triclinic monoclinic
Space group P 1 P 21/c
a / Å 7.8650(8) 10.4338(14)
b / Å 8.4741(8) 13.6460(14)
c / Å 12.8131(13) 19.816(3)
α / ° 105.541(9) 90.00
β / ° 91.317(8) 103.722(16)
γ / ° 116.677(10) 90.00
Volume / Å3 724.92(12) 2740.9(6)
Z 1 4
μ / mm-1 0.775 0.816
F(000) 325.0 1236.0
Data collection range / ° 6.26 ≤ θ ≤ 62.3 5.98 ≤ θ ≤ 62.46 
Index ranges -11 ≤ h ≤ 10 
-11 ≤ k ≤ 12 
-17 ≤ l ≤ 11 
-15 ≤ h ≤ 10 
-19 ≤ k ≤ 19 
-26 ≤ l ≤ 28 
Reflections collected 5365 21138
Independent reflections 3534 [Rint = 0.0333] 7795 [Rint = 0.0911]
Goodness of fit 1.061 1.087
Final R indices [I>2σ (I)] R1 = 0.0635, wR2 = 0.1534 R1 = 0.0840, wR2 = 0.1878
R indices (all data) R1 = 0.0807, wR2 = 0.1680 R1 = 0.1317, wR2 = 0.2179
Largest diff. / e Å-3 1.45 and -0.65 1.58 and -0.80
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Complex 3.5 3.7
Empirical formula CoC28H24N6O2S2 CoC28H24N6O4S2
Formula weight 599.58 1263.16
Size / mm3 0.35 × 0.07 × 0.04 0.24 × 0.07 × 0.02
Temperature / K 120.0(2) 120.2(6)
Wavelength 0.71073 (Mo-Kα) 1.54184 (Cu-Kα)
Crystal system monoclinic monoclinic
Space group C c C c
a / Å 8.2408(7) 8.51272(16)
b / Å 20.8725(16) 20.4558(3)
c / Å 16.2881(13) 16.2386(3)
α / ° 90.00 90.00
β / ° 98.690(8) 97.6694(17)
γ / ° 90.00 90.00
Volume / Å3 2769.5(4) 2802.40(9)
Z 4 2
μ / mm-1 0.808 6.584
F(000) 1236.0 1300.0
Data collection range / ° 6.24 ≤ θ ≤ 62.7 8.64 ≤ θ ≤ 147.44 
Index ranges -8 ≤ h ≤ 11 
-30 ≤ k ≤ 20 
-23 ≤ l ≤ 18 
-10 ≤ h ≤ 9 
-24 ≤ k ≤ 17 
-18 ≤ l ≤ 19 
Reflections collected 10913 5343
Independent reflections 5736 [Rint = 0.0497] 3493 [Rint = 0.0282]
Goodness of fit 1.039 1.036
Final R indices [I>2σ (I)] R1 = 0.0513, wR2 = 0.0791 R1 = 0.0298, wR2 = 0.0767
R indices (all data) R1 = 0.0656, wR2 = 0.0843 R1 = 0.0312, wR2 = 0.0777
Largest diff. / e Å-3 0.81 and -0.46 0.32 and -0.37
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Complex 3.8 3.9
Empirical formula CoC30H28N6O6S2 CoC24H20N4O2Cl2
Formula weight 691.63 526.27
Size / mm3 0.31 × 0.14 × 0.10 0.13 × 0.11 × 0.09
Temperature / K 119.99(14) 120.01(120
Wavelength 0.71073 (Mo-Kα) 0.71073 (Mo-Kα)
Crystal system triclinic monoclinic
Space group P 1 P 21/c
a / Å 14.4852(5) 10.3023(12)
b / Å 15.8534(5) 12.9556(8)
c / Å 27.0438(8) 9.3713(10)
α / ° 90.006(2) 90.00
β / ° 90.054(3) 115.732(13)
γ / ° 104.182(3) 90.00
Volume / Å3 6021.0(3) 1126.77(18)
Z 8 2
μ / mm-1 0.764 1.029
F(000) 2856.0 538.0
Data collection range / ° 5.59 ≤ θ ≤ 62.688 5.76 ≤ θ ≤ 62.42 
Index ranges -20 ≤ h ≤ 20 
-22 ≤ k ≤ 23 
-38 ≤ l ≤ 33 
-15 ≤ h ≤ 11 
-12 ≤ k ≤ 18 
-9 ≤ l ≤ 13 
Reflections collected 67052 6848
Independent reflections 31516 [Rint = 0.0525] 3193 [Rint = 0.0371]
Goodness of fit 1.005 1.059
Final R indices [I>2σ (I)] R1 = 0.0550, wR2 = 0.1026 R1 = 0.0500, wR2 = 0.0995
R indices (all data) R1 = 0.0882, wR2 = 0.1182 R1 = 0.0692, wR2 = 0.1075
Largest diff. / e Å-3 0.74 and -0.69 0.93 and -0.38
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Complex 3.10 4.1
Empirical formula CoC24H24N4O4I2 CoC33H21N4O4F12
Formula weight 745.20 824.47
Size / mm3 0.24 × 0.16 × 0.07 0.08 × 0.05 × 0.02
Temperature / K 120.01(10) 120.3(7)
Wavelength 0.71073 (Mo-Kα) 1.54184 (Cu-Kα)
Crystal system monoclininc tetragonal
Space group P 21/c I 41cd
a / Å 8.2666(2) 19.8988(6)
b / Å 11.2691(3) 19.8988(6)
c / Å 14.7572(5) 17.2717(11)
α / ° 90.00 90.00
β / ° 105.541(3) 90.00
γ / ° 90.00 90.00
Volume / Å3 1324.49(7) 6838.9(6)
Z 2 8
μ / mm-1 3.015 4.944
F(000) 722.0 3312.0
Data collection range / ° 6.26 ≤ θ ≤ 62.4 8.888 ≤ θ ≤ 147.232 
Index ranges -8 ≤ h ≤ 11 
-15 ≤ k ≤ 16 
-19 ≤ l ≤ 21 
-15 ≤ h ≤ 21 
-21 ≤ k ≤ 24 
-20 ≤ l ≤ 20 
Reflections collected 11519 7432
Independent reflections 3880 [Rint = 0.0552] 2869 [Rint = 0.0694]
Goodness of fit 1.070 1.025
Final R indices [I>2σ (I)] R1 = 0.0408, wR2 = 0.0826 R1 = 0.0597, wR2 = 0.1411
R indices (all data) R1 = 0.0542, wR2 = 0.0952 R1 = 0.0822, wR2 = 0.1548
Largest diff. / e Å-3 14.4 to -1.44 0.55 and -0.40
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Complex 4.2 4.3
Empirical formula CoC43H0.5N4O4F12 C38H23CoN4O4F12
Formula weight 923.90 886.53
Size / mm3 0.26 × 0.06 × 0.04 0.19 × 0.09 × 0.01
Temperature / K 120.0(2) 120.0(2)
Wavelength 1.54184 (Cu-Kα) 1.54184 (Cu-Kα)
Crystal system triclinic monoclinic
Space group P 1 P 21/n
a / Å 10.126(3) 20.8681(5)
b / Å 10.133(3) 15.8504(4)
c / Å 23.332(3) 22.6017(5)
α / ° 78.006(16) 90.00
β / ° 77.972(16) 99.010(2)
γ / ° 60.60(3) 90.00
Volume / Å3 2024.0(9) 7383.7(3)
Z 2 8
μ / mm-1 4.264 4.628
F(000) 907.0 3568.0
Data collection range / ° 7.808 ≤ θ ≤ 148.966 6.276 ≤ θ ≤ 148.944 
Index ranges -11 ≤ h ≤ 12 
-8 ≤ k ≤ 12 
-28 ≤ l ≤ 25 
-25 ≤ h ≤ 26 
-14 ≤ k ≤ 19 
-25 ≤ l ≤ 28 
Reflections collected 8696 41615
Independent reflections 5795 [Rint = 0.0748] 14917 [Rint = 0.1009]
Goodness of fit 2.106 1.017
Final R indices [I>2σ (I)] R1 = 0.2377, wR2 = 0.5589 R1 = 0.0687, wR2 = 0.1503
R indices (all data) R1 = 0.2586, wR2 = 0.5714 R1 = 0.1155, wR2 = 0.1777
Largest diff. / e Å-3 2.24 and -0.98 0.73 and -0.54
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Complex 4.4 4.6
Empirical formula CoC38H22N4O4F13 CoC39H22N4O4F15
Formula weight 904.53 954.54
Size / mm3 0.28 × 0.19 × 0.04 0.21 × 0.19 × 0.09
Temperature / K 120.00(15) 119.99(14)
Wavelength 1.54184 (Cu-Kα) 1.54184 (Cu-Kα)
Crystal system monoclinic monoclinic
Space group P 21/c P 21/c
a / Å 13.18694(13) 13.37591(16)
b / Å 15.53624(17) 15.71209(18)
c / Å 18.1682(2) 18.3039(2)
α / ° 90.00 90.00
β / ° 96.7273(10) 98.2790(12)
γ / ° 90.00 90.00
Volume / Å3 3696.59(7) 3806.72(8)
Z 4 4
μ / mm-1 4.676 4.655
F(000) 1816.0 1912.0
Data collection range / ° 6.74 ≤ θ ≤ 147.48 6.68 ≤ θ ≤ 147.42 
Index ranges -16 ≤ h ≤ 12 
-12 ≤ k ≤ 18 
-21 ≤ l ≤ 22 
-11 ≤ h ≤ 16 
-16 ≤ k ≤ 19 
-22 ≤ l ≤ 21 
Reflections collected 15160 16206
Independent reflections 7268 [Rint = 0.0294] 7489 [Rint = 0.0369]
Goodness of fit 1.015 1.016
Final R indices [I>2σ (I)] R1 = 0.0365, wR2 = 0.0882 R1 = 0.0398, wR2 = 0.0936
R indices (all data) R1 = 0.0441, wR2 = 0.0935 R1 = 0.0490, wR2 = 0.0993
Largest diff. / e Å-3 0.41 and -0.34 0.39 and -0.30
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Complex 4.8 4.9
Empirical formula CoC40H27N4O4F12Cl2 CoC39.6H26.2N4O5F12Cl1.2
Formula weight 985.48 967.51
Size / mm3 0.33 × 0.29 × 0.08 0.18 × 0.11 × 0.05
Temperature / K 120.0(2) 120.01(19)
Wavelength 1.54184 (Cu-Kα) 1.54184 (Cu-Kα)
Crystal system monoclinic monoclinic
Space group C c C c
a / Å 18.9964(3) 19.123(2)
b / Å 9.37144(13) 9.3137(11)
c / Å 22.8371(3) 22.8702(16)
α / ° 90.00 90.00
β / ° 96.2779(13) 96.100(9)
γ / ° 90.00 90.00
Volume / Å3 4041.16(10) 4050.2(7)
Z 4 4
μ / mm-1 5.481 5.003
F(000) 1984.0 1949.0
Data collection range / ° 7.79 ≤ θ ≤ 148.85 7.776 ≤ θ ≤ 147.17 
Index ranges -22 ≤ h ≤ 23 
-11 ≤ k ≤ 11 
-28 ≤ l ≤ 25 
-23 ≤ h ≤ 20 
-9 ≤ k ≤ 11 
-23 ≤ l ≤ 28 
Reflections collected 14844 8856
Independent reflections 5997 [Rint = 0.0643] 4807 [Rint = 0.0668]
Goodness of fit 1.060 1.029
Final R indices [I>2σ (I)] R1 = 0.0666, wR2 = 0.1667 R1 = 0.0997, wR2 = 0.2631
R indices (all data) R1 = 0.0740, wR2 = 0.1753 R1 = 0.1289, wR2 = 0.2972
Largest diff. / e Å-3 0.78 and -0.60 1.08 and -0.50
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Complex 4.11 4.13
Empirical formula CoC43H25N4O4F15Cl3Fe Co0.13C47H29.7N4O4.35F12Fe2
Formula weight 1167.80 1067.11
Size / mm3 0.10 × 0.10 × 0.06 0.15 × 0.06 × 0.04
Temperature / K 119.99(11) 120.2(5)
Wavelength 1.54184 (Cu-Kα) 1.54184 (Cu-Kα)
Crystal system orthorhombic monoclinic
Space group P na21 P 21/c
a / Å 15.6045(2) 18.0839(10)
b / Å 17.4409(2) 21.4884(16)
c / Å 16.7895(3) 21.4884(16)
α / ° 90.00 90.00
β / ° 90.00 99.405(6)
γ / ° 90.00 90.00
Volume / Å3 4569.36(12) 8762.5(10)
Z 4 8
μ / mm-1 7.999 6.588
F(000) 2328.0 4303.0
Data collection range / ° 7.308 ≤ θ ≤ 147.612 6.44 ≤ θ ≤ 148.988 
Index ranges -18 ≤ h ≤ 17 
-21 ≤ k ≤ 17 
-19 ≤ l ≤ 20 
-16 ≤ h ≤ 22 
-21 ≤ k ≤ 26 
-26 ≤ l ≤ 21 
Reflections collected 11890 40239
Independent reflections 7128 [Rint = 0.0330] 17035 [Rint = 0.0991]
Goodness of fit 1.022 1.054
Final R indices [I>2σ (I)] R1 = 0.0368, wR2 = 0.0836 R1 = 0.1010, wR2 = 0.2470
R indices (all data) R1 = 0.0431, wR2 = 0.0874 R1 = 0.1636, wR2 = 0.2886
Largest diff. / e Å-3 0.71 and -0.31 1.71 and -0.61
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Complex 4.14 4.15
Empirical formula CoC47H28N4O4F13Fe CoC49H30N4O4F13Cl6Fe
Formula weight 1074.51 1313.25
Size / mm3 0.13 × 0.10 × 0.09 0.18 × 0.08 × 0.07
Temperature / K 119.99(19) 119.99(17)
Wavelength 1.54184 (Cu-Kα) 1.54184 (Cu-Kα)
Crystal system monoclinic monoclinic
Space group P 2/c I a
a / Å 9.5681(7) 23.2888(3)
b / Å 9.9559(6) 11.92619(14)
c / Å 23.4877(19) 19.5918(2)
α / ° 90.00 90.00
β / ° 98.410(8) 106.1697(13)
γ / ° 90.00 90.00
Volume / Å3 2213.4(3) 5226.30(11)
Z 2 4
μ / mm-1 6.508 8.392
F(000) 1080.0 2624.0
Data collection range / ° 7.61 ≤ θ ≤ 148.26 7.906 ≤ θ ≤ 148.604 
Index ranges -11 ≤ h ≤ 11 
-12 ≤ k ≤ 12 
-29 ≤ l ≤ 24 
-28 ≤ h ≤ 29 
-14 ≤ k ≤ 14 
-23 ≤ l ≤ 24 
Reflections collected 14668 19257
Independent reflections 4461 [Rint = 0.0548] 7484 [Rint = 0.0304]
Goodness of fit 1.078 1.030
Final R indices [I>2σ (I)] R1 = 0.1409, wR2 = 0.3462 R1 = 0.0725, wR2 = 0.1965
R indices (all data) R1 = 0.1558, wR2 = 0.3560 R1 = 0.0779, wR2 = 0.2039
Largest diff. / e Å-3 0.96 and -0.86 1.81 and -0.95
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Complex 4.16 4.17
Empirical formula CoC47H27N4O4F14Fe CoC50.8H36.6N4O5.4F12Fe
Formula weight 1092.50 1132.22
Size / mm3 0.35 × 0.07 × 0.06 0.20 × 0.19 × 0.15
Temperature / K 120.0(2) 120.00(15)
Wavelength 1.54184 (Cu-Kα) 1.54184 (Cu-Kα)
Crystal system monoclinic orthorhombic
Space group P 21 P na21
a / Å 9.7396(7) 9.8368(2)
b / Å 22.542(3) 21.8083(6)
c / Å 20.980(2) 22.8353(6)
α / ° 90.00 90.00
β / ° 92.779(8) 90.00
γ / ° 90.00 90.00
Volume / Å3 4600.9(8) 4898.7(2)
Z 4 4
μ / mm-1 6.305 5.904
F(000) 2192.0 2294.0
Data collection range / ° 7.844 ≤ θ ≤ 101.442 7.744 ≤ θ ≤ 147.138 
Index ranges -9 ≤ h ≤ 9 
-22 ≤ k ≤ 20 
-15 ≤ l ≤ 20 
-6 ≤ h ≤ 11 
-14 ≤ k ≤ 26 
-27 ≤ l ≤ 26 
Reflections collected 12026 12661
Independent reflections 7818 [Rint = 0.1133] 7527 [Rint = 0.0442]
Goodness of fit 1.525 1.035
Final R indices [I>2σ (I)] R1 = 0.1644, wR2 = 0.4012 R1 = 0.0612, wR2 = 0.1595
R indices (all data) R1 = 0.1812, wR2 = 0.4203 R1 = 0.0687, wR2 = 0.1681
Largest diff. / e Å-3 2.42 and -0.98 0.77 and -0.81
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Complex 4.18 4.19
Empirical formula CoC48H31N4O4F12Fe CoC49.83H37.33N4O5.33F12Fe
Formula weight 1082.20 1120.26
Size / mm3 0.21 × 0.10 × 0.07 0.20 × 0.10 × 0.07
Temperature / K 120.01(16) 120.1(3)
Wavelength 1.54184 (Cu-Kα) 1.54184 (Cu-Kα)
Crystal system monoclinic orthorhombic
Space group P 21/c P na21
a / Å 19.7402(4) 9.7226(4)
b / Å 10.0264(2) 21.5917(12)
c / Å 23.0424(5) 23.4965(12)
α / ° 90.00 90.00
β / ° 104.191(2) 90.00
γ / ° 90.00 90.00
Volume / Å3 4421.45(16) 4932.5(4)
Z 4 4
μ / mm-1 6.882 5.854
F(000) 2183.0 2272.0
Data collection range / ° 7.916 ≤ θ ≤ 147.666 8.19 ≤ θ ≤ 147.416 
Index ranges -24 ≤ h ≤ 23 
-12 ≤ k ≤ 8 
-26 ≤ l ≤ 28 
-11 ≤ h ≤ 8 
-18 ≤ k ≤ 26 
-28 ≤ l ≤ 26 
Reflections collected 16774 12711
Independent reflections 8644 / 42 / 659 7418 [Rint = 0.0612]
Goodness of fit 1.012 1.035
Final R indices [I>2σ (I)] R1 = 0.0497, wR2 = 0.1142 R1 = 0.0853, wR2 = 0.2102
R indices (all data) R1 = 0.0761, wR2 = 0.1288 R1 = 0.1152, wR2 = 0.2341
Largest diff. / e Å-3 0.59 and -0.60 0.74 and -0.63
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Complex Hydrolysis product
Empirical formula FeC42H30O6F9
Formula weight 1025.06
Size / mm3 0.08 × 0.04 × 0.02
Temperature / K 119.97(16)
Wavelength 1.54184 (Cu-Kα)
Crystal system monoclinic
Space group P 21/c
a / Å 10.7214(2)
b / Å 36.8049(10)
c / Å 10.5177(3)
α / ° 90.00
β / ° 95.471(2)
γ / ° 90.00
Volume / Å3 4131.35(18)
Z 4
μ / mm-1 11.822
F(000) 2060.0
Data collection range / ° 8.284 ≤ θ ≤ 147.53  
Index ranges -13 ≤ h ≤ 10 
-30 ≤ k ≤ 41 
-12 ≤ l ≤ 9 
Reflections collected 18613
Independent reflections 7844 [Rint = 0.0408]
Goodness of fit 1.030
Final R indices [I>2σ (I)] R1 = 0.0451, wR2 = 0.0964
R indices (all data) R1 = 0.0640, wR2 = 0.1044
Largest diff. / e Å-3 0.51 and -0.44
